NZ614207B2 - Treatment of osteoarthritis and pain - Google Patents
Treatment of osteoarthritis and pain Download PDFInfo
- Publication number
- NZ614207B2 NZ614207B2 NZ614207A NZ61420712A NZ614207B2 NZ 614207 B2 NZ614207 B2 NZ 614207B2 NZ 614207 A NZ614207 A NZ 614207A NZ 61420712 A NZ61420712 A NZ 61420712A NZ 614207 B2 NZ614207 B2 NZ 614207B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- disease
- syndrome
- cancer
- poly
- binding protein
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title claims abstract description 84
- 201000008482 osteoarthritis Diseases 0.000 title claims abstract description 78
- 230000036407 pain Effects 0.000 title claims abstract description 78
- 102000024070 binding proteins Human genes 0.000 claims abstract description 214
- 108091007650 binding proteins Proteins 0.000 claims abstract description 214
- 239000003814 drug Substances 0.000 claims abstract description 33
- 238000004519 manufacturing process Methods 0.000 claims abstract description 16
- 102000004125 Interleukin-1alpha Human genes 0.000 claims abstract description 14
- 108010082786 Interleukin-1alpha Proteins 0.000 claims abstract description 14
- 102000003777 Interleukin-1 beta Human genes 0.000 claims abstract description 13
- 108090000193 Interleukin-1 beta Proteins 0.000 claims abstract description 13
- 102000004965 antibodies Human genes 0.000 claims description 257
- 108090001123 antibodies Proteins 0.000 claims description 257
- 239000000203 mixture Substances 0.000 claims description 148
- 102000004169 proteins and genes Human genes 0.000 claims description 125
- 108090000623 proteins and genes Proteins 0.000 claims description 125
- 230000027455 binding Effects 0.000 claims description 118
- 210000004027 cells Anatomy 0.000 claims description 96
- 108010045030 monoclonal antibodies Proteins 0.000 claims description 92
- 102000005614 monoclonal antibodies Human genes 0.000 claims description 92
- 201000010099 disease Diseases 0.000 claims description 87
- 238000000034 method Methods 0.000 claims description 63
- 102000018358 Immunoglobulins Human genes 0.000 claims description 40
- 108060003951 Immunoglobulins Proteins 0.000 claims description 40
- 239000003795 chemical substances by application Substances 0.000 claims description 34
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 claims description 33
- 229960000060 monoclonal antibodies Drugs 0.000 claims description 33
- 201000010874 syndrome Diseases 0.000 claims description 32
- -1 polyethylene Polymers 0.000 claims description 31
- 208000009856 Lung Disease Diseases 0.000 claims description 29
- 230000001154 acute Effects 0.000 claims description 29
- 201000011510 cancer Diseases 0.000 claims description 27
- 230000001684 chronic Effects 0.000 claims description 27
- 230000001363 autoimmune Effects 0.000 claims description 26
- 208000006897 Interstitial Lung Disease Diseases 0.000 claims description 20
- 210000000845 Cartilage Anatomy 0.000 claims description 18
- 206010020751 Hypersensitivity Diseases 0.000 claims description 18
- 230000002401 inhibitory effect Effects 0.000 claims description 18
- 150000002500 ions Chemical class 0.000 claims description 18
- 210000000056 organs Anatomy 0.000 claims description 18
- 229940079593 drugs Drugs 0.000 claims description 17
- 206010053552 Allodynia Diseases 0.000 claims description 16
- 206010003284 Arthropathy Diseases 0.000 claims description 16
- 208000006454 Hepatitis Diseases 0.000 claims description 16
- 208000009883 Joint Disease Diseases 0.000 claims description 16
- 231100000283 hepatitis Toxicity 0.000 claims description 16
- 239000004615 ingredient Substances 0.000 claims description 16
- 239000003112 inhibitor Substances 0.000 claims description 16
- 206010052779 Transplant rejections Diseases 0.000 claims description 15
- 201000008804 arthropathy Diseases 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 208000004454 Hyperalgesia Diseases 0.000 claims description 14
- 208000007999 Hyperesthesia Diseases 0.000 claims description 14
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 14
- 230000002757 inflammatory Effects 0.000 claims description 14
- 210000001519 tissues Anatomy 0.000 claims description 14
- 230000035693 Fab Effects 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 13
- 210000004602 germ cell Anatomy 0.000 claims description 13
- 201000009794 idiopathic pulmonary fibrosis Diseases 0.000 claims description 13
- 230000001404 mediated Effects 0.000 claims description 13
- 230000002093 peripheral Effects 0.000 claims description 13
- 238000002560 therapeutic procedure Methods 0.000 claims description 13
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 12
- 201000005794 allergic hypersensitivity disease Diseases 0.000 claims description 12
- 239000000969 carrier Substances 0.000 claims description 12
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 12
- 239000005541 ACE inhibitor Substances 0.000 claims description 11
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 claims description 11
- 229960001334 Corticosteroids Drugs 0.000 claims description 11
- 206010034277 Pemphigoid Diseases 0.000 claims description 11
- 210000003491 Skin Anatomy 0.000 claims description 11
- 206010047115 Vasculitis Diseases 0.000 claims description 11
- 239000003246 corticosteroid Substances 0.000 claims description 11
- 201000004624 dermatitis Diseases 0.000 claims description 11
- 230000036210 malignancy Effects 0.000 claims description 11
- 230000002459 sustained Effects 0.000 claims description 11
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 claims description 11
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 10
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 10
- 108010036949 Cyclosporine Proteins 0.000 claims description 10
- 206010024324 Leukaemias Diseases 0.000 claims description 10
- 229960001265 ciclosporin Drugs 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 230000004054 inflammatory process Effects 0.000 claims description 10
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3E)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 claims description 9
- 101710027066 ALB Proteins 0.000 claims description 9
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 9
- 206010003246 Arthritis Diseases 0.000 claims description 9
- 229960002170 Azathioprine Drugs 0.000 claims description 9
- 210000000988 Bone and Bones Anatomy 0.000 claims description 9
- 208000000594 Bullous Pemphigoid Diseases 0.000 claims description 9
- 206010012601 Diabetes mellitus Diseases 0.000 claims description 9
- 108010010803 Gelatin Proteins 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 206010061536 Parkinson's disease Diseases 0.000 claims description 9
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims description 9
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 9
- 229960001940 Sulfasalazine Drugs 0.000 claims description 9
- 210000001744 T-Lymphocytes Anatomy 0.000 claims description 9
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims description 9
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 9
- 239000008273 gelatin Substances 0.000 claims description 9
- 229920000159 gelatin Polymers 0.000 claims description 9
- 235000019322 gelatine Nutrition 0.000 claims description 9
- 235000011852 gelatine desserts Nutrition 0.000 claims description 9
- 201000009673 liver disease Diseases 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 9
- 102100001249 ALB Human genes 0.000 claims description 8
- 206010002556 Ankylosing spondylitis Diseases 0.000 claims description 8
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 208000007475 Hemolytic Anemia Diseases 0.000 claims description 8
- 206010021425 Immune system disease Diseases 0.000 claims description 8
- 210000003734 Kidney Anatomy 0.000 claims description 8
- 206010025323 Lymphomas Diseases 0.000 claims description 8
- 206010034636 Peripheral vascular disease Diseases 0.000 claims description 8
- 102100003095 TNFRSF1A Human genes 0.000 claims description 8
- 206010046851 Uveitis Diseases 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 229940050528 albumin Drugs 0.000 claims description 8
- 239000003146 anticoagulant agent Substances 0.000 claims description 8
- 239000001913 cellulose Substances 0.000 claims description 8
- 229920002678 cellulose Polymers 0.000 claims description 8
- 229920001577 copolymer Polymers 0.000 claims description 8
- 231100000406 dermatitis Toxicity 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 230000003394 haemopoietic Effects 0.000 claims description 8
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 8
- 201000004681 psoriasis Diseases 0.000 claims description 8
- 230000002685 pulmonary Effects 0.000 claims description 8
- 206010001897 Alzheimer's disease Diseases 0.000 claims description 7
- 206010007521 Cardiac arrhythmias Diseases 0.000 claims description 7
- 229940014259 Gelatin Drugs 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 102000019223 Interleukin-1 receptor family Human genes 0.000 claims description 7
- 108050006617 Interleukin-1 receptor family Proteins 0.000 claims description 7
- 108090000176 Interleukin-13 Proteins 0.000 claims description 7
- 108010002350 Interleukin-2 Proteins 0.000 claims description 7
- 108090001007 Interleukin-8 Proteins 0.000 claims description 7
- 206010027599 Migraine Diseases 0.000 claims description 7
- 208000008085 Migraine Disorders Diseases 0.000 claims description 7
- 206010025310 Other lymphomas Diseases 0.000 claims description 7
- 206010033128 Ovarian cancer Diseases 0.000 claims description 7
- 206010034695 Pernicious anaemia Diseases 0.000 claims description 7
- 206010038038 Rectal cancer Diseases 0.000 claims description 7
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims description 7
- 206010043554 Thrombocytopenia Diseases 0.000 claims description 7
- 230000003110 anti-inflammatory Effects 0.000 claims description 7
- 230000003902 lesions Effects 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 201000001275 rectum cancer Diseases 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 238000007920 subcutaneous administration Methods 0.000 claims description 7
- 238000002054 transplantation Methods 0.000 claims description 7
- 230000003612 virological Effects 0.000 claims description 7
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 6
- 201000004304 Addison's disease Diseases 0.000 claims description 6
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 6
- 206010003119 Arrhythmia Diseases 0.000 claims description 6
- 206010060963 Arterial disease Diseases 0.000 claims description 6
- 206010071068 Clinically isolated syndrome Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims description 6
- 206010012442 Dermatitis contact Diseases 0.000 claims description 6
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 6
- 206010022114 Injury Diseases 0.000 claims description 6
- 206010061255 Ischaemia Diseases 0.000 claims description 6
- 241000229754 Iva xanthiifolia Species 0.000 claims description 6
- 208000007766 Kaposi Sarcoma Diseases 0.000 claims description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 6
- 210000004072 Lung Anatomy 0.000 claims description 6
- 208000003250 Mixed Connective Tissue Disease Diseases 0.000 claims description 6
- 206010060880 Monoclonal gammopathy Diseases 0.000 claims description 6
- 208000010125 Myocardial Infarction Diseases 0.000 claims description 6
- 206010029331 Neuropathy peripheral Diseases 0.000 claims description 6
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 6
- 206010033799 Paralysis Diseases 0.000 claims description 6
- 206010035664 Pneumonia Diseases 0.000 claims description 6
- 229920001710 Polyorthoester Polymers 0.000 claims description 6
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000003385 Rhinitis, Allergic, Seasonal Diseases 0.000 claims description 6
- 208000006045 Spondylarthropathy Diseases 0.000 claims description 6
- 206010052775 Spondyloarthropathy Diseases 0.000 claims description 6
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims description 6
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims description 6
- 102100009534 TNF Human genes 0.000 claims description 6
- 101710040537 TNF Proteins 0.000 claims description 6
- 208000001106 Takayasu Arteritis Diseases 0.000 claims description 6
- 208000009174 Transverse Myelitis Diseases 0.000 claims description 6
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 claims description 6
- 230000001058 adult Effects 0.000 claims description 6
- 201000004384 alopecia Diseases 0.000 claims description 6
- 231100000360 alopecia Toxicity 0.000 claims description 6
- 231100000080 dermatitis contact Toxicity 0.000 claims description 6
- 201000010046 dilated cardiomyopathy Diseases 0.000 claims description 6
- 229960001680 ibuprofen Drugs 0.000 claims description 6
- 230000002458 infectious Effects 0.000 claims description 6
- 230000003834 intracellular Effects 0.000 claims description 6
- 238000007918 intramuscular administration Methods 0.000 claims description 6
- 230000000366 juvenile Effects 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 229960000485 methotrexate Drugs 0.000 claims description 6
- 201000008383 nephritis Diseases 0.000 claims description 6
- 201000001119 neuropathy Diseases 0.000 claims description 6
- 229920000747 poly(lactic acid) polymer Polymers 0.000 claims description 6
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 6
- 239000002464 receptor antagonist Substances 0.000 claims description 6
- 230000035945 sensitivity Effects 0.000 claims description 6
- 201000005671 spondyloarthropathy Diseases 0.000 claims description 6
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 6
- 229960004676 ANTITHROMBOTIC AGENTS Drugs 0.000 claims description 5
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims description 5
- 108009000283 Allograft Rejection Proteins 0.000 claims description 5
- IPOKCKJONYRRHP-FMQUCBEESA-N Balsalazide Chemical compound C1=CC(C(=O)NCCC(=O)O)=CC=C1\N=N\C1=CC=C(O)C(C(O)=O)=C1 IPOKCKJONYRRHP-FMQUCBEESA-N 0.000 claims description 5
- 101700033362 CD28 Proteins 0.000 claims description 5
- 102100019461 CD28 Human genes 0.000 claims description 5
- 101710040446 CD40 Proteins 0.000 claims description 5
- 102100013137 CD40 Human genes 0.000 claims description 5
- 102100005832 CD69 Human genes 0.000 claims description 5
- 101700080416 CD69 Proteins 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims description 5
- 102000008186 Collagen Human genes 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 5
- 208000002573 Connective Tissue Disease Diseases 0.000 claims description 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 5
- 101700033006 EGF Proteins 0.000 claims description 5
- 102100010813 EGF Human genes 0.000 claims description 5
- 206010014665 Endocarditis Diseases 0.000 claims description 5
- 229940116977 Epidermal Growth Factor Drugs 0.000 claims description 5
- 206010015218 Erythema multiforme Diseases 0.000 claims description 5
- 101710003421 FGF Proteins 0.000 claims description 5
- 210000004392 Genitalia Anatomy 0.000 claims description 5
- 206010018987 Haemorrhage Diseases 0.000 claims description 5
- 206010020243 Hodgkin's disease Diseases 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 102100006815 IL2RA Human genes 0.000 claims description 5
- 101700082799 IL2RA Proteins 0.000 claims description 5
- 101700015336 ISG20 Proteins 0.000 claims description 5
- 206010061598 Immunodeficiency Diseases 0.000 claims description 5
- 108090000174 Interleukin-10 Proteins 0.000 claims description 5
- 108090000172 Interleukin-15 Proteins 0.000 claims description 5
- 102000003812 Interleukin-15 Human genes 0.000 claims description 5
- 108090000978 Interleukin-4 Proteins 0.000 claims description 5
- 108010002586 Interleukin-7 Proteins 0.000 claims description 5
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 5
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims description 5
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims description 5
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims description 5
- 206010025650 Malignant melanoma Diseases 0.000 claims description 5
- KBOPZPXVLCULAV-UHFFFAOYSA-N Mesalazine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims description 5
- NBGAYCYFNGPNPV-UHFFFAOYSA-M NOC1=CC=CC=C1C([O-])=O Chemical class NOC1=CC=CC=C1C([O-])=O NBGAYCYFNGPNPV-UHFFFAOYSA-M 0.000 claims description 5
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 5
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims description 5
- QQBDLJCYGRGAKP-FOCLMDBBSA-N Olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 claims description 5
- 208000003435 Optic Neuritis Diseases 0.000 claims description 5
- 102100005499 PTPRC Human genes 0.000 claims description 5
- 101700059076 PTPRC Proteins 0.000 claims description 5
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 5
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 5
- 208000005987 Polymyositis Diseases 0.000 claims description 5
- 206010036105 Polyneuropathy Diseases 0.000 claims description 5
- 206010037162 Psoriatic arthropathy Diseases 0.000 claims description 5
- 206010063837 Reperfusion injury Diseases 0.000 claims description 5
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- 206010062164 Seronegative arthritis Diseases 0.000 claims description 5
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 5
- 101700026084 THY1 Proteins 0.000 claims description 5
- 102100008333 THY1 Human genes 0.000 claims description 5
- 101710040533 TNFRSF8 Proteins 0.000 claims description 5
- 102100009538 TNFRSF8 Human genes 0.000 claims description 5
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 5
- RZWIIPASKMUIAC-VQTJNVASSA-N Thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 claims description 5
- 206010043778 Thyroiditis Diseases 0.000 claims description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 5
- 229940074410 Trehalose Drugs 0.000 claims description 5
- 230000000111 anti-oxidant Effects 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims description 5
- 229960004168 balsalazide Drugs 0.000 claims description 5
- 230000000747 cardiac effect Effects 0.000 claims description 5
- 201000003861 cerebellar disease Diseases 0.000 claims description 5
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 5
- 229960005188 collagen Drugs 0.000 claims description 5
- 239000004074 complement inhibitor Substances 0.000 claims description 5
- 201000001981 dermatomyositis Diseases 0.000 claims description 5
- 230000002538 fungal Effects 0.000 claims description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 5
- 239000007943 implant Substances 0.000 claims description 5
- 238000007912 intraperitoneal administration Methods 0.000 claims description 5
- 229940072739 mesalamine Drugs 0.000 claims description 5
- 229960004963 mesalazine Drugs 0.000 claims description 5
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 230000002107 myocardial Effects 0.000 claims description 5
- 150000002482 oligosaccharides Polymers 0.000 claims description 5
- 229960004110 olsalazine Drugs 0.000 claims description 5
- 201000005737 orchitis Diseases 0.000 claims description 5
- 229960005205 prednisolone Drugs 0.000 claims description 5
- 201000001263 psoriatic arthritis Diseases 0.000 claims description 5
- 229960002930 sirolimus Drugs 0.000 claims description 5
- 201000004595 synovitis Diseases 0.000 claims description 5
- SZXUTTGMFUSMCE-UHFFFAOYSA-N 2-(1H-imidazol-2-yl)pyridine Chemical class C1=CNC(C=2N=CC=CC=2)=N1 SZXUTTGMFUSMCE-UHFFFAOYSA-N 0.000 claims description 4
- RTGDFNSFWBGLEC-SYZQJQIISA-N 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 4
- 102100000272 AIMP1 Human genes 0.000 claims description 4
- 210000001367 Arteries Anatomy 0.000 claims description 4
- 206010003591 Ataxia Diseases 0.000 claims description 4
- 206010003645 Atopy Diseases 0.000 claims description 4
- 208000003853 Autoimmune Hypothyroidism Diseases 0.000 claims description 4
- 208000000659 Autoimmune Lymphoproliferative Syndrome Diseases 0.000 claims description 4
- 102100006400 CSF2 Human genes 0.000 claims description 4
- 108090000426 Caspase 1 Proteins 0.000 claims description 4
- 206010008874 Chronic fatigue syndrome Diseases 0.000 claims description 4
- 210000002808 Connective Tissue Anatomy 0.000 claims description 4
- 229920001651 Cyanoacrylate Polymers 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 208000004275 Demyelinating Disease Diseases 0.000 claims description 4
- 108010002156 Depsipeptides Proteins 0.000 claims description 4
- 206010014801 Endophthalmitis Diseases 0.000 claims description 4
- 229950003499 FIBRIN Drugs 0.000 claims description 4
- 102000009123 Fibrin Human genes 0.000 claims description 4
- 108010073385 Fibrin Proteins 0.000 claims description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
- 208000002414 Hemophagocytic Lymphohistiocytosis Diseases 0.000 claims description 4
- 206010048595 Histiocytosis haematophagic Diseases 0.000 claims description 4
- 108010065637 Interleukin-23 Proteins 0.000 claims description 4
- VHOGYURTWQBHIL-UHFFFAOYSA-N Leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 4
- 210000004185 Liver Anatomy 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- VQHSOMBJVWLPSR-WUJBLJFYSA-N Maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 4
- 206010028417 Myasthenia gravis Diseases 0.000 claims description 4
- ZTUGCJNAJJDKDC-UHFFFAOYSA-N N-(3-hydroxypropyl)-2-methylprop-2-enamide Chemical compound CC(=C)C(=O)NCCCO ZTUGCJNAJJDKDC-UHFFFAOYSA-N 0.000 claims description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010036601 Premature menopause Diseases 0.000 claims description 4
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 claims description 4
- 206010037912 Raynaud's phenomenon Diseases 0.000 claims description 4
- 208000002574 Reactive Arthritis Diseases 0.000 claims description 4
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims description 4
- 229960004793 Sucrose Drugs 0.000 claims description 4
- 206010051379 Systemic inflammatory response syndrome Diseases 0.000 claims description 4
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 4
- 206010043207 Temporal arteritis Diseases 0.000 claims description 4
- 239000000464 adrenergic agent Substances 0.000 claims description 4
- 229940072056 alginate Drugs 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 239000003602 elastase inhibitor Substances 0.000 claims description 4
- 238000011156 evaluation Methods 0.000 claims description 4
- 150000004676 glycans Polymers 0.000 claims description 4
- 239000000832 lactitol Substances 0.000 claims description 4
- 229960003451 lactitol Drugs 0.000 claims description 4
- 235000010448 lactitol Nutrition 0.000 claims description 4
- 229960000681 leflunomide Drugs 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 108010000525 member 1 small inducible cytokine subfamily E Proteins 0.000 claims description 4
- 201000009457 movement disease Diseases 0.000 claims description 4
- 229960004866 mycophenolate mofetil Drugs 0.000 claims description 4
- 201000003793 myelodysplastic syndrome Diseases 0.000 claims description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 4
- 229920001542 oligosaccharide Polymers 0.000 claims description 4
- 125000000962 organic group Chemical group 0.000 claims description 4
- 229920001308 poly(aminoacid) Polymers 0.000 claims description 4
- 229920001888 polyacrylic acid Polymers 0.000 claims description 4
- 229920001610 polycaprolactone Polymers 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 150000004804 polysaccharides Polymers 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 201000000926 premature ovarian failure Diseases 0.000 claims description 4
- 230000000750 progressive Effects 0.000 claims description 4
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 201000009594 systemic scleroderma Diseases 0.000 claims description 4
- 206010065040 AIDS dementia complex Diseases 0.000 claims description 3
- 208000004622 Abetalipoproteinemia Diseases 0.000 claims description 3
- 206010049865 Achromotrichia acquired Diseases 0.000 claims description 3
- 206010000496 Acne Diseases 0.000 claims description 3
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 claims description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 3
- 208000005298 Acute Pain Diseases 0.000 claims description 3
- 206010000830 Acute leukaemia Diseases 0.000 claims description 3
- 208000009956 Adenocarcinoma Diseases 0.000 claims description 3
- 206010064930 Age-related macular degeneration Diseases 0.000 claims description 3
- 208000007848 Alcoholism Diseases 0.000 claims description 3
- 208000002205 Allergic Conjunctivitis Diseases 0.000 claims description 3
- 208000002029 Allergic Contact Dermatitis Diseases 0.000 claims description 3
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 208000003455 Anaphylaxis Diseases 0.000 claims description 3
- 206010002329 Aneurysm Diseases 0.000 claims description 3
- 206010002383 Angina pectoris Diseases 0.000 claims description 3
- 210000002226 Anterior Horn Cells Anatomy 0.000 claims description 3
- 208000008637 Anti-Glomerular Basement Membrane Disease Diseases 0.000 claims description 3
- 210000000709 Aorta Anatomy 0.000 claims description 3
- 210000000702 Aorta, Abdominal Anatomy 0.000 claims description 3
- 206010003226 Arteriovenous fistula Diseases 0.000 claims description 3
- 206010003267 Arthritis reactive Diseases 0.000 claims description 3
- 208000006673 Asthma Diseases 0.000 claims description 3
- 208000002102 Atrial Premature Complex Diseases 0.000 claims description 3
- 206010003658 Atrial fibrillation Diseases 0.000 claims description 3
- 206010003668 Atrial tachycardia Diseases 0.000 claims description 3
- 206010003671 Atrioventricular block Diseases 0.000 claims description 3
- 208000005783 Autoimmune Thyroiditis Diseases 0.000 claims description 3
- 206010003816 Autoimmune disease Diseases 0.000 claims description 3
- 208000001974 Autoimmune enteropathy Diseases 0.000 claims description 3
- 206010064539 Autoimmune myocarditis Diseases 0.000 claims description 3
- 206010003885 Azotaemia Diseases 0.000 claims description 3
- 208000003950 B-Cell Lymphoma Diseases 0.000 claims description 3
- 210000004227 Basal Ganglia Anatomy 0.000 claims description 3
- 206010004661 Biliary cirrhosis primary Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 208000010217 Blepharitis Diseases 0.000 claims description 3
- 210000001185 Bone Marrow Anatomy 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 206010006578 Bundle branch block Diseases 0.000 claims description 3
- 210000004375 Bundle of His Anatomy 0.000 claims description 3
- 208000009899 Burkitt Lymphoma Diseases 0.000 claims description 3
- 206010006895 Cachexia Diseases 0.000 claims description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 3
- 208000005846 Cardiomyopathy Diseases 0.000 claims description 3
- 210000001638 Cerebellum Anatomy 0.000 claims description 3
- 206010008635 Cholestasis Diseases 0.000 claims description 3
- 206010008748 Chorea Diseases 0.000 claims description 3
- 208000000094 Chronic Pain Diseases 0.000 claims description 3
- 206010009839 Coeliac disease Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 206010010741 Conjunctivitis Diseases 0.000 claims description 3
- 208000010247 Contact Dermatitis Diseases 0.000 claims description 3
- 206010010941 Coombs positive haemolytic anaemia Diseases 0.000 claims description 3
- 201000006306 Cor pulmonale Diseases 0.000 claims description 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 3
- 201000010450 Creutzfeldt-Jakob disease Diseases 0.000 claims description 3
- 206010011401 Crohn's disease Diseases 0.000 claims description 3
- 208000004921 Cutaneous Lupus Erythematosus Diseases 0.000 claims description 3
- 206010011703 Cyanosis Diseases 0.000 claims description 3
- 206010011844 Dacryocystitis Diseases 0.000 claims description 3
- 206010011878 Deafness Diseases 0.000 claims description 3
- 208000006313 Delayed Hypersensitivity Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 206010067889 Dementia with Lewy body Diseases 0.000 claims description 3
- 206010012310 Dengue fever Diseases 0.000 claims description 3
- 206010048768 Dermatosis Diseases 0.000 claims description 3
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims description 3
- 208000009190 Disseminated Intravascular Coagulation Diseases 0.000 claims description 3
- 102000015554 Dopamine receptor family Human genes 0.000 claims description 3
- 108050004812 Dopamine receptor family Proteins 0.000 claims description 3
- 201000010374 Down syndrome Diseases 0.000 claims description 3
- 206010072268 Drug-induced liver injury Diseases 0.000 claims description 3
- 208000005679 Eczema Diseases 0.000 claims description 3
- 208000001606 Epiglottitis Diseases 0.000 claims description 3
- 206010015084 Episcleritis Diseases 0.000 claims description 3
- 206010015108 Epstein-Barr virus infection Diseases 0.000 claims description 3
- 206010015832 Extrapyramidal disease Diseases 0.000 claims description 3
- 208000002633 Febrile Neutropenia Diseases 0.000 claims description 3
- 208000007984 Female Infertility Diseases 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- 208000003884 Gestational Trophoblastic Disease Diseases 0.000 claims description 3
- 208000005017 Glioblastoma Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- 206010018620 Goodpasture's syndrome Diseases 0.000 claims description 3
- 206010018634 Gouty arthritis Diseases 0.000 claims description 3
- 206010018651 Graft versus host disease Diseases 0.000 claims description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 3
- 208000005721 HIV Infections Diseases 0.000 claims description 3
- 206010018872 Haemochromatosis Diseases 0.000 claims description 3
- 206010019024 Haemosiderosis Diseases 0.000 claims description 3
- 208000004559 Hearing Loss Diseases 0.000 claims description 3
- 206010011879 Hearing loss Diseases 0.000 claims description 3
- 208000007890 Heart Neoplasms Diseases 0.000 claims description 3
- 208000002907 Heart Valve Disease Diseases 0.000 claims description 3
- 206010019315 Heart transplant rejection Diseases 0.000 claims description 3
- 208000005252 Hepatitis A Diseases 0.000 claims description 3
- 208000002672 Hepatitis B Diseases 0.000 claims description 3
- 208000005176 Hepatitis C Diseases 0.000 claims description 3
- 201000001971 Huntington's disease Diseases 0.000 claims description 3
- 208000000269 Hyperkinesis Diseases 0.000 claims description 3
- 101700036616 IL16 Proteins 0.000 claims description 3
- 206010021928 Infertility female Diseases 0.000 claims description 3
- 206010022489 Insulin resistance Diseases 0.000 claims description 3
- 108010065805 Interleukin-12 Proteins 0.000 claims description 3
- 102000003810 Interleukin-18 Human genes 0.000 claims description 3
- 108090000171 Interleukin-18 Proteins 0.000 claims description 3
- 108090001005 Interleukin-6 Proteins 0.000 claims description 3
- 206010022941 Iridocyclitis Diseases 0.000 claims description 3
- 206010061256 Ischaemic stroke Diseases 0.000 claims description 3
- 201000007313 Kawasaki disease Diseases 0.000 claims description 3
- 206010023332 Keratitis Diseases 0.000 claims description 3
- 208000001083 Kidney Disease Diseases 0.000 claims description 3
- 206010023439 Kidney transplant rejection Diseases 0.000 claims description 3
- 201000005099 Langerhans-cell histiocytosis Diseases 0.000 claims description 3
- 208000004554 Leishmaniasis Diseases 0.000 claims description 3
- 206010024229 Leprosy Diseases 0.000 claims description 3
- 210000004558 Lewy Bodies Anatomy 0.000 claims description 3
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 3
- 201000002832 Lewy body dementia Diseases 0.000 claims description 3
- 206010024515 Linear IgA disease Diseases 0.000 claims description 3
- 206010024558 Lip oedema Diseases 0.000 claims description 3
- 208000007021 Lipedema Diseases 0.000 claims description 3
- 206010024648 Livedo reticularis Diseases 0.000 claims description 3
- 206010067125 Liver injury Diseases 0.000 claims description 3
- 206010025169 Lyme disease Diseases 0.000 claims description 3
- 208000002502 Lymphedema Diseases 0.000 claims description 3
- 206010025282 Lymphoedema Diseases 0.000 claims description 3
- 208000007466 Male Infertility Diseases 0.000 claims description 3
- 210000002418 Meninges Anatomy 0.000 claims description 3
- 206010027191 Meningioma Diseases 0.000 claims description 3
- 206010058858 Meningococcal bacteraemia Diseases 0.000 claims description 3
- 206010061284 Mental disease Diseases 0.000 claims description 3
- 229960000282 Metronidazole Drugs 0.000 claims description 3
- 206010063344 Microscopic polyangiitis Diseases 0.000 claims description 3
- 210000002161 Motor Neurons Anatomy 0.000 claims description 3
- 210000004400 Mucous Membrane Anatomy 0.000 claims description 3
- 206010028154 Multi-organ failure Diseases 0.000 claims description 3
- 208000009525 Myocarditis Diseases 0.000 claims description 3
- 206010028665 Myxoedema Diseases 0.000 claims description 3
- 206010029151 Nephropathy Diseases 0.000 claims description 3
- 108009000551 Nephrotic syndrome Proteins 0.000 claims description 3
- 208000007538 Neurilemmoma Diseases 0.000 claims description 3
- 208000005890 Neuroma Diseases 0.000 claims description 3
- 206010053219 Non-alcoholic steatohepatitis Diseases 0.000 claims description 3
- 206010031149 Osteitis Diseases 0.000 claims description 3
- 208000003076 Osteolysis Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 206010033165 Ovarian failure Diseases 0.000 claims description 3
- 206010049169 Pancreas transplant rejection Diseases 0.000 claims description 3
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 3
- 208000002593 Pantothenate Kinase-Associated Neurodegeneration Diseases 0.000 claims description 3
- 206010067229 Paraneoplastic syndrome Diseases 0.000 claims description 3
- 206010034468 Pericardial disease Diseases 0.000 claims description 3
- 208000001297 Phlebitis Diseases 0.000 claims description 3
- 206010065159 Polychondritis Diseases 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 208000004358 Polyneuropathy Diseases 0.000 claims description 3
- 208000008425 Protein Deficiency Diseases 0.000 claims description 3
- 208000004186 Pulmonary Heart Disease Diseases 0.000 claims description 3
- 208000002815 Pulmonary Hypertension Diseases 0.000 claims description 3
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 claims description 3
- 208000005587 Refsum Disease Diseases 0.000 claims description 3
- 206010038428 Renal disease Diseases 0.000 claims description 3
- 206010038436 Renal failure acute Diseases 0.000 claims description 3
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 claims description 3
- 206010038915 Retinitis viral Diseases 0.000 claims description 3
- 208000004124 Rheumatic Heart Disease Diseases 0.000 claims description 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
- 206010039094 Rhinitis perennial Diseases 0.000 claims description 3
- 101710009148 SERPINA1 Proteins 0.000 claims description 3
- 241000607142 Salmonella Species 0.000 claims description 3
- 206010039447 Salmonellosis Diseases 0.000 claims description 3
- 206010039807 Secondary adrenocortical insufficiency Diseases 0.000 claims description 3
- 210000001625 Seminal Vesicles Anatomy 0.000 claims description 3
- 206010039966 Senile dementia Diseases 0.000 claims description 3
- 206010053879 Sepsis syndrome Diseases 0.000 claims description 3
- 206010040070 Septic shock Diseases 0.000 claims description 3
- 208000009714 Severe Dengue Diseases 0.000 claims description 3
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims description 3
- 208000006641 Skin Disease Diseases 0.000 claims description 3
- 206010041591 Spinal osteoarthritis Diseases 0.000 claims description 3
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 claims description 3
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 206010042772 Syncope Diseases 0.000 claims description 3
- 101710038526 TNFRSF1A Proteins 0.000 claims description 3
- 206010043189 Telangiectasia Diseases 0.000 claims description 3
- 208000009056 Telangiectasis Diseases 0.000 claims description 3
- 206010043540 Thromboangiitis obliterans Diseases 0.000 claims description 3
- 210000001541 Thymus Gland Anatomy 0.000 claims description 3
- 206010043709 Thyroid disease Diseases 0.000 claims description 3
- 206010044248 Toxic shock syndrome Diseases 0.000 claims description 3
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 3
- 206010070863 Toxicity to various agents Diseases 0.000 claims description 3
- 206010044688 Trisomy 21 Diseases 0.000 claims description 3
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 claims description 3
- 208000009852 Uremia Diseases 0.000 claims description 3
- 210000003932 Urinary Bladder Anatomy 0.000 claims description 3
- 210000001635 Urinary Tract Anatomy 0.000 claims description 3
- 206010048709 Urosepsis Diseases 0.000 claims description 3
- 210000003741 Urothelium Anatomy 0.000 claims description 3
- 206010046996 Varicose vein Diseases 0.000 claims description 3
- 208000003663 Ventricular Fibrillation Diseases 0.000 claims description 3
- 206010047642 Vitiligo Diseases 0.000 claims description 3
- 206010047680 Vogt-Koyanagi-Harada syndrome Diseases 0.000 claims description 3
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 3
- 201000003229 acute pancreatitis Diseases 0.000 claims description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 3
- 201000010105 allergic rhinitis Diseases 0.000 claims description 3
- 230000036783 anaphylactic response Effects 0.000 claims description 3
- 230000001475 anti-trypsic Effects 0.000 claims description 3
- 230000003143 atherosclerotic Effects 0.000 claims description 3
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 3
- 230000001580 bacterial Effects 0.000 claims description 3
- 201000008975 bone inflammation disease Diseases 0.000 claims description 3
- 201000009267 bronchiectasis Diseases 0.000 claims description 3
- 201000008031 cardiomyopathy Diseases 0.000 claims description 3
- 230000002490 cerebral Effects 0.000 claims description 3
- 230000000739 chaotic Effects 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 231100000359 cholestasis Toxicity 0.000 claims description 3
- 201000001973 choreatic disease Diseases 0.000 claims description 3
- 201000011231 colorectal cancer Diseases 0.000 claims description 3
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 3
- 201000006233 congestive heart failure Diseases 0.000 claims description 3
- 230000001054 cortical Effects 0.000 claims description 3
- 230000002594 corticospinal Effects 0.000 claims description 3
- 201000002950 dengue hemorrhagic fever Diseases 0.000 claims description 3
- 231100000595 drug-induced hepatitis Toxicity 0.000 claims description 3
- 201000008865 drug-induced hepatitis Diseases 0.000 claims description 3
- 231100001003 eczema Toxicity 0.000 claims description 3
- 201000002491 encephalomyelitis Diseases 0.000 claims description 3
- 201000009273 endometriosis Diseases 0.000 claims description 3
- 201000010063 epididymitis Diseases 0.000 claims description 3
- 201000011384 erythromelalgia Diseases 0.000 claims description 3
- 201000010934 exostosis Diseases 0.000 claims description 3
- 230000001605 fetal Effects 0.000 claims description 3
- 230000004761 fibrosis Effects 0.000 claims description 3
- 230000003176 fibrotic Effects 0.000 claims description 3
- 201000005917 gastric ulcer Diseases 0.000 claims description 3
- 230000001434 glomerular Effects 0.000 claims description 3
- 201000005569 gout Diseases 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 238000001631 haemodialysis Methods 0.000 claims description 3
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 3
- 231100000888 hearing loss Toxicity 0.000 claims description 3
- 201000011066 hemangioma Diseases 0.000 claims description 3
- 230000000322 hemodialysis Effects 0.000 claims description 3
- 231100000753 hepatic injury Toxicity 0.000 claims description 3
- 201000001820 human immunodeficiency virus infectious disease Diseases 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 201000010930 hyperostosis Diseases 0.000 claims description 3
- 230000003483 hypokinetic Effects 0.000 claims description 3
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 claims description 3
- 201000008319 inclusion body myositis Diseases 0.000 claims description 3
- 200000000018 inflammatory disease Diseases 0.000 claims description 3
- 200000000003 influenza A Diseases 0.000 claims description 3
- 238000000185 intracerebroventricular Methods 0.000 claims description 3
- 238000007919 intrasynovial administration Methods 0.000 claims description 3
- 201000004614 iritis Diseases 0.000 claims description 3
- 230000000302 ischemic Effects 0.000 claims description 3
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 3
- 201000004815 juvenile spinal muscular atrophy Diseases 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 230000000527 lymphocytic Effects 0.000 claims description 3
- 201000006812 malignant histiocytosis Diseases 0.000 claims description 3
- 229960001428 mercaptopurine Drugs 0.000 claims description 3
- 230000002503 metabolic Effects 0.000 claims description 3
- 200000000023 metastatic cancer Diseases 0.000 claims description 3
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 3
- 230000002438 mitochondrial Effects 0.000 claims description 3
- 201000009251 multiple myeloma Diseases 0.000 claims description 3
- 201000000585 muscular atrophy Diseases 0.000 claims description 3
- 231100000539 ovarian failure Toxicity 0.000 claims description 3
- 230000003071 parasitic Effects 0.000 claims description 3
- 230000000849 parathyroid Effects 0.000 claims description 3
- 230000001314 paroxysmal Effects 0.000 claims description 3
- 201000011152 pemphigus Diseases 0.000 claims description 3
- 230000000737 periodic Effects 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 229920005862 polyol Polymers 0.000 claims description 3
- 150000003077 polyols Chemical class 0.000 claims description 3
- 229920001296 polysiloxane Polymers 0.000 claims description 3
- 201000011461 pre-eclampsia Diseases 0.000 claims description 3
- 201000002728 primary biliary cirrhosis Diseases 0.000 claims description 3
- 201000007094 prostatitis Diseases 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 230000000306 recurrent Effects 0.000 claims description 3
- 200000000008 restenosis Diseases 0.000 claims description 3
- 201000000582 retinoblastoma Diseases 0.000 claims description 3
- 230000002441 reversible Effects 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 230000036303 septic shock Effects 0.000 claims description 3
- 230000035939 shock Effects 0.000 claims description 3
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 claims description 3
- 231100001005 telangiectasia Toxicity 0.000 claims description 3
- 230000002537 thrombolytic Effects 0.000 claims description 3
- 230000001988 toxicity Effects 0.000 claims description 3
- 231100000419 toxicity Toxicity 0.000 claims description 3
- 239000002753 trypsin inhibitor Substances 0.000 claims description 3
- 230000005951 type IV hypersensitivity Effects 0.000 claims description 3
- 201000006704 ulcerative colitis Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 238000007879 vasectomy Methods 0.000 claims description 3
- 208000010002 Alcoholic Liver Cirrhosis Diseases 0.000 claims description 2
- 208000004631 Alopecia Areata Diseases 0.000 claims description 2
- 206010002895 Aortic dissection Diseases 0.000 claims description 2
- 206010002967 Aplastic anaemia Diseases 0.000 claims description 2
- 206010053555 Arthritis bacterial Diseases 0.000 claims description 2
- 208000006740 Aseptic Meningitis Diseases 0.000 claims description 2
- 206010003549 Asthenia Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 102100006374 CASP1 Human genes 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 2
- 208000008818 Chronic Mucocutaneous Candidiasis Diseases 0.000 claims description 2
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 206010014612 Encephalitis viral Diseases 0.000 claims description 2
- 206010070904 Familial haemophagocytic lymphohistiocytosis Diseases 0.000 claims description 2
- 206010017374 Friedreich's ataxia Diseases 0.000 claims description 2
- 210000000232 Gallbladder Anatomy 0.000 claims description 2
- 206010017758 Gastric cancer Diseases 0.000 claims description 2
- 206010018691 Granuloma Diseases 0.000 claims description 2
- 201000004779 Graves' disease Diseases 0.000 claims description 2
- 206010020584 Hypercalcaemia of malignancy Diseases 0.000 claims description 2
- 206010020850 Hyperthyroidism Diseases 0.000 claims description 2
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims description 2
- 206010020993 Hypoglycaemia Diseases 0.000 claims description 2
- 208000000038 Hypoparathyroidism Diseases 0.000 claims description 2
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 claims description 2
- 208000006264 Korsakoff Syndrome Diseases 0.000 claims description 2
- 206010027201 Meningitis aseptic Diseases 0.000 claims description 2
- 206010028080 Mucocutaneous candidiasis Diseases 0.000 claims description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 2
- 229940010383 Mycobacterium tuberculosis Drugs 0.000 claims description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 208000009928 Nephrosis Diseases 0.000 claims description 2
- 206010053643 Neurodegenerative disease Diseases 0.000 claims description 2
- 206010053869 POEMS syndrome Diseases 0.000 claims description 2
- 206010056332 Panencephalitis Diseases 0.000 claims description 2
- 208000006551 Parasitic Disease Diseases 0.000 claims description 2
- 208000008223 Pemphigoid Gestationis Diseases 0.000 claims description 2
- 206010034674 Peritonitis Diseases 0.000 claims description 2
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 claims description 2
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 claims description 2
- 239000004698 Polyethylene (PE) Substances 0.000 claims description 2
- 206010037163 Psoriatic arthropathy Diseases 0.000 claims description 2
- 206010067953 Radiation fibrosis Diseases 0.000 claims description 2
- 208000003782 Raynaud Disease Diseases 0.000 claims description 2
- 206010038910 Retinitis Diseases 0.000 claims description 2
- 206010039667 Schwannoma Diseases 0.000 claims description 2
- 208000008765 Sciatica Diseases 0.000 claims description 2
- 206010039705 Scleritis Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 206010039811 Secondary amyloidosis Diseases 0.000 claims description 2
- 208000007056 Sickle Cell Anemia Diseases 0.000 claims description 2
- 206010073145 Soft tissue cancer Diseases 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims description 2
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims description 2
- 208000006379 Syphilis Diseases 0.000 claims description 2
- 101700044444 TKT Proteins 0.000 claims description 2
- 102100002615 TKT Human genes 0.000 claims description 2
- 208000001871 Tachycardia Diseases 0.000 claims description 2
- 229940035295 Ting Drugs 0.000 claims description 2
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 claims description 2
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 206010046766 Uterine cancer Diseases 0.000 claims description 2
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 claims description 2
- 230000002097 anti-phospholipid Effects 0.000 claims description 2
- 201000001320 atherosclerosis Diseases 0.000 claims description 2
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 claims description 2
- 201000005216 brain cancer Diseases 0.000 claims description 2
- 201000009030 carcinoma Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 201000009323 chronic eosinophilic pneumonia Diseases 0.000 claims description 2
- 230000003475 colitic Effects 0.000 claims description 2
- 201000008739 coronary artery disease Diseases 0.000 claims description 2
- 201000011523 endocrine gland cancer Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 2
- 201000001066 hemolytic-uremic syndrome Diseases 0.000 claims description 2
- 230000002218 hypoglycaemic Effects 0.000 claims description 2
- 201000006866 hypopharynx cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 230000001589 lymphoproliferative Effects 0.000 claims description 2
- 201000009906 meningitis Diseases 0.000 claims description 2
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims description 2
- 201000002481 myositis Diseases 0.000 claims description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 2
- 231100001027 nephrosis Toxicity 0.000 claims description 2
- 230000001272 neurogenic Effects 0.000 claims description 2
- 201000006958 oropharynx cancer Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 230000000505 pernicious Effects 0.000 claims description 2
- 201000000317 pneumocystosis Diseases 0.000 claims description 2
- 229920000117 poly(dioxanone) Polymers 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 230000002028 premature Effects 0.000 claims description 2
- 201000003068 rheumatic fever Diseases 0.000 claims description 2
- 201000001223 septic arthritis Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000011528 vascular disease Diseases 0.000 claims description 2
- 201000002498 viral encephalitis Diseases 0.000 claims description 2
- 230000029663 wound healing Effects 0.000 claims description 2
- 102400000025 Interleukin-1 receptor type 1, soluble form Human genes 0.000 claims 2
- 101800000542 Interleukin-1 receptor type 1, soluble form Proteins 0.000 claims 2
- 102400000027 Interleukin-1 receptor type 2, soluble form Human genes 0.000 claims 2
- 101800001003 Interleukin-1 receptor type 2, soluble form Proteins 0.000 claims 2
- 108090000177 Interleukin-11 Proteins 0.000 claims 2
- 102000013264 Interleukin-23 Human genes 0.000 claims 2
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl 2-cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 150000008064 anhydrides Chemical class 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 230000002611 ovarian Effects 0.000 claims 2
- 101710031992 pRL90232 Proteins 0.000 claims 2
- 101710035540 plaa2 Proteins 0.000 claims 2
- 239000003379 purinergic P1 receptor agonist Substances 0.000 claims 2
- 101710043085 ADAM17 Proteins 0.000 claims 1
- 102100010284 ADAM17 Human genes 0.000 claims 1
- 206010000349 Acanthosis Diseases 0.000 claims 1
- 210000001264 Anterior Cruciate Ligament Anatomy 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 206010008943 Chronic leukaemia Diseases 0.000 claims 1
- 229920001353 Dextrin Polymers 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- 229940096118 Ella Drugs 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000007465 Giant Cell Arteritis Diseases 0.000 claims 1
- 206010019755 Hepatitis chronic active Diseases 0.000 claims 1
- 206010021449 Immunodeficiency common variable Diseases 0.000 claims 1
- 229940014456 MYCOPHENOLATE Drugs 0.000 claims 1
- 229960000951 Mycophenolic Acid Drugs 0.000 claims 1
- 210000003635 Pituitary Gland Anatomy 0.000 claims 1
- 208000000813 Polyradiculoneuropathy Diseases 0.000 claims 1
- 206010057244 Post viral fatigue syndrome Diseases 0.000 claims 1
- 206010052381 Primary adrenal insufficiency Diseases 0.000 claims 1
- 206010037549 Purpura Diseases 0.000 claims 1
- 241001672981 Purpura Species 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000010157 Sclerosing Cholangitis Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- ODLHGICHYURWBS-LKONHMLTSA-N Trappsol Cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 230000003502 anti-nociceptive Effects 0.000 claims 1
- 230000001746 atrial Effects 0.000 claims 1
- 230000000271 cardiovascular Effects 0.000 claims 1
- 201000003874 common variable immunodeficiency Diseases 0.000 claims 1
- 230000003210 demyelinating Effects 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 201000000628 gas gangrene Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims 1
- 239000002745 poly(ortho ester) Substances 0.000 claims 1
- 150000004291 polyenes Polymers 0.000 claims 1
- 201000003099 renovascular hypertension Diseases 0.000 claims 1
- 201000002661 spondylitis Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 claims 1
- 229960000200 ulipristal Drugs 0.000 claims 1
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 120
- 241000282414 Homo sapiens Species 0.000 description 112
- 239000000427 antigen Substances 0.000 description 87
- 108091007172 antigens Proteins 0.000 description 85
- 102000038129 antigens Human genes 0.000 description 85
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 73
- 102000000589 Interleukin-1 Human genes 0.000 description 60
- 108010002352 Interleukin-1 Proteins 0.000 description 60
- 229920001184 polypeptide Polymers 0.000 description 40
- 230000000694 effects Effects 0.000 description 36
- 210000002683 Foot Anatomy 0.000 description 31
- 239000003981 vehicle Substances 0.000 description 31
- 241001465754 Metazoa Species 0.000 description 29
- 125000003275 alpha amino acid group Chemical group 0.000 description 29
- 235000001014 amino acid Nutrition 0.000 description 27
- 239000002953 phosphate buffered saline Substances 0.000 description 27
- 108090001095 Immunoglobulin G Proteins 0.000 description 24
- 102000004851 Immunoglobulin G Human genes 0.000 description 24
- 150000007523 nucleic acids Chemical class 0.000 description 24
- 230000003899 glycosylation Effects 0.000 description 23
- 238000006206 glycosylation reaction Methods 0.000 description 23
- 150000001413 amino acids Chemical class 0.000 description 22
- 125000000539 amino acid group Chemical group 0.000 description 21
- 210000004408 Hybridomas Anatomy 0.000 description 20
- 108020004707 nucleic acids Proteins 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 102100015418 SUCO Human genes 0.000 description 17
- 238000002347 injection Methods 0.000 description 16
- 239000007924 injection Substances 0.000 description 16
- 230000001225 therapeutic Effects 0.000 description 16
- 210000002303 Tibia Anatomy 0.000 description 15
- 108091006028 chimera Proteins 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 230000001965 increased Effects 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 12
- 230000000051 modifying Effects 0.000 description 12
- 241000894007 species Species 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 229940113118 Carrageenan Drugs 0.000 description 10
- 238000004166 bioassay Methods 0.000 description 10
- 235000010418 carrageenan Nutrition 0.000 description 10
- 239000000679 carrageenan Substances 0.000 description 10
- 229920001525 carrageenan Polymers 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 238000001356 surgical procedure Methods 0.000 description 10
- 210000001188 Cartilage, Articular Anatomy 0.000 description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 9
- 150000001720 carbohydrates Chemical class 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229920001850 Nucleic acid sequence Polymers 0.000 description 8
- 108020004511 Recombinant DNA Proteins 0.000 description 8
- 230000002708 enhancing Effects 0.000 description 8
- 230000035800 maturation Effects 0.000 description 8
- 230000002829 reduced Effects 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 210000003414 Extremities Anatomy 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 238000003259 recombinant expression Methods 0.000 description 7
- 210000004698 Lymphocytes Anatomy 0.000 description 6
- 108020004999 Messenger RNA Proteins 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 239000001963 growth media Substances 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 229920002106 messenger RNA Polymers 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000006011 modification reaction Methods 0.000 description 6
- 230000036515 potency Effects 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 101700043375 sing Proteins 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000036499 Half live Effects 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 208000005137 Joint Instability Diseases 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 230000003042 antagnostic Effects 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 230000002068 genetic Effects 0.000 description 5
- 125000003147 glycosyl group Chemical group 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 210000004962 mammalian cells Anatomy 0.000 description 5
- 238000002823 phage display Methods 0.000 description 5
- 229920000023 polynucleotide Polymers 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 4
- 208000007502 Anemia Diseases 0.000 description 4
- 210000003719 B-Lymphocytes Anatomy 0.000 description 4
- 229920002676 Complementary DNA Polymers 0.000 description 4
- 230000035687 Dissociation Rate Constant Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 210000002744 Extracellular Matrix Anatomy 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 4
- 210000002540 Macrophages Anatomy 0.000 description 4
- 210000004353 Menisci, Tibial Anatomy 0.000 description 4
- 210000001616 Monocytes Anatomy 0.000 description 4
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 4
- 229920002732 Polyanhydride Polymers 0.000 description 4
- 241000219061 Rheum Species 0.000 description 4
- 230000000240 adjuvant Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 239000008176 lyophilized powder Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000001264 neutralization Effects 0.000 description 4
- 230000003472 neutralizing Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 201000002911 peripheral artery disease Diseases 0.000 description 4
- 230000002335 preservative Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000013595 protein glycosylation Effects 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 210000000481 Breast Anatomy 0.000 description 3
- 208000008787 Cardiovascular Disease Diseases 0.000 description 3
- 210000001612 Chondrocytes Anatomy 0.000 description 3
- 229920001405 Coding region Polymers 0.000 description 3
- 102000020504 Collagenase family Human genes 0.000 description 3
- 108060005980 Collagenase family Proteins 0.000 description 3
- 229920000453 Consensus sequence Polymers 0.000 description 3
- 230000036947 Dissociation constant Effects 0.000 description 3
- 210000002889 Endothelial Cells Anatomy 0.000 description 3
- 102000018233 Fibroblast growth factor family Human genes 0.000 description 3
- 108050007372 Fibroblast growth factor family Proteins 0.000 description 3
- 101710007256 H1-10 Proteins 0.000 description 3
- 210000003035 Hyaline Cartilage Anatomy 0.000 description 3
- 102100018761 IL37 Human genes 0.000 description 3
- 206010065390 Inflammatory pain Diseases 0.000 description 3
- 210000003127 Knee Anatomy 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 3
- 229960001375 Lactose Drugs 0.000 description 3
- 210000000265 Leukocytes Anatomy 0.000 description 3
- 206010027603 Migraine headache Diseases 0.000 description 3
- 210000000929 Nociceptors Anatomy 0.000 description 3
- 229920000954 Polyglycolide Polymers 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 210000002784 Stomach Anatomy 0.000 description 3
- 102100014320 TGFB1 Human genes 0.000 description 3
- 101700041213 TGFB1 Proteins 0.000 description 3
- 206010046736 Urticarias Diseases 0.000 description 3
- 206010047461 Viral infection Diseases 0.000 description 3
- 208000001756 Virus Disease Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 230000000202 analgesic Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000903 blocking Effects 0.000 description 3
- 229940082638 cardiac stimulant Phosphodiesterase inhibitors Drugs 0.000 description 3
- 230000001413 cellular Effects 0.000 description 3
- 230000005591 charge neutralization Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 102000003675 cytokine receptors Human genes 0.000 description 3
- 108010057085 cytokine receptors Proteins 0.000 description 3
- 230000001687 destabilization Effects 0.000 description 3
- 229960001259 diclofenac Drugs 0.000 description 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 230000002255 enzymatic Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000011132 hemopoiesis Effects 0.000 description 3
- 201000003838 idiopathic interstitial pneumonia Diseases 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 230000000670 limiting Effects 0.000 description 3
- 239000002609 media Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 239000006199 nebulizer Substances 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 108091008022 nociceptors Proteins 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000036961 partial Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 238000002818 protein evolution Methods 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000004936 stimulating Effects 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002194 synthesizing Effects 0.000 description 3
- 230000000699 topical Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- 108010065166 AMG 108 Proteins 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 206010003662 Atrial flutter Diseases 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 2
- 210000000013 Bile Ducts Anatomy 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- 210000004556 Brain Anatomy 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 206010007554 Cardiac failure Diseases 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- 208000006332 Choriocarcinoma Diseases 0.000 description 2
- 210000000349 Chromosomes Anatomy 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N Colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 102000000503 Collagen Type II Human genes 0.000 description 2
- 108010041390 Collagen Type II Proteins 0.000 description 2
- 210000001072 Colon Anatomy 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- 101710007887 DHFR Proteins 0.000 description 2
- 102100005838 DHFR Human genes 0.000 description 2
- ODVDEPJSFWJDGU-UHFFFAOYSA-N Dihydroxythymoquinone Natural products CC(C)C1=C(O)C(=O)C(C)=C(O)C1=O ODVDEPJSFWJDGU-UHFFFAOYSA-N 0.000 description 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N Doxycycline Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 2
- 229960003722 Doxycycline Drugs 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229940088598 Enzyme Drugs 0.000 description 2
- 229920001272 Exogenous DNA Polymers 0.000 description 2
- IWKXDMQDITUYRK-KUBHLMPHSA-N Forodesine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)N[C@H]1C1=CNC2=C1N=CNC2=O IWKXDMQDITUYRK-KUBHLMPHSA-N 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapen Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 208000002183 Guillain-Barre Syndrome Diseases 0.000 description 2
- 208000001204 Hashimoto Disease Diseases 0.000 description 2
- 206010019280 Heart failure Diseases 0.000 description 2
- 206010019786 Hepatitis non-A non-B Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 229960002885 Histidine Drugs 0.000 description 2
- 201000006743 Hodgkin's lymphoma Diseases 0.000 description 2
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 2
- MUFXDFWAJSPHIQ-XDTLVQLUSA-N Ile-Tyr Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CC1=CC=C(O)C=C1 MUFXDFWAJSPHIQ-XDTLVQLUSA-N 0.000 description 2
- 210000000987 Immune System Anatomy 0.000 description 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 2
- 229940102223 Injectable Solution Drugs 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 229940067606 Lecithin Drugs 0.000 description 2
- 241000589248 Legionella Species 0.000 description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 description 2
- 229920002521 Macromolecule Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 210000004379 Membranes Anatomy 0.000 description 2
- 101710017500 MitHPPK/DHPS Proteins 0.000 description 2
- 108090000393 Muromonab-CD3 Proteins 0.000 description 2
- 241000545499 Mycobacterium avium-intracellulare Species 0.000 description 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 2
- 108091007229 NSP3 Papain-like protease domain Proteins 0.000 description 2
- 208000004296 Neuralgia Diseases 0.000 description 2
- 206010029888 Obliterative bronchiolitis Diseases 0.000 description 2
- 102100015381 PTGS2 Human genes 0.000 description 2
- 229950010131 PUROMYCIN Drugs 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N PUROMYCIN Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 241000721454 Pemphigus Species 0.000 description 2
- 108091005771 Peptidases Proteins 0.000 description 2
- 102000035443 Peptidases Human genes 0.000 description 2
- 210000002381 Plasma Anatomy 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 206010037175 Psychiatric disease Diseases 0.000 description 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 2
- 206010037779 Radiculopathy Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 210000002966 Serum Anatomy 0.000 description 2
- 240000003670 Sesamum indicum Species 0.000 description 2
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 2
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 2
- 208000002320 Spinal Muscular Atrophy Diseases 0.000 description 2
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- VEYJKJORLPYVLO-RYUDHWBXSA-N Val-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 VEYJKJORLPYVLO-RYUDHWBXSA-N 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 241000625014 Vir Species 0.000 description 2
- 241000607734 Yersinia <bacteria> Species 0.000 description 2
- 201000010272 acanthosis nigricans Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000890 antigenic Effects 0.000 description 2
- 229930015036 aurones Natural products 0.000 description 2
- 238000006065 biodegradation reaction Methods 0.000 description 2
- 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000003848 bronchiolitis obliterans Diseases 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229960001714 calcium phosphate Drugs 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000002612 cardiopulmonary Effects 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000000295 complement Effects 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 230000001082 cryoprotectant Effects 0.000 description 2
- 239000002577 cryoprotective agent Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000005712 crystallization Effects 0.000 description 2
- 238000010192 crystallographic characterization Methods 0.000 description 2
- NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 description 2
- 201000003883 cystic fibrosis Diseases 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003412 degenerative Effects 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002612 dispersion media Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003532 endogenous pyrogen Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 230000003628 erosive Effects 0.000 description 2
- 229960002870 gabapentin Drugs 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000035362 glycosylated proteins Human genes 0.000 description 2
- 108091005600 glycosylated proteins Proteins 0.000 description 2
- 201000010238 heart disease Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 108091008472 immunoglobulin binding proteins Proteins 0.000 description 2
- 102000029028 immunoglobulin binding proteins Human genes 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 230000003447 ipsilateral Effects 0.000 description 2
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000001473 noxious Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000004983 pleiotropic Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 201000008312 primary pulmonary hypertension Diseases 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 2
- 230000002588 toxic Effects 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 108010009962 valyltyrosine Proteins 0.000 description 2
- 230000003156 vasculitic Effects 0.000 description 2
- 201000005539 vernal conjunctivitis Diseases 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- AWIZJVIMVDVVFV-HJOGWXRNSA-N (2S)-2-amino-N-[(2S)-1-[[(2S)-1-[2-[5-(dimethylamino)naphthalen-1-yl]sulfonylhydrazinyl]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-3-methylbutanamide Chemical compound C1=CC=C2C(S(=O)(=O)NNC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)C(C)C)=CC=CC2=C1N(C)C AWIZJVIMVDVVFV-HJOGWXRNSA-N 0.000 description 1
- CFCUWKMKBJTWLW-BGLFSJPPSA-N (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5R,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5S,6R)-4-[(2S,4R,5S,6R)-4,5-dih Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BGLFSJPPSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dimercaptobutane-2,3-diol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 241000432074 Adeno-associated virus Species 0.000 description 1
- 206010001367 Adrenal insufficiency Diseases 0.000 description 1
- BUQICHWNXBIBOG-LMVFSUKVSA-N Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)N BUQICHWNXBIBOG-LMVFSUKVSA-N 0.000 description 1
- 241000182185 Alfalfa virus S Species 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N Anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010060945 Bacterial infection Diseases 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229960005069 Calcium Drugs 0.000 description 1
- 240000002804 Calluna vulgaris Species 0.000 description 1
- 235000007575 Calluna vulgaris Nutrition 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infection Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229960004424 Carbon Dioxide Drugs 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 210000002421 Cell Wall Anatomy 0.000 description 1
- 210000003169 Central Nervous System Anatomy 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 210000003679 Cervix Uteri Anatomy 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- 208000001590 Congenital Abnormality Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 210000004351 Coronary Vessels Anatomy 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 229960000640 Dactinomycin Drugs 0.000 description 1
- 229960000975 Daunorubicin Drugs 0.000 description 1
- 210000004443 Dendritic Cells Anatomy 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N Dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 229940087091 Dichlorotetrafluoroethane Drugs 0.000 description 1
- 229960004679 Doxorubicin Drugs 0.000 description 1
- 101700057458 Drice Proteins 0.000 description 1
- AUVVAXYIELKVAI-CKBKHPSWSA-N Emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
- 210000003372 Endocrine Glands Anatomy 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 210000003238 Esophagus Anatomy 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229960005420 Etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N Fucose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 206010058872 Fungal sepsis Diseases 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N Gadolinium Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 229940065521 Glucocorticoid inhalants for obstructive airway disease Drugs 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 108091022077 Glycosyltransferases Proteins 0.000 description 1
- 102000019483 Glycosyltransferases Human genes 0.000 description 1
- IUAYMJGZBVDSGL-UHFFFAOYSA-N Gramicidin Chemical compound N1C(=O)C(CC(C)C)NC(=O)C(CCCN)NC(=O)C(C(C)C)NC(=O)C2CCCN2C(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC(C)C)NC(=O)C(CCCN)NC(=O)C(C(C)C)NC(=O)C2CCCN2C(=O)C1CC1=CC=CC=C1 IUAYMJGZBVDSGL-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headache Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 1
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 1
- 241000282619 Hylobates lar Species 0.000 description 1
- 206010020583 Hypercalcaemia Diseases 0.000 description 1
- 210000003026 Hypopharynx Anatomy 0.000 description 1
- 210000003016 Hypothalamus Anatomy 0.000 description 1
- 208000003532 Hypothyroidism Diseases 0.000 description 1
- 102000026225 IL-1 family Human genes 0.000 description 1
- 108091013192 IL-1 family Proteins 0.000 description 1
- 102100008969 IL36A Human genes 0.000 description 1
- 101700016951 IL36A Proteins 0.000 description 1
- 102100008970 IL36B Human genes 0.000 description 1
- 101700037546 IL36B Proteins 0.000 description 1
- 101700076568 IL37 Proteins 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 108010023402 Interleukin 1 Receptor Antagonist Protein Proteins 0.000 description 1
- 102000011294 Interleukin 1 Receptor Antagonist Protein Human genes 0.000 description 1
- 102000004557 Interleukin-18 Receptors Human genes 0.000 description 1
- 108010017537 Interleukin-18 Receptors Proteins 0.000 description 1
- 229940100601 Interleukin-6 Drugs 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- UWBDLNOCIDGPQE-UHFFFAOYSA-N Isoleucyl-Lysine Chemical compound CCC(C)C(N)C(=O)NC(C(O)=O)CCCCN UWBDLNOCIDGPQE-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N Isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
- 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108060001084 Luciferase family Proteins 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 101710028361 MARVELD2 Proteins 0.000 description 1
- 101710034453 MT-CO3 Proteins 0.000 description 1
- 208000002780 Macular Degeneration Diseases 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 229960004452 Methionine Drugs 0.000 description 1
- 108060004843 Mical Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229960004857 Mitomycin Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 Mitoxantrone Drugs 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 210000002200 Mouth Mucosa Anatomy 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028323 Muscle pain Diseases 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-Acetylglucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000008795 Neuromyelitis Optica Diseases 0.000 description 1
- 108010061543 Neutralizing Antibodies Proteins 0.000 description 1
- 206010029379 Neutrophilia Diseases 0.000 description 1
- 210000000440 Neutrophils Anatomy 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 210000003300 Oropharynx Anatomy 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 210000002997 Osteoclasts Anatomy 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 229960001592 Paclitaxel Drugs 0.000 description 1
- 210000000496 Pancreas Anatomy 0.000 description 1
- 229940055729 Papain Drugs 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241000724284 Peanut stunt virus Species 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 229940072417 Peroxidase Drugs 0.000 description 1
- 108090000437 Peroxidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 241000186704 Pinales Species 0.000 description 1
- 229960003171 Plicamycin Drugs 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 229920001054 Poly(ethylene‐co‐vinyl acetate) Polymers 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 229940068977 Polysorbate 20 Drugs 0.000 description 1
- 229940068968 Polysorbate 80 Drugs 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N Proprasylyt Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 208000005069 Pulmonary Fibrosis Diseases 0.000 description 1
- 210000000664 Rectum Anatomy 0.000 description 1
- 206010038294 Reiter's syndrome Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N Rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 210000003705 Ribosomes Anatomy 0.000 description 1
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 description 1
- 229940081969 Saccharomyces cerevisiae Drugs 0.000 description 1
- 206010040767 Sjogren's syndrome Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229940074404 Sodium succinate Drugs 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- 210000001032 Spinal Nerves Anatomy 0.000 description 1
- 210000000952 Spleen Anatomy 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229940032147 Starch Drugs 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001179 Synovial Fluid Anatomy 0.000 description 1
- 210000001258 Synovial Membrane Anatomy 0.000 description 1
- 210000002437 Synoviocyte Anatomy 0.000 description 1
- 229940037128 Systemic Glucocorticoids Drugs 0.000 description 1
- 108091008153 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 229940014598 TAC Drugs 0.000 description 1
- 241000188156 Tamu Species 0.000 description 1
- 229960001278 Teniposide Drugs 0.000 description 1
- 210000001550 Testis Anatomy 0.000 description 1
- 229960002372 Tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N Tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 210000001685 Thyroid Gland Anatomy 0.000 description 1
- 206010043835 Tic disease Diseases 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N Trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- OHGNSVACHBZKSS-KWQFWETISA-N Trp-Ala Chemical compound C1=CC=C2C(C[C@H]([NH3+])C(=O)N[C@@H](C)C([O-])=O)=CNC2=C1 OHGNSVACHBZKSS-KWQFWETISA-N 0.000 description 1
- LWFWZRANSFAJDR-JSGCOSHPSA-N Trp-Val Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(O)=O)=CNC2=C1 LWFWZRANSFAJDR-JSGCOSHPSA-N 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 210000004291 Uterus Anatomy 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229960003048 Vinblastine Drugs 0.000 description 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229960004528 Vincristine Drugs 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 201000001203 Wilson disease Diseases 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Xylocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001919 adrenal Effects 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229920002892 amber Polymers 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 230000001680 brushing Effects 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 238000004850 capillary HPLC Methods 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture media Substances 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 230000002281 colonystimulating Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002089 crippling Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- 230000001086 cytosolic Effects 0.000 description 1
- 108010092570 dansylhydrazide trivaline Proteins 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000001627 detrimental Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L disodium butanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960002694 emetine Drugs 0.000 description 1
- AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
- 230000001804 emulsifying Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000002949 hemolytic Effects 0.000 description 1
- 230000002440 hepatic Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000001976 improved Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 108091005481 innate immune receptors Proteins 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 1
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 230000021995 interleukin-8 production Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 230000002601 intratumoral Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 108010052620 leukocyte endogenous mediator Proteins 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000004301 light adaptation Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 201000004044 liver cirrhosis Diseases 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000663 muscle cells Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000000626 neurodegenerative Effects 0.000 description 1
- 230000003040 nociceptive Effects 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 230000001254 nonsecretory Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 230000002148 osteoclast Effects 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N oxophosphanyl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 201000006518 pelvic inflammatory disease Diseases 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001817 pituitary Effects 0.000 description 1
- 201000002511 pituitary cancer Diseases 0.000 description 1
- 229920003250 poly(2-hydroxyethyl methacrylate) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000001402 polyadenylating Effects 0.000 description 1
- 229920001690 polydopamine Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000001185 psoriatic Effects 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003362 replicative Effects 0.000 description 1
- 230000001177 retroviral Effects 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 230000037322 slow-wave sleep Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 230000000392 somatic Effects 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000001954 sterilising Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000000576 supplementary Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229930003347 taxol Natural products 0.000 description 1
- 230000001331 thermoregulatory Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N α-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Disclosed is the use of a binding protein for the manufacture of a medicament for treating pain and/or osteoarthritis wherein the binding protein binds both IL-1alpha and IL-1beta.
Description
TREATMENT OF OSTEOARTHRITIS AND PAIN
Cross-Reference to Related Application
This application claims the benefit of priority to United States Provisional Application No.
61/440,853, filed February 8, 2011, the entire contents of which are orated herein by
reference.
Fieid 0f the Invention
The t invention relates to the treatment of osteoarthritis and pain, and more
specifically to the use of proteins that bind lL-loc andlor IL-lB to treat osteoarthritis and pain.
The articular age, or “hyaline cartilage”, of healthy vertebrates (including humans and
other mammals) is a semi-transparent, opalescent connective tissue characterized by a columnar
growth pattern of chondrocytes in an extracellular matrix (ECM) composed predominantly of
proteoglycans, type II collagen, and water. Articular cartilage provides an effective weight-bearing
cushion to prevent contact between opposing bones in a joint and thus is critical to the normal
function of the joint. Articular cartilage is not only tible to damage by joint trauma, but also
to a gradual process of erosion. lly, such an n may be simply an asymptomatic "partial
thickness defect" in which an area of reduced hyaline cartilage does not penetrate completely to the
subchondral bone. Such partial thickness defects are usually not painful and typically are only
detected during arthroscopic examination. However, if the erosive process is not treated, the base of
2O a partial thickness defect may continue to wear away and the diameter of the defect may increase
such that the defect eventually progresses to a "full thickness defect" that penetrates the underlying
bone. Such full thickness defects may become sufficiently large that surfaces of opposing bones of
the joint make t and begin to erode one another, leading to inflammation, pain, and other
degenerative changes, i.e., the c symptoms of osteoarthritis (OA). Osteoarthritis is thus a
degenerative, progressive, and crippling disease that results in joint deformity, instability,
impairment, and pain. ally, joint replacement surgery may be the only practical recourse for
restoring, at least in part, some level of mobility to an individual.
The lL—l superfamily is sed of ors of inflammatory processes with a wide
range of ical and physiological effects, including fever, prostaglandin sis (in, e.g.,
fibroblasts, muscle cells and endothelial cells), T-lymphocyte activation, and eukin-2
production. The original members of the IL-1 superfamily are IL-la, IL-1 [3, and the IL-1 Receptor
Antagonist (IL-1Ra, IL—lRA, IL—lra, lL-lRa). lL-la and IL-B are flammatory cytokines
involved in immune defense against infection. The IL-lRoc competes for receptor binding with IL-
lot and lL-lB, ng their role in immune activation. Other members of the IL-1 superfamily
include lL-18 (see Dinarello (1994) FASEB J. 8(15):1314—1325; Huising et al. (2004) Dev. Comp.
Immunol. 28(5):395—413) and six additional genes with ural homology to IL-la, IL-lB, or IL-
lRA, named ILlFS, IL1F6, IL1F7, IL1F8, ILlF9, and ILlFlO. In accordance, IL-la, IL-lB, and IL-
lRA have been renamed IL-lFl, IL—1F2, and IL—1F3, respectively (see Sims et al. (2001) Trends
Immunol. :536—537; Dunn et al. (2001) Trends Immunol. 22(10):533—536). A further
putative member of the IL-1 family has been described called IL-33 or IL-lFl 1, although this name
is not officially accepted in the HGNC gene family nomenclature database.
Both lL—lo. and IL—lB are produced by macrophages, monocytes, and dendritic cells. They
form an important part of the inflammatory response of the body against infection. These cytokines
increase the expression of adhesion factors on endothelial cells to enable transmigration of
leukocytes to sites of infection and re-set the hypothalamus thermoregulatory center, leading to an
increased body ature which ses itself as fever. IL-1 is therefore called an endogenous
pyrogen. The increased body temperature helps the body’s immune system to fight infection. IL-1 is
also important in the regulation of hematopoiesis. IL-lB production in peripheral tissue has also
been associated with hyperalgesia (increased sensitivity to pain) associated with fever (Morgan et al.
(2004) Brain Res. 1022(1-2):96—100). IL—l upregulates expression of cyclooxygenase-2 (COX-2)
associated with pain. For the most part, lL-loc and IL—ll3 bind to the same cellular receptor. This
receptor is ed of two related, but non-identical, subunits that transmit intracellular signals via
a pathway that is shared in large part with certain other receptors. These include the Toll family of
innate immune receptors and the IL—18 receptor. IL—ld and IL-lB also possess similar biological
2O properties, including induction of fever, slow wave sleep, and neutrophilia, T- and B-lymphocyte
tion, fibroblast proliferation, cytotoxicity for certain cells, induction of collagenases, synthesis
of hepatic acute phase proteins, and increased tion of colony stimulating s and collagen.
cDNAs encoding IL-10. and lL—IB have been isolated and expressed; these cDNAs represent
two different gene products, termed IL—loc (Lomedico et al. (1984) Nature 312:45 8) and lL-1[3
(Auron et al. (1984) Proc. Natl. Acad. Sci. USA 81:7909). Eight interleukin 1 family genes form a
cytokine gene cluster on chromosome 2. IL—l[3 is the predominant form ed by human
tes both at the mRNA and protein levels. The two forms of human IL-1 share only 26%
amino acid homology. Despite their ct polypeptide sequences, the two forms of IL-1 have
structural rities (Auron et al. (1985) J. Mol. Cell Immunol. 2: 169), in that the amino acid
homology is confined to discrete regions of the IL-1 molecule.
lL-la and IL-lB are produced as precursor peptides. In other words they are made as a long
protein that is then processed to release a shorter, active molecule, which is called the mature
protein. IL-lu is ed as a proprotein that is proteolytically processed by n and released
in a mechanism that is still not well studied. Mature IL-lB, for e, is released from -lB
following cleavage by a certain member of the caspase family of proteins, called caspase-1 or the
interleukin-1 converting enzyme (ICE). The 3-dimensional ure of the mature forms of each
member of the human IL-1 superfamily is composed of 12-14 B-strands producing a barrel-shaped
protein.
IL-lo. was originally termed "catabolin" because of its effect in increasing cartilage
resorption, but also as "monocyte cell factor" (MCF) because of its stimulatory effect on collagenase
and prostaglandin in synovial cells, and as "leukocyte endogenous factor" (LEM) having a
stimulatory effect on acute phase reactions. IL—la has a broad spectrum of biological activities,
since lL-la is synthesized by many different cells, such as monocytes, macrophages, fibroblasts,
endothelial cells and lymphocytes, and many cells possess specific receptors for IL-la. IL-la
ates thymocyte proliferation by inducing [L-2 release, B-cell maturation and proliferation, and
fibroblast growth factor activity. IL-lot proteins were identified as endogenous pyrogens and are
reported to stimulate the release of prostaglandin and collagenase from synovial cells. Thus, IL-lu
also es a central on as the trigger for various disorders and symptoms of disorders.
These disorders are often predominantly serious disorders for which there is little or no treatment. It
has been suggested that the polymorphism of these genes is associated with rheumatoid arthritis and
Alzheimer's disease. IL-1 in l has been implicated in many human es, including
arthritis, pulmonary fibrosis, diseases of the central nervous system, diabetes mellitus, and certain
cardiovascular diseases. The undesirable s of IL—la are described in, for example, Oppenheim
et al. (1986) Immunol. Today 7:45-56, Durum et al. (1985) Ann. Rev. Immunol. 3:263-287 and
2O Symons et al. (1989) Lymphokine Res. 8:365-372.
The initiation, maintenance, and progression of 0A is ed by a x cascade of
mechanical and mical pathways in which IL—l plays a pivotal role . IL-loc and IL-lB are
produced not only by monocytes, macrophages, and neutrophils, but by cells in joint tissues, such as
chondrocytes, synovial lasts, and osteoclasts (see, e.g., Dinarello et al. (2009) Ann. Rev.
l. 27: 519-550). In vitro, lL—l can stimulate chondrocytes and synoviocytes to produce
proteinases involved in cartilage destruction leading to OA (see, e.g., Dayer et al. (1977) Science
195: 181-183; Dayer et al. (1984) Biochem. Pharmacol. 33: 2893-2899; McGuire-Goldring et al.
(1984) Arthritis Rheum. 27: 654-662), as well as inhibit synthesis of proteoglycan and collagen type
II, the main components of the extracellular matrix (ECM) of normal hyaline cartilage (see, e.g.,
3O Goldring et a1. (1987) J. Biol. Chem. 262: 16724-16729; Goldring et al. (1988) J. Clin. Investig. 82:
2026-2037). Preclinical and clinical s have provided further evidence of IL-1 in the
pathogenesis of 0A. For e, intra-articular (ia) injection of IL-1 into animal knees resulted in
leukocyte infiltration and cartilage loss (Pettiphar et al. (1986) Proc. Natl. Acad. Sci. USA 83: 8749-
8753). In st, ia injection of IL—1 nist resulted in significant reduction in the progression
of experimental OA (see, e.g., Pelletier et al. (1997) Arthritis Rheum. 40: 1012-1019; Caron et al.
[Annotation] ggg
(1996) Arthritis Rheum. 39: 544); des et al. (1999) Am. J. Pathol. 154:
11590-11690); Zhang et al. (2006) Biochem. Biophys. Res. Commun. 341: 202-208). In
addition, IL-1 knockout (KO) mice were found to be resistant to surgically d
cartilage damage when compared to their ype counterparts (Glasson et al. (2009)
Osteoarthritis Cartilage, 18: 572-580).
Both IL-1α and IL-1β are sed in synovial membranes, cartilage, and synovial
fluid of human OA patients (see, e.g., Farahat et al. (1993) Ann. Rheum. Dis. 52: 870-875).
The IL-1 antagonist, Anakinra, which is an IL-1 or antagonist, and AMG-108, which
is an IL-1 receptor monoclonal dy, have demonstrated some efficacy in OA trials
with respect to symptoms and chondroprotection ("Results from a Randomized Controlled
Trial of AMG 108 (a fully human monoclonal antibody to IL-1R type I) in Patients With
rthritis of the Knee" Cohen et al., ACR2007). Both of these proposed therapies
await additional studies to demonstrate clear and robust clinical efficacy.
A need remains for new and ive methods and compositions for treating
individuals afflicted with osteoarthritis.
Summary of the Invention
The invention provides methods for ng osteoarthritis (OA) and for treating
pain. Such methods comprise administering to an individual (human or other mammal) one
or more binding proteins that bind IL-1α and IL-1β.
In an aspect of the ion, there is provided use of a binding n that binds
both IL-1α and IL-1β for the manufacture of a medicament for treating pain in an
individual.
In an aspect of the invention, there is provided use of a binding protein that binds
both IL-1α and IL-1β for the manufacture of a medicament of treating osteoarthritis in an
individual.
In an aspect of the invention, a method for treating osteoarthritis in an individual
(human or other mammal) comprises the step of administering to the individual a binding
protein that binds IL-1α in combination with (e.g., in a mixture, by successive
administration, or by concurrent administration with) a binding protein that binds IL-1β or
administering to the individual a binding protein that binds both IL-1α and IL-1β.
(10761989_1):GGG
In an ment, a method for treating osteoarthritis in an individual comprises
administering to the individual a g protein that binds IL-1α, wherein the binding
protein is an antibody to IL-1α, for example, a monoclonal antibody to IL-1α. In another
embodiment, a method for treating osteoarthritis in an dual comprises stering
to the individual a binding protein that binds IL-1β, wherein the binding protein is an
antibody that binds IL-1β, for example, a monoclonal antibody that binds IL-1β.
In another aspect of the invention, a method of treating osteoarthritis in an
individual (human or other mammal) comprises the step of administering to the individual
a g protein that binds both IL-1α and IL-Ιβ. Preferably, the binding protein is a dual
variable domain immunoglobulin binding protein (also ed herein as "DVD-Ig™" or
"DVD-Ig" binding protein or molecule) that comprises at least one binding site that binds
IL-1α and at least one binding site
(10084870_1):GGG
that binds . More preferably, the DVD—Ig binding protein comprises two binding sites that
bind IL-loc and two binding sites that bind IL-1 [3
In another embodiment, a method according to the invention for treating osteoarthritis in an
individual comprises administering to the individual a pharmaceutical composition comprising a
binding protein that binds IL—loc, a binding protein that binds IL-1 [3, a combination of a binding
protein that bind IL-lOL and a binding protein that binds IL—l[3, or a binding protein that binds both
IL-la and lL-1[3; and a ceutically acceptable carrier.
In an embodiment of the ion, a method for treating osteoarthritis comprises
administering to an individual a crystallized binding protein that binds IL-loc and a crystallized
binding protein that binds IL- 1 [3, or a crystallized binding protein that binds both IL-loc and .
Such crystallized binding proteins useful in the invention include, but are not limited to, a
crystallized antibody IL-loc, a crystallized dy to IL-l[3, and a crystallized DVD-Ig binding
protein that binds both IL—loc and IL—l[3.
Compositions useful in methods of the invention for ng osteoarthritis in an individual
include a composition for the e of a llized binding protein that binds IL-l (x, a crystallized
g protein that binds IL—l[3, a combination of a crystallized binding protein that binds IL-l 0c
and a llized binding protein that binds IL-1 [3, or a crystallized binding protein that binds both
ll-loc and IL-1 [3.
In an embodiment, a composition useful in a method for treating osteoarthritis according to
the invention comprises:
(a) a formulation, wherein said formulation comprises a llized binding protein that
binds IL-loc, a crystallized binding protein that binds IL—1[3, a combination of both a crystallized
g protein that binds IL-lOt, and a crystallized binding protein that binds IL-l[3, or a crystallized
binding n that binds both Il-los and IL—l[3; and, optionally, an ingredient; and
(b) at least one polymeric carrier.
In an ment, a composition described above comprises a combination of both a
crystallized binding protein that binds IL—loc and a crystallized binding protein that binds IL-1[3. In
another embodiment, the crystallized binding protein that binds IL—loc is a crystallized dy, for
example, a crystallized monoclonal antibody that binds IL-loc and the crystallized binding protein
that binds lL-1[3 is a llized antibody, for example, a monoclonal antibody that binds IL-1[3.
In an ment, a composition described above comprises a crystallized binding protein
that binds both ll-loc and lL—1[3. In another embodiment, the crystallized binding protein is a
crystallized dual variable domain (DVD-lg) binding protein the binds both IL-loc and IL-l[3-Ig.
In r embodiment, a method for treating osteoarthritis in an dual comprises
administering to the individual a composition comprising a crystallized binding protein that binds
IL-loc, a crystallized binding protein that binds , a combination of both a crystallized g
protein that binds IL-lot and a crystallized binding protein that binds IL-lB, or a crystallized binding
protein that binds both Il-l (X, and lL—l [3; wherein said at least one ric carrier is a polymer
selected from one or more of the group consisting of poly ic acid), poly (cyanoacrylates), poly
(amino acids), poly (anhydrides), poly (depsipeptide), poly s), poly (lactic acid), poly (lactic-
co-glycolic acid) or PLGA, poly (b-hydroxybutryate), poly (caprolactone), poly (dioxanone); poly
(ethylene glycol), poly ((hydroxypropyl) methacrylamide, poly [(organo)phosphazene], poly (ortho
esters), poly (vinyl alcohol), poly (vinylpyrrolidone), maleic anhydride- alkyl vinyl ether
copolymers, pluronic polyols, albumin, alginate, cellulose and cellulose derivatives, en, fibrin,
gelatin, hyaluronic acid, oligosaccharides, glycaminoglycans, sulfated polysaccharides, blends and
copolymers f.
In an embodiment, when the optional ingredient is present in a ition described above,
the ingredient is selected from the group consisting of albumin, sucrose, trehalose, lactitol, gelatin,
hydroxypropyl-[3-cyclodextrin, methoxypolyethylene glycol and polyethylene glycol.
In an embodiment, a method for treating osteoarthritis described above further comprises
administering to the individual a second agent, wherein the second agent provides an additional
ble property to the method or composition used in the method. Such a second agent can be one
2O or more molecules in the group consisting of side, epidermal growth factor, corticosteroids,
cyclosporin, sulfasalazine, aminosalicylates, aptopurine, azathioprine, idazole,
lipoxygenase inhibitors, mesalamine, olsalazine, balsalazide, antioxidants, thromboxane inhibitors,
IL-1 receptor antagonists, anti-IL—lB monoclonal antibodies, L-6 monoclonal antibodies,
growth s, elastase inhibitors, pyridinyl-imidazole nds, antibodies of TNF, LT, IL-2, IL-
6, IL-7, IL-8, IL-12, IL-13, IL—15, lL-l6, IL—18, IL—23, EMAP-II, GM-CSF, FGF, and PDGF,
antibodies of CD2, CD3, CD4, CD8, CD-19, CD25, CD28, CD30, CD40, CD45, CD69, CD90 or
their s, methotrexate, cyclosporin, FK506, rapamycin, mycophenolate mofetil, leflunomide, an
NSAID, ibuprofen, corticosteroids, prednisolone, phosphodiesterase inhibitors, adensosine agonists,
antithrombotic agents, complement inhibitors, adrenergic agents, IRAK, NIK, IKK, p38, MAP
kinase inhibitors, IL-1[3 converting enzyme inhibitors, TNFOL converting enzyme inhibitors, T-cell
signalling inhibitors, metalloproteinase inhibitors, sulfasalazine, azathioprine, 6-mercaptopurines,
angiotensin converting enzyme inhibitors, soluble cytokine receptors, soluble p55 TNF receptor,
soluble p75 TNF receptor, le-lRI, sIL-lRII, sIL—6R, anti-inflammatory cytokines, IL-4, IL-10, IL-
11, IL-13, and TGFB.
In another aspect of the invention, a method for treating osteoarthritis described herein
comprises administering to an individual one or more binding proteins described herein or a
ition described herein by at least one mode selected from parenteral, subcutaneous,
intramuscular, intravenous, intra-articular, intrabronchial, intraabdominal, intracapsular,
intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic,
intracervical, intragastric, epatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac,
intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal,
pinal, intrasynovial, intrathoracic, terine, intravesical, bolus, vaginal, rectal, buccal,
sublingual, intranasal, and transdermal.
In an aspect of the invention, a method for treating pain in an individual (human or other
mammal) comprises the step of administering to the individual a g protein that binds IL-loc in
combination with (e.g., in a mixture, by successive administration, or by rent administration
with) a binding protein that binds lL-1|3 or administering to the individual a binding protein that
binds both IL-loc and IL-lB.
Methods and compositions according to the invention can be used to treat pain in an
individual having any form of pain, ing pain from cancer, neuropathic pain, muscle pain, joint
pain, bone fracture pain, wound pain, pain from surgery, headache, migraine, as well as pain
conditions such as nia (allodynic pain), hyperalgesia, and a combination of allodynia and
hyperalgesia.
In an embodiment, a method for treating pain in an individual comprises administering to the
individual a binding protein that binds IL—loc, wherein the binding n is an antibody to IL-loc,
for example, a monoclonal dy to IL—loc. In another embodiment, a method for treating pain in
an individual comprises administering to the dual a binding protein that binds IL-1[3, wherein
the binding protein is an antibody that binds , for example, a monoclonal antibody that binds
IL- 1 B.
In another aspect of the invention, a method of treating pain in an individual comprises the
step of administering to the dual a binding protein that binds both IL-loc and IL-lB.
Preferably, the binding protein is a dual variable domain imrnunoglobulin binding protein (also
referred herein as "DVD-IgTM" or “DVD-1g" binding protein or molecule) that comprises at least one
binding site that binds IL-lOL and at least one binding site that binds IL-1 [3 Preferably, the DVD-Ig
g protein comprises two binding sites that bind IL-loc and two binding sites that bind IL-IB.
In another embodiment, a method according to the invention for treating pain in an
individual ses administering to the individual a ceutical composition comprising a
binding protein that binds , a binding protein that binds IL-1I3, a combination of a binding
protein that bind IL-loc and a g protein that binds IL-lB, or a binding protein that binds both
IL—loc and IL-lB; and a pharmaceutically acceptable carrier.
In an embodiment of the invention, a method for treating pain comprises administering to an
individual a crystallized binding protein that binds IL—loc and a crystallized binding protein that
binds IL-lB, or a crystallized binding protein that binds both IL-loc and IL-lB. Such crystallized
g proteins useful in the invention e, but are not limited to, a crystallized antibody IL-loc,
a crystallized antibody to lL-lB, and a crystallized DVD—Ig binding n that binds both IL-loc
and IL- 1 B
Compositions useful in methods of the invention for treating pain in an individual include a
composition for the release of a llized binding protein that binds IL-1 on, a llized g
protein that binds IL—lB, a combination of a crystallized binding protein that binds IL-loc and a
crystallized binding protein that binds IL—lB, or a crystallized binding protein that binds both ll-loc
and IL- 1 B.
In an embodiment, a composition useful in a method for treating pain according to the
invention comprises:
(a) a formulation, wherein said formulation comprises a crystallized binding protein that
binds IL-loc, a crystallized binding protein that binds IL—lB, a combination of both a llized
binding protein that binds IL-loc and a llized binding protein that binds IL-lB, or a llized
binding protein that binds both 11-100 and IL—1 B; and, optionally, an ingredient; and
(b) at least one ric carrier.
In an embodiment, a composition described above ses a combination of both a
crystallized binding protein that binds IL—loc and a crystallized binding protein that binds IL-lB. In
another embodiment, the crystallized binding protein that binds IL-loc is a crystallized antibody, for
example, a crystallized monoclonal antibody, that binds IL—loc and the crystallized g protein
that binds IL-lB is a crystallized antibody, for example, a monoclonal antibody that binds IL-lB.
In an embodiment, a composition described above comprises a crystallized binding protein
that binds both ll-loc and lL-lB. In another embodiment, the crystallized binding protein is a
crystallized dual variable domain (DVD-lg) binding protein the binds both IL-loc and IL-lB-Ig.
In another ment, a method for treating pain in an individual comprises administering
to the individual a composition comprising a crystallized binding protein that binds IL-loc, a
crystallized binding protein that binds IL-lB, a combination of both a crystallized binding protein
that binds lL-loc and a crystallized binding protein that binds IL-l B, or a crystallized binding protein
that binds both ll-loc and IL—lB; n said at least one polymeric r is a polymer selected
from one or more of the group consisting of poly (acrylic acid), poly (cyanoacrylates), poly (amino
acids), poly (anhydrides), poly (depsipeptide), poly (esters), poly (lactic acid), poly (lactic-co-
glycolic acid) or PLGA, poly (b-hydroxybutryate), poly (caprolactone), poly none); poly
(ethylene glycol), poly ((hydroxypropyl) methacrylamide, poly [(organo)phosphazene], poly (ortho
esters), poly (vinyl alcohol), poly (vinylpyrrolidone), maleic anhydride- alkyl Vinyl ether
copolymers, pluronic polyols, albumin, alginate, cellulose and cellulose derivatives, collagen, fibrin,
gelatin, hyaluronic acid, oligosaccharides, glycaminoglycans, sulfated polysaccharides, blends and
copolymers thereof.
In an embodiment, when the optional ingredient is present in a composition described above,
the ingredient is selected from the group consisting of albumin, sucrose, trehalose, lactitol, gelatin,
hydroxypropyl-l?)-cyclodextrin, methoxypolyethylene glycol and polyethylene glycol.
In an embodiment, a method for ng pain described above r ses
administering to the individual a second agent, wherein the second agent es an additional
desirable property to the method or composition used in the method. Such a second agent can be one
or more les in the group consisting of budenoside, epidermal growth factor, corticosteroids,
cyclosporin, sulfasalazine, aminosalicylates, 6-mercaptopurine, azathioprine, metronidazole,
lipoxygenase inhibitors, mesalamine, olsalazine, balsalazide, antioxidants, thromboxane inhibitors,
IL-1 receptor antagonists, anti-IL—ll3 monoclonal antibodies, anti-IL-6 monoclonal antibodies,
growth s, se inhibitors, pyridinyl-imidazole compounds, antibodies of TNF, LT, IL-2, IL-
6, IL-7, IL-8, IL-l2, IL-l3, IL-15, lL-16, IL—18, IL—23, EMAP-H, GM-CSF, FGF, and PDGF,
2O antibodies of CD2, CD3, CD4, CD8, CD-19, CD25, CD28, CD30, CD40, CD45, CD69, CD90 or
their s, methotrexate, cyclosporin, FK506, rapamycin, mycophenolate mofetil, mide, an
NSAlD, ibuprofen, corticosteroids, prednisolone, phosphodiesterase inhibitors, adensosine agonists,
antithrombotic agents, complement inhibitors, rgic agents, IRAK, NIK, IKK, p38, MAP
kinase inhibitors, IL-lB converting enzyme inhibitors, TNFoc converting enzyme inhibitors, T-cell
signalling inhibitors, metalloproteinase tors, sulfasalazine, azathioprine, 6-mercaptopurines,
angiotensin converting enzyme inhibitors, soluble cytokine receptors, e p55 TNF or,
soluble p75 TNF receptor, , sIL-lRII, sIL-6R, anti-inflammatory cytokines, IL-4, IL-10, IL-
11,IL-13, and TGFB.
In another aspect of the invention, a method for treating pain as described herein comprises
administering to an individual one or more binding proteins described herein or a composition
described herein by at least one mode selected from parenteral, subcutaneous, intramuscular,
intravenous, articular, intrabronchial, intraabdominal, intracapsular, intracartilaginous,
intracavitary, elial, intracerebellar, intracerebroventricular, intracolic, intracervical,
intragastric, intrahepatic, yocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal,
intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal,
intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual,
intranasal, and transdermal.
In another embodiment, the invention provides a method of treating pain in an individual
ing from a disease or disorder associated with lL-l expression. Such IL-1 expression in the
individual can result in increased IL-1 levels in the plasma and/or local tissue of the individual.
In an embodiment, the methods and compositions described herein are used to treat pain in
an individual suffering from a disease or disorder selected from the group comprising osteoarthritis,
rheumatoid arthritis, juvenile chronic arthritis, septic arthritis, Lyme arthritis, psoriatic arthritis,
reactive arthritis, spondyloarthropathy, systemic lupus erythematosus, Crohn's disease, ulcerative
colitis, inflammatory bowel disease, insulin dependent diabetes mellitus, thyroiditis, asthma, ic
diseases, psoriasis, dermatitis, derma, graft versus host disease, organ transplant rejection,
acute or c immune disease associated with organ transplantation, sarcoidosis, sclerosis,
disseminated intravascular coagulation, Kawasaki's disease, Grave's disease, nephrotic syndrome,
chronic fatigue syndrome, Wegener's granulomatosis, Henoch-Schoenlein purpurea, microscopic
vasculitis of the kidneys, chronic active tis, uveitis, septic shock, toxic shock syndrome, sepsis
syndrome, cachexia, infectious diseases, tic diseases, acute transverse myelitis, Huntington's
chorea, Parkinson's disease, Alzheimer's disease, stroke, primary biliary cirrhosis, hemolytic anemia,
malignancies, heart failure, myocardial tion, Addison‘s disease, sporadic polyglandular
ency type I, andular deficiency type II (Schmidt’s syndrome), adult (acute) respiratory
distress syndrome, alopecia, ia areata, seronegative arthropathy, arthropathy, 's disease,
psoriatic pathy, ulcerative c arthropathy, pathic synovitis, Chlamydia-associated
arthropathy, Yersinia-associated arthropathy, Salmonella-associated arthropathy,
spondyloarthropathy, atheromatous disease/arteriosclerosis, atopic allergy, autoimmune bullous
disease, pemphigus is, pemphigus foliaceus, pemphigoid, linear IgA disease, autoimmune
haemolytic anaemia, Coombs positive haemolytic anaemia, acquired pernicious anaemia, juvenile
pernicious a, c encephalitisiRoyal Free disease, chronic mucocutaneous candidiasis,
giant cell tis, primary sclerosing hepatitis, cryptogenic mune hepatitis, acquired
immunodeficiency syndrome, acquired immunodeficiency related diseases, hepatitis B, hepatitis C,
common varied immunodeficiency (common variable mmaglobulinaemia), dilated
cardiomyopathy, female infertility, ovarian failure, premature n failure, fibrotic lung disease,
cryptogenic fibrosing alveolitis, post-inflammatory interstitial lung disease, interstitial pneumonitis,
connective tissue e associated interstitial lung disease, mixed connective tissue disease
associated lung disease, systemic sclerosis associated interstitial lung disease, rheumatoid arthritis
associated titial lung disease, systemic lupus erythematosus associated lung disease,
dermatomyositis/polymyositis associated lung disease, Sjogren's disease ated lung disease,
ankylosing spondylitis associated lung e, vasculitic diffuse lung disease, haemosiderosis
ated lung disease, drug-induced interstitial lung disease, fibrosis, radiation fibrosis,
bronchiolitis obliterans, chronic philic pneumonia, lymphocytic infiltrative lung disease,
postinfectious interstitial lung disease, gouty arthritis, autoimmune hepatitis, type-l autoimmune
hepatitis (classical autoimmune or lupoid hepatitis), type-2 mune hepatitis (anti-LKM
antibody hepatitis), autoimmune mediated hypoglycemia, type B insulin resistance with acanthosis
nigricans, rathyroidism, acute immune disease associated with organ transplantation, chronic
immune disease associated with organ transplantation, osteoarthrosis, primary sclerosing cholangitis,
psoriasis type 1, psoriasis type 2, idiopathic leucopaenia, autoimmune neutropaenia, renal disease
NOS, glomerulonephritides, microscopic itis of the kidneys, Lyme disease, discoid lupus
erythematosus, male infertility idiopathic or NOS, sperm munity, multiple sclerosis (all
subtypes), sympathetic ophthalmia, pulmonary hypertension secondary to connective tissue disease,
Goodpasture's syndrome, pulmonary manifestation of polyarteritis nodosa, acute rheumatic fever,
rheumatoid spondylitis, Still's disease, systemic sis, Sjorgren's syndrome, Takayasu's
disease/arteritis, autoimmune ocytopaenia, idiopathic thrombocytopaenia, autoimmune
thyroid disease, hyperthyroidism, us autoimmune hypothyroidism (Hashimoto's disease),
atrophic mune hypothyroidism, primary myxoedema, phacogenic uveitis, primary vasculitis,
vitiligo, acute liver disease, c liver diseases, lic cirrhosis, alcohol-induced liver injury,
cholestasis, idiosyncratic liver disease, drug-induced hepatitis, non-alcoholic steatohepatitis, allergy,
group B streptococci (GBS) infection, mental disorders (e.g., depression and schizophrenia), Th2
2O Type and Th1 Type mediated diseases, acute and chronic pain rent forms of pain), cancers such
as lung, breast, stomach, bladder, colon, pancreas, ovarian, prostate and rectal cancer and
hematopoietic malignancies (leukemia and lymphoma), abetalipoproteinemia, acrocyanosis, acute
and chronic parasitic or infectious processes, acute leukemia, acute lymphoblastic leukemia (ALL),
acute d leukemia (AML), acute or chronic bacterial infection, acute pancreatitis, acute renal
failure, adenocarcinomas, atrial ectopic beats, AIDS dementia complex, alcohol-induced hepatitis,
allergic conjunctivitis, allergic contact dermatitis, allergic rhinitis, allograft rejection, alpha-l-
antitrypsin deficiency, amyotrophic lateral sclerosis, anemia, angina pectoris, anterior horn cell
degeneration, anti-CD3 therapy, antiphospholipid me, anti—receptor ensitivity reactions,
aortic and peripheral aneurysms, aortic tion, arterial hypertension, arteriosclerosis,
3O arteriovenous fistula, ataxia, atrial fibrillation (sustained or paroxysmal), atrial flutter,
atrioventricular block, B cell lymphoma, bone graft rejection, bone marrow transplant (BMT)
ion, bundle branch block, Burkitt's lymphoma, burns, cardiac hmias, cardiac stun
syndrome, cardiac tumors, cardiomyopathy, cardiopulmonary bypass inflammation response,
cartilage lant rejection, cerebellar cortical degenerations, cerebellar disorders, chaotic or
multifocal atrial tachycardia, chemotherapy associated disorders, chronic myelocytic ia
(CML), chronic alcoholism, c atory pathologies, chronic lymphocytic leukemia
(CLL), chronic obstructive pulmonary disease (COPD), chronic salicylate intoxication, colorectal
carcinoma, congestive heart failure, conjunctivitis, contact dermatitis, cor pulmonale, coronary
artery e, Creutzfeldt-Jakob disease, culture negative sepsis, cystic fibrosis, ne therapy
associated ers, dementia pugilistica, demyelinating diseases, dengue hemorrhagic fever,
dermatitis, dermatologic conditions, diabetes, diabetic arteriosclerotic disease, diffuse Lewy body
disease, dilated congestive cardiomyopathy, ers of the basal ganglia, Down's syndrome in
middle age, drug- d movement disorders induced by drugs which block CNS dopamine
receptors, drug sensitivity, eczema, encephalomyelitis, rditis, inopathy, epiglottitis,
Epstein-Barr virus infection, erythromelalgia, extrapyramidal and cerebellar disorders, familial
hemophagocytic lymphohistiocytosis, fetal thymus implant rejection, Friedreich's , functional
peripheral arterial disorders, fungal , gas ne, gastric ulcer, glomerular nephritis, graft
rejection of any organ or tissue, gram negative sepsis, gram positive sepsis, granulomas due to
intracellular organisms, hairy cell leukemia, Hallervorden-Spatz disease, oto's thyroiditis,
hay fever, heart transplant rejection, hemochromatosis, hemodialysis, hemolytic uremic
syndrome/thrombolytic thrombocytopenic purpura, hemorrhage, hepatitis A, His bundle arrhythmias,
HIV infection/HIV neuropathy, Hodgkin's disease, hyperkinetic movement disorders,
hypersensitivity reactions, hypersensitivity nitis, hypertension, hypokinetic movement
disorders, hypothalamic-pituitary-adrenal axis evaluation, idiopathic Addison's disease, idiopathic
pulmonary fibrosis, antibody mediated xicity, asthenia, infantile spinal muscular atrophy,
inflammation of the aorta, influenza A, ionizing radiation exposure, iridocyclitis/uveitis/optic
neuritis, ia- reperfusion injury, ischemic stroke, juvenile rheumatoid tis, juvenile spinal
muscular atrophy, Kaposi's sarcoma, kidney transplant rejection, legionella, leishmaniasis, leprosy,
lesions of the corticospinal system, lipedema, liver lant rejection, lymphedema, malaria,
malignant lymphoma, malignant histiocytosis, malignant melanoma, meningitis, meningococcemia,
metabolic migraine he, idiopathic migraine headache, mitochondrial ystem disorder,
mixed connective tissue disease, monoclonal gammopathy, multiple myeloma, multiple systems
degenerations (Menzel, Dejerine-Thomas, Shy-Drager, and Machado-Joseph), myasthenia graVis,
mycobacterium avium intracellulare, mycobacterium tuberculosis, ysplastic syndrome,
myocardial infarction, myocardial ischemic ers, nasopharyngeal carcinoma, al chronic
lung disease, nephritis, sis, neurodegenerative diseases, neurogenic muscular atrophies,
neutropenic fever, non- Hodgkin's lymphoma, occlusion of the abdominal aorta and its branches,
occlusive arterial disorders, OKT3® therapy, orchitis/ epididymitis, orchids/vasectomy reversal
procedures, organomegaly, osteoporosis, pancreas transplant rejection, pancreatic oma,
paraneoplastic syndrome/hypercalcemia of malignancy, parathyroid transplant rejection, pelvic
inflammatory e, perennial rhinitis, pericardial disease, peripheral atherosclerotic disease,
eral vascular disorders, nitis, pernicious anemia, pneumocystis i pneumonia,
pneumonia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal
gammopathy, and skin changes syndrome), post perfusion me, post pump syndrome, post-MI
cardiotomy syndrome, preeclampsia, progressive supranucleo palsy, primary pulmonary
hypertension, radiation therapy, d‘s phenomenon, Raynaud's e, Refsum's disease,
regular narrow QRS ardia, renovascular ension, reperfusion injury, restrictive
cardiomyopathy, sarcomas, senile chorea, senile dementia of Lewy body type, gative
arthropathies, shock, sickle cell anemia, skin allograft rejection, skin changes syndrome, small bowel
transplant rejection, solid tumors, specific arrhythmias, spinal ataxia, spinocerebellar degenerations,
streptococcal is, ural lesions of the cerebellum, te sclerosing panencephalitis,
syncope, is of the cardiovascular system, systemic anaphylaxis, ic inflammatory
response syndrome, systemic onset juvenile toid arthritis, T-cell or FAB ALL, telangiectasia,
thromboangiitis obliterans, thrombocytopenia, toxicity, transplants, trauma/hemorrhage, type III
hypersensitivity reactions, type IV hypersensitivity, unstable , uremia, urosepsis, urticaria,
valvular heart diseases, varicose veins, vasculitis, venous diseases, venous thrombosis, ventricular
fibrillation, viral and fungal infections, viral encephalitisiaseptic itis, viral-associated
hemophagocytic syndrome, Wernicke- Korsakoff me, Wilson's disease, xenograft rejection of
any organ or tissue, acute coronary syndromes, acute idiopathic polyneuritis, acute inflammatory
demyelinating polyradiculoneuropathy, acute ischemia, adult Still’s disease, alopecia ,
anaphylaxis, anti-phospholipid antibody syndrome, ic anemia, arteriosclerosis, atopic eczema,
atopic dermatitis, autoimmune dermatitis, autoimmune disorder associated with ococcus
infection, autoimmune enteropathy, autoimmune hearing loss, autoimmune lymphoproliferative
syndrome (ALPS), autoimmune myocarditis, autoimmune premature ovarian failure, blepharitis,
bronchiectasis, s pemphigoid, cardiovascular disease, catastrophic antiphospholipid syndrome,
celiac disease, cervical spondylosis, chronic ischemia, cicatricial pemphigoid, clinically isolated
syndrome (CIS) with risk for multiple sclerosis, childhood onset psychiatric disorder, chronic
obstructive pulmonary disease (COPD), dacryocystitis, dermatomyositis, diabetic pathy, disk
herniation, disk se, drug induced immune hemolytic anemia, endocarditis, endometriosis,
endophthalmitis, episcleritis, erythema multiforme, erythema multiforme major, gestational
goid, Guillain-Barré syndrome (GBS), hay fever, Hughes syndrome, thic Parkinson’s
disease, idiopathic interstitial pneumonia, IgE-mediated allergy, immune hemolytic anemia,
inclusion body myositis, infectious ocular inflammatory disease, inflammatory inating
disease, inflammatory heart disease, inflammatory kidney disease, IPF/UIP, iritis, keratitis,
keratojunctivitis sicca, Kussmaul disease or Kussmaul-Meier disease, Landry's paralysis,
Langerhan's cell histiocytosis, livedo reticularis, macular ration, microscopic polyangiitis,
Morbus Bechterev, motor neuron disorders, mucous membrane pemphigoid, multiple organ failure,
myasthenia gravis, myelodysplastic syndrome, myocarditis, nerve root disorders, neuropathy, non-A
non-B hepatitis, optic neuritis, osteolysis, ovarian cancer, pauciarticular JRA, peripheral artery
occlusive disease (PAOD), peripheral vascular disease (PVD), peripheral artery disease (PAD),
phlebitis, polyarteritis nodosa (or periarteritis nodosa), polychondritis, polymyalgia rheumatica,
poliosis, polyarticular JRA, polyendocrine deficiency me, polymyositis, polymyalgia
rheumatica (PMR), post-pump syndrome, primary Parkinsonism, prostate and rectal cancer and
hematopoietic malignancies (leukemia and ma), prostatitis, pure red cell aplasia, primary
l insufficiency, recurrent yelitis optica, restenosis, rheumatic heart disease, SAPHO
(synovitis, acne, pustulosis, hyperostosis, and osteitis), secondary dosis, shock lung, scleritis,
ca, secondary adrenal insufficiency, silicone associated connective tissue disease, Sneddon-
Wilkinson dermatosis, spondylitis ankylosans, Stevens-Johnson syndrome (SJS), systemic
inflammatory response syndrome, temporal arteritis, toxoplasmic retinitis, toxic epidermal
ysis, transverse myelitis, TRAPS (tumor-necrosis factor receptor type 1 (TNFR)-associated
periodic me), type 1 allergic reaction, type II diabetes, urticaria, usual interstitial pneumonia
(UIP), itis, vernal conjunctivitis, viral retinitis, Vogt-Koyanagi-Harada syndrome (VKH
syndrome), wet macular degeneration, and wound healing.
In an embodiment, the methods and compositions bed herein are used to treat pain in
an individual suffering The method for treating pain in an individual according to claim 16, n
the individual is suffering from a disease selected from the group consisting of a primary , a
metastatic cancer, breast , colon cancer, rectal cancer, lung cancer, oropharynx cancer,
hypopharynx cancer, esophagus cancer, stomach , pancreatic cancer, liver cancer, gallbladder
cancer, bile duct , small intestine cancer, colon cancer, urinary tract cancer, kidney ,
bladder cancer, urothelium cancer, female genital tract cancer, cervical cancer, uterine cancer,
ovarian cancer, choriocarcinoma, gestational trophoblastic disease, male genital tract cancer,
prostate cancer, seminal vesicle cancer, ular cancer, germ cell tumor, endocrine gland cancer,
thyroid cancer, adrenal cancer, pituitary gland cancer, skin cancer, hemangioma, melanoma,
a, bone cancer, soft tissue cancer, Kaposi’s sarcoma, tumor of the brain, nerve cancer, eye
cancer, cancer of the meninges, astrocytoma, glioma, glioblastoma, retinoblastoma, neuroma,
lastoma, Schwannoma, meningioma, a solid tumor arising from hematopoietic malignancy,
leukemia, Hodgkin's lymphoma, and non -Hodgkin's lymphoma.
3O Brie Descri tion 0 the Drawin s
Figure 1A is a schematic representation of Dual Variable Domain Immunoglobulin (DVD-
Ig) constructs and shows the strategy for generating a DVD-lg molecule from two parent antibodies.
Figure 1B shows schematic representations of c constructs for DVDl-Ig, DVD2—Ig,
and two chimeric, ecific, monoclonal dies 2D13.E3 lL—loc) and 13F5.G5 (anti-
IL—1[3). "VHB" and "VL[3" indicate, respectively, a heavy chain variable domain and a light chain
le domain of an antigen g site of the 13F5.G5 antibody that binds IL-[3. "VHoc" and
"VLoc" indicate, respectively, a heavy chain le domain and a light chain variable domain of the
3D12.E3 antibody that binds IL-lot. "L" indicates a leader ce. In m of genetic
construct for DVD2-Ig, horizontal markings between "VHB" and "VHoc" and between "VLB" and
"VLoc" indicate presence of a linker sequence.
Figure 2 shows bar graphs of histology scoring of articular cartilage of mice in a joint
instability model (JIM) of osteoarthritis. Each set of bar graphs provides scoring for articular
cartilage in lmees of mice in four treatment groups: treatment with phosphate buffered saline (PBS)
vehicle only ("PBS"), treatment with an anti-IL-la monoclonal antibody ("anti-IL-la mAb"),
treatment with an anti-IL-lB monoclonal antibody ("anti-IL-lB mAb"), and treatment with a
combination of anti-IL—lot and anti-IL-lB monoclonal antibodies ("anti-IL-lu mAb + anti-IL-IB
mAb"). Individual bar graphs within each set show a total histology score and scores for three
separate zones, wherein each zone is one-third of the area of the medial tibia cartilage (zone 1: inside
zone, zone 2: middle zone, and zone 3: outside zone). From left to right: bar graph of total score for
medial tibia zones 1, 2, and 3; bar graph of score for medial tibia zone 1; bar graph of score for
medial tibia zone 2; and bar graph of score for medial tibia zone 3. See e 3.3.1.
Figure 3 shows bar graphs of ogy scoring of articular cartilage of mice in a joint
instability model (JIM) of osteoarthritis. Each set of bar graphs provides scoring for articular
cartilage in knees of mice in four ent groups: treatment with PBS vehicle only cle"),
2O treatment with a combination of anti-IL—la monoclonal antibody and anti-IL-l B monoclonal
antibody ("anti-IL-loc mAb (6 mg/kg) + anti—IL-lB mAb (6 mg/kg)"), treatment with mIL-loc/[3
DVD-Ig binding protein at 6 mg/kg ("IL—1(x/[3 DVD-Ig (6 mg/kg)"), and treatment with mIL-loc/[3
DVD-Ig binding protein at 12 mg/kg ("IL—la/B DVD-Ig (12 mg/kg)"). Individual bar graphs within
each set show a total histology score and scores for three separate zones, wherein each zone is one-
third of the area of the medial tibia cartilage (zone 1: inside zone, zone 2: middle zone, and zone 3:
outside zone). From left to right: bar graph of total score for medial tibia zones 1, 2, and 3; bar
graph of score for medial tibia zone 1; bar graph of score for medial tibia zone 2; and bar graph of
score for medial tibia zone 3. See Example 3.3.2.
Figure 4 shows bar graphs of ogy scoring of articular cartilage of mice in a joint
instability model (JIM) of osteoarthritis. Each set of bar graphs provides scoring for articular
cartilage in lmees of mice in four treatment groups: treatment with PBS vehicle only cle"),
treatment with a combination of anti-IL-la monoclonal antibody (6 mg/kg) and anti-IL-IB
monoclonal dy (6 mg/kg) ("anti-IL—loc mAb (6 mgi’kg) + anti-IL-ll3 mAb (6 mg/kg)"),
ent with an L—lB monoclonal antibody (12 mg/kg) ("anti-IL-lB mAb (12 mg/kg)"),
treatment with an anti-IL—lB monoclonal antibody (6 mg/kg) ("anti-IL-lB mAb (6 mg/kg)"), and
treatment with an anti-IL-lB monoclonal antibody (3 mg/kg) ("anti-IL-lB mAb (3 mg/kg)").
Individual bar graphs within each set show a total histology score and scores for three separate
zones, wherein each zone is one-third of the area of the medial tibia cartilage (zone 1: inside zone,
zone 2: middle zone, and zone 3: outside zone). From left to right: bar graph of total score for
medial tibia zones 1, 2, and 3; bar graph of score for medial tibia zone 1; bar graph of score for
medial tibia zone 2; and bar graph of score for media] tibia zone 3. See Example 3.3.3.
Figure 5 shows the level of zymosan—induced IL—6 production ) in animals in a joint
instability model of osteoarthritis when treated with PBS vehicle only ("Vehicle"), with a
combination of anti-IL-la onal antibody (6 mgfkg) and anti-IL-lB monoclonal antibody (6
mg/kg) ("anti-IL-IOL mAb (6 mg/kg) + anti-IL-ll3 mAb (6 mg/kg)"), With mIL-loc/B DVD-lg binding
protein at 6 mg/kg ("lL—loc/B DVD (6 mg/kg)"), and treatment with mIL-loc/B DVD-lg binding
protein at 12 mg/kg ("IL-10MB DVD (12 "). See Example 3.3.4.
Figure 6 shows total sum score for cartilage degeneration in animals in a destabilization of
medial meniscus (DMM) model of osteoarthritis treated the PBS vehicle ("Vehicle"), with a
combination of anti-lL-ld monoclonal antibody (6 mg/kg) and L-lB monoclonal antibody (6
mg/kg) ("anti-lL-loc mAb (6 mg/kg) + anti-IL—ll3 mAb (6 mg/kg)"), and with mlL-loc/B DVD-lg
binding protein at 6 mg/kg oc/[3 DVD (6 mg/kg)"). See Example 3.3.5.
Figure 7 shows the results of an 8 week study of various treatments on cartilage
degeneration in animals in a ilization of medial meniscus (DMM) model of osteoarthritis.
2O Each bar graph indicates the mean sum score for cartilage degeneration in animals treated with PBS
vehicle only ("Vehicle"), with anti-IL—la onal antibody (6 mg/kg) ("anti-IL-loc mAb
6 mg/kg"), with anti-IL-lB monoclonal antibody (6 mg/kg) ("anti-lL-lB 6 mg/kg"), with a
combination of anti-IL-lo. monoclonal antibody (6 mg/kg) and anti-IL-lB monoclonal antibody (6
mg/kg) ("anti-IL-loc mAb (6 mg/kg) + anti-IL—ll3 mAb (6 mgi’kg)"), With mIL-loc/[3 DVD-lg g
protein at 1.5 mg/kg ("IL-10MB DVD 1.5 mg/kg"), with mIL-loc/B DVD-lg binding n at 3
mg/kg ("IL-10MB DVD 3 mg/kg"), or with mIL-loc/B DVD-lg binding protein at 6 mg/kg oc/B
DVD 6 mg/kg"). See Example 3.3.6.
Figure 8 shows the s of a 4 week study of ng animals in a destabilization of
medial meniscus (DMM) model of osteoarthritis with vehicle alone ("Vehicle"), doxycycline (30
3O mg/kg) ("Doxycycline (30 mg/kg)“), or a combination of an anti-IL-la monoclonal antibody (6
mg/kg) and an anti-IL-IB monoclonal antibody (6 mg/kg) ("anti-IL-l on mAb (6 mg/kg) + anti-lL-IB
mAb (6 mg/kg)"). See e 33?.
Figure 9 shows bar graphs of paw withdrawal old (grams, "g") in paws of mice with
DMM surgery on Days 7, 14, 21, 28, and 35. Paw withdrawal threshold of DMM paw ("DMM")
was significantly decreased as compared to paws from lateral (non-surgical) paw ("Contra")
and sham surgery ("Sham"). DMM paws were allodynic as early as day 7 and exhibited this pain
behavior through day 35. See Example 4.
Figure 10 shows bar graphs of paw withdrawal threshold (grams, "g") in DMM mice
following treatment vehicle alone ("PBS Control"), with IgG isotype control (positive control for
established disease and pain "IgG Control"), or with a combination of anti-IL-lu and anti-IL-lB
monoclonal antibodies ("anti-IL—los mAb (6 mg/kg) + anti-IL—lB mAb (6 mg/kg)") after 5 weeks
(day 35) compared to paws from contralateral (non—surgical) paw ("Contralateral") and sham surgery
("Sham"). The data indicate that neutralization of both IL-loc and IL-IB significantly prevented the
development of allodynia. Similar efficacy was observed in animals treated after one week (not
shown). See Example 4.
Figure 11 shows bar graphs of paw withdrawal threshold , "g") in DMM mice
previously treated with IgG isotype control (positive control for established disease and pain) for 35
days and then dosed with a combination of anti-lL—lo or L-lB monoclonal antibodies and
tested for paw withdrawal threshold 24 hours later at day 36 ("anti-lL-loc mAb (6 mg/kg) + anti-IL-
IB (6 mg/kg) (24 hours post dosing)"). For comparison, paw withdrawal threshold values at day 35
are provided for contralateral (non-surgical) paw ("Contralateral"), sham y paw ("Sham"),
vehicle only treatment ("PBS Control"), IgG isotype ent ("IgG Control"), and al paw
d with a combination of L-la and anti-IL—lB monoclonal antibodies -IL-loc mAb (6
mg/kg) + anti-lL-lB mAb (6 mg/kg)") after 5 weeks (day 35). The data indicate that the
2O neutralization of both IL-loc and IL—lB significantly reversed allodynia in mice with established
pain. See Example 4.
Figure 12 shows bar graphs of paw withdrawal threshold (grams, "g") in DMM mice treated
with PBS vehicle only ("Vehicle"), with anti-IL—la monoclonal antibody (6 mg/kg) ("anti-IL-loc
mAb (6 mg/kg)"), with anti-IL-lB onal antibody (6 mg/kg) ("anti-IL-lB mAb (6 mg/kg)"), or
with a combination of anti-lL—lo. monoclonal antibody (6 mgi’kg) and anti-IL-lB monoclonal
antibody (6 mg/kg) ("anti-lL-loc mAb (6 mg/kg) + anti-IL—lB mAb (6 mg/kg)") stered
intraperitoneally (ip) twice per week for four weeks. Animals were tested for allodynia on day 28.
"Contralateral" bar graph provides paw withdrawal threshold of a representative rgical a
lateral) limb. The teral (surgical) limb of animals in groups treated with vehicle was allodynic
3O (painful) compared to the contra lateral (non-surgical) limb or compared to animals that had
undergone sham y ("Sham"). See Example 5.
Figure 13 shows bar graphs of paw withdrawal threshold (grams, "g") in DMM mice treated
with PBS vehicle only ("Vehicle") or with a combination of anti-lL-lu monoclonal antibody and
anti-lL-lB monoclonal antibody, both administered eritoneally (ip) every four days for four
weeks at 1 mg/kg ("anti-IL—loc mAb (1 mg/kg) + anti-IL—ll3 mAb (1 mg/kg)"), at 3 mg/kg ("anti-IL-
10c mAb (3 mg/kg) + anti-lL-lB mAb (3 mg/kg)"), or at 6 mg/kg ("anti-lL-loc mAb (6 mg/kg) + anti-
IL-1[3 mAb (6 mg/kg)"). Animals were tested on day 28. The ipsilateral (surgical) limb of animals
in groups treated with PBS vehicle only was allodynic (painful) compared to the contra lateral (non-
al) limb ("Contralateral") or ed to animals that had undergone sham surgery ("Sham").
The results show that treatment with a ation of anti-IL-l (1 monoclonal antibody and anti-IL-
1B monoclonal antibody prevents allodynia development in DMM mice in a dose related manner.
See Example 6.
Figure 14 shows bar graphs of paw withdrawal threshold (grams, "g") when DMM mice
with ished osteoarthritis and mechanical allodynia were treated at day 27 with a combination
of anti-lL-la monoclonal antibody and anti-IL-lB monoclonal antibody, both stered
intraperitoneally (ip) at 1 mg/kg (“anti-IL-lrx mAb (1 mg/kg) + anti-IL-IB mAb (1 mg/kg)"), at 3
mg/kg ("anti-lL—loc mAb (3 mg/kg) + anti-lL-ll3 mAb (3 mgi’kg)"), or at 6 mg/kg ("anti-IL-loc mAb
(6 mg/kg) + anti-lL-lB mAb (6 mg!kg)") at 24 hours prior to testing for allodynia on day 28. The
ipsilateral (surgical) limb of animals in groups treated with vehicle ("Vehicle") was allodynic
(painful) compared to the contra lateral (non-surgical) limb ("Contralateral") or compared to animals
that had undergone sham surgery ("Sham"). The s show that treatment with a combination of
anti-lL-la monoclonal antibody and anti-lL—l B monoclonal antibody reverses established nia
in DMM mice with established e in a dose d manner. See Example 7.
Figure 15 shows bar graphs of paw withdrawal latency (seconds, "s") in animals in a mouse
2O carrageenan-induced inflammatory pain (hyperalgesia) model. At 30 hours after intraplantar
carrageenan injection, mice were treated with anti-IL-la monoclonal antibody alone (900 ug) -
IL-loc mAb"), anti-lL-lB monoclonal dy alone (900 ug) ("anti-IL-lB mAb"), a combination of
anti-lL-la monoclonal antibody (900 ug) and anti-IL—lB monoclonal antibody (900 ug) ("anti-IL-loc
mAb + anti-lL-lB mAb"), PBS vehicle ("PBS"), or IgG isotype control ("IgG"). Another group was
administered a dose (30 mg/kg) of diclofenac (non-steroidal anti-inflammatory analgesic control) at
47 and 95 hours after intraplantar administration of carrageenan. Thermal lgesia testing using
radiant heat stimulus was performed 48 hours (Figure 15A) and 96 hours (Figure 15B) after
intraplantar administration of carrageenan. Filled bars show paw withdrawal latency for l paw
(no eenan). Open bars show paw withdrawal latency for paw administered carrageenan. See
e 8.
Figure 16 shows bar graphs of paw withdrawal latency (seconds, "s") in s in a mouse
carrageenan-induced inflammatory pain (hyperalgesia) model in mice. At 30 hours after intraplantar
carrageenan injection, mice were treated with e ("PBS"), IgG isotype control ("IgG"), or one
of three doses of a combination of anti-lL-la monoclonal antibody and anti-IL-IB monoclonal
antibody, wherein each monoclonal antibody was administered at 100 ug ("anti-IL-loc mAb (100 ug)
+ anti-IL-lB mAb (100 ug) "), at 300 ug ("anti—IL-loc mAb (300 Mg) + anti-lL-lB mAb (300 ug)"),
or at 900 ug ("anti-IL-loc mAb (900 ug) + L—ll3 mAb (900 ug)"). Another group was
administered a dose (30 mg/kg) of diclofenac teroidal anti-inflammatory analgesic positive
control) at 47 and 95 hours after intraplantar administration of carrageenan. Thermal hyperalgesia
testing using radiant heat stimulus was performed at 48 hours (Figure 16A) and 96 hours (Figure
16B) after intraplantar administration of carrageenan. Filled bars show paw withdrawal latency for
control paw (no carrageenan). Open bars show paw withdrawal y for paw administered
eenan. See Example 9.
Figure 17 shows results of testing anti-IL-loc and anti-IL-ll3 monoclonal antibody
combination therapy in a CFA ("Complete Freund's Adjuvant) inflammatory pain model in mice. At
hours after intraplantar CFA injection, mice were treated with a combination of L-la
monoclonal antibody (900 ug) and anti-IL-IB monoclonal antibody (900 ug), with PBS vehicle
("PBS"), or with IgG isotype control ("IgG"). Another group was administered a dose (30 mg/kg) of
diclofenac (non-steroidal, anti-inflammatory analgesic positive control) at 47 hours after intraplantar
administration of CFA. Mechanical allodynia testing of animals using a von Frey monofilament was
performed at 48 hours after CFA administration. Figure 17A shows bar graphs of paw withdrawal
threshold (grams, "g"). Filled bars show paw withdrawal threshold for contra lateral (no CFA)
l paws. Open bars show paw withdrawal threshold for paw administered CFA in animals of
treatment groups. Figure 17B shows bar graphs for magnitude of efficacy (% MPE) for s of
2O ent groups. See Example 10.
Figure 18 shows bar graphs of paw withdrawal threshold (grams, "g") in animals of an
L5/L6 spinal nerve ligation (SNL) mouse model of neuropathic pain. Animals were treated at day 6
after SNL surgery with a combination of anti-lL-la monoclonal antibody (900 ug) and anti-lL-lB
onal antibody (900 ug) ("anti—IL—loc mAb + anti-IL—lB mAb"), PBS vehicle ("PBS"), or IgG
isotype control ("IgG"). ical allodynia testing of animals using a von Frey monofilament
was performed at 24 hours (Figure 18A) and 72 hours (Figure 18B) after SNL surgery. Another
group was treated with gabapentin (100 mg/kg, "Gabapentin") at 1 hour prior to testing as a positive
control. See Example 11.
Figure 19 shows bar graphs for magnitude of efficacy (% MPE) for animal treatment groups
at 24 and 72 hours as bed for Figure 18. "Vehicle" indicates SNL animals treated with PBS
vehicle d. "IgG" indicates SNL animals treated with IgG isotype control. "IL-locB" indicates
animals treated with ation anti-IL-la monoclonal antibody (900 ug) and L-ll3
onal antibody. See Example 11.
ed Description of the Invention
The invention is based on the discovery that blocking the function of interleukin-1 (IL-1) can
be an effective means to treat osteoarthritis (0A) in an individual (human or other ).
According to the invention, blocking IL—l function for treating OA may be achieved by
administering to an individual one or more proteins that bind IL-loc and IL-1 [3. Such a "dual-
specific" therapy can be achieved by stering to an OA patient a binding n (e.g., an
antibody) that binds lL-loc and a binding protein (e.g., an antibody) that binds IL-lB or by
administering a multivalent and multispecific binding protein that binds both IL-loc and IL-1[3. Such
a multivalent and multispecific binding protein useful in the ion includes a dual le
domain immunoglobulin binding protein (also referred herein as "DVD-IgTM" or "DVD-lg" binding
protein or molecule). See, e.g., PCT Publication No. and Wu et a1. (2007) Nature
Biotech. 25(11): 1290-1297. Whether a particular combination of IL-loc and IL-ll3 binding proteins
or a specific DVD-lg molecule that binds both lL-loc and IL—lB will be useful for the treatment of
OA can be assessed using an animal model of OA, such as the joint instability model (JIM) of 0A or
the destabilization of medial meniscus (DMM) model of 0A (Glasson et al. (2007) Osteoarthrit.
Cart. 1061-9).
Unless otherwise defined herein, scientific and cal terms used in connection with the
present invention shall have the meanings that are ly understood by those of ry skill
in the art. The g and scope of the terms should be clear, however, in the event of any latent
2O ambiguity, definitions ed herein take precedent over any dictionary or extrinsic ion.
Further, unless otherwise required by context, singular terms shall include pluralities and plural
terms shall include the singular. In this application, the use of the term "or" means "and/or" unless
stated otherwise. Furthermore, the use of the term "including", as well as other forms, such as
"includes" and "included", is not limiting. Also, terms such as "element" or "component"
encompass both ts and components comprising one unit and elements and components that
comprise more than one subunit unless specifically stated otherwise.
Generally, nomenclatures used in connection with, and techniques of, cell and tissue
culture, molecular biology, immunology, microbiology, genetics, protein and nucleic acid
chemistry, and nucleic acid hybridization described herein are those well known and commonly
used in the art. The methods and techniques of the present invention are lly performed
according to conventional s well lmown in the art and as described in various general and
more specific references that are cited and sed throughout the present specification unless
otherwise indicated. Enzymatic reactions and purification techniques are performed according to
manufacturer's specifications, as commonly accomplished in the art or as described herein. The
nomenclatures used in connection with, and the laboratory procedures and techniques of, analytical
chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described
herein are those well known and ly used in the art. Standard techniques are used for
chemical syntheses, chemical analyses, pharmaceutical preparation, ation, and delivery, and
treatment of patients.
That the present invention may be more readily understood, select terms are defined below.
The term "polypeptide" means any polymeric chain of amino acids. The terms "peptide" and
"protein" are used interchangeably with the term polypeptide and also refer to a polymeric chain of
amino acids. The term eptide“ encompasses native or artificial proteins, protein fragments
and polypeptide analogs of a protein sequence. A polypeptide may be monomeric or polymeric.
The term "isolated protein“ or "isolated ptide" means a protein or polypeptide that by
virtue of its origin or source of derivation is not associated with naturally associated components that
accompany it in its native state, is substantially free of other proteins from the same species, is
expressed by a cell from a different s, or does not occur in nature. Thus, a ptide that is
chemically synthesized or sized in a cellular system different from the cell from which it
naturally originates will be "isolated" from its naturally associated ents. A protein may also
be ed substantially free of naturally ated components by isolation, using protein
purification techniques well known in the art.
The term "recovering" means the process of rendering a chemical species such as a
polypeptide substantially free of naturally associated components by isolation, e.g., using protein
purification ques well known in the art.
The term "human IL-loc" (also abbreviated herein as "hIL-loc" or "IL-10c"), includes a
pleiotropic cytokine involved in various immune responses, inflammatory processes, and
hematopoiesis. For example, IL—loz includes the human cytokine produced by activated
macrophages; it ates thymocyte proliferation by inducing IL-2 release, B-cell maturation and
proliferation, and fibroblast growth factor activity. The term "human IL-loc" is intended to include
recombinant human IL-10L("rh IL—los") that can be prepared by standard recombinant expression
methods.
The term IL—1[3" (also abbreviated herein as "hIL—l [3", or "IL—lb") includes a
pleiotropic cytokine involved in various immune responses, inflammatory processes, and
hematopoiesis. The term human “IL-15" includes recombinant human IL-ll3 ("rh IL-ll3") that can
be prepared by rd inant sion methods.
The amino acid sequences of human IL-lu and IL-lB are shown in Table l.
Table 1: ces of Human IL-la and IL-lfi
Protein Sequence Sequence
Identifier
123456789012345678901234567890
Human pro IL—la SEQ ID N021 MAKVPDMFEDLKNCYSENEEDSSSIDHnSL
NQKSFYHVSYGPLHEGCMDQSVSLSISETS
KTSKLTFKESMVVVATNGKVLKKRRLSLSQ
SITDDDLEAIANDSEEEIIKPRSAPFSFLS
NVKYNFMRIIKYEFILNDALNQSIIRANDQ
YLTAAALHNLDEAVKFDMGAYKSSKDDAKI
TVILRISKTQLYVTAQDEDQPVLLKEMPEI
PKTITGSETNLLFFWETHGTKNYFTSVAHP
NLFIATKQDYWVCLAGGPPSITDFQILENQ
Human mature Residues 113- SAPFSFLSNVKYNFMRIIKYEFILNDALNQ
IL—la 271 of SEQ ID SIIRANDQYLTAAALHNLDEAVKFDMGAYK
no;1 SSKDDAKITVILRISKTQLYVTAQDEDQPV
LLKEMPEIPKTITGSETNLLFFWETHGTKN
YFTSVAHPNLFIATKQDYWVCLAGGPPSIT
DFQILENQA
Human mature SEQ ID NO:2 APVRSLNCTLRDSQQKSLVMSGPYELKALH
IL—lB LQGQDMEQQVVFSMSFVQGEESNDKIPVAL
GLKEKNLYLSCVLKDDKPTLQLESVDPKNY
PKKKMLKRthNKIbINNKthbSAQtPNW
YISTSQAENMPVFLGGTKGGQDITDFTMQF
The term "biological ty" refers to all inherent ical properties of the cytokine.
Biological properties of IL-lu and lL-IB include, but are not limited to, binding to an IL-1 receptor.
"Biological activity" refers to all inherent biological ties of IL-loc. ical
properties of IL-loc include, but are not limited to, binding to the IL-loc or; stimulating
thymocyte proliferation by inducing IL—2 release, B-cell maturation and proliferation, and fibroblast
growth factor activity.
The terms "specific binding" or fically binding", in reference to the interaction of an
antibody, a protein, or a peptide with a second chemical species, mean that the interaction is
ent upon the presence of a particular structure (e.g., an antigenic inant or epitope) on
the chemical species, for example, an antibody recognizes and binds to a c protein structure
rather than to proteins generally. If an antibody is specific for e "A", the presence of a
molecule containing epitope A (or free, unlabeled A), in a on containing labeled "A" and the
antibody, will reduce the amount of labeled A bound to the antibody.
The term "antibody", broadly refers to any immunoglobulin (lg) molecule comprised of four
polypeptide chains, two heavy (H) chains and two light (L) chains, or any functional fragment,
mutant, variant, or derivative thereof, that retains the essential e binding features of an lg
molecule. Such mutant, variant, or derivative antibody formats are known in the art, nonlimiting
embodiments of which are discussed below.
In a full-length antibody, each heavy chain is comprised of a heavy chain variable region
(abbreviated herein as HCVR or VH) and a heavy chain constant region. The heavy chain constant
region is comprised of three domains, CH1, CH2 and CH3. Each light chain is comprised of a light
chain variable region (abbreviated herein as LCVR or VL) and a light chain constant region. The
light chain constant region is sed of one domain, CL. The VH and VL regions can be further
subdivided into regions of hypervariability, termed complementarity determining regions (CDR),
interspersed with regions that are more ved, termed framework regions (FR). Each VH and
VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in
the following order: FRI, CDRl, FR2, CDR2, FR3, CDR3, FR4. Immunoglobulin molecules can
be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG 1, IgG2, IgG 3, IgG4, IgAl
and IgA2) or subclass.
The term "antigen-binding portion" of an antibody refers to one or more fragments of an
antibody that retain the y to specifically bind to an antigen (e.g., hlL-loc). The n-binding
function of an antibody can be performed by fragments of a full-length antibody. Such antibody
embodiments may also have bispecific, dual specific, or multi-specific formats, specifically binding
to two or more ent ns. Examples of binding fragments encompassed within the term
"antigen-binding portion" of an antibody include (i) an Fab fragment, which is a monovalent
fragment consisting of the VL, VH, CL, and CH1 domains; (ii) an F(ab')2 fragment, which is a
bivalent fragment sing two Fab fragments linked by a disulfide bridge at the hinge region;
2O (iii) an Fd fragment consisting of the VH and CH1 s; (iv) an FV fragment consisting of the
VL and VH domains of a single arm of an antibody; (v) a dAb fragment (Ward et al. (1989) Nature
341 :544-546, PCT Publication No. WO 90/05144), which comprises a single variable domain; and
(vi) an isolated complementarity determining region (CDR). Furthermore, although the two s
of the Fv fragment, VL and VH, are coded for by separate genes, they can be , using
recombinant methods, by a synthetic linker that s them to be made as a single protein chain in
which the VL and VH regions pair to form monovalent molecules (known as single chain FV (scFv);
see e.g., Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA
85 :5 879-5 883). Such single chain antibodies (scFvs) are also intended to be encompassed within the
term "antigen-binding portion" of an antibody. Other forms of single chain dies, such as
diabodies are also encompassed. Diabodies are bivalent, ific antibodies in which VH and VL
s are expressed on a single polypeptide chain, but using a linker that is too short to allow for
pairing between the two domains on the same chain, thereby forcing the domains to pair with
complementary domains of another chain and ng two antigen binding sites (see, e.g., Holliger
et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448; Poljak et al. (1994) Structure 2:1121-1123).
Such antibody binding portions are known in the art (Kontermann and Dubel eds., Antibody
Engineering (Springer-Verlag, New York, 2001) (ISBN 341354-5».
The term "antibody uct" refers to a polypeptide comprising one or more the antigen
binding portions of the invention linked to a linker polypeptide or an immunoglobulin constant
domain. Linker polypeptides comprise two or more amino acid residues joined by peptide bonds
and are used to link one or more antigen binding portions. Such linker polypeptides are well known
in the art (see, e.g., Holliger et a1. (1993) Proc. Natl. Acad. Sci. USA 4-6448; Poljak et a1.
(1994) Structure 2:1121-1123). An immunoglobulin constant domain refers to a heavy or light chain
nt . Human IgG heavy chain (gamma) and light chain (kappa and ) constant
domain amino acid sequences are lmown in the art and represented in Table 2.
Table 2: Sequences of Human IgG Heavy and Light Chain Constant Domains
Sequence Sequence
Identifier
123456789012345678901234567890
Ig gamma—l SEQ ID N013 ASTKGPSVFFLAPSSKS-SGG-AALGCLVK
constant region DYFPEPVTVSW.SGALTSGVJTFPAVAQSS
GLYSLSSVVTVPSSSLGTQTYICNV iKPS
2HN<OWN<m wW U] 0UWHE I]0w 'U0www' ‘J mGG
PSVFLFPPKPKJLLMISRLPL CVVVDVS
HEDPEVKFNWYVJGVLVJNA< <PRddQY
STYRVVSVLTVAAQDWL GKE <C<VSN<A
LPAPIEKTISKAKGQPRdPQVY -PPSR**
MTKNQVSLTCAVKGFYPSDIAV W451 GQP
ENNYKTTPPVADSDGSFFLYSKJTVD<SRW
QQGNVFSCSV iEALiNiY"QKS-S-SPG<
Ig gamma—l SEQ ID NO:4 ASTKGPSVFPAAPSS<S SGG AA-GC-V<
constant region VTVSW GV4"FPAV4QSS
mutant GLYSLSSVVTVPSSSAG Q YIC V {<PS
NTKVDKKVEPKSCDKTi"CPPCPAPEAAGG
PSVFLFPPKPKDTLMISRLPLV CVVVDVS
HEDPEVKFNWYVDGVLVHNA<1<PR 1 *QY
STYRVVSVLTVVHQDWVNGKTY<C<VS <A
LPAPIEKTISKAKGQ?RFPQVY -PPSR**
MTKNQVSLTCLVKGFY?SDIAV WdSVGQP1
ENNYKTTPPVLDSDGSTFLYSKLTVD{SRW
QQGNVFSCSVWHEALHVHYTQKSLSLS?G<
Ig Kappa constant SEQ ID N025 TVAAPSVFIF3?SDEQLKSGTASVVCVVVW_
region FYPREAKVQWKVDNALQSGNSQESVTE 35
KDSTYSLSSTLTLSKADYEKHKVYACEVTH
QGLSSPVTKSTQRGECL
Ig Lambda SEQ ID N026 QPKAAPSVTLT?PSSEELQANKATLVCLISL
constant region DFYPGAVTVAWKADSSPVKAGVETTTPSKQ
ASSYLSLTPEQWKSHRSYSCQVTH
EGSTVEKTVAPTECS
Still further, an antibody or antigen-binding portion thereof may be part of a larger
immunoadhesion molecule, formed by covalent or noncovalent association of the antibody, or
antigen binding portion thereof, with one or more other ns or peptides. Examples of such
immunoadhesion les include use of the avidin core region to make a tetrameric scFV
molecule (Kipriyanov, S. et al. (1995) Human Antibod. Hybridomas 6:93-101) and use of a cysteine
residue, a marker peptide and a C-terminal polyhistidine tag to make bivalent and biotinylated scFv
molecules (Kipriyanov, S. et al. (1994) Mol. Immunol. 31: 1047-105 8). Antigen binding portions of
antibodies, such as Fab and 2 fragments, can be prepared from whole antibodies using
conventional techniques, such as papain or pepsin digestion, tively, of whole antibodies.
Moreover, antibodies, n binding portions thereof, and immunoadhesion molecules can be
obtained using standard recombinant DNA techniques, as described herein.
An "isolated antibody" refers to an antibody that is substantially free of other antibodies
having different antigenic specificities (e.g., an isolated antibody that specifically binds hIL-loc is
substantially free of antibodies that specifically_bind antigens other than hIL-loc). An isolated
antibody that specifically binds hIL-loc may, however, have cross-reactivity to other antigens, such
as IL-loc molecules from other species. Moreover, an ed antibody may be substantially free of
other cellular material and/or chemicals.
The term "human antibody" includes dies having variable and nt s
derived from human germline immunoglobulin sequences. The human antibodies of the invention
may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g.,
ons introduced by random or site-specific mutagenesis in vitro or by somatic mutation in
vivo), for example in the CDRs and in particular CDR3. However, the term "human antibody", does
not include antibodies in which CDR sequences derived from the germline of r mammalian
species, such as a mouse, have been grafted onto human framework sequences.
2O The term "recombinant human antibody" includes all human antibodies that are prepared,
expressed, created or isolated by recombinant means, such as antibodies expressed using a
inant expression vector transfected into a host cell (described further in Section II C, ,
antibodies isolated from a recombinant, combinatorial human dy library (Hoogenboom, H.
(1997) Trends Biotechnol. 15: 62-70; Azzazy and ith (2002) Clin. Biochem. 35: 425-445;
Gavilondo and Larrick (2000) BioTechniques 29: 128-145; Hoogenboom and Chames (2000)
l. Today 21: 371-378 ), antibodies isolated from an animal (e.g., a mouse) that is transgenic
for human immunoglobulin genes (see, e.g., Taylor et al. (1992) Nucl. Acids Res. 20: 6287-6295;
Kellermann and Green (2002) Curr. Opin. Biotechnol. 13: 593—597; Little et al. (2000) Immunol.
Today 21:364-370) or antibodies prepared, expressed, created or isolated by any other means that
involves ng of human immunoglobulin gene sequences to other DNA sequences. Such
recombinant human antibodies have variable and constant regions derived from human germline
immunoglobulin ces. In certain embodiments, however, such recombinant human antibodies
are subjected to in vitro nesis (or, when an animal transgenic for human lg sequences is used,
in viva somatic mutagenesis) and thus the amino acid sequences of the VH and VL regions of the
recombinant antibodies are sequences that, while derived from and related to human germline VH
and VL sequences, may not naturally exist within the human antibody ne repertoire in vivo.
The term "chimeric antibody" refers to antibodies that comprise heavy and light chain
variable region sequences from one species and constant region sequences from another species,
such as antibodies having murine heavy and light chain variable regions linked to human constant
regions.
The term "CDR-grafted antibody" refers to antibodies that comprise heavy and light chain
variable region ces from one species but in which the sequences of one or more of the CDR
regions of VH and/or VL regions are replaced with CDR sequences of another species, such as
antibodies that have human heavy and light chain variable regions in which one or more of the
human CDRs (e.g., CDR3) has been replaced with murine CDR sequences, for example, as obtained
from a murine monoclonal antibody to human IL-loc.
As used herein, the term "CDR" refers to the complementarity determining region within
antibody variable sequences. There are three CDRs in each of the variable regions of the heavy
chain and the light chain, which are designated CDRl, CDR2, and CDR3, for each of the variable
regions. The term "CDR set" as used herein refers to a group of three CDRs that occur in a single
variable region (i.e., VH or VL) of an antigen binding site. The exact boundaries of these CDRs
have been defined differently according to different systems. The system bed by Kabat (Kabat
et al. (1987, 1991) ces of Proteins of Immunological Interest (National utes of Health,
2O Bethesda, Maryland) not only provides an guous residue numbering system applicable to any
variable region of an antibody, but also provides e e boundaries defining the three
CDRs. These CDRs may be referred to as Kabat CDRs. Chothia and coworkers (Chothia and Lesk
(1987) J. Mol. Biol. 196: 901-917 and Chothia et al. (1989) Nature 342: 877-883) found that certain
sub-portions within Kabat CDRs adopt nearly identical peptide backbone conformations, despite
having great diversity at the level of amino acid sequence. These sub-portions were designated as
L1, L2, and L3 or H1, H2, and H3, where the "L" and the "H" designates the light chain and the
heavy chains regions, respectively. These regions may be ed to as Chothia CDRs, which have
boundaries that overlap with Kabat CDRs. Other boundaries ng CDRs pping with the
Kabat CDRs have been described by Padlan et al. (1995) FASEB J. 9: 133-139 and MacCallum
3O (1996) J. Mol. Biol. 262(5): 732-?45). Still other CDR ry definitions may not strictly follow
one of the above systems, but will nonetheless overlap with the Kabat CDRs, although they may be
shortened or lengthened in light of prediction or experimental findings that particular residues or
groups of residues or even entire CDRs do not significantly impact n binding. The methods
used herein may utilize CDRs defined according to any of these systems, gh certain
embodiments use Kabat or Chothia defined CDRs.
The terms "Kabat numbering", "Kabat definition" and "Kabat labeling" are used
interchangeably herein. These terms refer to a system of numbering amino acid residues which are
more variable (i.e., hypervariable) than other amino acid residues in the heavy and light chain
variable s of an antibody, or an n binding portion thereof (Kabat et al. (1971) Ann. NY
Acad. Sci. 190: 382-391 and Kabat, E. et a1. (1991) Sequences of Proteins of Immunological
Interest Fifth Edition, US. Department of Health and Human es, NIH Publication No. 91-
3242). For the heavy chain variable region, the hypervariable region ranges from amino acid
positions 31 to 35 for CDRl, amino acid positions 50 to 65 for CDR2, and amino acid positions 95
to 102 for CDR3. For the light chain variable region, the hypervariable region ranges from amino
acid ons 24 to 34 for CDRl, amino acid positions 50 to 56 for CDR2, and amino acid positions
89 to 97 for CDR3.
The growth and analysis of extensive public databases of amino acid sequences of variable
heavy and light regions over the past twenty years have led to the understanding of the typical
boundaries between framework regions (FR) and CDR sequences within variable region sequences
and enabled persons skilled in this art to tely determine the CDRs according to Kabat
numbering, Chothia numbering, or other systems. See, e.g., Martin, "Protein Sequence and Structure
Analysis of Antibody Variable Domains," In Kontermann and Dubel, eds., Antibody ering
(Springer-Verlag, Berlin, 2001), r 31, pages 432—433. A useful method of determining the
amino acid sequences of Kabat CDRs within the amino acid sequences of variable heavy (VH) and
2O variable light (VL) regions is provided below:
To identify a CDR-L1 amino acid sequence:
Starts approximately 24 amino acid residues from the amino terminus of the
VL region;
Residue before the CDR—Ll sequence is always cysteine (C);
Residue after the CDR-L1 sequence is always a phan (W) residue,
typically Trp-Tyr-Gln (W-Y-Q), but also Trp-Leu-Gln (W-L-Q), Trp-Phe-
Gln (W-F-Q), and Trp-Tyr-Leu (W-Y-L);
Length is typically 10 to 17 amino acid residues.
To identify a CDR-L2 amino acid sequence:
3O Starts always 16 residues after the end of ;
Residues before the CDR-L2 sequence are lly Ile-Tyr (I-Y), but also
Val-Tyr (V-Y), Ile-Lys (I-K), and fle-Phe (I-F);
Length is always 7 amino acid es.
To identify a CDR-L3 amino acid sequence:
Starts always 33 amino acids after the end of CDR-L2;
Residue before the CDR-L3 amino acid sequence is always a cysteine (C);
Residues after the CDR—L3 sequence are always y-X-Gly (E-G-X-G)
(SEQ ID NO:7), where X is any amino acid;
Length is typically 7’ to 11 amino acid residues.
To identify a CDR-Hl amino acid sequence:
Starts approximately 31 amino acid residues from amino us of VH
region and always 9 residues after a cysteine (C);
Residues before the CDR-Hl sequence are always Cys—X—X-X-X-X-X-X-X
(SEQ ID NO: 151), where X is any amino acid;
Residue after CDR-Hl sequence is always a Trp (W), typically Trp-Val (W-
V), but also Trp-He (W-I), and Trp-Ala (W-A);
Length is typically 5 to 7 amino acid residues.
To identify a CDR-H2 amino acid sequence:
Starts always 15 amino acid es after the end of CDR-Hl;
Residues before CDR-H2 sequence are typically Leu-Glu-Trp-Ile-Gly (L-E-
W-I—G) (SEQ ID NO:8), but other variations also;
es after CDR-H2 sequence are LysiArg-Leu/Ile/VaUPhe/Thr/Ala-
Thr/Ser/Ile/Ala (K/R-L/I/V/F/T/A—T/S/IiA);
Length is typically 16 to 19 amino acid residues.
To identify a CDR-H3 amino acid sequence:
2O Starts always 33 amino acid residues after the end of CDR-H2 and always 3
after a ne (C)'
Residues before the CDR—H3 sequence are always Cys-X-X (C-X-X),
where X is any amino acid, typically Cys-Ala-Arg );
Residues after the CDR—H3 sequence are always Trp-Gly-X-Gly (W-G-X-
G) (SEQ ID NO:9), where X is any amino acid;
Length is typically 3 to 25 amino acid residues.
As used , the terms “acceptor" and "acceptor antibody" refer to the antibody or nucleic
acid sequence providing or ng at least 80%, at least 85%, at least 90%, at least 95%, at least
98%, or 100% of the amino acid sequences of one or more of the framework regions. In some
embodiments, the term "acceptor“ refers to the antibody amino acid or nucleic acid sequence
providing or encoding the constant region(s). In yet another embodiment, the term "acceptor" refers
to the antibody amino acid or nucleic acid sequence providing or encoding one or more of the
framework regions and the constant region(s). In a specific embodiment, the term "acceptor" refers
to a human antibody amino acid or nucleic acid sequence that provides or encodes at least 80%, at
least 85%, at least 90%, at least 95%, at least 98%, or 100% of the amino acid sequences of one or
more of the framework s. In accordance with this embodiment, an acceptor may contain at
least 1, at least 2, at least 3, least 4, at least 5, or at least 10 amino acid residues that does (do) not
occur at one or more specific ons of a human dy. An acceptor framework region and/or
acceptor constant region(s) may be, e.g., derived or obtained from a germline antibody gene, a
mature dy gene, a functional antibody (e.g., antibodies well-known in the art, antibodies in
development, or antibodies commercially available).
As used herein, the term “canonical" residue refers to a residue in a CDR or framework that
defines a particular canonical CDR structure as defined by Chothia et a1. (1987) J. Mol. Biol.
196:901-917 and Chothia et a1. (1992) J. Mol. Biol. 9-817). According to Chothia et a1.,
critical portions of the CDRs of many antibodies have nearly identical peptide backbone
confirmations despite great diversity at the level of amino acid sequence. Each canonical structure
specifies ily a set of peptide backbone torsion angles for a contiguous segment of amino acid
residues g a loop.
As used herein, the terms "donor" and "donor antibody" refer to an antibody ing one
or more CDRs. In one embodiment, the donor antibody is an antibody from a s different from
the antibody from which the framework regions are obtained or derived. In the context of a
humanized dy, the term "donor antibody" refers to a non-human antibody providing one or
more CDRs.
As used herein, the term "framework" or "framework sequence" refers to the remaining
sequences of a le region minus the CDRs. Because the exact definition of a CDR sequence
2O can be determined by different systems, the meaning of a ork sequence is subject to
correspondingly different interpretations. The six CDRs (CDR-L1, -L2, and -L3 of light chain and
CDR-H1, -H2, and -H3 of heavy chain) also divide the framework regions on the light chain and the
heavy chain into four sub-regions (FRl, FR2, FR3 and FR4) on each chain, in which CDRl is
positioned between FR1 and FR2, CDR2 between FR2 and FR3, and CDR3 between FR3 and FR4.
Without specifying the particular sub—regions as FRl, FR2, FR3 or FR4, a framework region, as
referred by , represents the combined FR's within the le region of a single, naturally
occurring immunoglobulin chain. As used herein, a FR represents one of the four sub- regions, and
FRs represents two or more of the four sub— regions constituting a framework region.
Human heavy chain and light chain acceptor sequences are known in the art. In one
embodiment of the invention the human heavy chain and light chain acceptor sequences are selected
from the sequences described in Table 3 and Table 4.
Table 3: Heavy Chain Acceptor Sequences
SEQ Protein region Sequence
I 123456789012345678901234567890
I VH2—70/JH6 FRl EVTLRESGPALVKPTQTLTLTCTFSGFSLS
I VH2—70/JH6 FRZ WIRQPPGKALEWLA
SEQ n region ce
123456789012345678901234567890
12 VH2—70/JH6 FR3 RLTISKDTSKNQVVLTMTNWDPVDTATYYC
13 VH2—70/JH6 FR4 WGQGTTVTVSS
14 VH2—26/JH6 FRl EVTLKESGPVLVKPTETLTLTCTVSGFSLS
VH2—26/JH6 FR2 WIRQPPGKALEWLA
16 VH2—26/JH6 FR3 DTSKSQVVLTMTNWDPVDTATYYC
17 VH2—26/JH6 FR4 WGQGTTVTVSS
18 VH3—72/JH6 FRl EVQLVESGGGLVQPGGSLRLSCAASGFTFS
19 VHa—vz/Jna FR2
VH3—72/JH6 FR3 RFTISRDDSKNSLYLQMNSLKTEDTAVYYC
21 VHa—vz/Jna FR4
22 VH3—21/JH6 FRl EVQLVESGGGLVKPGGSLRLSCAASGFTFS
23 VH3—21/JH6 FR2 WVRQAPGKGLEWVS
24 Vh3—21/JH6 FR3 RFTISRDNAKNSLYLQMNSARAEDTAVYYC
Vh3—21/JH6 FR4 WGQGTTVTVSS
26 Vhl—69/JH6 FRl EVQLVQSGAEVKKPGSSVKVSCKASGGTFS
27 Vhl—69/JH6 FR2 WVRQAPGQGLEWMG
28 Vhl—69/JH6 FR3 DKSTSTAYMELSSLRSEDTAVYYC
29 Vhl—69/JH6 FR4 WGQGTTVTVSS
so vu—ls/Jms m
31 Vhl—l8/JH6 FR2 WVRQAPGQGLEWMG
32 Vhl—l8/JH6 FR3 RVTMTTDTSTSTAYMELRSLRSJDTAVYYC
33 Vhl—l8/JH6 FR4 WGQGTTVTVSS
34 1/JH6 FRl QVQLVQSGSELKKPGASVKVSC<ASGYTFT
VH7—4.1/JH6 FR2 WVRQAPGQGLEWMG
36 1/JH6 FR3 RFVFSLDTSVSTAYLQISSLKAEDTAVYYC
37 VH7—4.l/JH6 FR4 WGQGTTVTVSS
Table 4: Light Chain Acceptor Sequences
SEQ Protein region Sequence
123456789012345678901234567890
38 B3/JK4 FRl DIVMTQSPDSLAVSLGERATINC
39 B3/JK4 FR2 WYQQKPGQPPKLLIY
40 B3/JK4 FR3 GVPDRFSGSGSGTDFTLTISSLQAEDVAVY
41 B3/JK4 FR4 VEIKR
42 L2/JK4 FRl EIVMTQSPATLSVSPGERATLSC
43 L2/JK4 FR2 WYQQKPGQAPRLLIY
44 L2/JK4 FR3 GIPARFSGSGSGTEFTLTISSLQSEDFAVY
45 L2/JK4 FR4 FGGGTKVEIKR
46 L15/JK4 FRl DIQMTQSPSSLSASVGDRVTITC
47 L15/JK4 FR2 WYQQKPEKAPKSLIY
48 L15/JK4 FR3 GVPSRFSGSGSGTDFTLTISSLQPEDFATY
49 L15/JK4 FR4 FGGGTKVEIKR
50 L5/JK4 FRl DIQMTQSPSSVSASVGDRVTITC
51 L5/JK4 FR2 WYQQKPGKAPKLLIY
SEQ Protein region Sequence
123456789012345678901234567890
52 L5/JK4 FR3 GVPSRFSGSGSGTDFTLTISSLQPEDFATY
53 L5/JK4 FR4 FGGGTKVEIKR
54 l8/JK2 FRl DIQMTQSPSSLSASVGDRVTITC
55 l—33/Ol8/JK2 FR2 WYQQKPGKAPKLLIY
56 1—33/018/JK2 GVPSRFSGSGSGTDFTFTISSLQPEDIATY
FR3 YC
57 1—33/018/JK2 FGQGTKLEIKR
58 1—33/018/JK4 FGGGTKVEIKR
As used herein, the term “germline dy gene" or "gene fragment" refers to an
globulin sequence encoded by non- lymphoid cells that have not undergone the maturation
process that leads to genetic rearrangement and mutation for expression of a particular
globulin (see, e.g., Shapiro et al. (2002) Crit. Rev. Immunol. 22(3): 183-200; Marchalonis et
al. (2001) Adv. Exp. Med. Biol. 484:13-30). One of the advantages provided by s
embodiments of the present invention stems from the recognition that germline antibody genes are
more likely than mature antibody genes to conserve essential amino acid sequence structures
teristic of duals in the species, hence less likely to be recognized as from a foreign
source when used therapeutically in that species.
As used herein, the term "key" residues refer to certain residues within the variable region
that have more impact on the binding specificity and/or affinity of an dy, in particular a
humanized antibody. A key residue includes, but is not limited to, one or more of the following: a
residue that is adjacent to a CDR, a potential glycosylation site (can be either N— or O-glycosylation
site), a rare residue, a residue capable of interacting with the n, a residue capable of interacting
with a CDR, a canonical residue, a contact residue between heavy chain variable region and light
chain variable region, a residue within the Vernier zone, and a residue in the region that overlaps
between the Chothia definition of a variable heavy chain CDRl and the Kabat tion of the first
heavy chain framework.
2O The term "humanized antibody" refers to antibodies that comprise heavy and light chain
variable region sequences from a man species (e.g., a mouse) but in which at least a portion
of the VH and/or VL sequence has been altered to be more "human-like", i.e., more similar to human
germline variable sequences. One type of zed antibody is a CDR-grafted antibody, in which
mmhmmmCDmewmwamhMmmwdmwhmmnVHmmVquwmmMommmeme
corresponding non-human framework (FR) sequences. For example, a "humanized antibody" is an
antibody or a variant, derivative, , or nt thereof which immunospecifically binds to an
antigen of interest and which comprises a framework (FR) region having substantially the amino
acid sequence of a human antibody and a mentary determining region (CDR) having
substantially the amino acid sequence of a non-human dy. As used herein, the term
"substantially" in the context of a CDR refers to a CDR having an amino acid sequence at least 80%,
at least 85 %, at least 90%, at least 95%, at least 98% or at least 99% identical to the amino acid
sequence of a non-human dy CDR. A zed antibody comprises substantially all of at
least one, and typically two, variable domains (Fab, Fab’, F(ab‘)2, FabC, Fv) in which all or
substantially all of the CDR regions correspond to those of a non—human immunoglobulin (i.e.,
donor antibody) and all or ntially all of the framework regions are those of a human
immunoglobulin consensus sequence. In an ment, a humanized antibody also comprises at
least a n of an immunoglobulin constant region (Fc), typically that of a human
immunoglobulin. In some embodiments, a humanized antibody contains both the light chain as well
as at least the variable domain of a heavy chain. The dy also may include the CH1, hinge,
CH2, CH3, and CH4 s of the heavy chain. In some embodiments, a humanized antibody only
contains a humanized light chain. In some embodiments, a humanized antibody only contains a
humanized heavy chain. In specific embodiments, a humanized antibody only contains a zed
variable domain of a light chain andior humanized heavy chain.
The humanized antibody can be selected from any class of immunoglobulins, including IgM,
IgG, IgD, IgA and IgE, and any isotype, including without limitation IgGl, IgG2, IgG3, and IgG4.
The humanized antibody may comprise sequences from more than one class or isotype, and
2O ular constant domains may be selected to optimize desired effector functions using techniques
well-known in the art.
The framework and CDR regions of a zed dy need not correspond precisely to
the parental sequences, e.g., the donor antibody CDR or the consensus framework may be
mutagenized by substitution, insertion and/or deletion of at least one amino acid residue so that the
CDR or framework residue at that site does not correspond to either the donor antibody or the
consensus framework. In one embodiment, such mutations, however, will not be extensive.
Usually, at least 80%, at least 85%, at least 90%, and at least 95% of the humanized antibody
residues will correspond to those of the parental FR and CDR sequences. As used herein, the term
"consensus framewor " refers
to the framework region in the consensus immunoglobulin sequence.
As used herein, the term "consensus immunoglobulin sequence" refers to the sequence formed from
the most frequently occurring amino acids (or nucleotides) in a family of related immunoglobulin
sequences (see, e.g., Winnaker (1987) From Genes to Clones gsgesellschaft, Weinheim,
Germany». A "consensus immunoglobulin sequence" can thus comprise a nsus variable
domain" and/or a "consensus constant domain". A "consensus variable domain" can in turn
comprise one or more "consensus framework s" andior one or more "consensus CDRs". In a
family of immunoglobulins, each position in the consensus sequence is occupied by the amino acid
occurring most frequently at that position in the family. If two amino acids occur equally frequently,
either can be included in the consensus ce.
As used herein, "Vernier" zone refers to a subset of framework residues that may adjust
CDR structure and fine-tune the fit to antigen as described by Foote and Winter (1992) J. Mol. Biol.
224:487-499. Vernier zone residues form a layer underlying the CDRs and may impact on the
ure of CDRs and the affinity of the antibody.
The term "multivalent binding protein" is used in this specification to denote a g
protein comprising two or more antigen binding sites. The multivalent binding protein is engineered
to have the three or more antigen binding sites, and is generally not a naturally occurring antibody.
The term "multispecific binding n" refers to a binding n capable of binding two or more
related or unrelated targets. Dual variable domain (DVD) binding proteins are binding proteins that
comprise two or more antigen binding sites and are alent or multivalent binding proteins. Such
DVD binding proteins may be monospecific, i.e., e of binding one antigen or pecific,
i.e., capable of binding two or more antigens. DVD binding proteins sing two heavy chain
DVD polypeptides and two light chain DVD polypeptides are referred to as a DVD-IgTM molecule.
Each half of a DVD-IgTM molecule comprises a heavy chain DVD polypeptide, and a light chain
DVD polypeptide, and two antigen binding sites. Each binding site comprises a heavy chain
variable domain and a light chain variable domain with a total of 6 CDRs involved in antigen
binding per antigen binding site. DVD binding ns and methods of making DVD binding
2O proteins are disclosed in U.S. Patent No. 7,612,181.
One aspect of the invention ns to a DVD binding protein comprising binding proteins
capable of binding human IL-lot. In another aspect, the DVD binding protein is capable of binding
IL-loc and a second . In one embodiment, the DVD binding protein is capable of binding
IL-loc and IL-lB.
The term "neutralizing" refers to neutralization of biological activity of a cytokine when a
binding protein specifically binds the cytokine. In an embodiment, a neutralizing binding n is
a neutralizing antibody, whose binding to hlL-l on results in inhibition of a biological ty of hIL-
10L. In an embodiment, the neutralizing binding protein binds hIL—l 0c and reduces a biologically
activity of hIL-lOL by at least about 20%, at least about 40%, at least about 60%, at least about 80%,
at least about 85%, at least about 90%, at least about 95%, or at least about 100%. Inhibition of a
biological activity of L by a neutralizing binding protein can be assessed by ing one or
more indicators of hIL—loc biological activity well known in the art.
The term "epitope" includes any polypeptide determinant e of specific binding to an
immunoglobulin or T-cell receptor. In certain embodiments, epitope determinants include
chemically active surface groupings of molecules such as amino acids, sugar side chains,
phosphoryl, or sulfonyl, and, in certain embodiments, may have specific three dimensional structural
characteristics, and/or specific charge characteristics. An epitope is a region of an antigen that is
bound by an antibody. An e thus ts of the amino acid residues of a region of an antigen
(or fragment thereof) known to bind to the complementary site on the specific binding r. An
nic fragment can contain more than one epitope. In certain embodiments, an antibody is said to
specifically bind an n when it recognizes its target antigen in a complex mixture of proteins
and/or macromolecules. Antibodies are said to "bind to the same epitope" if the antibodies cross-
compete (one ts the binding or modulating effect of the other). In addition structural
definitions of epitopes apping, similar, identical) are informative, but functional definitions are
often more relevant as they encompass structural (binding) and functional (modulation, competition)
parameters.
The term "surface plasmon nce", refers to an optical phenomenon that allows for the
analysis of real-time biospecific interactions by detection of alterations in protein trations
within a biosensor matrix, for example using the BIACORETM system (Biacore International AB, a
GE Healthcare company, Uppsala, Sweden and Piscataway, New Jersey). For further descriptions,
see J6nsson, U. et al. (1993) Ann. Biol. Clin. 51:19-26; Jonsson, U. et al. (1991) BioTechniques 11:
620-627; Johnsson, B. et al. (1995) J. Mol. it. 8: 125-131; and Johnsson, B. et al. (1991)
Anal. Biochem. 198: 268-277.
The term "Kon" refers to the on rate constant for association of a binding protein (e.g., an
antibody) to the antigen to form the, e.g., antibody/antigen complex as is known in the art. The
"Kon" also is known by the terms "association rate constant," or "ka," as used interchangeably
herein. This value indicating the g rate of an antibody to its target antigen or the rate of
complex formation between an antibody and antigen also is shown by the equation:
Antibody ("Ab") + n ("Ag")—>Ab-Ag.
The term "Koff" refers to the off rate nt for dissociation of a binding protein (e.g., an
antibody) from the, e.g., antibody/antigen complex as is known in the art. The "Koff" also is known
by the terms "dissociation rate constant" or "kd" as used interchangeably herein. This value
indicates the dissociation rate of an antibody from its target antigen or separation of Ab-Ag complex
over time into free antibody and antigen as shown by the equation below:
Ab + Ag<—Ab-Ag.
The terms "equilibrium dissociation constant" or "KD," as used interchangeably herein, refer
to the value obtained in a titration measurement at equilibrium, or by dividing the dissociation rate
constant (koff) by the association rate constant (kon). The association rate nt, the dissociation
rate constant, and the equilibrium dissociation constant are used to represent the binding affinity of
an antibody to an antigen. s for determining association and dissociation rate constants are
well known in the art. Using fluorescence—based techniques offers high sensitivity and the ability to
examine samples in physiological buffers at equilibrium. Other experimental ches and
instruments such as a BIACORETM (biomolecular interaction analysis) assay can be used (e.g.,
instrument available from Biacore International AB, a GE Healthcare company, Uppsala, Sweden).
Additionally, a KinExA® tic on Assay) assay, available from Sapidyne Instruments
(Boise, Idaho) can also be used.
The term "labeled binding protein" as used herein, refers to a protein with a label
incorporated that provides for the identification of the binding protein. In one aspect, the label is a
able marker, e.g., incorporation of a radiolabeled amino acid or ment to a polypeptide of
biotinyl es that can be detected by marked avidin (e.g., streptavidin containing a fluorescent
marker or enzymatic activity that can be detected by optical or colorimetric methods). Examples of
labels for polypeptides include, but are not limited to, the following: radioisotopes or radionuclides
(e.g., 3H, 14C, 358, 90Y, 99Tc, 111In, 125I, 131I, 177Lu, 166Ho, and 153Sm); fluorescent labels (e.g., FITC,
rhodamine, and nide phosphors), enzymatic labels (e.g., adish peroxidase, luciferase,
alkaline phosphatase); chemiluminescent markers; biotinyl ; ermined polypeptide
epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for
secondary antibodies, metal binding domains, and epitope tags); and magnetic agents, such as
gadolinium chelates.
The term "antibody ate" refers to a binding protein, such as an antibody, chemically
linked to a second chemical moiety, such as a therapeutic or cytotoxic agent. The term "agent" is
used herein to denote a chemical compound, a mixture of chemical compounds, a biological
macromolecule, or an extract made from biological als. In one aspect the therapeutic or
cytotoxic agents include, but are not limited to, pertussis toxin, taxol, cytochalasin B, gramicidin D,
um bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine,
doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D,
drotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin
and analogs or homologs thereof.
The terms "crystal" and "crystallized" refer to an antibody, or antigen binding portion
thereof, that exists in the form of a crystal. Crystals are one form of the solid state of matter, which
is distinct from other forms such as the amorphous solid state or the liquid crystalline state. ls
are composed of regular, repeating, dimensional arrays of atoms, ions, molecules (e.g., proteins
such as antibodies), or molecular assemblies (e.g., antigen/antibody complexes). These three-
dimensional arrays are arranged according to specific mathematical relationships that are well-
tood in the field. The fundamental unit, or building block, that is repeated in a l is called
the tric unit. Repetition of the asymmetric unit in an arrangement that conforms to a given,
well-defined crystallographic symmetry provides the "unit cell" of the crystal. Repetition of the unit
cell by r translations in all three dimensions provides the l. See Giegé and Ducruix
(1999) Chapter 1, In Crystallization of c Acids and Proteins, a cal Approach, 2nd ed.,
(Ducruix and Giegé, eds.) (Oxford University Press, New York, 1999) pp. l-l6.
The term "polynucleotide" means a polymeric form of two or more nucleotides, either
cleotides or deoxynucleotides, or a modified form of either type of nucleotide. The term
includes single and double ed forms of DNA or RNA, but in an embodiment is -
stranded DNA.
The term "isolated polynucleotide" means a cleotide (e.g., of genomic, cDNA, or
synthetic origin, or a combination thereof) that is not associated with all or a portion of a
polynucleotide with which it is associated in nature, with which it is operably linked to in nature, or
with which it occurs in nature as part of a larger sequence.
The term "vector" refers to a nucleic acid le capable of orting another nucleic
acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double
stranded DNA loop into which additional DNA segments may be d. Another type of vector is a
Viral vector, wherein additional DNA segments may be ligated into the Viral genome. Certain vectors
are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial
vectors having a bacterial origin of replication and episomal mammalian vectors). Other s
(e. g., isomal mammalian vectors) can be integrated into the genome of a host cell upon
introduction into the host cell, and thereby are replicated along with the host genome. Moreover,
certain vectors are capable of directing the expression of genes to which they are operatively linked.
Such vectors are ed to herein as "recombinant expression vectors" (or simply, "expression
vectors"). In general, expression vectors of utility in recombinant DNA techniques are often in the
form of plasmids. In the present specification, id" and "vector" may be used interchangeably
as the plasmid is the most commonly used form of vector. However, the invention is intended to
include such other forms of expression s, such as viral vectors (e.g., replication defective
retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.
The term "operably linked“ refers to a positioning of components such that they function in
their intended manner. A control sequence "operably linked" to a coding ce is ligated in such
3O a way that sion of the coding sequence is achieved under conditions compatible with the
control sequences. "Operably linked“ sequences include expression control sequences that are
contiguous with a nucleic acid of interest, expression control sequences that act in trans, i.e., are
located on a different nucleic acid molecule than a nucleic acid of interest but nevertheless exert
control over the nucleic acid of interest, and expression control sequences that are located on the
same nucleic acid molecule as, but at a distance from, a nucleic acid of interest. The term
"expression control sequence" as used herein refers to polynucleotide ces that are necessary
to effect the sion and processing of coding sequences to which they are ligated. Expression
control sequences include appropriate transcription tion, termination, promoter and enhancer
sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences
that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (i.e., Kozak
consensus sequence); sequences that enhance protein stability; and when desired, sequences that
enhance protein ion. The nature of such control sequences differs depending upon the host
organism; in yotes, such control ces generally include er, ribosomal binding site,
and transcription termination sequence; in eukaryotes, generally, such control sequences include
promoters and transcription termination ce. The term "control sequences" is intended to
include components whose presence is essential for expression and processing, and can also include
additional components whose presence is advantageous, for example, leader sequences and fusion
partner sequences.
"Transformation" refers to any process by which ous DNA enters a host cell.
ormation may occur under natural or artificial conditions using various methods well known
in the art for the ion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host
cell, for example. The method is selected based on the host cell being ormed and may include,
but is not limited to, viral infection, electroporation, lipofection, and particle bombardment. Such
"transformed" cells include stably transformed cells in which the inserted DNA is capable of
replication either as an autonomously replicating plasmid or as part of the host chromosome. They
also include cells which ently express the inserted DNA or RNA for limited periods of time.
The term "recombinant host cell" (or simply "host , as used herein, is intended to refer
to a cell into which exogenous DNA has been introduced. Such terms are intended to refer not only
to the particular subject cell, but to the progeny of such a cell. Because certain modifications may
occur in succeeding generations due to either mutation or environmental influences, such progeny
may not, in fact, be identical to the parent cell, but are still ed within the scope of the term
"host cell" as used herein. In one aspect, host cells include prokaryotic and eukaryotic cells selected
from any of the Kingdoms of life. Eukaryotic cells e t, fungal, plant and animal cells. In
another aspect, host cells include, but are not limited to, the prokaryotic cell line Escherichia coli;
mammalian cell lines CHO, HEK 293, and COS; the insect cell line Sf9; and the fungal cell
3O Saccharomyces cerevisiae.
Standard techniques may be used for recombinant DNA, oligonucleotide synthesis, and
tissue culture and ormation (e.g., electroporation and lipofection). Enzymatic reactions and
purification techniques may be performed according to manufacturer's specifications or as
commonly accomplished in the art or as described herein. The foregoing ques and procedures
may be lly performed according to conventional methods well known in the art and as
described in various general and more specific references that are cited and discussed throughout the
present specification. See e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2d ed.
(Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989).
The term "transgenic organism" refers to an organism having cells that contain a transgene,
wherein the transgene introduced into the organism (or an ancestor of the organism) ses a
polypeptide not naturally expressed in the organism. A "transgene" is a DNA construct that is stably
and operably integrated into the genome of a cell from which a transgenic organism develops,
directing the expression of an d gene product in one or more cell types or tissues of the
transgenic organism.
The terms "regulate" and “modulate" are used interchangeably and refer to a change or an
alteration in the activity of a molecule of interest (e.g., the biological activity of hIL-lu). Modulation
may be an increase or a decrease in the magnitude of a certain activity or function of the molecule of
st. Exemplary ties and functions of a molecule e, but are not limited to, binding
characteristics, enzymatic activity, cell or activation, and signal transduction.
Correspondingly, the term "modulator" is a compound capable of changing or altering an
activity or function of a molecule of st (e.g., the ical ty of c). For example, a
modulator may cause an increase or decrease in the magnitude of a certain activity or function of a
molecule compared to the magnitude of the activity or function observed in the absence of the
modulator. In certain embodiments, a modulator is an inhibitor, which decreases the magnitude of at
least one ty or function of a molecule. Exemplary inhibitors include, but are not limited to,
proteins, peptides, antibodies, peptibodies, carbohydrates or small organic molecules. Peptibodies
are described, e.g., in PCT Publication No. WO 01/83525.
The term "agonist" refers to a modulator that, when contacted with a molecule of interest,
causes an increase in the magnitude of a certain activity or function of the le compared to the
magnitude of the activity or function observed in the absence of the agonist. Particular ts of
interest may include, but are not limited to, a polypeptide, a c acid, a carbohydrate, or any
other molecule that binds to IL—loc andior IL—l[3.
The term "antagonist" or “inhibitor" refers to a modulator that, when contacted with a
molecule of interest, causes a decrease in the magnitude of a certain ty or function of the
molecule compared to the ude of the activity or function observed in the absence of the
antagonist. nists include those that block or modulate the biological or immunological
activity of IL-lOL and/or IL-ll3. Antagonists and inhibitors of IL-loc may include, but are not limited
to, a polypeptide, a nucleic acid, a carbohydrate, or any other molecule that binds to lL-loc.
nists and inhibitors of IL—lB may e, but are not limited to, a polypeptide, a nucleic acid,
a carbohydrate, or any other molecule that binds to IL-1 [3.
The term "effective amount" refers to the amount of a therapy that is sufficient to reduce or
ameliorate the severity and/or duration of a er or one or more symptoms thereof, t the
advancement of a disorder, cause regression of a disorder, prevent the ence, development,
onset or progression of one or more symptoms associated with a disorder, detect a disorder, or
enhance or improve the lactic or therapeutic effect(s) of another y (e.g., prophylactic or
therapeutic agent).
The term "sample" is used in its broadest sense. A gical sample" includes, but is not
limited to, any quantity of a substance from a living thing or ly living thing. Such living
things e, but are not limited to, humans, mice, rats, monkeys, dogs, rabbits and other animals.
Such substances include, but are not limited to, blood, serum, urine, al fluid, cells, organs,
tissues, bone marrow, lymph nodes, and spleen.
An "affinity matured" antibody is one with one or more alterations in one or more CDRs or
frameworks thereof which result in an improvement in the affinity of the antibody for antigen
compared to a parent antibody that does not possess such alteration(s). red affinity matured
dies will have nanomolar or even picomolar affinities for the target antigen. Affinity matured
antibodies are ed by procedures known in the art. Marks et al. (1992) BioTechnology 10: 779-
783 describes y maturation by VH and VL domain shuffling. Random mutagenesis of CDR
and/or framework residues is described by Barbas et al. (1994) Proc Nat. Acad. Sci. USA 91: 3809-
3813; Schier et al. (1995) Gene 169: 147-155; Yelton et al. (1995) J. Immunol. 155: 1994-2004;
2O n et al. (1995) J. Immunol. 154(7): 3310-3319; and Hawkins et al. (1992) J. Mol. Biol., 226:
889-896.
Pain that persists in an individual after an initial cause for pain has disappeared is no longer
a symptom but a recognized disease in its own right. The term "allodynia" as used herein refers to a
condition in which an individual experiences a painful se to a normally innocuous stimulus,
typically of a mechanical nature, such as brushing of the skin. Allodynic pain does not involve
nociceptors and therefore may also be referred to as "non-nociceptive" pain. The term
"hyperalgesia" as used herein refers to a condition in which an individual has an increased sensitivity
to pain that results from a noxious stimulus, especially a stimulus that activates nociceptors, such as
a painful mechanical, thermal, or chemical stimulation. A stimulus that activates nociceptors causes
3O pain. Hyperalgesia is a condition in which an dual has an increased pain response to a
normally noxious stimulus. An dual may suffer from allodynia, hyperalgesia, or a combination
of allodynia and hyperalgesia.
1. Generation of DVD-IgTM Binding Proteins that Bind IL-loc and IL-ll3
The design and production of dual variable domain immunoglobulin (DVD-IgTM) binding
proteins that are capable of binding one or more target antigens (or epitopes) have been described
(see, e.g., PCT Publication No. ). A DVD—lg binding protein useful in the methods
and compositions described herein for treating osteoarthritis binds IL-loc and IL-ll3. In an
embodiment, a TM binding protein comprises at least two polypeptide chains, wherein the
first ptide chain comprises l)n-VD2-C-(X2)n, wherein VDl is a first heavy chain
variable domain, VD2 is a second heavy chain variable domain, C is a heavy chain constant ,
X1 is a linker with the proviso that it is not CH1, and X2 is an Fc region; and wherein said second
polypeptide chain comprises VDl-(Xl)n-VD2—C-(X2)n, n VDl is a first light chain variable
domain, VD2 is a second light chain variable domain, C is a light chain constant , X1 is a
linker with the proviso that it is not CH1, and X2 does not comprise an Fc region; and n is 0 or 1. A
DVD-lgTM g protein consisting of the first and second polypeptide chains has two antigen
binding sites.
In another embodiment, a DVD-lgTM binding protein comprises four polypeptide chains
wherein each of the first two polypeptide chains comprises VDl -(Xl)n-VD2-C-(X2)n, respectively
wherein VDl is a first heavy chain variable domain, VD2 is a second heavy chain variable domain,
C is a heavy chain constant domain, X1 is a linker with the proviso that it is not CH1, and X2 is an
Fc ; and each of the second two polypeptide chains comprises VDl-(X1)n-VD2-C-(X2)n
respectively, wherein VDl is a first light chain variable domain, VD2 is a second light chain
variable domain, C is a light chain constant domain, X1 is a linker with the proviso that it is not
CH1, and X2 does not comprise an Fc region; and n is 0 or 1. Such a DVD-IgTM g protein has
four antigen binding sites.
2O By way of example, a DVD-Ig binding protein useful in the methods and compositions
described herein for treating osteoarthritis in an dual may be engineered to have a g site
for IL-1[3 formed by the ation of the VDl variable domains of the two (first and second
polypeptides) and a binding site for IL—loc formed by the association of the VD2 variable domains of
the two (first and second polypeptides). In an ative arrangement, a DVD-Ig binding protein
useful in the methods and compositions described herein for treating osteoarthritis in an individual
may have a binding site for IL—loc formed by the association of the VDl variable domains of the two
(first and second polypeptides) and a binding site for IL—l[3 formed by the association of the VD2
variable domains of the two (first and second polypeptides).
A. Generation of Parent Monoclonal Antibodies
The variable domains of the DVD binding protein can be ed from parent antibodies,
including polyclonal and onal antibodies capable of binding antigens of interest. These
antibodies may be naturally occurring or may be generated by recombinant technology.
Monoclonal antibodies can be prepared using a wide y of techniques known in the art
including the use of hybridoma, recombinant, and phage display technologies, or a combination
thereof. For example, monoclonal antibodies can be produced using hybridoma techniques including
those known in the art and taught, for example, in Harlow et al., Antibodies: A tory Manual,
2nd ed., (Cold Spring Harbor Laboratory Press, 1988); Hammerling, et al., Monoclonal Antibodies
and T-Cell Hybridomas (Elsevier, N.Y., 1981), pages 563-581 (said references orated by
reference in their entireties). The term "monoclonal antibody" (abbreviated "mAb") as used herein
is not limited to antibodies produced h hybridoma technology. The term "monoclonal
antibody" refers to an antibody that is derived from a single clone, including any otic,
prokaryotic, or phage clone, and not the method by which it is produced. Hybridomas are selected,
cloned and further screened for desirable characteristics, including robust oma growth, high
antibody production and desirable antibody characteristics using standard methods. Hybridomas
may be cultured and expanded in vivo in syngeneic animals, in animals that lack an immune system,
e. g., nude mice, or in cell culture in vitro. Methods of selecting, cloning, and expanding hybridomas
are well known to those of ordinary skill in the art. In a red embodiment, hybridomas are
mouse hybridomas. In another ment, hybridomas are produced in a non-human, non-mouse
species such as rats, sheep, pigs, goats, cattle, or horses. In r embodiment, the omas are
human hybridomas in which a human non-secretory a is fused with a human cell expressing
an antibody capable of binding a specific desired antigen, such as IL-10t or IL-1B.
Recombinant monoclonal antibodies are also generated from , isolated lymphocytes
using a procedure referred to in the art as the selected lymphocyte antibody method (SLAM), as
described in U.S. Patent No. 5,627,052, PCT Publication WO 92/02551 and Babcook et al. (1996)
2O Proc. Natl. Acad. Sci. USA 93:7843-7848. In this method, single cells secreting antibodies of
interest, e.g., lymphocytes derived from an immunized animal, are identified, and, heavy- and light-
chain le region cDNAs are rescued from the cells by reverse transcriptase-PCR and these
variable s can then be expressed, in the t of appropriate immunoglobulin constant
regions (6. g., human constant regions), in mammalian host cells, such as COS or CHO cells. The
host cells transfected with the amplified immunoglobulin sequences, derived from in viva selected
lymphocytes, can then undergo further analysis and selection in vitro, for e by panning the
transfected cells to isolate cells expressing antibodies to the antigen of interest. The amplified
immunoglobulin sequences further can be manipulated in vitro, such as by in vitro ty
maturation methods such as those described in PCT Publication No. WO 97/29131 and PCT
Publication No. WO 00/56772.
Monoclonal antibodies are also produced by immunizing a non-human animal comprising
some or all of a human immunoglobulin locus with an antigen of interest. In an embodiment, the
non-human animal is a XENOMOUSE transgenic mouse, which is an engineered mouse strain that
comprises large fragments of the human immunoglobulin loci and is ent in mouse antibody
production. See, e.g., Green et al. (1994) Nature Genetics 7:13-21 and US Patent Nos. 5,916,771;
598; 5,985,615; 5,998,209; 6,075,181; 6,091,001; 6,114,598; and 6,130,364. See also PCT
Publication Nos. W0 91/10741; W0 94/02602; W0 96/34096; W0 96/33735; W0 98/16654; W0
98/24893; W0 33; W0 99/45031; W0 99/53049; W0 00/09560; and W0 00/037504. The
XENOMOUSE transgenic mouse produces an adult-like human oire of fully human
antibodies, and generates antigen-specific human monoclonal antibodies. The XENOMOUSE
transgenic mouse contains approximately 80% of the human antibody repertoire through
uction of se sized, germline configuration YAC fragments of the human heavy chain
loci and x light chain loci. See, Mendez et al. (1997) Nature Genet. 15: 146-156 and Green and
Jakobovits (1998) J. Exp. Med. 188: 483-495.
In vitro s also can be used to make the parent antibodies, wherein an antibody library
is screened to identify an dy having the desired binding specificity. Methods for such
screening of recombinant antibody libraries are well known in the art and include methods described
in, for example, US Patent No. 5,223,409; PCT Publication Nos. W0 92/18619; W0 91/17271; W0
92/20791; W0 92/15679; W0 93/01288; WO 92/01047; W0 92/09690; W0 97/29131; and Fuchs et
al. (1991) Bio/Technology 9: 1369-1372; Hay et al. (1992) Hum. Antibod. Hybridomas 3: 81-85;
Huse et al. (1989) Science 246: 1275-1281; McCafferty et al. (1990) Nature 348: 4; Griffiths
et al. (1993) EMBO J. 12: 725-734; Hawkins et al. (1992) J. Mol. Biol. 226: 889-896; Clackson et
al. (1991) Nature 352: 624-628; Gram et al. (1992) Proc. Natl. Acad. Sci. USA 89: 3576-3580;
Garrard et al. (1991) Bio/Technology 9: 377; Hoogenboom et al. (1991) Nucl. Acid Res. 19:
2O 4133-4137; and Barbas et al. (1991) Proc. Natl. Acad. Sci. USA 88: 7978-7982, and US Patent
Publication No. 2003/0186374.
Parent antibodies useful in the present invention can also be generated using various phage
display methods known in the art. In phage display methods, functional dy domains are
displayed on the surface of phage particles which carry the polynucleotide sequences encoding them.
In a particular, such phage can be utilized to display antigen-binding domains expressed from a
oire or atorial antibody library (e.g., human or murine). Phage expressing an antigen
binding domain that binds the antigen of st can be selected or identified with antigen, e.g.,
using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these
methods are typically filamentous phage including fd and M13 binding domains expressed from
3O phage with Fab, Fv or disulfide ized FV antibody domains recombinantly fused to either the
phage gene III or gene VIII protein. Examples of phage display methods that can be used to make
the antibodies of the present invention include those disclosed in Brinkman et a1. (1995) J. l.
s 182:41-50; Ames et al. (1995) J. Immunol. Methods 184: 177-186; Kettleborough et a1.
(1994) Eur. J. Immunol. 24: 952-958; Persic et al. (1997) Gene 187: 9-18; Burton et al. (1994) Adv.
l. 57: 0; PCT Application Nos. PCT/GB91i01134; PCT Publication Nos. W0
90/02809; W0 91/10737; W0 92/01047; WO 92/18619; W0 93/11236; W0 95/15982; and W0
01; and US Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,821,047;
,571,698; 5,427,908; 5,516,637; 5,780, 225; 5,658,727; 5,733,743 and 108.
As described in the above references, after phage selection, the antibody coding regions
from the phage can be isolated and used to generate whole dies including human antibodies or
any other desired antigen binding fragment, and expressed in any desired host, including mammalian
cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example,
techniques to recombinantly produce Fab, Fab', and F(ab’)2 fragments can also be employed using
methods lmown in the art such as those disclosed in PCT Publication No. WO 92/22324; Mullinax et
a1. (1992) BioTechniques 12(6): 864-869; and Sawai et a1. (1995) AJRI 34: 26-34; and Better et a1.
(1988) Science, 240: 1041-1043. Examples of techniques which can be used to produce single-chain
Fvs and antibodies include those described in US Patent Nos. 4,946,778 and 5,258,498; Huston et a1.
(1991) Methods Enzymol. 203: 46-88; Shu et al. (1993) Proc. Natl. Acad. Sci. USA 90: 7995-7999;
and Skerra et al. (1988) Science 240: 1038-1041.
Alternative to screening of recombinant antibody libraries by phage display, other
methodologies known in the art for screening large combinatorial libraries can be applied to the
identification of parent antibodies. One type of alternative expression system is one in which the
recombinant antibody library is sed as RNA—protein fusions, as described in PCT Publication
No. WO 98/31700 by Szostak and Roberts, and in Roberts, R.W. and Szostak, J.W. (1997) Proc.
Natl. Acad. Sci. USA, 94: 12297-12302. In this system, a covalent fusion is created between an
2O mRNA and the e or protein that it encodes by in vitro translation of synthetic mRNAs that
carry puromycin, a peptidyl or otic, at their 3‘ end. Thus, a specific mRNA can be
enriched from a complex mixture of mRNAs (e.g., a combinatorial library) based on the properties
of the encoded peptide or protein, e.g., dy, or portion thereof, such as binding of the antibody,
or portion thereof, to the dual icity antigen. Nucleic acid sequences encoding antibodies, or
portions thereof, recovered from screening of such libraries can be expressed by recombinant means
as bed above (e.g., in mammalian host cells) and, moreover, can be subjected to further affinity
maturation by either additional rounds of screening of mRNA-peptide fusions in which mutations
have been introduced into the originally selected sequence(s), or by other s for affinity
maturation in vitro of recombinant antibodies, as described above.
3O In another approach the parent antibodies can also be generated using yeast display methods
lmown in the art. In yeast display methods, genetic s are used to tether antibody s to
the yeast cell wall and display them on the surface of yeast. In particular, such yeast can be utilized
to display antigen-binding domains expressed from a repertoire or combinatorial antibody y (e.
g., human or ). Examples of yeast display methods that can be used to make the parent
antibodies e those sed in US Patent No. 6,699,658.
The antibodies described above can be further modified to te CDR-grafted and
humanized parent antibodies. CDR-grafted parent antibodies comprise heavy and light chain
variable region sequences from a human antibody wherein one or more of the CDR regions of VH
and/or VL are replaced with CDR sequences of murine antibodies capable of binding antigen of
st. A framework sequence from any human antibody may serve as the te for CDR-
grafting. However, straight chain ement onto such a framework often leads to some loss of
binding affinity to the antigen. The more homologous a human antibody is to the original murine
antibody, the less likely the possibility that combining the murine CDRs with the human framework
will introduce distortions in the CDRs that could reduce affinity. ore, it is preferable that the
human variable framework that is chosen to replace the murine variable framework apart from the
CDRs have at least a 65% sequence identity with the murine antibody variable region framework. It
is more preferable that the human and murine variable regions apart from the CDRs have at least
70% sequence identify. It is even more preferable that the human and murine variable regions apart
from the CDRs have at least 75% sequence identity. It is most preferable that the human and murine
variable s apart from the CDRs have at least 80% sequence identity. Methods for producing
such antibodies are known in the art (see, EP 0; PCT Publication WO 91/09967; US Patent
Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596;
Padlan (1991) Mol. Immunol. 28(4/5): 489-498; Studnicka et al. (1994) Protein Engineering 7(6):
805-814; Roguska et al. (1994) Proc. Natl. Acad. Sci. USA 91: 969-973), and chain shuffling (US.
2O Patent No. 5,565,352).
Humanized antibodies are antibody molecules from non-human species antibody that binds
the desired antigen having one or more complementarity determining regions (CDRs) from the non-
human s and framework regions from a human immunoglobulin molecule. Known human lg
sequences are disclosed, e.g., www.ncbi.nlm.nih.gov/entrez- /query.fcgi;
www.atcc.org/phage/hdbhtml; iquest.coml; www.abcam.coml;
www.antibodyresource.com/onlinecomp.html;
www.public.iastate.edul.about.pedroiresearch_tools.html; www.mgen.uni-
heidelberg.de/SD/IT/IThtml; www.whfreeman.com/immunology/CH— 05/kuby05.htm;
brary.thinkquest.org/ l 2429/Immune/Antibodyhtml;
www.hhmi.org/grants/lectures/ l996/vlab/; www.path.cam.ac.uk/.about.mrc7/m- geshtml;
www.antibodyresource.com/; mcb.harvard.edu/BioLinks/Innnuno-
logy.html.www.innnunologylink.com/; pathbox.wustl.edu/.about.hcenter/index.- html;
www.biotech.ufl.edu/.about.hcl/; www.pebio.com/paf3409 13.13409 l3.html- ;
l.usda.gov/awic/pubs/antibodyi; www.m.ehime-u.acjp/.about.yasuhito- /Elisa.html;
www.biodesign.com/table.asp; www.icnet.uk/axp/facsidavies/lin- ks.html;
www.biotech.ufl.edu/.about.fccl/protocol.html; www.isac—net.org/sites_geo.html; aximtl.imt.uni-
marburg.de/.about.rek/AEP- Start.html; baserv.uci.kun.nl/.about.jraats/linksl.html; www.recab.uni-
hd.de/immuno.bme.nwu.edu/; www.mrc—cpe.cam.ac.uk/imt-doc/pu- blic/INTROhtml;
www.ibt.unam.mX/vir/V_mice.html; imgt.cnusc.fr:8104l;
www.biochem.ucl.ac.uk/.about.martin;’abs/index.html; antibody.bath.ac.uk/;
abgen.cvm.tamu.edu/lab/wwwabgenhtml; izh.ch/.about.honegger/AHOsem—
inar/Slide01.html; www.cryst.bbk.ac.uk;’.about.ubcg07s/;
www.nimr.mrc.ac.uk/CC/ccaewgiccaewghtm; www.path.cam.ac.uk/.about.mrc7/h-
umanisation/TAHHPhtml; t.unam.mx/vir/structure/stat_aim.html;
www.biosci.missouri.edu/smithgp/indexhtml; www.cryst.bioc.cam.ac.uk/.abo- ut.fmolina/Web-
pages/Pept/spottechhtml; www.jerini.deffr roducts.htm; wwwpatents.ibm.com/ibm.html.Kabat et
al., Sequences of Proteins of Immunological Interest, US. Dept. Health (1983), each entirely
orated herein by nce. Such imported sequences can be used to reduce genicity
or reduce, enhance or modify binding, affinity, on-rate, off-rate, avidity, specificity, half-life, or any
other suitable characteristic, as known in the art.
Framework residues in the human framework regions may be tuted with the
corresponding residue from the CDR donor dy to alter, preferably improve, antigen binding.
These framework substitutions are identified by methods well known in the art, e.g., by modeling of
the interactions of the CDR and framework residues to identify framework residues important for
antigen binding and sequence comparison to identify unusual framework residues at ular
2O positions. See, e.g., US Patent No. 089; Riechmann et a1. (1988) Nature 332: 323. Three-
dimensional immunoglobulin models are commonly available and are familiar to those skilled in the
art. Computer programs are available which illustrate and display probable three-dimensional
mational structures of selected candidate immunoglobulin sequences. Inspection of these
displays permits analysis of the likely role of the residues in the functioning of the candidate
immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate
immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the
consensus and import sequences so that the desired antibody characteristic, such as increased affinity
for the target antigen(s), is achieved. In l, the CDR es are directly and most substantially
ed in influencing antigen binding. Antibodies can be humanized using a variety of ques
lmown in the art, such as but not d to those described in Jones et al. (1986) Nature 321 :522;
Verhoeyen et a1. (1988) Science 239: 1534; Sims et al. (1993) J. Immunol. 151: 2296; Chothia and
Lesk (1987) J. Mol. Biol. 196:901; Carter et al. (1992) Proc. Natl. Acad. Sci. USA 89:4285; Presta et
a1. (1993) J. Immunol. 15122623; Padlan (1991) Mol. Immunol. 28(4/5):489-498; Studnicka et a1.
(1994) Protein Engineering 7(6):805-814; Roguska, et al. (1994) Proc. Natl. Acad. Sci. USA 91:969-
973; PCT ation Nos. WO 91I09967; W0 43; W0 90/14424; W0 90/14430;
WO 99/06834 (PCT/US98/16280); WO 97/20032 (PCTiUS96/18978); WO 92/11272
(PCT/US91/09630); WO 92/03461 (PCT/US91/05939); W0 94/18219 (PCT/US94/01234);
WO 92/01047 (PCT/GB91/01134); and WO 93/06213 (PCT/GB92/01755); EP 0 592 106;
EP 0 519 596; EP 0 239 400; US Patent Nos. 5,565,332; 5,723,323; 862; 5,824,514;
483; 5,814,476; 5,763,192; 5,723,323; 5,766,886; 5,714,352; 6,204,023; 370; 5,693,762;
,530,101; 5,585,089; 539; and 4,816,567.
Parent monoclonal antibodies may be selected from various monoclonal antibodies capable
of binding lL—loc or lL-lf).
Parent onal antibodies may also be selected from various therapeutic antibodies
ed for use, in clinical trials, or in development for clinical use.
B. Construction of DVD-lg les
A dual variable domain immunoglobulin (DVD-lg) molecule is designed such that two
different light chain variable s (VL) from the two different parent monoclonal antibodies are
linked in tandem directly or Via a short linker by recombinant DNA techniques, followed by the light
chain constant domain. Similarly, the heavy chain comprises two different heavy chain variable
domains (VH) linked in tandem, followed by the constant domain CH1 and Fc . See, PCT
Publication No. WO 24715.
The variable domains can be obtained using recombinant DNA techniques from a parent
antibody generated by any one of the methods described above. In a red embodiment the
variable domain is a murine heavy or light chain variable domain. More preferably the variable
2O domain is a CDR grafted or a humanized variable heavy or light chain domain. Most preferably the
variable domain is a human heavy or light chain variable domain.
In one embodiment the first and second variable s are linked directly to each other
using recombinant DNA techniques. In another embodiment the variable domains are linked via a
linker sequence. Preferably two variable domains are linked. Three or more variable domains may
also be linked directly or via a linker sequence. The variable domains may bind the same antigen or
may bind ent antigens. DVD-lg molecules of the invention may include one immunoglobulin
variable domain and one non- immunoglobulin variable domain such as ligand binding domain of a
or, active domain of an enzyme. DVD—lg molecules may also comprise 2 or more non-Ig
domains.
3O The linker sequence may be a single amino acid or a polypeptide sequence. Examples of
linker sequences that can be used in designing and producing DVD-Ig g proteins useful in the
methods and compositions described herein include, but are not limited to, AKTTPKLEEGEFSEAR
(SEQ ID NO:59); AKTTPKLEEGEFSEARV (SEQ ID NO:60); AKTTPKLGG (SEQ ID NO:61);
SAKTTPKLGG (SEQ ID NO:62); SAKTTP (SEQ ID NO:63); RADAAP (SEQ ID NO:64);
RADAAPTVS (SEQ ID NO:65); AGGPGS (SEQ ID NO:66); RADAAAA(G4S)4 (SEQ
1D NO:67); SAKTTPKLEEGEFSEARV (SEQ ID NO:68); ADAAP (SEQ ID NO:69);
ADAAPTVSIFPP (SEQ ID NO:70); TVAAP (SEQ ID NO:71); TVAAPSVEIPPP (SEQ ID NO:72);
QPKAAP (SEQ ID NO:73); QPKAAPSVTLFPP (SEQ ID NO:74); AKTTPP (SEQ ID NO:75);
AKTTPPSVTPLAP (SEQ ID NO:76); AKTTAP (SEQ ID NO:77); AKTTAPSVYPLAP (SEQ ID
NO:78); ASTKGP (SEQ ID NO:79); ASTKGPSVFPLAP (SEQ ID NO:80); GGSGGGGSG (SEQ
ID NO:81); GGGGSGGGGSGGGGS (SEQ ID NO:82); GENKVEYAPALMALS (SEQ ID NO:83);
GPAKELTPLKEAKVS (SEQ ID NO:84); GHEAAAVMQVQYPAS (SEQ ID NO:85);
TVAAPSVFIFPPTVAAPSVFIFPP (SEQ 1D NO:86); and ASTKGPSVFPLAPASTKGPSVFPLAP
(SEQ ID NO:87). The choice of linker sequences is based on crystal structure analysis of several
Fab les. There is a natural flexible linkage n the variable domain and the CH1/CL
constant domain in Fab or antibody molecular structure. This natural linkage comprises
approximately 10-12 amino acid residues, contributed by 4-6 residues from C-terminus of V domain
and 4-6 residues from the N-terminus of CL/CHl . In an embodiment, a DVD-Ig molecule
useful in the invention is generated using N-terminal 5-6 amino acid residues or 11-12 amino acid
residues of CL or CH1 as linker in light and heavy chains of a DVD-Ig molecule, respectively. The
N—terminal residues of CL or CH1 domains, particularly the first 5-6 amino acid residues, adopt a
loop conformation without strong secondary structures, and therefore can act as e linkers
between the two variable domains. The N-terminal residues of CL or CH1 domains are natural
extensions of the variable domains, as they are part of the immunoglobulin sequences, and ore
minimize to a large extent any immunogenicity potentially g from the linkers and ons.
Other linker ces may include any sequence of any length of CL/CHl domain but not
all residues of CL/CHl domain; for e the first 5-12 amino acid residues of the CL/CHl
domains; the light chain linkers can be from CK or C)»; and the heavy chain linkers can be derived
from CH1 of any isotypes, including C71, CYZ, C73, C74, Cocl, COLZ, C5, C8, and Cit. Linker
sequences may also be d from other proteins such as Ig-like proteins, (e.g., TCR, FcR, KIR);
G/S based sequences (e.g., G4S (SEQ ID NO:88) repeats); hinge region-derived ces; and
other natural sequences from other proteins.
In an embodiment, a constant domain is linked to the two linked variable domains using
recombinant DNA techniques. Preferably, a sequence sing linked heavy chain variable
domains is linked to a heavy chain constant domain and a sequence comprising linked light chain
variable domains is linked to a light chain constant domain. Preferably, the constant domains are
human heavy chain constant domain and human light chain constant domain, respectively, when the
DVD-Ig binding protein is to be used in a human. Preferably, a DVD-lg heavy chain is further
linked to an Fc region. The Fc region may be a native ce Fc , or a t Fc region.
Most preferably, the Fc region is a human Fc region. In a preferred embodiment the Fc region
includes Fc region from IgGl, IgG2, IgG3, IgG4, IgA, IgM, IgE, or IgD.
In an embodiment, two heavy chain DVD-Ig polypeptides and two light chain DVD-Ig
polypeptides are combined to form a DVD-Ig le. Detailed descriptions of examples of
specific DVD-Ig molecules capable of binding specific targets and methods of making the same have
been described. See, e.g., PCT ation No. WO 24715.
C. Production of DVD-lg Binding Proteins
DVD-1g proteins that bind IL-loc and [L-lB and are useful in the methods and compositions
described herein for treating osteoarthritis may be produced by any of a number of techniques known
in the art. See, for example, PCT Publication No. 2007/024715. For example, expression from host
cells, n expression vector(s) ng the DVD-lg heavy and DVD-lg light chains is (are)
transfected into a host cell by standard techniques. The various forms of the term "transfection" are
ed to encompass a wide variety of techniques commonly used for the introduction of
exogenous DNA into a yotic or eukaryotic host cell, e.g., electroporation, calcium-phosphate
precipitation, extran transfection and the like. Although it is possible to express DVD-Ig
binding proteins in either prokaryotic or eukaryotic host cells, expression of DVD-Ig proteins in
eukaryotic cells is preferable, and most preferable in mammalian host cells, because such eukaryotic
cells (and in particular mammalian cells) are more likely than prokaryotic cells to assemble and
secrete a properly folded and immunologically active DVD-Ig protein.
2O Preferred mammalian host cells for expressing the recombinant antibodies of the invention
include e Hamster Ovary (CHO cells) (including dhfr- CHO cells, described in Urlaub and
Chasin (1980) Proc. Natl. Acad. Sci. USA 77: 4216-4220, used with a DHFR selectable marker, e.g.,
as described in RI. Kaufman and PA. Sharp (1982) Mol. Biol. 159: 601-621), NSO myeloma cells,
COS cells, and SP2 cells. When recombinant expression vectors encoding DVD-Ig proteins are
introduced into mammalian host cells, the DVD-Ig proteins are produced by culturing the host cells
for a period of time sufficient to allow for expression of the DVD-Ig proteins in the host cells or,
more ably, secretion of the DVD-lg proteins into the culture medium in which the host cells
are grown. DVD-1g proteins can be recovered from the culture medium using standard protein
purification methods.
In a red system for recombinant expression of DVD-lg ns useful in the invention,
a inant expression vector encoding both the DVD-lg heavy chain and the DVD-lg light chain
is uced into dhfr- CHO cells by calcium phosphate-mediated transfection. Within the
recombinant expression vector, the DVD-lg heavy and light chain genes are each operatively linked
to CMV enhancer/AdMLP promoter regulatory elements to drive high levels of transcription of the
genes. The recombinant expression vector also carries a DHFR gene, which allows for selection of
CHO cells that have been transfected with the vector using methotrexate selection/amplification.
The selected ormant host cells are cultured to allow for expression of the DVD-lg heavy and
light chains and intact DVD-lg protein is recovered from the culture medium. Standard molecular
biology techniques are used to prepare the recombinant expression vector, transfect the host cells,
select for transformants, culture the host cells and recover the DVD-lg protein from the culture
medium. Still further the invention provides a method of synthesizing a DVD-lg n of the
invention by culturing a host cell of the invention in a suitable culture medium until a DVD-1g
protein of the invention is synthesized. The method can further comprise isolating the DVD-lg
n from the culture medium.
An important e of a DVD-lg binding protein is that it can be produced and purified in a
similar way as a conventional antibody. The production of DVD-lg binding protein results in a
homogeneous, single major product with desired dual-specific activity, without any sequence
modification of the constant region or chemical modifications of any kind. Other previously
described methods to generate "bi-specific", -specific", and "multi-specific multivalent" full
length binding proteins do not lead to a single primary product but instead lead to the intracellular or
secreted production of a mixture of led inactive, mono-specific, multi-specific, multivalent,
full length binding proteins, and multivalent full length binding proteins with combination of
ent binding sites. As an example, based on the design described by Miller and Presta (PCT
Publication No. WO2001/077342, there are 16 possible ations of heavy and light chains.
2O Consequently only 6.25% of protein is likely to be in the desired active form. Separation of fully
active forms of the protein from inactive and partially active forms of the n using standard
chromatography techniques, typically used in large scale manufacturing, is yet to be trated.
singly, the design of the DVD—lg binding proteins, which are "dual-specific
multivalent full-length binding proteins", led to a dual variable domain light chain and a dual
variable domain heavy chain that assemble primarily to the d "dual-specific multivalent full
length binding proteins", i.e., a functional DVD-lg binding protein. See, PCT ation No. WO
2007/024715.
II. lline and Derivatized Binding Proteins
The invention includes methods and compositions for ng osteoarthritis that a binding
3O protein that is a l. In an embodiment, the crystallized binding protein has a greater half-life in
vivo than the soluble counterpart of the binding protein. In another embodiment, the binding protein
retains biological activity after crystallization.
Crystallized binding proteins useful in the invention may be produced according to s
known in the art and as disclosed in PCT Publication No. WO 02072636, incorporated herein by
reference.
Another embodiment of the invention employs a ylated binding protein wherein a
binding protein or antigen-binding portion thereof comprises one or more carbohydrate residues.
Nascent in viva protein production may undergo further sing, known as post-translational
modification. In particular, sugar (glycosyl) es may be added enzymatically, a process known
as glycosylation. The resulting proteins bearing covalently linked oligosaccharide side chains are
known as glycosylated proteins or glycoproteins. Antibodies are glycoproteins with one or more
carbohydrate residues in the Fc domain, as well as the variable domain. Carbohydrate residues in
the Fc domain have important effect on the effector function of the Fc domain, with minimal effect
on antigen binding or half-life of the antibody (Jefferis (2005) Biotechnol. Prog, 21: 11—16). In
contrast, glycosylation of the variable domain may have an effect on the antigen g activity of
the antibody. ylation in the variable domain may have a negative effect on antibody binding
affinity, likely due to steric hindrance (Co et al. (1993) Mol. Immunol. 30: 1361-1367), or result in
increased ty for the antigen (Wallick et al. (1998) Exp. Med. 99-1109; Wright et al.
(1991) EMBO J. 10:27 17-2723).
It is also le to generate glycosylation site mutants in which an O- or N—linked
glycosylation site of s g protein has been mutated. One skilled in the art can te such
s using standard technologies. ylation site mutants that retain the ical activity
but have increased or sed binding activity may also be used in the s and compositions
described herein for treating rthritis.
2O The glycosylation of a binding protein or antigen-binding portion thereof useful in the
methods and compositions of the invention may be modified. For example, an aglycoslated antibody
can be made (i.e., the antibody lacks glycosylation). Glycosylation can be altered to, for example,
increase the affinity of the antibody for antigen. Such carbohydrate modifications can be
accomplished by, for example, altering one or more sites of glycosylation within the antibody
sequence. For example, one or more amino acid tutions can be made that result in elimination
of one or more variable region glycosylation sites to thereby eliminate glycosylation at that site.
Such aglycosylation may increase the affinity of the antibody for antigen. Such an approach is
described in further detail in PCT Publication No. WO 20031016466 and US Patent Nos. 5,714,350
and 6,350,861.
3O Additionally or alternatively, a modified binding protein useful in the invention can be made
that has an altered type of glycosylation, such as a hypofucosylated antibody having reduced
amounts of fucosyl residues or an antibody having increased bisecting GlcNAc structures. Such
altered glycosylation patterns have been demonstrated to increase the ADCC ability of antibodies.
Such carbohydrate modifications can be lished by, for example, expressing the binding
protein in a host cell with altered ylation machinery. Cells with altered glycosylation
machinery have been described in the art and can be used as host cells in which to express
recombinant antibodies of the invention to thereby produce an antibody with altered ylation.
See, for example, Shields et al. (2002) J. Biol. Chem. 277: 26733-26740; Umana et al. (1999) Nat.
Biotech. 17: 176-181, as well as, European Patent No. EP 1,176,195; and PCT Publication Nos. WO
03/035835 and WO 99/5434280.
Protein glycosylation depends on the amino acid sequence of the protein of st, as well
as the host cell in which the protein is expressed. Different organisms may produce different
glycosylation enzymes (e.g, glycosyltransferases and glycosidases), and have different substrates
(nucleotide sugars) available. Due to such factors, protein glycosylation pattern, and ition of
glycosyl residues, may differ depending on the host system in which the ular protein is
expressed. Glycosyl residues of a g protein useful in the invention may include, but are not
limited to, glucose, galactose, mannose, fucose, ylglucosamine and sialic acid. Preferably the
glycosylated g protein comprises glycosyl residues such that the glycosylation pattern is
human.
It is known to those skilled in the art that differing protein ylation may result in
differing protein characteristics. For instance, the efficacy of a therapeutic protein produced in a
microorganism host, such as yeast, and glycosylated utilizing the yeast endogenous pathway may be
d compared to that of the same protein expressed in a mammalian cell, such as a CHO cell
line. Such glycoproteins may also be immunogenic in humans and show reduced half-life in viva
after administration. Specific receptors in humans and other animals may recognize specific
2O glycosyl residues and e the rapid clearance of the protein from the bloodstream. Other
adverse effects may include changes in protein folding, solubility, susceptibility to proteases,
trafficking, transport, compartmentalization, ion, recognition by other proteins or factors,
antigenicity, or allergenicity. Accordingly, a practitioner may prefer a therapeutic protein with a
specific ition and n of glycosylation, for example glycosylation composition and
pattern identical, or at least similar, to that produced in human cells or in the s-specific cells of
the intended subject animal.
Expressing ylated proteins different from that of a host cell may be achieved by
genetically modifying the host cell to express logous glycosylation enzymes. Using
techniques lmown in the art a practitioner may generate dies or antigen-binding portions
3O thereof exhibiting human protein glycosylation. For example, yeast strains have been genetically
modified to express turally ing glycosylation s such that glycosylated proteins
(glycoproteins) produced in these yeast strains exhibit protein glycosylation identical to that of
animal cells, especially human cells (US Patent Publication Nos. 2004/0018590 and 2002/0137134
and PCT Publication No. WC 2005!1005 84).
Further, it will be appreciated by one skilled in the art that a protein of interest may be
expressed using a library of host cells genetically engineered to express various glycosylation
s, such that member host cells of the library produce the protein of interest with variant
ylation patterns. A practitioner may then select and isolate the n of interest with
particular novel glycosylation patterns. Preferably, the protein having a particularly selected novel
glycosylation pattern exhibits improved or altered biological properties.
IV. Pharmaceutical Compositions
The methods of the invention employ pharmaceutical compositions for treating rthritis
or pain in an individual that comprise one or more binding proteins that bind IL-loc and/or IL-1 [3.
Such compositions can also se a pharmaceutically acceptable carrier, a diluent, and/or
excipient, or any other compound(s) that es a desirable therapeutic, pharmaceutical, or
pharmacological benefit to the ition other than the activity of the one or more binding
proteins to bind IL—loc and/or IL—lfi. In an embodiment, a composition useful in treating
osteoarthritis or pain in an individual according to the invention comprises a binding protein that
binds lL-loc, for example an L—loc antibody, and a binding protein that binds lL-lB, such as an
anti-lL-lB antibody, or a binding protein that binds both IL-loc and/or IL-lB, such as an IL-loc/B
DVD-lg binding protein.
Binding proteins useful in the methods of the invention can be incorporated into
pharmaceutical compositions suitable for administration to a subject. Typically, a ceutical
composition comprises one or more binding proteins that bind IL-loc and/or IL-lB and a
pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" broadly
includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents,
isotonic and absorption delaying agents, and the like that are physiologically compatible. Examples
of pharmaceutically acceptable rs e one or more of water, saline, phosphate buffered
saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof. In many cases, it
will be preferable to include an isotonic agent, for example, sugar, polyalcohol (e.g., mannitol or
sorbitol), or sodium chloride in a composition. Pharmaceutically acceptable carriers may further
comprise minor amounts of auxiliary substances such as wetting or emulsifying , preservatives
or s, which enhance the shelf life or effectiveness of the antibody or dy portion.
Various delivery systems are known and can be used to administer one or more binding
proteins useful in the invention or a combination of one or more binding proteins and a prophylactic
agent or other therapeutic agent useful for preventing, ng, treating, or ameliorating
osteoarthritis or pain in an individual, e.g., ulation in liposomes, microparticles,
microcapsules, inant cells capable of expressing the binding protein or fragment, and
receptor-mediated endocytosis (see, e.g., Wu and Wu (1987) J. Biol. Chem, 262: 4429-4432),
construction of a nucleic acid as part of a iral or other vector, etc. Methods of administering to
an individual a binding protein that binds lL-loc and/or IL-lB include, but are not limited to,
parenteral administration (e.g., intradermal, intramuscular, intraperitoneal, intravenous, and
subcutaneous), epidural administration, intratumoral administration, and mucosal administration
(e. g., intranasal and oral routes). In addition, pulmonary administration can be employed, e.g., by
use of an inhaler or nebulizer, and formulation with an aerosolizing agent. See, e.g., U.S. Patent
Nos. 6,019,968; 5,985,320; 5,985,309; 5,934,272; 5,874,064; 913; and 5,290,540; and PCT
ation Nos. W0 44, WO 9782572, WO 97/44013, WO 98/31346, and WO 99/66903.
In one embodiment, a binding protein useful in the invention is administered using Alkermes AIR®
pulmonary drug delivery technology (Alkermes, Inc., dge, Mass.). In a specific embodiment,
a binding protein useful in the invention is administered uscularly, intravenously,
umorally, orally, intranasally, pulmonary, or subcutaneously. A binding n may be
administered by any ient route, for example by infusion or bolus injection, by absorption
through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and inal mucosa, etc.)
and may be administered together with other biologically active agents. Administration can be
systemic or local.
In a specific embodiment, it may be desirable to administer a binding protein locally to the
area in need of treatment, such as ly into the joint area. This may be ed by, for example,
and not by way of limitation, local infusion, by injection, or by means of an implant, wherein the
t is a porous or non-porous material, including membranes and matrices, such as tic
membranes, polymers, fibrous matrices (e.g., Tissuel®), or collagen matrices. In an embodiment, an
2O effective amount of one or more binding proteins is administered locally to the affected joint to treat,
manage, ameliorate, and/or prevent r progression of cartilage degeneration as otherwise occurs
in osteoarthritis, including pain. In r embodiment, an effective amount of one or more binding
proteins is administered locally to an affected joint in combination with an effective amount of one
or more other therapies (e. g., one or more prophylactic or therapeutic agents) other than the binding
protein(s) to prevent, treat, manage, andfor ameliorate osteoarthritis or one or more symptoms
thereof, including pain.
In another embodiment, IL—loc and lL-l[3 binding proteins can be delivered in a controlled
release or sustained release system. In one ment, a pump may be used to achieve controlled
or sustained release (see Langer (1990) Science 249: 1527-1533; Sefton (1987) CRC Crit. Rev.
3O Biomed. Eng, 14: 201-240; Buchwald et al. (1980) Surgery, 88: 507-516; Saudek et a1. (1989) N.
Engl. J. Med., 321: 574-579). In r embodiment, polymeric materials can be used to e
controlled or sustained release of binding proteins useful in the invention (see, e.g., Medical
Applications of Controlled Release, (Langer and Wise, eds.) (CRC Press, Inc., Boca Raton, 1984);
Controlled Drug Bioavailability, Drug Product Design and Performance, (Smolen and Ball, eds.)
(Wiley, New York, 1984); Langer and Peppas (1983) J. Macromol. Sci. Rev. Macromol. Chem.
Phys., C23: 61-126; see also Levy et al. (1985) Science 228:190-192; During et al. (1989) Ann.
., 25: 351-356; Howard et al. (1989) J. Neurosurg. -112); U.S. Patent Nos. 377;
,916,597; 5,912,015; 5,989,463; and 5,128,326; and PCT Publication Nos. WO 99/15154 and
WO 99/20253. Examples of polymers that be used in ned release formulations include, but are
not limited to, poly(2-hydroxy ethyl methacrylate), poly(methyl methacrylate), poly(acrylic acid),
poly(ethylene-co-vinyl acetate), poly(methacrylic acid), polyglycolides (PLG), polyanhydrides,
- vinyl pyrrolidone), poly(vinyl l), polyacrylamide, poly(ethylene glycol), polylactides
(PLA), poly(lactide-co-glycolides) (PLGA), and polyorthoesters. In an embodiment, the polymer
used in a sustained release formulation is inert, free of leachable impurities, stable on storage, sterile,
and biodegradable. In yet another embodiment, a lled or sustained release system can be
placed in proximity of the prophylactic or eutic target, thus requiring only a fraction of the
systemic dose (see, e.g., Goodson, J .M., Chapter 6, In Medical Applications of lled Release,
Vol. II, Applications and Evaluation, (Langer and Wise, CRC Press, Inc., Boca Raton, 1984),
pp. 115-138).
Controlled e systems are discussed in the review by Langer, Science, 249: 1527-1533
(1990). Any technique known to one of skill in the art can be used to e sustained release
formulations comprising one or more therapeutic agents of the invention. See, e.g., U.S. Patent No.
4,526,938; PCT ation Nos. WO 91/05548 and WO 96/20698; Ning et al. (1996) Radiother.
Oncol., 39: 179-189; Song et al. (1996) PDA J. Pharm. Sci. Technol., 50: 372-377; Cleek et al.
2O (1997) d. Int'l. Symp. Control. Rel. Bioact. Mater. 24: 853-854; and Lam et al. (1997)
Proceed. Int'l. Symp. Control Rel. . Mater., 24: 759-760.
In a specific embodiment, where a composition useful in the invention is a nucleic acid
encoding a protein that binds IL-lot and/or IL—l[3, the c acid can be administered in vivo to
promote expression of its encoded prophylactic or therapeutic agent, by constructing it as part of an
appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g.,
by use of a retroviral vector (see, e.g., U.S. Patent No. 4,980,286), or by direct injection, or by use of
microparticle bombardment (e.g., a gene gun; Biolistic, DuPont), or coating with lipids or cell-
surface receptors or transfecting agents, or by administering it in linkage to a homeobox-like peptide,
which is lmown to enter the nucleus (see, e.g., Joliot et al. (1991) Proc. Natl. Acad. Sci. USA
3O 88:1864-1868). atively, a nucleic acid can be introduced intracellularly and incorporated
within host cell DNA for expression by homologous recombination.
A pharmaceutical composition useful in the invention for treating osteoarthritis or pain is
formulated to be compatible with its intended route of administration. Examples of routes of
stration include, but are not limited to, parenteral, e.g., intravenous, intradermal,
subcutaneous, oral, intranasal (e.g., inhalation), transdermal (e.g., topical), transmucosal, and rectal
administration. In a specific embodiment, the composition is formulated in accordance with routine
procedures as a pharmaceutical composition adapted for intravenous, subcutaneous, intramuscular,
oral, intranasal, or topical administration to human beings. Typically, compositions for enous
administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition
may also include a solubilizing agent and a local anesthetic such as lignocamne to ease pain at the
site of the ion.
If the compositions useful in the invention for treating osteoarthritis or pain are to be
administered topically, the compositions can be formulated in the form of an ointment, cream,
transdermal patch, lotion, gel, shampoo, spray, aerosol, solution, emulsion, or other form well-
known to one of skill in the art. See, e.g., Remington’s Pharmaceutical Sciences and uction to
Pharmaceutical Dosage Forms, 19th ed., (Mack Publishing Co., Easton, Pennsylvania, 1995). For
non-sprayable l dosage forms, s to semi-solid or solid forms comprising a carrier or one
or more excipients compatible with topical application and having a dynamic ity preferably
greater than water are typically employed. Other suitable formulations include, without limitation,
suspensions, s, liniments, salves, and the like. In an embodiment, such ations are
sterilized or mixed with auxiliary agents (e.g., preservatives, stabilizers, wetting agents, buffers, or
salts) for influencing various properties, such as, for example, osmotic pressure. Other suitable
topical dosage forms include sprayable aerosol preparations wherein the active ingredient, for
example, in combination with a solid or liquid inert carrier, is packaged in a mixture with a
pressurized le (e.g., a s propellant, such as FREON®) or in a squeeze bottle.
Moisturizers or humectants can also be added to pharmaceutical compositions and dosage forms if
desired. Examples of such additional ingredients are well known in the art.
If a method of the invention for treating rthritis or pain ses intranasal
administration of a composition, the composition can be formulated in an aerosol form, spray, mist,
or in the form of drops. In particular, a binding protein for use according to the present invention
can be conveniently red in the form of an aerosol spray presentation from pressurized packs or
a nebulizer, with the use of a suitable propellant (e.g., dichlorodifluoromethane,
trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas). In the case
of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered
amount. Capsules and dges (composed of, e.g., n) for use in an r or insufflator may
be formulated containing a powder mix of the nd and a suitable powder base such as lactose
or starch.
If a method of the invention for treating osteoarthritis or pain comprises oral administration,
a composition can be formulated orally in the form of tablets, capsules, cachets, gelcaps, solutions,
suspensions, and the like. Tablets or capsules can be prepared by conventional means with
ceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch,
polyvinylpyrrolidone, or hydroxypropyl methylcellulose); s (e.g., lactose, microcrystalline
cellulose, or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc, or silica);
disintegrants (e.g., potato starch or sodium starch ate); or wetting agents (e.g., sodium lauryl
sulphate). The tablets may be coated by methods well known in the art. Liquid ations for oral
administration may take the form of, but not limited to, solutions, syrups or suspensions, or they may
be presented as a dry product for constitution with water or other suitable vehicle before use. Such
liquid preparations may be prepared by tional means with pharmaceutically acceptable
additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives, or enated
edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily
, ethyl alcohol, or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-
hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavoring,
coloring, and sweetening agents as appropriate. Preparations for oral administration may be suitably
formulated for slow e, controlled release, or sustained release of a binding protein(s) useful in
the invention for treating osteoarthritis or pain.
A method for treating osteoarthritis or a method of treating pain according to the invention
may comprise ary administration, e.g., by use of an inhaler or nebulizer, of a composition
formulated with an aerosolizing agent. See, e.g., US Patent Nos. 6,019, 968; 5,985,320; 5,985,309;
272; 5,874,064; 5,855,913; and 5,290,540; and PCT Publication Nos. WO 92/19244;
WO 97/32572; WO 97/44013; WO 98/31346; and WO 99/66903. In a specific embodiment, a
2O binding protein that binds lL-loc and/or IL—lB or combination therapy for treating osteoarthritis is
administered using Alkermes AIR® pulmonary drug delivery logy (Alkermes, Inc.,
Cambridge, Massachusetts).
A method of the invention may comprise administration of a composition sing a
g protein that binds IL-lot andt’or IL—1[3 that is formulated for parenteral administration by
injection (e.g., by bolus injection or continuous infusion). Formulations for injection may be
presented in unit dosage form (e.g., in ampoules or in multi-dose ners) with an added
preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily
or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or
dispersing agents. Alternatively, a g protein may be in powder form for constitution with a
suitable e (e.g., e pyrogen-free water) before use.
Methods of the invention may additionally comprise of administration of compositions
formulated as depot preparations. Such long acting formulations may be administered by
tation (e.g., subcutaneously or intramuscularly) or by intramuscular injection. Thus, for
example, the compositions may be formulated with suitable polymeric or hydrophobic materials
(e. g., as an on in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives
(e.g., as a sparingly soluble salt).
s of the invention encompass administration of compositions formulated as neutral
or salt forms. Pharmaceutically acceptable salts include those formed with anions such as those
derived from hloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with
cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides,
isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.
Generally, the ients of compositions are supplied either separately or mixed together
in unit dosage form, for e, as a dry lyophilized powder or water free concentrate in a
hermetically sealed container such as an ampoule or te indicating the quantity of active agent.
Where the mode of administration is infusion, composition can be dispensed with an infusion bottle
containing sterile ceutical grade water or saline. Where the mode of administration is by
injection, an e of sterile water for injection or saline can be provided so that the ingredients
may be mixed prior to administration.
The invention also provides one or more binding proteins that bind IL-1oc and/or IL-1[3 or a
pharmaceutical composition comprising such binding proteins packaged in a hermetically sealed
container such as an ampoule or sachette indicating the quantity of the agent. In an embodiment, one
or more binding proteins that bind IL—loc and/or IL—lB or a pharmaceutical composition comprising
such binding protein(s) is ed as a dry sterilized lyophilized powder or water free concentrate in
2O a hermetically sealed container and can be reconstituted (e.g., with water or saline) to the appropriate
concentration for administration to a subject to treat tis or pain. In an embodiment, one or
more g proteins that bind IL-lot and/or IL—1[3 or a pharmaceutical ition comprising
such binding protein(s) is supplied as a dry sterile lyophilized powder in a hermetically sealed
container at a unit dosage of at least about 5 mg, at least about 10 mg, at least about 15 mg, at least
about 25 mg, at least about 35 mg, at least about 45 mg, at least about 50 mg, at least about 75 mg, or
at least about 100 mg. The lyophilized binding protein(s) or ceutical composition comprising
such binding protein(s) should be stored at between about 2°C and about 8°C in its original container
and binding protein(s) or pharmaceutical composition comprising such binding protein(s) should be
administered within 1 week, within 5 days, within 72 hours, within 48 hours, within 24 hours, within
3O 12 hours, within 6 hours, within 5 hours, within 3 hours, or within 1 hour after being tituted.
In an alternative embodiment, one or more binding proteins that bind IL-loc and/or IL-ll3 or a
pharmaceutical composition comprising such binding protein(s) is supplied in liquid form in a
hermetically sealed container indicating the quantity and concentration of the agent. In an
embodiment, the liquid form of the administered composition is ed in a hermetically sealed
container at least about 0.25 mg/ml, at least about 0.5 mg/ml, at least about 1 mg/ml, at least about
2.5 mg/ml, at least about 5 mg/ml, at least about 8 mg/ml, at least about 10 mg/ml, at least about 15
mg/kg, at least about 25 mg/ml, at least about 50 mg/ml, at least about 75 mg/ml or at least about 100
mg/ml. The liquid form should be stored at between about 2°C and about 8°C in its original
ner.
Binding proteins useful in the methods and itions described herein can be
incorporated into a pharmaceutical composition suitable for parenteral administration. In one aspect,
binding proteins will be prepared as an injectable solution ning about 0.1 mg/ml to about 250
mg/ml antibody. The injectable solution can be composed of either a liquid or lyophilized dosage
form in a flint or amber vial, ampoule, or led syringe. The buffer can be L-histidine (about 1
mM to about 50 mM), lly about 5 mM to about 10 mM, at about pH 5.0 to about 7.0
(optimally about pH 6.0). Other suitable buffers include but are not limited to, sodium succinate,
sodium citrate, sodium phosphate or potassium phosphate. Sodium chloride can be used to modify
the ty of the solution at a concentration of about 0 to about 300 mM (optimally about 150 mM
for a liquid dosage form). Cryoprotectants can be included for a lyophilized dosage form,
principally about 0% to about 10% e (optimally about 0.5% to about 1.0%). Other suitable
cryoprotectants include trehalose and lactose. Bulking agents can be included for a lyophilized
dosage form, pally about 1% to about 10% mannitol (optimally about 2% to about 4%).
Stabilizers can be used in both liquid and lyophilized dosage forms, pally about 1 mM to about
50 mM L-methionine (optimally about 5 mM to about 10 mM). Other suitable bulking agents
2O include glycine, arginine, can be included as about 0% to about 0.05% polysorbate-80 (optimally
about 0.005% to about 0.01%). Additional surfactants include but are not d to polysorbate 20
and BRIJ surfactants.
Compositions useful for treating osteoarthritis or pain according to the invention may be in a
variety of forms. These e, for example, liquid, semi-solid and solid dosage forms, such as
liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, tablets, pills,
powders, liposomes and itories. The particular form depends on the intended mode of
administration and therapeutic application. Typical compositions are in the form of injectable or
infusible solutions, such as compositions similar to those used for passive immunization of humans
with antibodies. The mode of administration is parenteral (e.g., intravenous, subcutaneous,
3O intraperitoneal, intramuscular). In an embodiment, the dy is administered by intravenous
infusion or injection. In r embodiment, the antibody is administered by intramuscular or
subcutaneous injection.
Therapeutic compositions typically must be sterile and stable under the conditions of
manufacture and storage. The composition can be formulated as a solution, microemulsion,
dispersion, me, or other d structure suitable to high drug concentration. Sterile injectable
solutions can be prepared by incorporating the active compound (i.e., antibody, or antigen binding
portion thereof) in the required amount in an appropriate solvent with one or a combination of
ingredients enumerated above, as required, ed by filtered sterilization. Generally, dispersions
are prepared by incorporating the active compound into a sterile vehicle that contains a basic
dispersion medium and the required other ingredients from those enumerated above. In the case of
sterile, lyophilized powders for the preparation of sterile injectable solutions, exemplary methods of
preparation are vacuum drying and spray-drying that yields a powder of the active ingredient plus any
additional desired ingredient from a previously sterile—filtered solution thereof. The proper y of
a solution can be maintained, for example, by the use of a coating such as lecithin, by the maintenance
of the required particle size in the case of dispersion and by the use of surfactants. ged
absorption of injectable compositions can be brought about by including, in the composition, an agent
that delays absorption, for example, monostearate salts and gelatin.
The binding proteins useful for ng osteoarthritis or pain according to the invention can be
administered by a y of methods known in the art, although an ary route/mode of
administration is subcutaneous injection, intravenous ion, or infusion. As will be appreciated by
the skilled artisan, the route and/or mode of administration will vary ing upon the desired
results. In certain embodiments, a binding protein(s) may be prepared with a carrier that will protect
the binding protein(s) against rapid release, such as a controlled release formulation, including
implants, transdermal s, and microencapsulated delivery systems. Biodegradable,
patible polymers can be used, such as ethylene vinyl e, polyanhydrides, polyglycolic
acid, en, polyorthoesters, and polylactic acid. Many methods for the preparation of such
formulations are patented or generally known to those skilled in the art. See, e.g., Sustained and
Controlled Release Drug Delivery Systems, J.R. Robinson, ed., (Marcel Dekker, Inc., New York,
1978).
In certain embodiments, a binding protein(s) useful in the invention may be orally
administered, for example, with an inert t or an lable edible carrier. The binding
protein(s) (and other ingredients, if d) may also be enclosed in a hard or soft shell gelatin
capsule, compressed into tablets, or incorporated directly into the t's diet. For oral therapeutic
stration, the compounds may be incorporated with excipients and used in the form of
ingestible s, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
3O To ster a compound of the invention by other than parenteral administration, it may be
necessary to coat the compound with, or co-administer the compound with, a material to prevent its
inactivation.
Supplementary active compounds can also be incorporated into the compositions. In certain
embodiments, a binding protein (e.g., an antibody), or antigen binding portion thereof, useful in the
invention is coformulated with andfor coadministered with one or more additional therapeutic agents
that are useful for treating osteoarthritis or pain. For example, a g protein that binds hIL-loc
and/or hIL-1[3, or antigen binding portion(s) thereof, may be coformulated and/or coadministered
with one or more additional antibodies that bind other targets (e.g., antibodies that bind other
cytokines or that bind cell surface molecules). Furthermore, one or more binding proteins may be
used in combination with one or more other therapeutic agents. Such combination ies may
advantageously utilize lower dosages of the administered therapeutic agents, thus avoiding possible
toxicities or complications associated with the various monotherapies.
In certain embodiments, a protein(s) that binds IL— let and/or IL—1[3, or binding portion
f, is linked to a half-life extending vehicle lmown in the art. Such vehicles include, but are
not d to, the Fc domain, polyethylene , and dextran. Such vehicles are described, e.g.,
in US. Patent No. 6,660,843.
In a specific embodiment, nucleic acid molecules comprising nucleotide sequences ng
one or more polypeptides of a binding protein are administered to treat, prevent, manage, or
ameliorate osteoarthritis by way of gene therapy. Gene therapy refers to y performed by the
administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the
invention, the nucleic acids produce their encoded binding polypeptide(s) for a g n(s)
that binds IL-loc and/or IL-1[3 and mediates a prophylactic or therapeutic effect with respect to
osteoarthritis or pain.
Any of the methods for gene therapy available in the art can be used according to the present
invention. For general reviews of the methods of gene y, see Goldspiel et al. (1993) Clin.
2O Pharm. 12:488-505; Wu and Wu (1991) rapy 3: 87-95; Tolstoshev (1993) Ann. Rev.
col. Toxicol. 32: 573-596; Mulligan (1993) Science 260: 926-932; Morgan and Anderson
(1993) Ann. Rev. Biochem. 62:191-21?; and on, C. (1993) Trends Biotechnol. 11(5): 155.
Methods commonly known in the art of recombinant DNA technology which can be used are
bed in Ausubel et al. (eds.), Current Protocols in Molecular Biology (John Wiley & Sons, New
York, 1993); and Kriegler, Gene Transfer and Expression, A Laboratory Manual, ton Press,
New York, 1990). Detailed descriptions of various methods of gene therapy are disclosed in US
patent application publication No. 20030042664.
A binding protein(s) that binds lL—loc and/or IL—lB can be used alone or in combination with
one or more additional agents useful in the treatment of osteoarthritis or pain. For example, an
additional agent can be a therapeutic agent art-recognized as being useful to treat one or more
symptoms of osteoarthritis or to affect a target other than IL-l that is associated with pain. An
additional agent also can be an agent that s a beneficial attribute to the therapeutic
ition e.g., an agent that affects the viscosity of the composition to be administered to an
individual.
It should r be understood that the combinations that are to be included within this
invention are those combinations useful for their intended purpose. The agents set forth below are
illustrative for purposes and not ed to be limiting. The ations, which are part of this
invention, can be a binding protein(s) that binds lL-loc andi'or IL-lB and at least one additional agent
that provides a desirable ty. A combination can also include more than one additional agent,
e.g., two or three additional agents, if the combination is such that the formed composition can
perform its ed function. Preferred combinations to treat osteoarthritis or pain include nonsteroidal
anti-inflammatory drug(s) also referred to as "NSAIDS", which include drugs like
ibuprofen. Other preferred combinations are nflammatory agents, including corticosteroids,
such as solone; the well lmown side-effects of steroid use can be reduced or even eliminated
by tapering the steroid dose required when treating patients in combination with a binding protein(s)
that binds lL-loc and/or 1L-1[3. Non-limiting es of therapeutic agents for use in treating an
individual suffering from osteoarthritis or pain may include, but are not limited to, one or more the
following: budenoside, epidermal growth factor, corticosteroids, cyclosporin, sulfasalazine,
aminosalicylates, aptopurine, azathioprine, metronidazole, lipoxygenase inhibitors,
mesalamine, olsalazine, balsalazide, antioxidants, thromboxane inhibitors, IL-1 receptor antagonists,
anti-lL-lB monoclonal antibodies, anti-IL—6 monoclonal antibodies, growth factors, elastase
inhibitors, pyridinyl-imidazole compounds, antibodies of TNF, LT, IL-2, IL-6, IL-7, IL-8, lL-l2, IL-
13, lL-15, IL-16, lL-18, lL-23, EMAP-II, GM-CSF, FGF, and PDGF, antibodies of CD2, CD3, CD4,
2O CD8, CD-19, CD25, CD28, CD30, CD40, CD45, CD69, CD90 or their ligands, methotrexate,
cyclosporin, FK506, rapamycin, mycophenolate mofetil, leflunomide, an NSAlD, ibuprofen,
corticosteroids, prednisolone, phosphodiesterase inhibitors, adensosine agonists, antithrombotic
agents, complement inhibitors, adrenergic agents, IRAK, NIK, IKK, p38, MAP kinase inhibitors, IL-
l[3 converting enzyme tors, TNFos converting enzyme inhibitors, T-cell ling inhibitors,
oproteinase inhibitors, sulfasalazine, azathioprine, 6-mercaptopurines, ensin converting
enzyme inhibitors, soluble cytokine receptors, soluble p55 TNF receptor, soluble p75 TNF receptor,
le-lRI, le-lRH, le-6R, anti-inflammatory cytokines, IL-4, lL-10, IL-1 1, lL-l3, and TGFB.
The pharmaceutical compositions of the invention may include a "therapeutically effective
amount" or a "prophylactically effective " of one or more binding protein(s) that binds IL-loc
and/or IL-IB. A "therapeutically effective amount" refers to an amount effective, at dosages and for
periods of time necessary, to achieve the desired therapeutic result. A therapeutically effective
amount of the binding protein may be determined by a person skilled in the art and may vary
according to factors such as the disease state, age, sex, and weight of the individual, and the ability
of the g protein to elicit a desired se in the individual. A therapeutically effective
amount is also one in which any toxic or detrimental effects of the g protein(s), or portion(s)
thereof, are outweighed by the therapeutically beneficial effects. A "prophylactically effective
amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the
desired prophylactic , such as preventing further degeneration or loss of articular cartilage in an
affected joint in osteoarthritis or to prevent onset or intensification of pain. Typically, since a
prophylactic dose is used in subjects prior to or at an earlier stage of disease, the lactically
effective amount will be less than the therapeutically ive amount.
In an embodiment, a method for treating an individual for pain wherein the individual is
suffering from a disease or disorder associated with IL-1 accumulation. Such IL-l accumulation in
an individual can be the result of reduced IL-1 expression or reduced metabolism of IL-1.
Accumulation of lL-l can occur in the blood (including plasma, serum) or a local tissue of the
individual.
In an embodiment, the invention provides a method for treating an individual for pain
n the individual is suffering from a disease or disorder associated with IL-1 lation.
In an embodiment, compositions and s described herein can be used to treat pain
in an individual suffering a disease or disorder selected from the group comprising osteoarthritis,
rheumatoid arthritis, juvenile chronic arthritis, septic tis, Lyme tis, psoriatic arthritis,
reactive arthritis, spondyloarthropathy, systemic lupus erythematosus, Crohn's e, ulcerative
colitis, inflammatory bowel disease, n dependent diabetes us, thyroiditis, asthma, allergic
diseases, psoriasis, dermatitis, scleroderma, graft versus host disease, organ transplant rejection,
acute or chronic immune disease associated with organ transplantation, sarcoidosis, atherosclerosis,
disseminated intravascular coagulation, Kawasaki's disease, s disease, nephrotic syndrome,
chronic e syndrome, Wegener's granulomatosis, Henoch-Schoenlein purpurea, microscopic
vasculitis of the kidneys, c active hepatitis, uveitis, septic shock, toxic shock syndrome, sepsis
syndrome, cachexia, infectious diseases, parasitic diseases, acute transverse myelitis, Huntington's
chorea, Parkinson's disease, Alzheimer‘s disease, stroke, primary biliary cirrhosis, hemolytic anemia,
malignancies, heart failure, myocardial infarction, Addison‘s disease, sporadic polyglandular
deficiency type I, polyglandular deficiency type II (Schmidt's me), adult (acute) respiratory
distress syndrome, alopecia, alopecia , seronegative arthropathy, arthropathy, Reiter's disease,
psoriatic arthropathy, ulcerative colitic arthropathy, enteropathic synovitis, Chlamydia-associated
arthropathy, Yersinia-associated arthropathy, Salmonella-associated arthropathy,
spondyloarthropathy, atheromatous diseasefarteriosclerosis, atopic allergy, mune bullous
disease, pemphigus is, pemphigus foliaceus, pemphigoid, linear IgA disease, autoimmune
haemolytic anaemia, Coombs positive haemolytic anaemia, acquired pernicious anaemia, juvenile
pernicious anaemia, c encephalitisiRoyal Free disease, chronic taneous candidiasis,
giant cell tis, primary sclerosing hepatitis, cryptogenic mune hepatitis, acquired
immunodeficiency syndrome, acquired immunodeficiency related diseases, hepatitis B, hepatitis C,
common varied immunodeficiency (common variable hypogammaglobulinaemia), dilated
cardiomyopathy, female infertility, ovarian failure, premature ovarian failure, fibrotic lung e,
cryptogenic fibrosing alveolitis, post-inflammatory interstitial lung disease, interstitial pneumonitis,
connective tissue disease associated interstitial lung disease, mixed connective tissue disease
associated lung disease, systemic sclerosis associated interstitial lung disease, rheumatoid arthritis
associated interstitial lung disease, systemic lupus erythematosus associated lung disease,
dermatomyositis/polymyositis associated lung disease, n's disease associated lung disease,
ankylosing spondylitis associated lung disease, vasculitic diffuse lung disease, haemosiderosis
associated lung disease, drug-induced interstitial lung disease, fibrosis, radiation s,
bronchiolitis obliterans, chronic eosinophilic pneumonia, lymphocytic infiltrative lung disease,
fectious interstitial lung disease, gouty arthritis, autoimmune hepatitis, type-l autoimmune
hepatitis ical autoimmune or lupoid hepatitis), type-2 autoimmune tis (anti-LKM
antibody hepatitis), mune mediated ycemia, type B insulin resistance with acanthosis
nigricans, hypoparathyroidism, acute immune disease ated with organ lantation, chronic
immune disease associated with organ transplantation, rthrosis, primary sing gitis,
psoriasis type 1, psoriasis type 2, thic leucopaenia, autoimmune neutropaenia, renal disease
NOS, glomerulonephritides, microscopic vasculitis of the kidneys, Lyme disease, discoid lupus
erythematosus, male infertility idiopathic or NOS, sperm autoimmunity, multiple sis (all
2O subtypes), hetic ophthalmia, pulmonary hypertension ary to connective tissue e,
Goodpasture's syndrome, pulmonary manifestation of polyarteritis nodosa, acute tic fever,
rheumatoid spondylitis, Still's disease, ic sclerosis, Sjorgren's syndrome, Takayasu's
disease/arteritis, mune thrombocytopaenia, idiopathic thrombocytopaenia, autoimmune
thyroid disease, hyroidism, goitrous autoimmune hypothyroidism (Hashimoto's disease),
atrophic autoimmune hypothyroidism, primary myxoedema, phacogenic uveitis, primary vasculitis,
vitiligo, acute liver disease, chronic liver diseases, alcoholic cirrhosis, alcohol-induced liver injury,
cholestasis, idiosyncratic liver disease, drug-induced hepatitis, non-alcoholic steatohepatitis, allergy,
group B streptococci (GBS) infection, mental disorders (e.g., depression and schizophrenia), Th2
Type and Th1 Type mediated diseases, acute and chronic pain (different forms of pain), cancers such
3O as lung, breast, stomach, bladder, colon, as, ovarian, prostate and rectal cancer and
hematopoietic malignancies (leukemia and lymphoma), abetalipoproteinemia, acrocyanosis, acute
and chronic parasitic or infectious processes, acute leukemia, acute lymphoblastic leukemia (ALL),
acute myeloid leukemia (AML), acute or chronic ial infection, acute pancreatitis, acute renal
failure, adenocarcinomas, atrial ectopic beats, AIDS dementia complex, alcohol-induced hepatitis,
allergic conjunctivitis, allergic contact dermatitis, allergic rhinitis, allograft rejection, alpha-l-
antitrypsin deficiency, amyotrophic lateral sclerosis, anemia, angina pectoris, anterior horn cell
degeneration, anti-CD3 therapy, ospholipid syndrome, anti-receptor hypersensitivity reactions,
aortic and peripheral aneurysms, aortic dissection, arterial hypertension, arteriosclerosis,
arteriovenous fistula, ataxia, atrial fibrillation (sustained or paroxysmal), atrial flutter,
atrioventricular block, B cell lymphoma, bone graft rejection, bone marrow transplant (BMT)
rejection, bundle branch block, Burkitt‘s lymphoma, burns, cardiac arrhythmias, cardiac stun
syndrome, cardiac tumors, cardiomyopathy, cardiopulmonary bypass inflammation response,
cartilage transplant ion, cerebellar cortical degenerations, llar disorders, chaotic or
multifocal atrial tachycardia, chemotherapy associated ers, chronic myelocytic leukemia
(CML), chronic alcoholism, chronic inflammatory pathologies, chronic lymphocytic leukemia
(CLL), chronic obstructive pulmonary disease (COPD), chronic salicylate intoxication, colorectal
carcinoma, congestive heart failure, conjunctivitis, contact dermatitis, cor pulmonale, coronary
artery disease, Creutzfeldt-Jakob disease, culture negative sepsis, cystic fibrosis, ne therapy
associated ers, dementia pugilistica, inating diseases, dengue hemorrhagic fever,
dermatitis, dermatologic conditions, diabetes, ic arteriosclerotic disease, diffuse Lewy body
disease, dilated congestive cardiomyopathy, disorders of the basal ganglia, Down's syndrome in
middle age, drug- d movement ers induced by drugs which block CNS dopamine
receptors, drug sensitivity, eczema, encephalomyelitis, endocarditis, endocrinopathy, epiglottitis,
Epstein-Barr virus infection, erythromelalgia, extrapyramidal and cerebellar disorders, al
hemophagocytic lymphohistiocytosis, fetal thymus implant rejection, Friedreich's ataxia, functional
peripheral arterial disorders, fungal sepsis, gas ne, gastric ulcer, glomerular nephritis, graft
rejection of any organ or tissue, gram negative sepsis, gram positive sepsis, omas due to
intracellular organisms, hairy cell leukemia, Hallervorden-Spatz disease, oto's thyroiditis,
hay fever, heart transplant rejection, hemochromatosis, hemodialysis, hemolytic uremic
me/thrombolytic thrombocytopenic purpura, hemorrhage, hepatitis A, His bundle arrhythmias,
HIV infection/HIV neuropathy, Hodgkin‘s e, hyperkinetic movement disorders,
hypersensitivity reactions, hypersensitivity pneumonitis, ension, hypokinetic nt
disorders, hypothalamic-pituitary-adrenal axis evaluation, idiopathic Addison's e, idiopathic
pulmonary fibrosis, antibody mediated cytotoxicity, ia, infantile spinal muscular atrophy,
inflammation of the aorta, influenza A, ng radiation exposure, iridocyclitis/uveitis/optic
3O neuritis, ischemia- reperfusion injury, ischemic stroke, juvenile rheumatoid arthritis, juvenile spinal
muscular atrophy, Kaposi's sarcoma, kidney transplant rejection, legionella, leishmaniasis, leprosy,
lesions of the corticospinal , lipedema, liver transplant ion, lymphedema, malaria,
malignant lymphoma, malignant histiocytosis, ant melanoma, itis, meningococcemia,
metabolic migraine headache, idiopathic migraine headache, mitochondrial multisystem disorder,
mixed connective tissue disease, monoclonal gammopathy, multiple myeloma, multiple systems
degenerations (Menzel, Dejerine-Thomas, Shy-Drager, and Machado-Joseph), myasthenia gravis,
mycobacterium avium intracellulare, cterium tuberculosis, myelodysplastic syndrome,
myocardial tion, myocardial ischemic disorders, nasopharyngeal oma, neonatal chronic
lung disease, nephritis, nephrosis, neurodegenerative es, enic muscular atrophies,
neutropenic fever, non- Hodgkin's lymphoma, occlusion of the abdominal aorta and its branches,
occlusive arterial disorders, OKT3® therapy, orchitis/ epididymitis, orchitis/vasectomy reversal
procedures, organomegaly, osteoporosis, pancreas transplant rejection, pancreatic carcinoma,
paraneoplastic syndrome/hypercalcemia of ancy, parathyroid transplant rejection, pelvic
inflammatory disease, perennial rhinitis, pericardial disease, eral atherosclerotic disease,
peripheral vascular disorders, peritonitis, pernicious anemia, pneumocystis carinii pneumonia,
pneumonia, POEMS me (polyneuropathy, organomegaly, inopathy, monoclonal
gammopathy, and skin changes me), post perfusion syndrome, post pump syndrome, post-MI
tomy syndrome, preeclampsia, progressive supranucleo palsy, primary pulmonary
hypertension, radiation therapy, Raynaud's phenomenon, Raynaud's disease, Refsum's disease,
regular narrow QRS tachycardia, renovascular ension, reperfusion injury, restrictive
cardiomyopathy, sarcomas, senile chorea, senile dementia of Lewy body type, seronegative
arthropathies, shock, sickle cell , skin allograft ion, skin changes syndrome, small bowel
transplant rejection, solid tumors, specific arrhythmias, spinal , spinocerebellar degenerations,
streptococcal myositis, structural lesions of the cerebellum, subacute sclerosing panencephalitis,
syncope, syphilis of the cardiovascular system, systemic anaphylaxis, systemic inflammatory
response syndrome, systemic onset juvenile rheumatoid arthritis, T-cell or FAB ALL, telangiectasia,
thromboangiitis obliterans, thrombocytopenia, toxicity, transplants, trauma/hemorrhage, type III
hypersensitivity reactions, type IV hypersensitivity, unstable angina, uremia, urosepsis, urticaria,
valvular heart diseases, varicose veins, vasculitis, venous diseases, venous thrombosis, ventricular
fibrillation, viral and fungal infections, viral encephalitis/aseptic meningitis, associated
hemophagocytic syndrome, Wernicke- Korsakoff syndrome, 's e, xenograft rejection of
any organ or tissue, acute coronary syndromes, acute idiopathic uritis, acute inflammatory
demyelinating polyradiculoneuropathy, acute ischemia, adult Still’s disease, alopecia areata,
anaphylaxis, anti-phospholipid antibody syndrome, aplastic anemia, arteriosclerosis, atopic ,
atopic dermatitis, autoimmune dermatitis, autoimmune disorder ated with streptococcus
3O infection, autoimmune enteropathy, autoimmune hearing loss, autoimmune lymphoproliferative
me (ALPS), autoimmune myocarditis, mune premature ovarian failure, blepharitis,
bronchiectasis, bullous goid, cardiovascular disease, rophic antiphospholipid syndrome,
celiac disease, cervical spondylosis, chronic ischemia, cicatricial pemphigoid, clinically isolated
syndrome (CIS) with risk for multiple sclerosis, childhood onset psychiatric disorder, chronic
obstructive pulmonary disease (COPD), dacryocystitis, dermatomyositis, diabetic retinopathy, disk
herniation, disk prolapse, drug induced immune tic anemia, endocarditis, endometriosis,
endophthalmitis, episcleritis, erythema multiforme, erythema multiforme major, gestational
pemphigoid, Guillain-Barré syndrome (GBS), hay fever, Hughes syndrome, idiopathic Parkinson’s
disease, idiopathic interstitial pneumonia, IgE-mediated allergy, immune hemolytic anemia,
inclusion body myositis, infectious ocular inflammatory disease, inflammatory demyelinating
disease, inflammatory heart disease, inflammatory kidney disease, lPF/UIP, iritis, keratitis,
keratojunctivitis sicca, Kussmaul disease or Kussmaul-Meier disease, Landry's paralysis,
Langerhan‘s cell histiocytosis, livedo reticularis, macular degeneration, microscopic polyangiitis,
Morbus rev, motor neuron disorders, mucous membrane pemphigoid, multiple organ failure,
enia gravis, myelodysplastic syndrome, myocarditis, nerve root disorders, neuropathy, non-A
non-B hepatitis, optic neuritis, osteolysis, ovarian cancer, pauciarticular JRA, peripheral artery
ive disease (PAOD), peripheral vascular disease (PVD), peripheral artery disease (PAD),
phlebitis, polyarteritis nodosa (or periarteritis nodosa), polychondritis, polymyalgia rheumatica,
poliosis, polyarticular JRA, polyendocrine deficiency syndrome, ositis, polymyalgia
rheumatica (PMR), post-pump syndrome, primary Parkinsonism, te and rectal cancer and
hematopoietic malignancies (leukemia and ma), prostatitis, pure red cell aplasia, y
adrenal insufficiency, recurrent neuromyelitis optica, restenosis, rheumatic heart disease, SAPHO
itis, acne, pustulosis, hyperostosis, and osteitis), secondary amyloidosis, shock lung, tis,
sciatica, secondary adrenal insufficiency, silicone associated connective tissue disease, Sneddon-
Wilkinson dermatosis, spondylitis ankylosans, Stevens—Johnson syndrome (SJS), systemic
inflammatory se me, temporal arteritis, asmic tis, toxic epidermal
necrolysis, transverse myelitis, TRAPS (tumor-necrosis factor receptor type 1 (TNFR)-associated
periodic me), type 1 allergic reaction, type II es, ria, usual titial pneumonia
(UIP), vasculitis, vernal conjunctivitis, viral retinitis, Vogt—Koyanagi-Harada syndrome (VKH
syndrome), wet macular degeneration, and wound g.
itions and methods described herein can be used to treat pain in an individual
suffering from a disease selected from the group consisting of primary and metastatic cancers,
including carcinomas of breast, colon, rectum, lung, oropharynx, hypopharynx, esophagus, stomach,
pancreas, liver, gallbladder and bile ducts, small intestine, urinary tract (including kidney, bladder
and urothelium), female genital tract (including cervix, uterus, and s as well as
choriocarcinoma and gestational trophoblastic disease), male genital tract ding prostate,
seminal vesicles, testes and germ cell tumors), endocrine glands (including the thyroid, adrenal, and
pituitary ), and skin, as well as hemangiomas, melanomas, sarcomas (including those arising
from bone and soft tissues as well as Kaposi’s sarcoma), tumors of the brain, nerves, eyes, and
meninges (including astrocytomas, gliomas, glioblastomas, retinoblastomas, neuromas,
neuroblastomas, Schwannomas, and meningiomas), solid tumors arising from hematopoietic
malignancies such as leukemias, and lymphomas (both Hodgkin's and non-Hodgkin's lymphomas).
Dosage ns may be adjusted to provide the optimum desired response (e.g., a
therapeutic or prophylactic response). For e, a single bolus may be stered, several
divided doses may be administered over time or the dose may be proportionally reduced or increased
as indicated by the cies of the therapeutic situation. It is especially advantageous to formulate
parenteral compositions in dosage unit form for ease of administration and uniformity of dosage.
Dosage unit form as used herein refers to physically te units suited as unitary s for the
mammalian subjects to be treated; each unit ning a predetermined quantity of active compound
calculated to produce the desired therapeutic effect in association with the required pharmaceutical
carrier. The specification for the dosage unit forms of the invention are dictated by and directly
dependent on (a) the unique characteristics of a binding protein(s) that binds IL-loc and/or lL-ll3 and
the particular therapeutic or prophylactic effect to be achieved, and (b) the tions inherent in the
art of compounding such protein(s) for the treatment of individuals.
An exemplary, miting range for a therapeutically or prophylactically ive amount
of a binding protein useful in the treatment of osteoarthritis or pain is 0.1-20 mg/kg, more ably
1-10 mg/kg. It is to be noted that dosage values may vary with the type and severity of the condition
to be alleviated. It is to be further understood that for any particular subject, specific dosage
regimens should be adjusted over time according to the individual need and the professional
judgment of the person administering or supervising the administration of the compositions, and that
dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice
of the claimed composition.
It will be readily apparent to those skilled in the art that other suitable modifications and
adaptations of the methods and compositions of the invention described herein are obvious and may
be made using suitable equivalents without departing from the scope of the invention or the
embodiments disclosed . Having now described the present invention in detail, the same will
be more y understood by reference to the following examples, which are included for purposes
of illustration only and are not ed to be limiting of the invention.
Examples
e 1. Generation of Dual Variable Domain Immunoglobulin (DVD-lg) Protein
A dual variable domain immunoglobulin (DVD-lg) molecule is ed such that two
different light chain variable domains (VL) from two different parent mAbs are linked in tandem
directly or via a short linker by inant DNA techniques, followed by a light chain constant
domain. Similarly, the heavy chain comprises two different heavy chain variable domains (VH)
linked in tandem directly or via a short linker, followed by a constant domain CH1 and Fc region.
See Figure 1A. The design and production of DVD-lg binding proteins from parental monoclonal
antibodies, including examples of a DVD-lg binding protein that bind to IL-loc and IL-lB as
ed from a parental anti-IL-l (x monoclonal antibody and a parental anti-IL-1[3 monoclonal
antibody, has been described. See, PCT Publication No. A2 and Wu et al., Nature
Biotechnol, 25(11): 1290-1297 (200?), incorporated herein by nce. Descriptions of selected
monoclonal antibodies to IL-lot and IL-l[3 and their use as parental monoclonal antibodies for the
production of DVD-Ig molecules that bind both IL—loc and IL—l[3 are provided herein. The DVD-Ig
molecules were terized for possible therapeutic activity using known animal models for
toid arthritis and osteoarthritis.
Example 1.1. Generation of Murine Monoclonal Antibodies to IL-la and IL-1|3
Monoclonal antibodies (mAbs) to lL-loc and IL-ll3 were generated as follows using standard
hybridoma technology.
Example 1.1.A. Immunization Of Mice
Purified recombinant human IL-loc and murine IL-lB (R&D Systems) were used as
immunogens as well as g antigens in titer assays and screening ELISA. Immunizing dosages
ranged from 5.0 to 20.0 ug/mouse/injection for all antigens for both primary and boost
immunizations. ImmunEasy nt was purchased from Qiagen (Waltham, MA) and used at
nt/antigen ratio of 20 ml ImmunEasy adjuvant per 10.0 ug antigen. Each group of animals to
be immunized contained five IL-1(x[3 KO mice obtained from Dr. Yoichiro Iwakura (University of
Tokyo, -ku, Tokyo, Japan). The mice were immunized according to dosing schedule
2O described below. MRC-S cells were purchased from ATCC sas, VA) and used for IL-1
bioassay. Human IL-8 ELISA kits and control mouse anti-hIL-loc and anti-hIL-1[3 antibodies
(MAB200 and MAB201) were purchased from R&D Systems (Minneapolis, MN).
Briefly, adjuvant-antigen mixture was ed by first gently mixing the nt in a vial
using a vortex. The desired amount of adjuvant was removed from the vial and put into an
aved 1.5 mL microcentrifuge tube. The antigen was prepared in PBS or saline with
concentration ranging from 0.5-1.0 mgiml. The calculated amount of antigen was then added to the
microcentrifuge tube with the adjuvant and the on was mixed by gently pipetting up and down
times. The adjuvant-antigen mixture was incubated at room temperature for 15 minutes and then
mixed again by gently pipetting up and down 5 times. The adjuvant-antigen solution was drawn into
the proper syringe for animal injection. A total of 5-20 ug of antigen was injected in a volume of 50-
100u1. Each animal was immunized, and then boosted 2 to 3 times depending on the titer. Animals
with good titers were given a final intravenous boost before fusion and generation of hybridomas.
Example 1.1.B. Screening Hybridomas
Hybridomas, generated as described above, were screened and antibody titer determined
using ELISA. Protein antigens were directly coated on ELISA plates for detecting the specific
antibodies using standard ELISA procedures. Briefly, ELISA plates were coated with 100 til of
either rhIL-loc or rhIL-lB (1.0 ug/ml in PBS) overnight at 4°C. Plates were washed 3 times with 250
til PBS/0.5%Tween20 and blocked with 200 u] blocking buffer (2% BSA in PBS with 0.5 20).
Diluted sera or hybridoma supernatant (100 pl) was added to each well, and incubated at room
temperature for 2 hours. Plates were then washed three times with PBS/0.5%Tween20. HRP-goat
anti-murine IgG was used for detection, and binding ODs were observed at 450 nm. Hybridoma
clones producing dies that showed high specific binding activity in the ELISA were subcloned
and ed, and affinity (Biacore) and potency (MRC-S bioassay) of the antibodies were
characterized as s.
e 1.1.C. Characterization of Murine Monoclonal Antibodies to IL-lot And IL-1|3
The following assays were used to terize the antibodies produced by the hybridomas
described in e 1.1.B.
Example 1.1.C.1. Surface Plasmon Resonance
Real-time binding interactions between antibody (mouse anti-recombinant mIL-l dy)
captured on a biosensor matrix Via goat anti-mouse IgG and rmIL-l were measured by surface
plasmon resonance (SPR) using the BIAcore system (Biacore AB, Uppsala, Sweden) according to
manufacturer's instructions and standard procedures. Briefly, rmIL-l was diluted in HBS running
buffer (Biacore AB) and 50 pl ts were injected through the immobilized protein matrices at a
flow rate of 5 ml/minutes. The concentrations of rhIL—l employed were 62.5, 125, 187.5, 250, 375,
2O 500, 750, 1000, 1500, and 2000 nM. To determine the dissociation constant (off-rate), association
constant (on-rate), BIAcore kinetic evaluation software (version 3.1) was used.
Example 1.1.C.2. L-l Bioassay
The MRC-S cell line is a human lung fibroblast cell line that produces lL-8 in response to
human IL-1oc and IL-1[3 in a dose-dependent manner (see, Dinarello, Muegge, and Durum (2000)
Curr. Protocols l. 6:1). MRC-S cells were cultured in 10% FBS te MEM and grown
at 37°C in a 5% C02 incubator. To determine lizing potencies of the monoclonal antibodies
(mAbs) against recombinant human IL—loc or ll.—1[3, different concentrations (0-10 ug/ml) of mAb
(50 ill) was added to a 96-well plate and pre-incubated with 50 u] of rhIL—loc or rhIL-lB (10-50
pg/ml) for 1 hour at 37°C. The supematants were harvested, diluted, and IL-8 concentrations
ed by ELISA using a standard lL-8 ELISA kit (R&D Systems). dy potency was
determined by its ability to inhibit IL-8 production by MRC-S cells.
Based on Biacore and MRC-S bioassay, a number of murine anti-hIL-lu and anti-hIL-lB
antibodies with high affinity and potency were identified, as shown in Table 1 below:
Table 1. Generation And terization Of Murine Anti-Hil-lot/B Mabs
mAb Clone# city KD (M) IC50 (M)
3D12.E3 hIL—loc 1.11 x 10‘9 6.70 x10'10
C8 hIL—loc 5.78 x 10‘10 8.90 x 10'11
6H3.1A4.3E11 hIL—loc 3.54 x10‘10 2.40 x10"10
13F5.G5 hIL—IB 2.91 x 10‘10 6.00 x 10’10
1B12.4H4 hIL—IB 2.13 x10‘10 5.30 x10’10
6B12.4F6 hIL-lfi 5.54 x 10‘10 3.20 x 10'10
Example 1.1.D. Cloning and Sequencing of the Murine Monoclonal Antibodies (mAbs) to
IL-loc and IL-1[3
Cloning and sequencing of the variable heavy (VH) and light (VL) genes of all anti-IL-lodB
mAbs described in Table 1 ) and additional antibodies were carried out after isolation and
purification of the total RNA from the each oma cell line using Trizol reagent (Invitrogen)
according to the manufacturer's instructions. ication of both VH and VL genes was carried
out using the IgGVH and ngVL oligonucleotides from the Mouse Ig-Primer Set (Novagen, Madison,
WI) with One-tube RT-PCR kit (Qiagen) as suggested by the cturer. DNA fragments
resulting from productive amplifications were cloned into pCR-TOPO vector (Invitrogen) according
to the manufacturer's instructions. Multiple VH and VL clones were then sequenced by the dideoxy
chain termination method using an ABI 3000 sequencer (Applied Biosystems, Foster City, CA). The
sequences of all mAb VL and VH genes are shown below in Table 2.
TABLE 2. Murine Monoclonal Antibodies Capable 0f Binding Human IL-la 0r IL-1[3
Protein Sequence Identification Number Sequence
12345678901234567890
QIQLVQSGPfiLKKPGfiiVKI
SCKASGYTFQNYGMNWVKQA
PGKDLKRMAWINTYTGESTY
ADDFKGRFATSLETSASTAY
VH 3D12.E3 SEQ ID N0:89
LQINNLKNEDTATYFCARGI
YYYGSSYAMDYWGQGTSVTV
TTSSLSASLGDRVT
ISCRASQDISNCLNWYQQKP
DGTVKLLIYYTSRLHSGVPS
RFSGSGSGTDYSLTISNLEQ
VL 3D12.E3 SEQ ID NO:90
EDIATYFCQQGKTLPYAFGG
GTKLEINR
Protein Sequence Identification Number Sequence
12345678901234567890
EVQLQQSGAELVKPGASVKL
LNIKDTYMHWLKQ?
PEQGLEWIGQIDPANGNAKY
DPRFLGKATITADTSSNTAY
VH 18F4.2C8 SEQ ID N0:91
TSEDTAVYYCARGD
GNFHTDYWGQGTTLTVSS
DIVMTQSQRTMSTSVGDRVS
VTCKASQNVGTNIAWYQQKP
GQSPRALIYSASYRYSGVPD
SEQ ID N0:92 RFTGSGSGTDFTLTISNVQS
VL 18F4.2C8 VDLAEYFCQQYTRYPLTFGG
GTKLEIKR
QVQLQQPGAELVRPGASVKL
SCKASGY-E1-YWMNWVKQR
PEQGLEW-GR-DPYDSETLY
SEQ ID N0:93 SQKtKD_AIL_VDKSSSTAY
VH 6H3.1A4.3E11 TSEDSAVYYCARYG
FDYWGQG_1L-VSS
QIVLTQSPALMSASPGE<VT
MTCSASSSVVYMYWYQQ<PR
SSPKPWIYLTSN_4ASGVPAR
FSGSGSGISYSTIIISS *.A*.
SEQ ID N0:94
VL 6H3.1A4.3E11 DAATYYCQQWNSVPYTFGGG
QVQIQQSGAELVRPGSSVKI
SC<ASGYAFSSYWMNWVKQR
PGQGLEWIGQIYPGDGD"NY
NG<FKGKAT_4TADKSSS"SY
VH 13F5.G5 SEQ ID N0:95
MQ'ISG ITSEDSA YFCVRFP
TGVDYYAMDYWGQGTSV"VS
NIVLTQSPASLAVSLGQRAT
ISCRASESVDSYGNSYMIWY
QQKPGQPPKLLIYLASNLES
GVPARFSGSGSRTDFTLTID
VL 13F5.G5 SEQ ID N0:96
PVEADDAATYYCQQNNEDPF
TFGSGTKLEIKR
QVHLKESGPGLVAPSQSLSI
TCTVSGFSLTDYGVSWIRQP
WLGLIWGGGDTYYN
VH 1B12.4H4 SEQ ID N0:97 SPLKSRLSIRKDNSKSQVFL
KMNSLQTDDTAVYYCAKQRT
LWGYDLYGMDYWGQGTSVTV
Protein Sequence Identification Number Sequence
12345678901234567890
ETTVTQSPASLSMAIGEKVT
IRCITSTDIDVDMWWYQQKP
4LISQGNTLRPGVPS
RFSSSGSGTDFVE‘I IzawMLs
VL 1312 4H4‘ SEQ ID N0-98'
EDVADYYCLQSDNVPVTFGA
GTKLELKR
EVQLQQSGPELVKTGTSVKI
SCKASGYSFTGYYMHWVRQS
HGKSLEWIGYISCYNGFTSY
KATFTVDTSSSTAY
VH 6B12.4F6 SEQ ID No.99,
IQFSRLTSEDSAVYYCARSD
YYGTNDYWGQGTTLTVSS
QIVLTQSPAIMSASPGEKVT
ITCSASSSVSYMHWFQQKPG
ASPKLWIYSTSNLASGVPAR
FSGSGSGTSYSLTVSRMEAA
VL 6B12.4F6 SEQ ID N0:100
CQQRSTYPYTFGGG
TKLEIKR
Example 1.2. Generation and Characterization of Murine-Human Chimeric Antibodies
All mAbs described above were ted to chimeric antibodies (with human constant
region) and expressed, purified, and characterized to confirm activity. The antibodies were also used
for ls for subsequent DVD-lg binding n analysis. To convert 3D12.E3 into chimeric
form, 3D12.E3-VL was PCR amplified using primers P1 and P2; meanwhile human CK gene (in
pBOS vector generated in-house, Abbott Bioresearch Center, Worcester, MA) was amplified using
primers P3 and P4. Both PCR reactions were performed according to standard PCR techniques and
procedures. The two PCR products were rified, and used together as overlapping template for
the subsequent overlapping PCR reaction using primers P1 and P4 using rd PCR conditions.
The final PCR product, the chimeric light chain 3D12.E3-VL-hCK, was subcloned into pEF6 TOPO
mammalian expression vector (Invitrogen) by TOPO cloning ing to the manufacturer's
instructions. Table 3 shows the sequences of each of the PCR s used in this procedure.
Table 3. PCR Primers
P3: 5 CGT ACG GTG GCT GCA CCA TCT GTC 3' SEQ ID NO: 103
Pm 5TCAACACTCTCCCCTGTTGAAGC3' SEQHDNOJO4
To convert 3D12.E3 heavy chain into chimeric form, 3D12.E3-VH was PCR amplified using
primers P5 and P6; meanwhile human C71 gene (in pBOS vector generated in-house at ABC) was
amplified using primers P7 and P8. Both PCR reactions were performed according to standard PCR
techniques and procedures. The two PCR products were rified, and used together as
overlapping template for the subsequent overlapping PCR reaction using primers P5 and P8 using
standard PCR conditions. The final PCR t, the chimeric light chain 3-VH-hCyl, was
ned into pcDNA3.l TOPO mammalian expression vector (Invitrogen) according to the
manufacturer’s ctions. Table 4 shows the sequences of each of the PCR primers used in this
procedure.
Table 4. PCR Primers
SEQ ID NO: 105
P6: 5' GGG CCC TTG GTC GAC GCT GAG GAG ACG GTG ACT GAG G 3' SEQ 1]) NO: 106
P7: 5' GCG TCG ACC AAG GGC CCA TCG GTC TTC C 3' SEQ 1]) NO: 107
P8: 5' TC ATT TAC CCG GAG ACA GGG AGA GGC 3' SEQ 1D NO:108
Similarly, chimeric l3F5.G5-VH-Cyl was generated using primers P21/P22 (for VH) and
P7/P8 (for hCyl) and cloned into pcDNA3.1 TOPO vector, and chimeric 13F5.G5-VL-CK was
generated using primers P23/P24 (for VL) and P3/P4 (for hCK) and cloned into pEF6 TOPO vector.
Table 5 shows the sequences of each of the PCR primers used in this procedure.
Table 5. PCR s
P21: 5' ATA GAA TGG AGC TGG GTT TTC CTC 3' SEQ ID NO: 109
P22: 5' GGG CCC TTG GTC GAC GC TGA GGA GAC GGT GAC TGA 3' SEQ ID NO: 110
P23: 5' ATG GTC CTC ATG TCC TTG CTG TTC 3' SEQ ID NO:111
P24: 5' GC AGC CAC CGT ACG CCG TTT TAT TTC CAG CTT TG 3' SEQ ID NO: 112
To express chimeric antibodies, 13F5.G5-VL—CK and 13F5.G5-VH-Cyl were co-expressed
in COS cells using Lipofectamin (Invitrogen) for 72 hours, and the medium collected and lgG
purified by Protein A chromatography. Similarly, l3F5.G5-VL-CK and l3F5.G5-VH-Cyl were co-
2O expressed in COS using Lipofectamin (Invitrogen) for 72 hours, and the medium ted and IgG
d by Protein A chromatography. Both purified chimeric Abs were characterized by Biacore
and MRC-S bioassay to confirm activity. The results showed that these chimeric Abs displayed
similar affinity and potency to that of the al murine mAbs.
Example 1.3. Construction, sion, and Purification of IL-loz/B Dual Variable Domain
Immunoglobulin (DVD-lg) Molecule
The construct used to generate DVD-1g binding protein capable of binding hIL- 10c and hIL-
l[3 is illustrated in Figure 1B. , parent mAbs including two high affinity murine antibodies,
anti-hlL-loc (clone 3D12.E3) and anti-hIL—ll3 (clone 13F5.G5), were obtained by immunizing Balb/c
3O mice with recombinant lL-loc protein (rhlL-loc) and recombinant IL-IB protein (rhIL—l B),
respectively. The VL/VH genes of these two hybridoma clones were isolated by RT-PCR using the
mouse lg Primer Kit (Novagen, Madison, WI). The VL/VH genes were first ted into chimeric
antibodies (with human constant regions) to confirm activity and potency. To generate DVDl-lg
binding protein, the VH and VL of 13F5.G5 was directly fused to the N-terminus of the VH and VL
of 3D12.E3, respectively (as shown in Figure 1B). The DVD2-lg binding protein was constructed
similarly, except that it had a linker between the two variable s in both the light chain (the
linker sequence is ADAAP) and the heavy chain (the linker sequence is AKTTPP). These sequences
were selected from the N-termini of murine Ck and CH1 sequences. These linker sequences,
ed from the N-termini of murine Ck and CH1, are natural extension of the variable domains
and exhibit a flexible conformation without significant secondary structures based on the analysis of
several Fab crystal structures. The detailed procedures of the PCR cloning are described below.
e 1.3.A. Molecular Cloning of hIl-lor/B DVDl-Ig Binding Protein
13F5.G5-VH was PCR amplified using primers P21 and P25. 3D12.E3-VH-hCyl was
amplified using primers P14 and P8. Both PCR reactions were performed according to standard
PCR techniques and procedures. The two PCR products were gel-purified, and used together as
overlapping template for the uent pping PCR reaction using primers P21 and P8 using
standard PCR conditions. The final PCR product, the DVDl-Ig heavy chain x/[3DVD1-VH-
hCyl, was subcloned into pcDNA3.1 TOPO mammalian expression vector (Invitrogen) according to
the manufacturer's instructions. Table 6 shows the sequences of the PCR primers used in this
2O procedure.
Table 6. PCR Primers
P14: 5’ CAG ATC CAG TTG GTG CAG TCT GG3’ SEQ ID NO; 113
P25: 5’ CAC CAA CTG GAT CTG TGA GGA GAC GGT GAC TGA GG 3’ SEQ ID NO; 114
To generate hIL-loL/BDVDl—Ig light chain, 13F5.G5-VL was PCR amplified using primers
P23 and P26; ile 3D12.E3-VL—hCK was amplified using primers P16 and P4. Both PCR
reactions were med according to standard PCR techniques and procedures. The two PCR
products were rified, and used together as overlapping template for the subsequent
pping PCR reaction using primers P23 and P4 using standard PCR ions. The final PCR
product, the z/[3 DVD 1 -Ig light chain hIL- 1 oc/BDVDl-VL-hCK, was subcloned into pEF6
TOPO mammalian expression vector rogen) according to the manufacturer’s instructions.
Table 7 shows the sequences of each of the PCR primers used in this procedure.
Table 7. PCR Primers
P16: 5' AAT ATC CAG ATG ACA CAG ACT ACA TCC 3' SEQ ID NO: 115
P26: 5' GTGT CAT CTG GAT ATT CCG TTT TAT TTC CAG CTT TG 3' SEQ ID NO: 116
Example 1.3.B. Molecular cloning of x/B g
13F5.G5-VH was PCR amplified using primers P21 and P17. 3D12.E3-VH-hCy1 was
amplified using primers P18 and P8. Both PCR reactions were performed according to standard
PCR techniques and procedures. The two PCR products were gel-purified, and used er as
pping te for the subsequent overlapping PCR reaction using primers P21 and P8 using
standard PCR ions. The final PCR product, the DVD2—Ig heavy chain hIL-l (x/BDVD2-VH-
hCyl, was subcloned into pcDNA3.1 TOPO mammalian expression vector (Invitrogen) according to
the manufacturer’s instructions. Table 8 shows the sequences of each of the PCR s used in
this ure.
Table 8. PCR Primers
P17: 5' TGG GGG TGT CGT TTT GGC TGA GG 3' SEQlDNO:117
P18: 5' GCC AAA ACG ACA CCC CCA CAG ATC CAG TTG GTG CAG 3' SEQ ID NO:118 |
To generate hIL-1a/[3DVD2-Ig light chain, 13F5.G5-VL was PCR amplified using primers
P23 and P19. 3D12.E3-VL—hCK was amplified using primers P20 and P4. Both PCR reactions were
performed according to standard PCR techniques and procedures. The two PCR ts were gel-
d, and used together as overlapping template for the subsequent pping PCR reaction
using primers P23 and P4 using standard PCR conditions. The final PCR product, the hIL-
1(x/[3DVD2-Ig light chain hIL-loc/BDVDZ-VL—hCK, was subcloned into pEF6 TOPO mammalian
expression vector (Invitrogen) according to the manufacturer’s instructions. Table 9 shows the
sequences of each of the PCR primers used in this procedure.
Table 9. PCR Primers
P19: 5’ TGG TGC AGC ATC AGC CCG TTT TAT TTC 3’ SEQ ID NO:119
P20: 5’ GCT GAT GCT GCA CCA AAT ATC CAG ATG ACA CAG 3’ SEQ ID NO: 120
The final sequences of hlL-loni'fiDVDl-Ig and hIL—loc/[3DVD2-Ig are described in TablelO.
Table 10. Amino Acid Sequence of hIl-la/BDVDl-Ig and hIl-la/[SDVDZ-Ig Binding Protein
Protein Sequence
Protein region Sequence Identifier l 2 3 4 5 6 7 8 9 0 l 2 3 4 5 6 7 8 9 0
QVQLQQSGAELVRPGSSVKI
SCKASGYAFSSYWMNWVKQR
PGQGLEWIGQIYPGDGDTNY
NGKFKGKATLTADKS S STSY
DVD-1g HEAVY SEQ ID N03121
MQLSGLTSEDSAMYFCVRFP
VARIABLE TGNDYYA_-DYWGQGTSVTVS
SQIQLVQSGPELKKPGETVK
hIL'l‘x/BDVDI'Ig I SCKASGYTFRNYGMNWVKQ
APGKDLKRMAWINTYTGEST
YADDFKGRFAF S LET SAS TA
Sequence
Protein region Sequenceldenfifier 12345678901234567890
YLQINNLKNEDTATYFCARG
IYYYGSSYAWDYWGQGTSVT
VH 13F5.G5 SEQ ID NO:95 QVQLQQSGAELVRPGSSVKI
SCKASGYAFSSYWMNWVKQR
PGQGLEWIGQIYPGDGDTNY
NGKTKGKATLTADKSSSTSY
TSEDSAMYFCVRFP
TGNDYYAMDYWGQGTSVTVS
Linker None
3D12.E3 VH SEQ ID NO:89 QIQLVQSGPELKKPGETVKI
SCKASGYTFRNYGMNWVKQA
PGKDLKRMAWINTYTGESTY
ADDFKGRFAFSLETSASTAY
LQINNLKNEDTATYFCARGI
YYYGSSYAMDYWGQGTSVTV
SEQ ID NO:122 ASTKGPSVFPAAPSSKS"SG
GTAALGCAVKDYtPLPV vs
WNSGALTSGV{"FPAV4QSS
GLYSLSSVVTVPSSSAG"QT
YICNVNH<PSV"<VD<<
KSCDKTHTCPPCPAP?
PSVFLFPPKP<DTL 18' P
VJVS{«JP«V<tww
YVDGVLViNA<i<PRn.« w
S"YRVVSVLTV.{QDW.WG <
EY<C<VSWKA.PAPI?<TIS
<A<GQPRnPQVYiLPPSRnn
"(WQVS.TC.V<GFYPSDI
AVthSNGQPnNVY<iiPPV
LDSDGSFFLYSKATVDKSRW
QQGVVFSCSV H?A.HN{Y"
QKSLSLSPGK
VIVLTQSPAS.AVS.GQRA"
ISCRASESVDSYGNSYMiWY
DVD-Ig LIGHT QQK?GQPPKLVIYLASN.?S
GVPARFSGSGSRTDTTLTID
SEQ ID N0:123
VARIABLE PVEADDAATYYCQQVNED?F
TFGSGTKLEIKRNIQMTQTT
hIL-lot/BDVDl-Ig SSLSASLGDRVTISCRASQD
ISNCLNWYQQKPDGTVKLLI
HSGVPSRFSGSGSG
ISNLEQEDIATYFC
QQGKTLPYAFGGGTKLEINR
13F5.G5 VL SEQ ID NO:96 SPASLAVSLGQRAT
ISCRASESVDSYGNSYMHWY
QQKPGQPPKLLIYLASNLES
GVPARFSGSGSRTDFTLTID
PVEADDAATYYCQQNNEDPF
TFGSGTKLEIKR
Linker None
Sequence
Protein region Sequenceldenfifier 12345678901234567890
3D12.E3 VL SEQ ID N0:90 TTSSLSASLGDRVT
QDISNC_LVWYQQ<P
DGTVKLLIYYTSRLHSGVPS
RFSGSGSGTDYSLTISN.?Q
EDIATYTCQQGKTLPYATGG
GTKLEIVR
CL SEQ ID NO:124 TVAAPSVFIFPPSDEQLKSG
TASVVCLLNNFYPREAKVQW
KVDNALQSGNSQESVTEQDS
KDSTYSLSSTLTLSKADYEK
HKVYACEVTHQGLSSPVTKS
FNRGEC
QVQLQQSGAELVRPGSSVKI
SCKASGYAFSSYWMNWVKQR
PGQGLEWIGQIYPGDGDTNY
NGKFKGKATLTADKSSSTSY
DVD-1g HEAVY SEQ ID NO:125
”QLSGLTSEDSAMYFCVRFP
VARIABLE TGNDYYAHDYWGQG-SV-VS
SAKTTPPQIQLVQSGPflIK<
hIL-1a/[3DVD2-Ig PGETVKISCKASGYTFRWYG
”NWVKQAPGKDL<RMAWINT
YiGES-YADDtKGRbAbSLL
TSASTAYIQINNI<NflDlA
IYYYGSSYA DYWG
QGTSVTVSS
13F5.G5 VH SEQ ID N0:95 QVQLQQSGAELVRPGSSVKI
SCKASGYAFSSYWMNWVKQR
PGQGLEWIGQIYPGDGDTNY
NGKFKGKATLTADKSSSTSY
MQTSGITSPDSA YFCVRFP
TGNDYYAMDYWGQGTSVTVS
Linker SEQ ID N0:75 AKTTPP
3D12.E3 VH SEQ ID N0:89 QIQLVQSGPflLK<PGfliVKI
SCKASGYTFRNYGMNWVKQA
PGKDLKRMAWINLYLGLS Y
ADDTKGRFATSLETSASTAY
LQIVNLKNEDTATYFCARGI
YYYGSSYAMDYWGQGTSVTV
CH SEQ ID NO:122 ASTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTVS
WNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQT
YICNVNHKPSNTKVDKKVEP
KSCDKTHTCPPCPAPELLGG
PSVFLFPPKPKDT'MISRTP
EVTCVVVDVSjEDPEVKFNW
YVDGVEVflNAKTKPREEQYN
STYRVVSVLTVLHQDWLNGK
EYKCKVSNKALPAPIEKTIS
REPQVYLLPPSRfifl
SLTCLVKGFYPSDI
AVEWESNGQPENNY<TTPPV
Sequence
Protein region celdenfifier 1234567890123 4567890
LDSDGSFFLYSKLTVDKSRW
QQGVVFSCSVMHLAIHNiY"
LSPGK
SPAS' IIAVS'GQ3A"
ISC3ASESVDSYGNSYMHWY
QQK?GQPPKLLIYLASNLES
GVPARFSGSGSRTDTTLTID
SEQ ID NO:126
DVD-lg LIGHT PVEADDAATYYCQQVNEDPF
KLEIKRADAAPVIQ
VARIABLE HIL-
MTQTTSSLSASLGDRVTISC
lot/BDVDZ-Ig RASQDISNCLNWYQQKPDGT
VKLLIYYTSRLHSGVPSRFS
GSGSGTDYSLTISNLEQEDI
ATYFCQQGKTLPYAFGGGTK
LEINR
13F5.G5 VL SEQ ID NO:96 NIVLTQSPASLAVSLGQRAT
ESVDSYGNSYUjWY
QQKPGQPPKLLIYLASNLLS
GVPARFSGSGSRTDFTLTID
PVEADDAATYYCQQNNLDPF
TFGSGTKLEI<3
Linker SEQ ID NO:69 ADAAP
3D12.E3 VL SEQ ID NO:90 NIQMTQTTSSLSASLGD3VT
ISCRASQDISWCLVWYQQ<P
DGTV<LLIYYTS3LHSGVPS
3FSGSGSGTDYS .TISV I3Q
LDIATYFCQQGKT.LPYAFGG
GTKLLIV3
CL SEQ ID N0:124 "VAAPSVFIFPPS DTQ I<SG
"ASVVCI INNFYP3LA<VQW
KVDNALQSGNSQ fiSVi*IQDS
KDSTYS ISSTTIT IS<ADYLK
HKVYACLVTHQG .SSPVT<S
FNRGEC
Example 1.3.C. Expression and Purification of hIL-lodBDVDl-Ig g Protein
The heavy and light chain of each construct was subcloned into pcDNA3.l TOPO and pEF6
TOPO vectors (Invitrogen Inc), respectively, and sequenced to ensure accuracy. The plasmids
encoding the heavy and light chains of each construct were transiently expressed using
Lipofectamine 2000 and 293fectin reagents, respectively in COS cells as well as human embryonic
kidney 293 cells (American Type Culture Collection, Manassas, VA). The cell culture media were
ted 72 hour-post transient transfection and antibodies purified using protein A
chromatography (Pierce, Rockford, IL) according to manufacturer's instructions. The dies
were analyzed by SDS-PAGE and quantitated by A280 and BCA (Pierce, Rockford, IL). Table 11
shows that the expression levels of hIL—lw’BDVDl-Ig and hlL-loc/BDVDZ-Ig are comparable to that
of the chimeric antibodies, ting that the DVD-lg binding protein can be expressed efficiently
in mammalian cells.
Table 11. Expression and Molecular Weight Analysis of hIL-lu/B DVD-lg Binding
Protein
Expression Level (ngiml) Molecular Mass (Dalton)
yle 293
Light Chain Heavy Chain Full length
0 0
3D12.E3-Ch 2788 3886 23,696 49,914 147,220
13F5.G5-Ch 3260 3562 24,084 49,518 147,204
DVDl-I_ 2988 3300 (35,790) (64,371) (200,521)
36,222 64,976 202,354
DVD2-Ig 2433 (36,220) (64,973) (202,573)
The molecular mass of the light chain, heavy chain, and full length of DVDl-lg binding protein
and DVD2-Ig binding n determined experimentally by mass spectrometry are shown in
parenthesis.
Example 1.4. Mass Spectrometry and SEC Analysis of hIL-la/BDVD-Ig Binding Protein
For measuring lar weight (MW) of light and heavy chains of DVD-lg binding
protein, 10 ltL of DVD-lg molecule (0.8 ug/uL) was reduced by 1.0 M DTT solution (5 liL). A
, 8”, 4000A, and 1 x 150 mm protein column (Michrom ource, Auburn, MA) was
used to te heavy and light chains of DVD-lg molecule. Agilent HP1100 Capillary HPLC
(Agilent Technologies Inc., Pala Alto, CA) was used with the mass spectrometer QSTAR (Applied
Biosystems, Foster City, CA). The valco valve was set at 10 minutes to switch the flow from waste
to MS for desalting sample. Buffer A was 0.02% TFA, 0.08% FA, 0.1% ACN and 99.8% HPLC-
H20. Buffer B contained 0.02% TFA, 0.08% PA, 0.1% HPLC-H20, and 99.8% ACN. The HPLC
flow rate was 50 liL/minute and the sample injection volume was 8.0 mL. The temperature of the
column oven was set at 60°C, and separation gradient was: 5%B for 5 minutes; 5%B to 65%B for 35
minutes; 65%B to 95%B for r 5 minutes, and 95%B to 5%B for 5 minutes. TOFMS scan was
from 800 to 2500 amu, and cycles were 3600. To determine the MW of full length DVD-1g binding
protein, 21 Protein MicroTrap cartridge (Michrom BioResource, Auburn, MA) was used for ing
the sample. The HPLC gradient was: 5%B for 5 minutes; 5%B to 95%B in 1 minute; and from
95%B to 5%B in another 4 minutes. The QSTAR TOFMS scan was from 2000 to 3500 amu, and
cycles were 899. All MS raw data were ed using the Analyst QS software ed
Biosystems). For SEC analysis of the DVD-lg binding protein, purified DVD-lg binding protein and
ic Abs, in PBS, were applied on a Superose 6 10i300 G2, 300 x 10 mm column (Amersham
Bioscience, Piscataway, NJ). An HPLC instrument, Model 10A (Shimadzu, Columbia, MD) was
used for SEC. All ns were determined using UV detection at 280 nm and 214 nm. The elution
was isocratic at a flow rate of 0.5 mL/minute. For stability study, samples in the tration range
of 0.2-0.4 mg/ml in PBS ent 3 freeze-thaw cycles between -80°C and 25°C, or were
ted at 4°C, 25°C, or 40°C, for 4 weeks and 8 weeks, followed by SEC analysis.
DVD-lg binding protein and chimeric antibodies were purified by protein A
chromatography. The purification yield (3-5 mg/L) was consistent with hIgG quantification of the
expression medium for each protein. The composition and purity of the d DVD-Ig binding
proteins and chimeric antibodies were analyzed by SDS-PAGE in both reduced and non-reduced
conditions. In non-reduced condition, each of the four proteins migrated as a single band. The
DVD-lg proteins showed greater molecular weight than the chimeric dies, as expected. In
non-reducing condition, each of the four proteins yielded two bands, one heavy chain and one light
chain. Again, the heavy and light chains of the DVD-lg binding proteins were larger in size than that
of the ic antibodies. The SDS-PAGE showed that each DVD-lg binding protein is expressed
as a single species, and the heavy and light chains are efficiently paired to form an IgG-like
molecule. The sizes of the heavy and light chains as well as the full-length protein of two DVD-lg
molecules are consistent with their calculated molecular mass based on amino acid sequences (see
Table 11).
In order to determine the precise molecular weight of the DVD-lg binding proteins, mass
spectrometry was employed. As shown in Table 1, the experimentally determined molecular mass of
2O each DVD-lg binding protein, including the light chain, heavy chain, and the full-length protein, is in
good agreement with the ted value. To further study the physical properties of DVD-lg
g n in solution, size exclusion tography (SEC) was used to analyze each protein.
Both ic Abs and DVD2—Ig binding protein exhibited a single peak, demonstrating physical
homogeneity as monomeric proteins. The 3D12.E3 chimeric Ab showed a r physical size then
13E5.G5 ic Ab, indicating that 3D12.E3 chimeric Ab adopted a more compact, globular
shape. DVDl-Ig binding protein revealed a major peak as well as a shoulder peak on the right,
suggesting that a portion of DVDl-Ig binding protein is possibly in an aggregated form in current
buffer condition.
Example 1.5: Analysis of In Vitro Stability of hIL-lw’B DVD-lg Binding Proteins
The physical stability of DVD-lg was tested as follows. Purified antibodies in the
concentration range of 0.2-0.4 mg/ml in PBS underwent 3 freeze-thaw cycles between -80°C and
°C, or were incubated at 4°C, 25°C, or 40°C, for 4 weeks and 8 weeks, followed by analysis using
size exclusion chromatography (SEC) analysis (see Table 12).
Table 12. In Vitro Stability Analysis of hIl-ltx/B DVD-lg by SEC
3D12.E3-Ch 13F5.G5-Ch DVDl-Ig DVD2-Ig
Ab Frgm Agg Ab Frgm Agg Ab Frgm Agg
3xFreeze
—ThaW . 98.28 0.00 13.0 87.0 0.0 46.50 53.50 0.00 0.0 .
l 0‘0 0.0
. . . 100.0 0.0 . .0 .0
_-fl__
_-fl__
_-fl__
40°C @
8 Wks 4.74 81.47 13.79 34.6 65.4 0.0 20.55 67.16 12.29 0.0 100.0 0.0
The degree of ation and fragmentation are shown in percentage, whereas the tage of Ab
represents intact molecule.
Agg: aggregates;
Ab: intact antibody;
Frgm: fragments.
Both chimeric antibodies showed minor degrees of aggregation and fragmentation, normal
for a regular IgG molecule. DVDl-Ig binding protein showed some aggregation on SEC after
purification. In the ity analysis, DVDl-Ig binding protein also showed aggregations in PBS
under different conditions; however the percentage of aggregated form of DVDl-Ig binding protein
did not increase during prolonged storage or at higher temperatures. The percentage of the
fragmented form of DVDl-Ig binding protein was in the normal range, similar to that of the chimeric
3D12.E3 Ab. In contrast, DVDZ-Ig binding protein showed exceptional stability. Neither
aggregation nor fragmentation was detected for DVDZ-Ig binding protein in all conditions tested,
and 100% of DVDZ-Ig binding protein maintained as intact monomeric molecule.
Example 1.6. Determination of n g Affinity of hIL-lot/B DVD-lg Binding
Proteins
The cs of DVD-Ig les binding to rhILl—oc and rhILl—B was determined by
surface plasmon resonance-based measurements with a Biacore 3000 instrument re AB,
a, Sweden) using HBS-EP (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, and
0.005% surfactant P20) at 25°C. All als were obtained from Biacore AB (Uppsala, Sweden)
or otherwise from a different source as described herein. Approximately, 5000 RU of goat anti-
human IgG Fey fragment specific polyclonal antibody e Biotechnology Inc, Rockford, IL)
diluted in 10 mM sodium acetate (pH 4.5) was directly immobilized across a CM5 research grade
biosensor chip using a standard amine coupling kit according to manufacturer’s instructions and
procedures at 25 mg/ml. Unreacted es on the biosensor surface were blocked with
ethanolamine. Modified carboxymethyl dextran surface in flowcell 2 and 4 was used as a reaction
surface. Unmodified carboxymethyl dextran without goat anti-human IgG in flow cell 1 and 3 was
used as the reference surface. For kinetic analysis, rate ons derived from the 1:1 Langmuir
binding model were fitted simultaneously to association and dissociation phases of all ten injections
(using global fit analysis) using the Bioevaluation 4.0.1 software. d DVD-lg samples were
diluted in HEPES-buffered saline for capture across goat anti—human IgG Fc specific reaction
surfaces and injected over reaction es at a flow rate of 5 ml/minute. The association and
dissociation rate constants, kon (M-ls-l) and koff (s-l) were determined under a uous flow
rate of 25 ml/minute. Rate constants were derived by making kinetic binding measurements at ten
different antigen concentrations ranging from 1.25 to 1000 nM. The equilibrium dissociation
constant (M) of the reaction between DVD-Ig le and rhIthx/B was then calculated from the
kinetic rate constants by the following formula: KD = on. Aliquots of rhILloc/B samples were
also aneously injected over a blank reference and reaction CM surface to record and subtract
any nonspecific binding background to eliminate the majority of the refractive index change and
injection noise. Surfaces were regenerated with two subsequent 25 ml injections of 10 mM Glycine
(pH 1.5) at a flow rate of 5 ml/minute. The anti-Fc antibody immobilized surfaces were completely
rated and retained their full capture capacity over twelve cycles. The apparent stoichiometry
of the captured DVD-lg- rhIL1(X,/ [3 complex was calculated under saturating binding conditions
2O (steady-state equilibrium) using the following formula:
/B se (RU) DVD-lg (MW)
Stoichiometry = ———— x ——___
DVD response (RU) rhILl (x/[3 (MW)
The Biacore is indicated the chimeric antibodies possessed similar binding kinetics
and affinities to IL-1 as the al hybridoma monoclonal antibodies, indicating that the correct
VL/VH sequences had been isolated (Table 13). The overall binding parameters of the two DVD-lg
binding proteins to hIL—IOL were similar, with the affinities of the DVD—1g binding proteins being
only 2-3 fold less than that of the chimeric 3D12.E3 antibody. The binding affinity of DVD2-Ig
binding protein to hIL—ll?) was slightly less than the chimeric antibody 13F5.G5, but 3-fold higher
than that of DVDl-Ig binding n. The affinity of the two DVD-lg binding proteins to hIL-l as
compared to the affinity of chimeric antibodies to hIL-l was similar as ted by the tion of
the stoichiometry to IL-1. Both chimeric antibodies, being bivalent ecific, bound to IL-loc
and lL-1[3 on Biacore with a stoichiometry of 1.6 and 1.7, respectively. This is common for an IgG
due to inter-molecular interference when antibodies are immobilized y on the Biacore sense
chip resulting in stoichiometry being in the range from 1.5 to 2.0. The stoichiometries of both DVD-
Ig binding proteins for c and hL—IB were similar to that of the two chimeric antibodies,
indicating that both DVD-lg binding proteins possessed bivalent binding capability to each antigen.
Table 13. Functional Characterization of IL-1 Binding Proteins
IL-l
Binding ken koff Kd Stoichio- Potency
Protein Antigen (M-l 8—1) (8—1) (M) metry ICso (M)
3D13.E3 hIL-101 6.43 x 10+5 7.13 x 104 1.11 x 10‘9 2.0 6.70 x 10'10
3D12.E3-Ch hIL-loc 4.12 x 10+5 5.52 x 10“ 1.34 x 10'9 1.6 7.00 x 10'10
DVDl-Ig hIL-loc 3.70 x 10+4 1.05 x 10“ 2.83 x 10'9 1.8 2.30 x 10‘9
DVD2-I c 7.35 x 10+4 2.52 x 10“ 3.42 x 10'9 2.0 2.90 x 10‘9
13F5.G5 hIL-1[3 2.13 x 10+6 6.21 x 10“ 2.91 x 10'10 1.8 6.00 x 10-10
13F5.G5-Ch hIL—1[3 1.41 x 10*6 6.54 x 104 4.62 x 10-10 1.7 5.30 x 10'10
g hIL-1[3 6.09 x 10+5 1.59 x 10-3 2.60 x 10-9 1.5 3.10 x 10'9
DVD2-Ig hIL-1[3 1.19 x 10+6 9.50 x 104 7.98 x 10'10 1.8 1.60 x 10'9
Affinity and stoichiometry were measured by Biacore; Potency (ICSO) was determined by
MRC-5 bioassay; Ch = chimeric
In addition, alent pecific antigen binding of DVD-lg binding protein was also
analyzed by Biacore (Table 14). DVD-lg g protein was first captured via a goat anti-human
Fc antibody on the Biacore sensor chip, and the first antigen was injected and a binding signal
observed. As the DVD-lg binding protein was saturated by the first antigen, the second antigen was
then injected and the second signal observed. This was done either by first injecting IL—1[3 then
IL—loc or by first injecting lL—loc followed by IL—1[3 for DVD2-Ig binding protein. In either
sequence, a dual-binding ty was detected. r results were obtained for DVDl-lg binding
protein. Thus, each DVD-lg binding protein was able to bind both antigens simultaneously as a
dual-specific tetravalent molecule. As shown in Table 14, the stoichiometry of both DVD-lg binding
protein to the first antigen, either c or hlL—IB, were larger than 1.5, similar to that of monospecific
bivalent binding. Upon the injection of the second antigen, while DVD-lg binding protein
was already occupied by the first antigen, the stoichiometry of both DVD—Igs binding protein to the
second antigen (i.e., hIL-IOL or hIL—1[3) was between 1.0 and 1.3. Thus, DVD—1g binding n
was able to bind two lL—lOL and two IL-B molecules. DVD-1g binding protein was first captured via
a goat anti-human Fc antibody on the e sensor chip, and the first n was injected and a
binding signal observed, followed by the injection of the second antigen.
Table 14. Stoichiometry Analysis of hIL-lot/B DVD-lg Binding Protein in Tetravalent
Dual-S ecific Bindin_ to IL-10t/ 5
Response Unit Stoichiometry
Captured
Binding Protein 1st antigen 2nd antigen hIL-10t:DVD-Ig hIL-l S :DVD-Ig
DVDl-Ig: 932 hIL-10L: 190 hIL-1[3: 75
DVDl-Ig: 1092 hIL-IB: 141 hIL—loc: 107
DVD2-Ig: 1324 hIL-loc: 209 3: 137
DVD2-Ig: 1184 : hIL—loc: 131
Example 1.7. ination of Functional Homogeneity of DVD-lg Molecules
Because DVD2-Ig binding protein was purified by n A chromatography instead of
target-specific affinity chromatography, any potential misfolded and/or mismatched VL/VH
domains, if present, can be ed by binding s against the two different antigens. Such
binding analysis was conduced by size exclusion liquid chromatography (SEC). DVD2-Ig binding
protein, alone or after a 120-minute incubation period at 37°C with IL-loc, IL-IB, or both IL-10t and
IL-ll3, in equal molar ratio, were applied to the . Each of the antigens was also run alone as
controls. The SEC results indicated that DVD2-Ig binding protein was able to bind IL-10t and IL-1[3
in solution, and such binding ed in a shift to the SEC signal indicating an se in the
dynamic size of DVD2-Ig binding protein when it was in complex with either antigen. The shift of
the DVD2-Ig binding protein signal was 100%, not partial, suggesting all DVD2-Ig molecules were
able to bind the n. In the ce of both IL-loc and , there was a further and complete
shift of the DVD2-Ig g protein signal, indicating all DVD2-Ig molecules were able to bind
both antigens in a uniform fashion. This experiment demonstrated that DVD-lg binding protein was
expressed as a functionally homogeneous protein. This has significant implications as it
demonstrates that DVD-lg binding protein can be produced as a homogeneous single, functional
s, which differs from all previously described cific, multi-specific, and multi-valent
immunoglobulin-like and immunoglobulin-derived molecules.
2O Example 1.8. Determination of Biological Activity of DVD-lg Binding Proteins
The biological activity of DVD—lg was measured using MRC—S bioassay. The MRC-5 cell
line is a human lung fibroblast cell line that produces IL—8 in response to human IL—loc and IL—ll?) in
a dose-dependent manner. MRC-5 cells were obtained from ATCC and cultured in 10% FBS
complete MEM at 37°C in a 5% C02 incubator. To determine neutralizing activity of the DVD-lg
against human IL—loc or 1L—1[3, 50 n1 of dy (1 x 10'7 to 1 x 10‘12 M) in MEM/10%FBS was
added to a 96 well plate and pre-incubated with 50 ul of hIL—loc or hIL—ll3 (200 pg/ml) for 1 hour at
37°C, 5% C02. MRC-5 cells at a concentration of 1 x 105fml were then added (100 pl) to all wells,
and the plates were incubated overnight at 37°C in a 5% C02 incubator. The supernatants were
harvested and human IL-8 production measured by standard ELISA (R&D Systems, Minneapolis,
MN). Neutralizing activity of the DVD—lg binding protein was determined by its ability to inhibit
IL-8 tion.
As shown in Table 13, both DVD-Ig binding proteins were able to neutralize hlL-loc and
hIL-lB. Consistent with the g affinity to hIL—loc, the neutralizing activities of g
binding protein and DVD2-Ig binding protein against hIL-loc were also similar, i.e., 3-fold less than
that of the ic antibodies (see, Table 13). Consistent with its g affinity for hIL—lB, the
neutralizing activity of g binding protein to hIL—IB is slightly less than that of the chimeric
Ab 13F5.G5, but 3-fold higher than that of DVDl-Ig binding protein. Overall there was no
significant decrease in the biological activities of DVD-lg molecules compared to the original
monoclonal antibodies.
To determine if DVD-lg binding protein was able to inhibit IL-8 production in the presence
of both IL-loc and IL-l[3, equal s of hIL—loc and hIL-lB were added in the same culture
system of MRC-5 assay. Both the DVDl-Ig binding protein and the DVD2-Ig binding protein were
able to inhibit IL-8 synthesis by MRC-S cells in the presence of both IL-loc and IL—lB, with activities
similar to that of mono-assays where only one cytokine was present (Table 13). In this assay where
both IL-loc and IL-l[3 were present, the nhibition activity of DVD2-Ig binding protein (1.2 nM)
was higher than that of DVDl-Ig binding protein (2.2 nM).
Example 2. Analysis of Linker Size and Variable Domain Orientation in DVD-lg Binding
2O Proteins
onal DVD-Ig molecules with different parent mAb pairs, as shown in Table 15, were
constructed. For each pair of mAbs, four different DVD-Ig ucts were generated: 2 with a short
linker and 2 with a long linker, each in two different domain orientations: a-b-C (alpha-beta-constant
domain) and b-a-C (beta-alpha-constant domain). The linker ces were derived from the N-
terminal sequence of human Ck or CH] domain, as follows: Short linker: light chain: TVAAP (SEQ
ID ; heavy chain: ASTKGP (SEQ ID NO:79); and Long linker: light chain: TVAAPSVEIFPP
(SEQ ID NO:72); heavy chain: ASTKGPSVFPLAP (SEQ ID .
All heavy and light chain ucts were ned into the pBOS expression vector, and
expressed in COS cells or freestyle 293 cells.
To construct new DVD-lg clones, the variable domains of the two mAbs, both light chain
and heavy chain, were first jointed in tandem using overlapping PCR as described for hIL-
1(x/[3DVD1-Ig and hIL—loc/BDVD2-Ig. The jointed pieces were then subcloned in pBOS vector
using homologous recombination. Briefly, vectors were linearized by restriction digestion (2 ug of
pBOS-th vector were digested with FspAI and Bsin in 0+ buffer, and 2 ug of pBOS-hCy z,non a
vector was digested with FspAI and SaII in 0+ ). The digested samples were run on a 1%
agarose gel and the backbone fragment purified in 50 ul water. For homologous recombination and
transformation, DHSoc competent cells were thaw on ice, and mixed with 20-50 ng jointed PCR
product and 20-50 ng of linearized vector (in every 50 Ml DHSOL cells). The e was mixed
gently and incubated on ice for 45 minutes, followed by heat shock at 42°C for 1 minute. Then 100
til SOC medium were added and incubated at 37°C for 1 hour. The transformation culture was
inoculated on LB/agar plates containing ampicillin and incubated at 37°C for 18-20 hours. The
bacterial clones were isolated, from which DNA was purified and ted to sequencing analysis.
The final sequence-verified clones were co-transfected (matching HV and LC of the same antibody
pair) in COS or 293 cells for antibody expression and purification, as usly described.
Characteristics of the purified DVD-lg proteins are summarized in Table 16. The left
section of the Table 16 shows the specificity, binding affinity, and neutralization potency of the 2
pairs of mAbs used for the construction of the new hIL-loc/B DVD-lg molecules. Antibodies
18F4.2C8 and 1B12.4H4 (see, Example 1.1.D) were used to construct hlL-la/B DVD3a-Ig, hlL-
10c/[3 Ig, hIL-loc/[3 DVD3b-Ig, and hIL-loc/B DVD4b-lg. hlL-loc/BDVD3a-lg and hlL-
10c/[3DVD4a-Ig were in a-b-C orientation, with a short and long linker, respectively. hlL-
DVD3b-Ig and X,/[3DVD4b-Ig were in b-a-C orientation, with a short and long ,
respectively. Antibodies 6H3.1A4 and 6B12.4F6 were used to construct hlL-1(x/[3DVD5a-Ig, hlL-
1(x/[3DVD6a-lg, hlL-loc/B Ig, and hIL—loc/B DVD6b-Ig. hIL-loc/B Ig and hlL-
1(x/[3DVD6a-lg were in a-b-C orientation, with a short and long linker, respectively. hlL-loc/B
2O DVDSb-Ig and hIL-loc/BDVD6b-lg were in b-a—C orientation, with a short and long linker,
respectively. The molecular cloning of these additional hIL-loc/[3 DVD-lg binding proteins were
performed using the procedure previously described for hIL-loc/B DVDl-lg (see, Example 1.3),
using overlapping PCR procedures. The amino acid sequences of these onal hlL-loc/[3 DVD-lg
g proteins are disclosed in Table 15.
Table 15. Amino Acid Sequence of Heavy Chain and Light Chain of Six DVD-Ig Proteins
e of Binding IL-10. and IL-1[3
Protein region Sequenceldenfifier 12345678901234567890
EVQLQQSGAELVKPGASVKJ
SCTASGLNIKDTYMHWLKQR
PEQGLEWIGRIDPANGNAKY
KATITADTSSNTAY
DVD-Ig HEAVY SEQ ID N0:127
LQLSSLTSEDTAVYYCARGD
VARIABLE
GNFHFDYWGQGTTLTVSSQS
hIL-la/B DVD3a-Ig TKGPQVHLKESGPGLVAPSQ
SLSITCTVSGFSLTDYGVSW
KGLEWLGLIWGGGD
LKSRLSIRKDNSKS
QVFLKMNSLQTDDTAVYYCA
KQRTLWGYDLYGMDYWGQGT
SVTVSS
18F4.2C8 VH SEQ ID NO:91 EVQLQQSGAELVKPGASVKL
SCTASGLNIKDTYMHWLKQR
PEQGLEWIGRIDPANGNAKY
DPRFLGKATITADTSSNTAY
LQASSATSED"AVYYCARGD
GNFHFDYWGQGTTLTVSS
LINKER SEQ ID NO:79 ASTKGP
1B12.4H4 VH SEQ ID NO:97 QViL<ESGPGLVAPSQSDSI
iC VSGhSL DYGVSWIQQP
PG<G.?WLGIIWGGGDTYYN
SPAKSRLSIQKDNSKSQVFL
KMVSAQTDD"AVYYCAKQRT
LWGYDAYGMDYWGQGTSVTV
SEQ ID N0:122 ASTKGPSVFPJAPSS<S"SG
GTAAIGCIV<DYEPLPV VS
WNSGALTSGV{"FPAV4QSS
GLYSLSSVVTVPSSSDG"QT
YICVVNH<PSW"KVD<<VEP
KSCDKTHTCPPCPAP?.IGG
PSVTLFP?KPKDT4WISQTP
EVTCVVVDVSHED?EV<FVW
YVDGVEVHVAKTK??EEQYN
STYRVVSVVTVLHQDWVVGK
EYKCKVSWKALPA?IEKTIS
KAKGQPRE?QVYTL?PSREE
MTKNQVSLTCLVKGFYPSDI
AVEWESNGQPENNYKTTPPV
LDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYT
SPGK
DIVQTQSQRFMSTSVGDRVS
VTCSASQNVGTNIAWYQQKP
GQSPRALIYSASYRYSGVPD
RtiGSGSG-Db-AiISNVQS
SEQ ID N0:128
DVD-Ig LIGHT VDLAEYFCQQYTRYPLTFGG
GiKAEIKR-VAAPEiiV QS
VARIABLE HIL-
PASASMAIGEKVTIRCI"ST
Sequence
Protein region Sequenceldenfifier 12345678901234567890
lot/[3 DVD3a-Ig DIDVDMVWYQQKPG?PP<.L
ISQGNTLRPGVPSRFSSSGS
GTDFVFIIENMLSEDVADYY
LPLTFGAG"KLE.K
18F4.2C8 VL SEQ ID N0:92 DIVMTQSQRFMSTSVGDRVS
VTCKASQNVGTNIAWYQQKP
GQSPRALIYSASYRYSGV?D
SGTDFTLTISNVQS
VDLAEYFCQQYTRYPLTFGG
LINKER SEQ ID NO:71 TVAAP
1B12.4H4 VL SEQ ID NO:98 ETTVTQSPASLSMAIGEKVT
TDIDVDMNWYQQKP
GEPPKLLISQGNTLRPGVPS
RFSSSGSGTDFVFIIENMLS
EDVADYYCLQSDNLPLTFGA
GTKLELKR
SEQ ID N0:124 TVAAPSVFIFPPSDEQJKSG
TASVVCALNNFYPREA<VQW
KVDNALQSGNSQflSVifiQDS
KDSTYSASSTITIS<ADYEK
HKVYACEVTHQG.SSPVT<S
FNRGEC
QViL<ESGPGLVAPSQSDSI
TCTVSGFSJ"DYGVSWIRQP
PG<GIEWIG.IWGGGDTYYN
SPJKSRLSIRKDNSKSQVFL
DVD-lg HEAVY SEQ ID N0:129
KMVSJQTDD"AVYYCAKQR"
VARIABLE
YG DYWGQGTSVTV
hIL-lot/B DVD3b- SSAST<GPEVQLQQSGA7.VJ.
1g KPGASVKJSCTASGLNI<D"
YMHW1<QRPflQGIflWIGRID
PANGVAKYDPRFJGKATI"A
DTSSVTAYVQussuiSflD A
VYYCARGDGVTHTDYWGQGT
TLTVSS
1B12.4H4 VH SEQ ID N0:97 QVHLKESG?GLVA?SQSLSI
TCTVSGFSLTDYGVSWIQQP
PGKGLEWLGLIWGGGDTYYN
SPLKSRLSIRKDNSKSQVFL
KMNSLQTDDTAVYYCAKQRT
LWGYDLYGMDYWGQGTSVTV
LINKER SEQ ID NO:79 ASTKGP
18F4.2C8 VH SEQ ID NO:91 EVQLQQSGAELVKPGASVKL
SCTASGLNISDTYMHWLKQR
WIGRIDPANGNAKY
DPRELGKAII-ADISSN-AY
LQLSSLTSEDT VYYCARGD
GNFHFDYWGQGTTLTVSS
CH SEQ ID NO:122 ASTKGPSVFPLAPSSKS"SG
GTAALGCLVKDYEPLPV VS
Sequence
Protein region Sequenceldenfifier 12345678901234567890
WNSGALTSGVHTFPAVJQSS
GLYSLSSVVTVPSSSJGTQT
YICVVNHKPSNTKVD<<VE
KSCDKTHTCPPCPAP7.LGGJ.
PPKPKDTLMISRTP
EVTCVVVDVSHEDPEVKFVW
YVDGVEVHNAKTKPREEQYN
STYQVVSVLTVWHQDWVNGK
EYKCKVSNKAL?APIEKTIS
KAKGQPREPQVYTLPPSREE
MTKNQVSLTCLVKGFYPSD:
AVEWESNGQPENNYKTTPPV
DSDGSFFLYSKLTVDKSRW
QGNVFSCSVMjEALHNHYT
XSASLSPGK
TTVTQSPASLSMAIGEKVT
RCITSTDIDVDMNWYQQKP
PPKLLISQGNTARPGVPS
SSSGSGTDFVFIIENMJS
SEQ ID NO:130
DVD-1g LIGHT VADYYCLQSDNuPITFGA
,_] KEELKRTVAAPDIVMTQS
VARIABLE HIL- IOOWSUg—IDHFJIOIOF'U'TJRFMSTSVGDRVSVTCKASQ
1a/[3 Ig NVGTNIAWYQQ<PGQSPRAL
IYSASYRYSGVPDRFTGSGS
N06) 10 10 ._<Db JIISNVQSVDLAEYF
RYPLitGGGiKuflIK
H4 VL SEQ ID N0:98 DL‘J/UGDHD 1V QSPASLSMAIGE<VT
RCI"STDIDVDMVWYQQKP
EPP<.LISQGNT4RPG
FSSSGSGTDFVFIIEV LS
CIQSDNIPITFGA
TK.?.KR
LINKER SEQ ID N0:71 TVAAP
18F4.2C8 VL SEQ ID N0:92 DIVMTQSQRF RVS
VTCKASQNVGTNIAWYQQKP
GQS?RALIYSASYRYSGVPD
RFTGSGSGTDTTLTISNVQS
VDLAEYTCQQYTQYPLTFGG
GTKLEIKR
SEQ ID NO:124 TVAAPSVFIF?PSDEQLKSG
TASVVCLLNNTY?REAKVQW
KVDVALQSGNSQESVTEQDS
KDSTYSLSSTLTLSKADYEK
HKVYACEVTHQGLSSPVTKS
FNRGEC
SGAELVKPGASVKL
SCTASGLNIKDTYMHWAKQR
PEQGLEWIGRIDPANGNAKY
DPRFLGKATITADTSSNTAY
DVD-Ig HEAVY SEQ ID NO:131
LQLSSLTSEDTAVYYCARGD
VARIABLE hIL-
GNFHFDYWGQGTTLTVSSEE
1(x/[3 DVD4a-Ig TKGPSVFPLAPQVHLKESGP
GLVAPSQSLSITCTVSGFSA
Sequence
Protein region Sequence Identifier 12345678901234567890
TDYGVSWIRQPPGKG.LWLG
LIWGGGDTYYVSPLKSQLSI
RKDVSKSQVFLKMNSIQTDD
TAVYYCAKQRTLWGYDLYGM
C8 VH SEQ ID NO:91 EVQLQQSGAELVKPGASVKL
SCTASGLNIKDTYMHWLKQR
PEQGLEWIGRIDPANGVAKY
DPRFLGKATITADTSSNTAY
LQLSSLTSEDTAVYYCARGD
GNFHFDYWGQGTTLTVSS
LINKER SEQ ID NO:80 ASTKGPSVFPLAP
1B12.4H4 VH SEQ ID NO:97 QVH'KESGPGLVAPSQSLSI
TCTVSGFSLTDYGVSWIRQP
WLGLIWGGGDTYYN
SPLSSRLSIRKDNSKSQVFL
KMNSLQTDDTAVYYCAKQRT
LWGYJLYGMDYWGQGTSVTV
CH SEQ ID N0:122 ASTK PSVFPLAPSS<S"SG
CLVKDYEPLPV VS
WNSGALTSGV{"FPAVLQSS
GLYSLSSVVTVPSSSL
YICNVVH<PSV"<VD<<VL
PSVF_LFPPKP<DTL 18' P
LViCVVVDVSiLDPLV<bVW
YVDGV.LV{NA<1<PRL.« w
STYRVVSVLTvuiQDWIVG <
LYKC<VSVKAIPAPIE<TIS
{AKGQPRLPQVYLTIPPSRLL
WTKVQVSITCIV<GFYPSDI
AVEWLSNGQP*.NVYK11PPV
.LDSDGSFFLYSKLTVD<S?W
SCSV HEALHVHYT
QKSLSLSPGK
DIVWTQSQRFWSTSVGDRVS
VTCKASQNVGTNIAWYQQKP
GQS?RALIYSASYRYSGVPD
SEQ ID N0:132 RFTGSGSGTDTTLTISVVQS
DVD—1g LIGHT VDLAEYTCQQYTRYPLTFGG
GTKLEIKRTVAAPSVFIFPP
VARIABLE HILETTVTQSPASLSMAIGLKVT
1u/[3 DVD4a-Ig IRCITSTDIDVDMNWYQQKP
GEPPKLLISQGNTLRPGVPS
RFSSSGSGTDFVFIIENMLS
EDVADYYCLQSDNLPLTFGA
GTKLELKR
18F4.2C8 VL SEQ ID NO:92 DIVMTQSQRFMSTSVGDRVS
QNVGTNIAWYQQKP
GQSPRALIYSASYRYSGVPD
SGTDFTLTISNVQS
VDLAEYFCQQYTRYPLTFGG
GTKLEIKR
Sequence
Protein region Sequence Identifier l 2 3 4 5 6 7 8 9 0 l 2 3 4 5 6 7 8 9 0
LINKER SEQ ID N0:72 TVAAPSVFIFPP
1312.4H4 VL SEQ ID N0:98 ETTVTQSPAS .SMAIGEKVT
TDIDVDMEWYQQKP
GEPPKLLISQGNTLRPGVPS
RFSSSGSGTDEVEIIEEMLS
EDVADYYCLQSDNLPLTFGA
GTKLELKR
SEQ ID N0:124 TVAAPSVFIF?PSDEQLKSG
TASVVCLLNNFYPREAKVQW
KVDNALQSGNSQESVTEQDS
KDSTYSLSSTLTLSKADYEK
HKVYACEVTHQGLSSPVTKS
FNRGEC
QVHLSESGPGDVAPSQSLSI
TCTVSGFSDTDYGVSWIRQP
WLGLIWGGGDTYYN
DVD-1g HEAVY SEQ ID N0:133 EDPEESRTEEERKfiiggvfi“Q ‘ Q
VARIABLE hIL-
LWGYDLYGUDYWGQGTSVTV
“VBIDVD4ng GPSVE9.APEVQ.Q
QSGAELVKPGASVKSSCTAS
GLNIKDTY HW.<QRP?QG.
EWIGRIDPANGEAKYJPRES
GKATI"ADTSSETAY.Q.SS
LISLD AVYYCARGDGVFHF
TTD"VSS
1B12.4H4 VH SEQ ID N0:97 QVH u<T-SGPGT-VAPSQS.JS I
TCTVSGFSD"DYGVSWIRQP
PGKG.?WLG.IWGGGDTYYN
SPL<SRLSIRKDNSKSQVFL
KMNSSQTD3"AVYYCAKQRT
LWGYDDYG DYWGQGTSVTV
LINKER SEQ ID N0:80 ASTKGPSVFPDAP
18F4.2C8 VH SEQ ID N0:91 F-VQTIQQSGAT. .V <PGASVKS
SCTASGLNIKDTYMHWLKQR
PEQGLEWIGRIDPANGNAKY
DPRFLGKATITADTSSNTAY
LQLSSLTSEDTAVYYCARGD
GNFHTDYWGQGTTLTVSSL
CH SEQ ID N0:122 ASTKGPSVE‘?LA?SSKSTSG
GTAAVGCVVKDYEPEPVTVS
WNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQT
YICNVNHKPSNTKVDKKVEP
KSCDKTHTCPPCPAPELLGG
PSVFLFPPKPKD LMISRTP
EVTCVVVDVSjEJPEVKFNW
YVDGVEVjNAKTKPREEQYN
SVLTVLjQDWLNGK
EYKCKVSNKADPAPIEKTIS
RLPQVYIDPPSRnfi
MTKNQVSDTCDVKGFYPSDI
AVEWESNGQPENNY<TTPPV
Sequence
Protein region Sequenceldenfifier 12345678901234567890
LDSDGSFFLYSKLTVD<SRW
QQGVVTSCSVMHEALHWHY"
QKS'S'ISPGK
ETTVTQSPASLSWAIG.LKV
IRCITSTDIDVDWVWYQQKP
GEP?KLLISQGN LRPGVPS
RFSSSGSGTDFVTIIEVMLS
SEQ ID N0:134
DVD—1g LIGHT EDVADYYCLQSD LPLTFGA
GTK'E'<RTVAA?SVFIFPP
VARIABLE HIL-
DIVMTQSQRFMSTSVGDRVS
1a/[3 DVD4b-Ig VTCKASQNVGTNIAWYQQKP
GQSPRALIYSASYRYSGVPD
RFTGSGSGTDFTLTISNVQS
VDLAEYFCQQYTRYPLTFGG
GTKLEISR
1B12.4H4 VL SEQ ID NO:98 b-1V-QSPASLSMAIGEKVT
IRCITSTDIDVDMNWYQQKP
GEPPKLLISQGNTLRPGVPS
SGTDFVFIIENMLS
EDVADYYCLQSDNLPLTFGA
GTKLELKR
LINKER SEQ ID N0:72 TVAAPSVFIFPP
18F4.2C8 VL SEQ ID NO:92 DLVMTQSQRFMSTSVGDRVS
VTCKASQNVGTNIAWYQQKP
GQSPQALIYSASYRYSGVPD
RFTGSGSGTDF"_LTISVVQS
VDIALYECQQY RYPLitGG
CL SEQ ID N0:124 "VAAPSVFIFPPSDLQIKSG
"ASVVCIINVFYPREA<VQW
KVDNALQSGVSQLSVILQDS
ISSTITIS<ADYL<
LVTIQGISSPVT<S
QVQLQQ?GA7.VRPGASV<L
SCKASGYTFTTYWMNWVKQ?
PEQGLEWIGQIDPYDSL .Y
SEQ ID N0:135 SQK?KDTAILTVDKSSS"AY
DVD-lg HEAVY
MQLSSLTSEDSAVYYCARYG
VARIABLE hIL-
FDYWGQGTTLTVSSASTKGP
1a/B DVDSa-Ig EVQLQQSGPELV<TGTSVKI
SCKASGYSFTGYYMHWVRQS
HGKSLEWIGYISCYNGFTSY
NPKFKGKATFTVDTSSSTAY
IQFSRLTSEDSAVYYCARSD
YYGTNDYWGQGTTLTVSS
4.3E11 SEQ ID NO:93 QVQLQQPGAELVRPGASVKL
VH SCKASGY-ti-YWMNWVKQR
PEQGLEWLGRLDPYDSETLY
LAILLVDKSSSTAY
MQLSSLTSEDSAVYYCARYG
G-1L-VSS
LINKER SEQ ID N0:79 ASTKGP
6B12.4F6 VH SEQ ID NO:99 EVQLQQSGPELVKTGTSVKI
Protein region Sequenceldenfifier 12345678901234567890
SCKASGYSFTGYYMHWVRQS
HGKSLEWIGYISCYNGF"SY
NPKFKGKATFTVDTSSS"AY
IQFS LTSEDSAVYYCAQSD
YYGTVDYWGQGTTLTVSS
CH SEQ ID N0:122 ASTKG?SVFPLA?SSKSMSG
GTAALGCLVKDYTPEPVHVS
WNSGALTSGVHTTPAVLQSS
GLYSLSSVVTV?SSSLGMQT
HKPSNTKVDKKVEP
KSCDKTHTCPPCPAPELLGG
PSVFLFPPKPKDTLMISRTP
EVTCVVVDVSHEDPEVKFNW
YVDGVEVjNAXTXPREEQYN
STYRVVSVLTVLjQDWLNGK
SNKALPAPIEKTIS
KAKGQPREPQVYTLPPSREE
MTKNQVSLTCLVKGFYPSDI
MTCSASSSVVY YWYQQ<PR
SSP<PWIYLTSVLASGVPAR
FSGSGSG SYSuiISS *A*
SEQ ID N0:136
DVD-Ig LIGHT DAATYYCQQWNSNPYTFGGG
R VAAPQIVLTQSP
VARIABLE HIL-
AIMSASPGE<VTITCSASSS
1a/[3 DVDSa-Ig VSY PGASP<LWIY
STSWLASGVPARFSGSGSG"
SYS. VSR DADDAAIYYCQ
QRSTYPYTFGGGTKLEI<R
6H3.1A4.3E11 SEQ ID N0:94 QIVL"QSPA.MSASPGL<V
VL MTCSASSSVVY YWYQQ<PR
SSPKPWIYLTSWLASGVPA?
FSGSGSGTSYSLLISS *A*
DAATYYCQQWNSNPYTFGGG
TKLEMKR
LINKER SEQ ID N0:71 TVAAP
6B12.4F6 VL SEQ ID NO:100 QIVLTQSPAIMSASPGEKVT
ITCSASSSVSYMHWFQQKPG
ASPKLWIYSTSNLASGVPAR
FSGSGSGTSYSLTVSRMEAE
DAATYYCQQRSTYPYTFGGG
TKLEIKR
SEQ ID NO:124 TVAAPSVFIFPPSDEQLKSG
TASVVCLLNNFYPREAKVQW
KVDNALQSGNSQESVTEQDS
KDSTYSLSSTLTLSKADYEK
HKVYACEVTHQGLSSPVTKS
FNRGEC
EVQLQQSGPELVKTGTSVKI
SCKASGYSFTGYYMHWVRQS
Sequence
Protein region Sequenceldenfifier 78901234567890
HGKSLEWIGYISCYNGF"SY
DVD-lg HEAVY SEQ ID N0:137 NPKFKGKATFTVDTSSS"AY
VARIABLE hIL- TSEDSAVYYCARSD
let/B DVDSb-Ig YYGTNDYWGQGTTLTVSSEE
TKGPQVQLQQPGAELVRPGA
SVKLSCKASGYTFTTYWMNW
VKQRPEQGLEWIGRIDPYDS
ETLYSQKFKDTAILTVDKSS
STAYMQLSSLTSEDSAVYYC
ARYGFDYWGQGTTLTVSS
6B12.4F6 VH SEQ ID NO:99 EVQLQQSGPELVKTGTSVKI
SCKASGYSFTGYYMHWVRQS
HGKSLEWIGYISCYNGFTSY
NPKFKGKATFTVDTSSSTAY
IQFSRLTSEDSAVYYCARSD
YYGTNDYWGQGTTLTVSS
LINKER SEQ ID N0:79 ASTKGP
6H3.1A4.3E11 SEQ ID N0:93 QVQLQQPGAELVRPGASVKD
VH SCKASGY-E1-YWMNWVKQR
PEQGLEWIGRIDPYDSL LY
SQKEKD_AI4 VDKSSS"AY
MQLSSL SLDSAVYYCARYG
FDYWGQG 14 V88
SEQ ID N0:122 ASTKGPSVFPJAPSS<S"SG
GTAAIGC.V<DYEPLPV VS
WNSGALTSGV{"FPAV4QSS
GLYSJSSVVTVPSSS
YICNVNH<PSV"KVD<<VE
<8CD<THTCPPCPAP?.IGG
PSVFAFPPKP<DTL ISRTP
LVICVVVDVSIfiDPflV<bWW
YVDGVLVINA<1KPRfifiQYV
STYQVVSVLTVIHQDWIWG<
SVKAIPAPIE<TIS
RflPQVYlLPPSRflfl
MTKVQVSVTCIVKGFYPSDI
AVEWESNGQPENNYKTTPPV
LDSDGSFTLYSKLTVDKSRW
QQGVVFSCSVMHEALHNHYT
QKSLSLS?GK
QIVLTQS?AIMSASPGEKVT
ITCSASSSVSYMHWFQQKPG
ASPKLWIYSTSNLASGVPAR
FSGSGSGTSYSLTVSRMEAE
DVD—1g LIGHT SEQ ID N0:138
DAATYYCQQRSTYPYTFGGG
TKLEIKRTVAAPQIVLTQSP
VARIABLE HIL-
ALMSASPGEKVTMTCSASSS
1(x/[3 DVDSb-Ig VNYMYWYQQKPRSSPKPWIY
LTSNLASGVPARFSGSGSGT
SYSLTISSMEAEDAATYYCQ
QWNSNPYTFGGGTKLEMKR
6B12.4F6 VL SEQ ID N0:100 QIVLTQSPAIMSASPGEKV"
ITCSASSSVSYMHWFQQKPG
ASPKLWIYSTSNLASGVPAR
Sequence
Protein region Sequenceldenfifier 12345678901234567890
FSGSGSGISYSTIVSRM*A*
DAATYYCQQRSTYPYTFGGG
LINKER SEQ ID N0:71 TVAAP
6H3.1A4.3E11 SEQ ID N0:94 QIVLTQSPALMSASPGEKVT
VL MTCSASSSVNYMYWYQQKPR
SSPKPWIYLTSNLASGVPAR
FSGSGSGTSYSLTISSMEAE
CQQWNSNPYTFGGG
TKLEMKR
CL SEQ ID NO:124 TVAAPSVFIFPPSDEQLKSG
TASVVCLLNNFYPREAKVQW
KVDNALQSGNSQESVTEQDS
KDSTYSLSSTLTLSKADYEK
HKVYACEVTHQGLSSPVTKS
FNRGEC
QVQLQQPGAELVRPGASVKL
SCKASGY-EI-YWMNWVKQR
PEQGLEW-GR-DPYDS.L LY
SQKtKD-AIL_VDKSSS"AY
DVD-lg HEAVY SEQ ID NO:139
MQLSSLTSEDSAVYYCARYG
VARIABLE hIL-
FDYWGQG i. VSSAS {GP
10t/[3 DVD6a-Ig SVFPIAPTVQTQQSGPTIVK
TGTSVKISC<ASGYSF"GYY
MHWVRQSiG<SIEWIGYISC
YWP<F<GKATFTVD
SSS AYIQESRIISLDSAV
YYCARSDYYG"VDYWGQGTT
LTVSS
6H3.1A4.3E11 SEQ ID N0:93 PGAELVRPGASVKL
VH YTFT"YWMNWVKQ3
PLQGLLWIGRIDPYDS.L LY
SQKbKD AIL VDKSSS"AY
MQLSS: SLDSAVYYCARYG
FDYWGQGTTL"VSS
LINKER SEQ ID N0:80 ASTKG3SVT?LAP
6B12.4F6 VH SEQ ID N0:99 EVQLQQSG3ELVKTGTSVKI
SCKASGYSTTGYYMHWVRQS
HGKSLEWIGYISCYNGFTSY
NPKFKGKATFTVDTSSSTAY
TSEDSAVYYCARSD
YYGTNDYWGQGTTLTVSS
CH SEQ ID NO:122 ASTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTVS
WNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQT
YICNVNHKPSNTKVDKKVEP
KSCDKTHTCPPCPAPELLGG
PSVFLFPPK3KDTLUISRT?
EVTCVVVDVSHEDPEVKFNW
YVDGVEVHNAKTKPREEQYN
STYRVVSVLTVLHQDWLVGK
EYKCKVSNKALPAPIEKTIS
KAKGQPREPQVYIIPPSRLL
Sequence
Protein region Sequence Identifier 12345678901234567890
MTKEQVSLTCEVKGEYPSDI
AVEWESNGQPENNYKTTPPV
LDSDGSFFLYSKLTVDKSRW
QQGEVESCSVWHEALHNHYT
QKSLSLSPGK
SPALWSASPGEKVT
MTCSASSSVNYMYWYQQKPR
SSPKPWIYLTSNLASGVPAR
FSGSGSGTSYSLTISSMEAE
DVD-1g LIGHT SEQ ID NO:140
DAATYYCQQWNSNPYTFGGG
TKLEMKRTVAAPSVFIFPPQ
VARIABLE HIL-
IVLTQSPAIMSASPGEKVTI
1a/[3 DVD 6a-Ig TCSASSSVSYMHWFQQKPGA
SPKLWIYSTSNLASGVPARF
TSYSLTVSRMEAED
AATYYCQQRSTYPYTFGGGT
6H3.1A4.3E11 SEQ ID NO:94 QIVLTQSPALMSASPGEKV"
VL MTCSASSSVNYMYWYQQ<PR
SSPKPWIYLTSNLASGVPAR
FSGSGSGiSYSTiISSM*A*
DAATYYCQQWNSNPYTFGGG
TKLEMKR
LINKER SEQ ID N0:72 TVAAPSVFIFPP
6B12.4F6 VL SEQ ID NO:100 QIVATQSPAIMSASPGE<VT
ITCSASSSVSYMHWFQQ<PG
ASP<LWIYSTSNLASGVPAQ
FSGSGSGLSYSTILVS? fiA*.
DAATYYCQQRSTYPYTFGGG
TKLEIKR
CL SEQ ID NO:124 R"VAAPSVFIFPPSD?Q.KS
C4LNNFYPREA<VQ
WKVDNADQSGNSQESVifiQD
SKDSTYSISSTLTIS<ADY?
KHKVYACEVTHQGISSPVT<
EVQLQQSGPELVKTGTSVKI
SCKASGYSFTGYYMHWVRQS
HGKSLEWIGYISCYNGFTSY
KATFTVDTSSSTAY
DVD-lg HEAVY SEQ ID NO:141
TSEDSAVYYCARSD
VARIABLE hIL-
YYGTNDYWGQGTTLTVSS§§
lot/[3 DVD6b-Ig TKG?SVFPLAPQVQLQQPGA
ELVRPGASVKLSCKASGYTF
TTYWMNWVKQRPEQGLEWIG
RIDPYDSETLYSQKFKDTAI
LTVDKSSSTAYMQLSSLTSE
DSAVYYCARYGFDYWGQGTT
LTVSS
6B12.4F6 VH SEQ ID NO:99 EVQLQQSGPELVKTGTSVKI
SCKASGYSFTGYYMHWVRQS
HGKSLEWIGYISCYNGFTSY
NPKtKGKAibiVD_SSS AY
IQFSRLTSEDSAVYYCARSD
Sequence
Protein region Sequence Identifier l 2 3 4 5 6 7 8 9 0 l 2 3 4 5 6 7 8 9 0
YYGTNDYWGQGTTLTVSS
LINKER SEQ ID N0:80 ASTKGP SVF?_4AP
6H3.1A4.3E11 SEQ ID N0:93 QVQLQQPGAELVRPGASVKJ
VH SCKASGYTFTTYWMNWVKQ?
PEQGLEWIGRIDPYDSETLY
TAILTVDKSSSTAY
MQLSSLTSEDSAVYYCARYG
FDYWGQGTTLTVSS
SEQ ID N0:122 ASTKGPSVFPLAPSSKSTSG
GTAALGCLVKDYFPEPVTVS
WNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQT
YICNVNHKPSNTKVDKKVEP
HTCPPCPAPELLGG
PSVFLFPPKPKDTAMISRT?
EVTCVVVDVSjEDPEVKFNW
YVDGVEV_NAKT PREEQYN
SVATVAjQDWLNGK
EYKCKVSNKAAPAPIEKTIS
R PQVYIIPPSRflfl
4V<GFYPSDI
TPPV
LDSDGSFFuYS<ITVD<SRW
{EALHW{Y"
QKSJSLSPGK
QIVJTQSPAI SASPGL<V
ITCSASSSVSY iWFQQ<PG
ASP<LWIYSTSV4ASGVPAR
FSGSGSG SYSILVS? flAfl
SEQ ID N0:142
DVD-1g LIGHT DAA"YYCQQRSTYPYTFGGG
iKuflIKR VAAPSVFIFPPQ
VARIABLE HIL-
IVJ"QSPALMSASPGE<VTJ.
1a/[3 DVD6b-Ig TCSASSSVNYMYWYQQ<PRS
SPK?WIYLTSN4ASGVPARF
SGSGSGTSYSLLISS flAflD
AATYYCQQWNSWPYTFGGG"
6B12.4F6 VL SEQ ID N0:100 QIVLTQSPAIMSASPGLKV
ITCSASSSVSYWHWFQQKPG
ASPKLWIYSTSVLASGVFAR
FSGSGSGTSYSLTVSRWEAE
CQQRSTYPYTTGGG
TKLEIKR
LINKER SEQ ID NO:72 TVAAPSVFIFPP
6H3.1A4.3E11 SEQ ID NO:94 QIVLTQSPALMSASPGEKVT
VL MTCSASSSVNYMYWYQQKPR
SSPKPWIYLTSNLASGVPAR
FSGSGSGTSYSLTISSMEAE
DAATYYCQQWNSNPYTFGGG
TKLEMKR
CL SEQ ID N0:124 TVAAPSVFIFPPSDEQAKSG
TASVVCLLNNFYPREAKVQW
KVDNALQSGNSQESVTEQDS
KDSTYSLSSTLTISKADYEK
Sequence
Protein region Sequence Identifier l 2 3 4 5 6 7 8 9 0 l 2 3 4 5 6 7 8 9 0
EVTHQGLS SPVTKS
FNRGEC
Characteristics of the new DVD-lg constructs are summarized in Table 16. Affinity (Kd)
and biological activity (ICSO) were determined by Biacore and MRC-S bioassay, respectively. SDS-
PAGE analysis of all new DVD-lg proteins showed normal migration patterns in both reduced and
non-reduced ions, similar to a regular antibody and DVD1/2-Ig.
Table 16. Characterization of New DVD-lg les Derived from New mAb Pairs
Affinity (Kd)
. Kd IC50
Spec1f. DVD Orient.. Llnker. IL- 1a IL-IB
(M) (M)
8.37 6.37
DVD3a a—b—C short
X1010 X103
.95 3.30 7.01 9.30
18F4.2C8 rhlL—lot DVD4a a—b—C
X1040 X1040 long X1040 X1040
2.61 6.00 1.24 1.90
1B12.4H4 I‘l’llL-lB DVD3b b—a—C short
X1040 X1040 X103 X1040
.60 1.28
DVD4b b—a—C long X1040 X1040
.08 1.25
DVD5a a—b—C short
><1 0.10 X10'8
3.54 2.40 1.06 2.09
6H3.1A4 rhlL—lot 10 10 DVD6a a—b—C long
X10. X10. X103 X109
.54 4.00 1.32 6.71
6B12.4F6 I‘l’llL-lB 10 10 DVDS]? b—a—C short
X10. X10. XlO_8 X1040
8.20 6.97
DVD6b b—a—C long X1040 X1040
mAb = monoclonal antibody; NA = no neutralization activity ed.
The functional terization of the new DVD-lg molecules revealed that with either
orientation, DVD-lg molecules with the long linker med better than the ones with the short
linker in terms of binding and neutralizing of both antigens. With respect to DVD-1g molecules with
the long linkers, those with the b-a—C orientation showed good binding to and lization of both
antigens, while the DVD-1g molecules with an a-b-C orientation showed good binding to and
neutralization of lL-lOL and reduced binding to and neutralization of IL-ll3 (e. g., DVD4b vs.
DVD4a). The DVD-lg molecule, DVD4b, bound and neutralized both IL-loc and IL-ll3 with sub-nM
and fully retained the binding and neutralizing characteristics of the parent mAbs.
Example 3. Generation of mIL-lu/B DVD-lg Molecules
To study key issues concerning pharmacokinetics, in Vivo efficacy, tissue penetration, and
immunogenicity of DVD-lg molecules, mouse-anti-mouse IL-1(x/[3 DVD-lg molecules were
constructed as described below.
Example 3.1. Construction of mIL-lw’B DVD-lg Molecules
Mouse anti-mouse IL—1(x/[3 DVD-lg molecules were constructed using two mouse anti-
mouse IL-lodB onal antibodies (9H10 and lOGl 1) generated from l3 double KO mice.
Mouse anti-mouse lL-loc, and mouse anti-mouse IL-lB, monoclonal antibodies (mAbs) were
generated by immunizing IL-loc/[3 double KO mice with mouse IL-loc, or mouse IL-ll3, respectively.
One mouse anti-mouse IL-10L (Clone 9H10) and one mouse anti-mouse IL-ll3 mAb (clone 10G11),
were selected and used to generate mIL-lou’B DVD-lg les. Various linker sizes and different
domain ations were tested. The final functional mIL-loc/B DVD-lg molecule was constructed
in an orientation of V(anti-m1L-1[3)-linker-V(anti-mIL-loo-murme constant region (CYZa and CK).
The cloning, expression, and purification procedures were similar to that of the hIL-loc/B DVD-lg
g protein. The cloning of mIL-IOLIB DVD-lg binding protein was carried out using similar
overlapping PCR and homologous recombination as described for hIL-loc/B DVD3-Ig. The
sequences of c/B DVD-lg binding proteins are shown below in Table 17.
Table 17. Amino Acid Sequence of mIL-lu/B DVD-lg Binding Protein
Sequence
Protein region Sequence Identifier l 2 3 4 5 6 7 8 9 0 l 2 3 4 5 6 7 8 9 0
?VQLQQSGPTLVKPGTSV
SCKTSGYTFTSYV'HWV<Q<
?GQGLEWIGYIIPYNDNT<Y
mIL-la/[3 DVD-lg SEQ ID NO:143 VE?FK§KAT_JTSD<SSST"AY
TSEDSAVYYCARRW
HEAVY
FFDYWGQGTTLTVS
VARIABLE
SAKTTAPSVYP'A?QVI.<?
SG?GI'QPSQT'S'TCSTSG
FSLSTYGTAVNWIRQPSGKG
LEWLAQIGSDDQK'YNPT'K
SRITLSEDTSNSQVFLKITS
ATYYCANGVMEYWG
LGTSVTVSS
10G11 VH SEQ ID NO:144 EVQLQQSGPELVKPGTSVKM
SCKTSGYTFTSYVMHWVKQK
PGQGLEWIGYIIPYNDNTKY
NEKFKGKATLTSDKSSSTAY
MELSSLTSEDSAVYYCARRN
FFDYWGQGTTLTVS
LINKER SEQ ID NO:78 AKTTAPSVYPLAP
9H10 VH SEQ ID NO:145 QVILKESGPGILQPSQTLSJ
TCSFSGFSLSTYGTAVNWI?
Sequence
Protein region Sequence Identifier l 2 3 4 5 6 7 8 9 0 l 2 3 4 5 6 7 8 9 0
QPSGKGV?WLAQIGSDDRKL
SRIT.S?DTSNSQV
FLKITSVDTEDSATYYCANG
VMEYWGLGTSVTVSS
CH SEQ ID N0:146 AKTTAPSVYPLA?VCGDTTG
SSVTLGCLVKGY?PEPVTLT
WNSGSLSSGViTTPAVLQSD
SVTVTSSTWPSQSI
TCNVAHPASSTKVDKKIEPR
GPTIKPCPPCKCPAPNLLGG
PSVFIFPPKIKDVLMISLSP
IVTCVVVDVSEDDPDVQISW
FVNNVEVHTAQTQTHREDYN
STLRVVSALPIQHQDWMSGK
EFKCKVNNKDLPAPIERTIS
KPKGSVRAPQVYVAPPPEEE
MTKKQVTLTCMVTDFMPEDI
NGKTEANYKNTEPV
LDSDGSYFMYSKLRVEKKNW
VERNSYSCSVVjEGLHwHH"
SPASLSASVGLLV
ITCRGSGILHNY_4VWYQQKQ
GKSPQ. IVYSAKILADGVPS
SEKQHDDKMI47 RFSGSGSGTQYSIKINsuQP
mIL-la/[3 DVD-lg EDFGSYYCQHFWS"PFTFGS
G KuflI<RADAAP"VSIFPP
LIGHT VARIABLE
SIVMTQTPKFALVSAGDRVT
I"C<ASQSVN{DVAWYQQMP
GQSP<L4IYFASNRYTGVPD
RFTGSGYGTDFTFTIS"VQA
EDLAVYFCQQDYSSPYHFGG
GTK.:I<R
10G11 VL SEQ ID N0:148 DIQMTQSPAS .SASVGWVT
ITCQGSGILHVY_4VWYQQKQ
GKS?QL_4VYSAKILADGVPS
RFSGSGSGTQYS_4KINSLQP
EDFGSYYCQHTWSTPFTFGSL
GTKLEIKR
LINKER SEQ ID N0:70 ADAAPTVS IF?P
9H10 VL SEQ ID N0:149 S IVMTQTPKFJLVSAGDRVT
ITCKASQSVNHDVAWYQQMP
GQSPKLLIYFASNRYTGVPD
YGTDFTFTISTVQA
EDLAVYFCQQDYSSPYTFGG
GTKLEIKR
CL SEQ ID N0:150 ADAAPTVSIFPPSSEQLTSG
GASVVCFLNNFYPKDINVKW
KIDGSERQNGVLNSWTDQDS
KDSLYSMSS14-L-KDbeR
HNSYiCbAiHK-S-SPIVKS
FNRNEC
Murine mIL-loc/B DVD-1g binding proteins retained affinity/in vitro potency against both
murine IL-loc (mIL-loc) and murine IL—IB (m]L-1[3). Table 18 shows the characterization of mAbs
9H10 (anti-mlL-loc), 10G11 (anti-mIL—IB), and mIL-lodl?) DVD-lg binding proteins.
Table 18. Characterization of mDVD4-Ig
Antigen KD (M) ICSO (M)
miL—ia/sDVD—Ig mIL-loc 7.66 x 10‘10 2.00 x 10'9
—_-694x10“ 800x10”
Example 3.2. In Vivo Activity of mIL-lw‘BDVD-Ig Binding Proteins in Rheumatoid Arthritis
Model
The therapeutic effects of anti-IL—loc, anti-IL—lB, combined anti-IL-loc/anti-IL-IB, and
murine IL-loc/B DVD4-Ig, were evaluated in a collagen-induced arthritis mouse model well known
in the art. , male DBA-l mice were immunized with bovine type II collagen in CFA at the
base of the tail. The mice were boosted with Zymosan intraperitoneally (i.p) at day 21. After
disease onset at day 24-27, mice were selected and divided into te groups of 10 mice each.
The mean arthritis score of the control group, and anti—cytokine groups was comparable at the start
of treatment. To neutralize IL—l, mice were injected every other day with 1-3 mg/kg of anti-IL-loc
mAb, anti-IL-lB mAb, combination of anti-IL—loc and anti-IL-lB mAbs, or murine IL-loc/B DVD4-Ig
intraperitoneally. Mice were carefully examined three times a week for the visual appearance of
arthritis in peripheral joints, and scores for disease activity determined.
Blockade of IL-1 in the therapeutic mode effectively reduced the ty of arthritis, with
anti-IL-lB showing greater efficacy (24% ion in mean arthritis score compared to control
2O group) than anti-IL-loc (10% reduction). An additive effect was observed between anti-IL-loc and
anti-IL-IB, with a 40% reduction in mean arthritis score in mice d with both anti-IL-loc and
anti-IL-IB mAbs. Surprisingly, at the same dose level, the treatment of mDVD-Ig g protein
exhibited 47% reduction in mean arthritis score, demonstrating the in vivo therapeutic efficacy of
g binding protein. Similar efficacy was also observed in the measurements of joint swelling
in this animal model.
e 3.3. In Vivo ty of a Murine B DVD-lg Binding Protein in Osteoarthritis
Models
The above study showed that the blockade of both IL—lu and IL-ll?) with a ation of
anti-mouse IL-lu and lL-IB dies as well as a murine anti-mouse IL-la/B DVD-lg binding
proteins was significantly more efficacious than either single antibody alone in the mouse collagen-
induced arthritis (CIA) model for rheumatoid arthritis (see, also, Wu et al., Nature Biotech, 25(11):
12901297 (2007)). The efficacy of anti—IL—l therapy in osteoarthritis (0A) was studied two animal
models of OA, i.e., the joint ility model ("JIM") and the destabilization of medial meniscus
("DMM") in mice.
Example 3.3.1. In Vivo Activity of Mouse Anti-Murine IL-1oc and Anti-Murine IL-1[3
Monoclonal Antibodies in Joint Instability Model (JIM) of Osteoarthritis in Mice
Example 3.3.1.A. Study Design
The design of study of the in viva activity of a mlL—loc/B DVD—Ig molecule in the joint
instability model (JIM) of osteoarthritis in mice is shown in Table 19. All groups contained 25 mice
(n = 25), ng imately 30 grams (BW = 30 g). The study was terminated after 21 days.
Two and a half month old, male Swiss Webster mice (25fgr0up/time point), housed 5/cage, were
anesthetized with isoflurane anesthesia. Anterior cruciate ligament (ACL) trauma was administered
on the right and left knees on day 0 in an t to induce OA lesions. Intraperitoneal (ip)
treatments with IL-1 inhibitory dies IL-loc (9H 10) and IL-ll3 (10G11), alone and in
combination, were initiated the day of ACL trauma and continued every 4th day (q4d) for 20 days.
The vehicle for the non-treatment control was PBS. Right and left knees were harvested on day 21,
and histopathologic tions were scored and characterized. Data were analyzed using only joints
that had proliferative responses indicative of successful instability induction. The proliferative
response/instability was scored 0-3, and only unstable joints (scores of 1, 2, or 3) were used in the
2O final is. Medial and lateral femoral and tibial cartilage degeneration was scored for severity of
cartilage degeneration on a scale 0-5. Four days after the last antibody dose, blood was drawn from
all animals from each group for serum harvest. Body weights were recorded weekly. On the final
day, s (10 animals in Groups 1, 2, 3, 4) were dosed with Zymosan A and blood drawn 4 hours
later (at termination) for serum analysis of IL—6 TNF dependent). Animals were killed on day
21 and right and left knee joints collected into formalin.
Table 19. Design of Study in Joint Instability Animal Model for Osteoarthritis
Treatment Group Compound Route Dosing Regimen
Group 1 Vehicle 1 ip Q4D
(PBS) (2 times per week)
Group 2 anti-IL— 1 (x ip Q4D
(9H10) (2 times per week)
Group 3 anti-lL-ll3 ip Q4D
(10G11) (2 times per week)
Group 4 L— 1 (x ip Q4D
(9H10) (2 times per week)
anti-lL-l [3
(10G1 1 )
Example 3.3.1.B. Tissue Preparation and Analysis
Tissue preparation: Following 2-3 days in a decalcifying e (Surgipath Decalifier, Surgipath
Medical Ind, Inc, Richmond VA), both lmee joints were trimmed of extraneous tissue, embedded in
the frontal plane and sectioned. One section was taken from each animal (2 joints/block) at the
approximate mid point of the frontal plane. All sections were 8 pm and were stained with ine
blue. Slides were examined by a board-certified veterinary pathologist blinded to study group
designation, and were scored according to the method below. Statistical is was performed
using Microsoft Excel, and included a 2-tailed t-test comparing all treatment groups to the control
group using a confidence level of 95%.
Histopathologic scoring of joints: Medial and lateral femoral and tibial cartilage degeneration
were scored for severity of cartilage degeneration using the following system: Depth/extent 0f
chondrocyte and proteoglycan loss with fibrillation :
1= superficial damage, tangential layer of collagen absent over 50% or greater of the zone surface or
up to 10% loss of proteoglycan and/0r chondrocytes in focal or diffuse distribution in zone
2=matrix loss extends into upper 1/4 of 50% or greater area of the zone or up to 25% loss of
glycan and/0r chondrocytes in focal or diffuse bution in zone
3: matrix loss extends through 1/2 of cartilage thickness over 50% or greater of the zone or up to
50% loss of proteoglycan and/or chondrocytes in focal or e distribution in zone
2O 4: matrix loss extends through 3/4 of cartilage thiclmess over 50% or greater of the zone or up to
75% loss of proteoglycan and/or chondrocytes in focal or diffuse distribution in zone
: matrix loss extends through entire cartilage thiclmess over 50% or greater of the zone or up to
100% loss of proteoglycan and/or chondrocytes in focal or diffuse distribution in zone
Scores were assigned with attention to zonal (inside, middle and outside) distribution of
lesions, and the scores (0-5) for each third were summed for each area of the joint and then for the
whole joint.
Osteophytes st on tibial or femoral surface under evaluation) were measured using
digital software (NIS-Elements version 3.0).
Osteophyte tion = 1, 2, or 3 for small, medium or large depending on size
Small osteophytes = 1 (up to 150 um)
Medium hytes = 2 (151-300 pm)
Large hytes = 3 (>301 um)
Synovial reaction was described and characterized with respect to inflammation type and
degree if present was not included in the score.
The mean i SE for each of the various parameters for each animal was determined and
summed to arrive at a total joint score.
Joints with histologic evidence of instability ion were identified by the presence of
proliferative s in the medial synovium and collateral ligaments. In addition, an instability
score was ed for each joint according to the following criteria.
0=No instability
1=Mild instability (minimal to mild proliferative changes in ligaments and marginal zones)
2=Moderate instability (moderate proliferative changes in ligaments and marginal zones)
re instability (severe proliferative s in ligaments and al zones)
Results: Only unstable joints with scores of 1, 2, or 3 (0r 2, 3) were used in the final data analysis.
Data were ultimately analyzed on a total affected joint basis rather than affected animal basis. The
results of this study indicated that joints of animals treated with either anti-IL-loc or IL-lB
monoclonal antibodies exhibited cartilage degeneration similar to that seen in vehicle-treated control
joints. However, a combination therapy with both a mouse anti-mouse IL-lu mAb (9H10) and a
mouse anti-mouse IL-lB mAb (10G11) significantly decreased medial tibial cartilage degeneration
scores. Figure 2 shows bar graphs of cartilage degeneration scores in the joints of the animals in the
2O various treatment .
Example 3.3.2. In Vivo Activity of mIL-lu/B DVD-lg Binding Protein in Joint Instability
Model (JIM) 0f Osteoarthritis in Mice
The joint ility model for osteoarthritis as described above in Example 3.3.1, was also
used to compare the efficacy of anti-IL—l therapy as provided by a combination of a mouse anti-mIL-
la monoclonal antibody (9H10) and a mouse anti-mIL-IB monoclonal antibody (lOGl 1) with that
provided by a mIL-loL/B DVD-Ig binding protein generated from the two monoclonal antibodies.
Example A. Study Design
The design of this study was r to that described above in Example 3.3.1. Two and a
half month old, male Swiss r mice oup/time point), housed 5/cage, were anesthetized
3O with isoflurane anesthesia and the right and left knee area clipped and prepared for intra-articular
trauma to the te ligaments on day 0. Dosing (initiated on day 0, ip) was carried out once every
4 days (Q4D) with animals terminated on day 21 (for Group 2). Dosing (initiated on day 0, ip) was
carried out three times weekly with animals terminated on day 21 (for Groups 1, 3 and 4). Four days
after the last antibody dose, all animals from each group had blood drawn for serum harvest. Body
weights were recorded weekly. On the final day, animals (10 animals in Groups 1, 2, 3, 4) were
dosed with Zymosan A and blood drawn 4 hours later (at termination) for serum analysis of IL-6 (IL-
l/TNF ent). Animals were ized on day 21 and right and left knee joints ted into
in. See the study design table below.
Table 20. Design of Study of Joint Instability Animal Model for Osteoarthritis
Treatment Compound Route Dosing Regimen Dose Level
Group (mg/kg)
Group 1 Vehicle 1 ’ 3 times per week 6.7 ml/kg
(PBS)
Group 2 anti-IL-loe Q4D anti-IL-l on at 6 mg/kg
(9H 10) (3 times per (180 ug/mouse)
and week) and
anti-IL- 1|3 anti-IL-IB at 6 mg/kg
) (180 pig/mouse)
Group 3 3 times per week 12 mg/kg
(500 ttg/mouse)
Group 4 3 times per week 6 mg/kg
(250 ttg/mouse)
Example 3.3.2.B. Tissue Preparation and Analysis
Tissue preparation and histological scoring of articular cartilage from joints of animals in
the various treatments groups were carried out as described above in e 3.3.1.
Results: The results indicated that treatment of mice with the mIL-la/B 10Gl l-9H10 DVD-lg
binding protein significantly inhibited the progression of osteoarthritis (P < 0.05 vs. vehicle) with
comparable efficacy to the combination of the parental mAbs 9H10 and 10Gl 1. Figure 3 shows bar
graphs of cartilage degeneration scores in the joints of the animals in the various treatment groups.
As shown in Figure 3, results of ent with 6 or 12 mgi’kg the DVD—1g binding protein were
similar in their efficacy in terms of preventing osteoarthritic lesions. (A treatment using 3 mg/kg
DVD-lg binding protein had not effect on cartilage ration and results were similar to vehicle
treated joints. See, Example 3.3.3, below.) The results of this study indicated that treatment with a
combination of anti-IL—loc and anti-lL-1|3 monoclonal antibodies or with an IL-la/B DVD-lg binding
protein had significant beneficial s on histopathological parameters in the mouse model of
2O osteoarthritis.
Example 3.3.3. Follow Up Study in Joint Instability Model of Osteoarthritis to Compare
Treatment with Anti-IL-IB Monoclonal Antibody and Other g Proteins
A follow up study was performed using the joint instability model of rthritis to more
closely ine whether or not there may be any significant effect on medial tibial cartilage
degeneration scores in animals treated with an anti-lL-IB monoclonal antibody alone compared to
other treatments. The effect of treatment with an L—lB monoclonal antibody was evaluated in a
21 day study.
Example 3.3.3.A. Study Design
The design of this study was similar to that described above in Example 3.3.1.
Table 21. Design Of 21 Day Joint Instability Animal Model For Osteoarthritis
Treatment Compound Route Dosing Regimen Dose Level
Group (mg/kg)
Group 1 Vehicle 1 ' Q4D 6.7 ml/kg
(PBS)
Group 2 '
anti-IL—loc L-l Ct at 6 mg/kg
(9H10) (180 ug/mouse)
and and
anti-IL—ll3 anti-IL-IB at 6 mg/kg
(10G11) (180 se)
Group 3 anti-IL-IB ' 12 mg/kg
) (360 ug/mouse)
Group 4 anti-IL-IB ‘ 6 mg/kg
(10G11) (180 ug/mouse)
Group 5 anti-IL-IB 3 mg/kg
(10G11) (90 ug/mouse)
Example 3.3.3.B. Tissue Preparation and Analysis
Tissue preparation and histological scoring of articular cartilage from joints of animals in
the various treatments groups were carried out as described above in Example 3.3.1.
Results: As shown in the Figure 4, the results confirmed those of previous studies where similar
positive treatment effects were noted using a combination of anti-IL-loc and anti-IL-lB monoclonal
antibodies and that treatment with an anti-IL—lB monoclonal antibody alone was not ive in
preventing cartilage degradation at any dose tested.
Example 3.3.4. Zymosan-Induced Interleukin-6 (IL-6) Production in a Joint Instability Model
Study
As a pharmacodynamic readout to determine if anti-IL-loc and anti-IL-ll?) monoclonal
antibodies as well as mIL-lot/B DVD-Ig g protein were functional and capable of lizing
IL-loc and IL-1[3 in viva, zymosan-induced c and IL—lB dependent) production of eukin 6
(IL-6) was measured in a joint instability model study of OA.
Briefly, on day 21 in the model, zymosan was ded in PBS vehicle and placed in
boiling water for half an hour, then allowed to cool before using. The mice were then injected ip
with 50 mg/kg zymosan in suspension (mixed well before injection) in 0.5 ml PBS. The mice were
then bled 4 hours after zymosan injection. Serum was collected for lL-6 ements.
Results: As shown in Figure 5, a combination of anti-IL—loc monoclonal antibody (6 mg/kg) and
anti-IL-ll3 onal antibody (6 mgikg) monoclonal antibodies as well as mJL-loc/B DVD-lg
binding protein (at 6 mg/kg or at 12 mgikg) significantly neutralized zymosan-induced IL-6
production as ed to vehicle-treated control animals. Accordingly, the antibodies exhibited
functional ty in viva.
Example 3.3.5. Effect Of Cytokine Inhibitory Antibody Treatments on Osteoarthritis Induced
by Destabilization of Medial Meniscus (DMM) Model in SV129 Mice
An alternative animal model was also employed to study the affect of anti-IL-loc and anti-IL-
1[3 activity on slowing progression of cartilage ration in osteoarthritis. The mouse
destabilization of medial meniscus (DMM) model for osteoarthritis is less invasive and
inflammatory than the JIM procedure (see, above) and results in s primarily on the central
weight-bearing region of the medial tibial plateau and medial femoral condyle. The severity and
location of lesions following DMM are more consistent when compared to JIM.
Example 3.3.5.A. Study Design
Male SV129 mice weighing approximately 30 grams, housed 5/cage, were anesthetized on
Day 0 with ketamine/xylazine cocktail, administered eritoneally (ip), and then the medial
eral ligament was exposed by blunt dissection, and transected to reflect the meniscus toward
the femur. The joint space was closed with 8—0 vicryl suture. The skin was closed with wound glue.
For sham surgeries, a vertical skin incision was made over the medial aspect of the knee and the
joint capsule was opened. The capsule was closed with 8-0 vicryl suture and the skin was closed
with wound glue. Groups of animals were then treated with intraperitoneal (ip) injections of
antibody or vehicle according to the study design table below. Two sex-matched, age-matched, and
strain-matched naive mice were also included in the study. Animals were euthanized after 8 weeks
of treatment, and knee joints were harvested in 10% neutral buffered formalin.
Table 22. Design of Study Using Destabilization of Medial Meniscus (DMM) Model of
Osteoarthritis
Treatment
Com oundp N11233:]? Dose, Route, and Sacrifice
Group Regimen Time Point
sham
A 8 weeks
(none)
B vehicle (PBS) 8 weeks
anti-IL-la mAb
180 pig/mouse for
C and 11 8 weeks
each antibody ip
anti-IL-IB mAb
every 4th day
mlL-l d/B 250 se, ip,
D 10 8 weeks
DVD-1g 3x/week
Example 3.3.5.B. ation of Tissues
in-fixed samples were decalcified, and specimens were sectioned in the frontal plane
into 15 step sections each. Each section was approximately 6 pm thick, and step sections were
separated by 70 um. All slides were stained with toluidine blue (T. Blue). Slides were assessed
according to the Chambers method (Chambers et al. (2001) Arthritis Rheum 44: 1455-65) for
cartilage ration (see below) by a board-certified veterinary pathologist. Each of the four
age surfaces, the medial femoral condyle (MFC), the medial tibial u (MTP), the lateral
femoral condyle (LFC), and the lateral tibial plateau (LTP), was scored from 0-6 according to the
scale in the table below.
Table 23. Chambers Scoring System for Cartilage Degeneration
Grade rthritic Damage
0 No damage
1 Roughened articular surface and small fibrillations
Fibrillation down to the layer immediately below
the superficial layer (zone 2) and some loss of
surface lamina
Loss of surface lamina and fibrillations extending
down to the calcified cartilage
Major fibrillations and cartilage erosion down to
the subchondral bone
Major fibrillations and erosion of up to 80% of the
cartilage
—Morethan 80% loss of cartilage
tical analysis was performed using GraphPad Prism software version 4.03 using Mann-
Whitney U test.
Example C. Results
As shown in Figure 6, a combination therapy with both anti-mouse IL-la monoclonal
antibody (9H10, 6 mg/kg) and anti-mouse lL-lB onal antibody (10G11, 6 mg/kg) or with
lL-la/B DVD-Ig binding protein (6 mg/kg) significantly d cartilage degeneration in the mouse
DMM model of osteoarthritis.
e 3.3.6. Titration of Anti-IL-loe and Anti-IL-lB Activities in Mice in a Destabilization
of Medial Meniscus (DMM) Model for Osteoarthritis (8 Week Study)
An 8 week study was conducted on the effects on cartilage degeneration in response to
various doses of anti-mIL-loc monoclonal antibody (9H10 mAb) and anti-mIL-IB monoclonal
antibody (10G11 mAb), alone or in combination, and of mlL-lu/B 10G11-9H10 DVD-lg binding
protein in the DMM model of osteoarthritis.
Example 3.3.6.A. Study Design
Male SV129 mice ng approximately 30 grams, housed 5/cage, were anesthetized on
Day 0 with ketamine/xylazine cocktail, administered intraperitoneally (ip), and then the medial
collateral ligament was exposed by blunt dissection, and transected to reflect the meniscus toward
the femur. The joint space was closed with 8—0 vicryl suture. The skin was closed with wound glue.
For sham surgeries, a al skin incision was made over the medial aspect of the knee and the
joint capsule was opened. The capsule was closed with 8-0 vicryl suture, and the skin was closed
with wound glue. Groups of s were then treated with intraperitoneal (ip) injections of anti-
mIL-la monoclonal antibody, anti-mlL-l B (alone or in combination), mIL-la/B DVD-lg binding
protein, or vehicle according to the study design table below (Table 24). Animals were euthanized
after 8 weeks of treatment and lmee joints were harvested in 10% l buffered in.
Table 24. Design of Study to Test Various Treatments in DMM Model of Osteoarthritis
ent Number Of Dose, Route and Sacrifice
Compound Animals
Group Regimen. Time Pomt. .
| A | Sham (None) 5 None | 8 weeks |
| B | Vehicle (PBS) ip, 3X/week | 8 weeks |
anti-IL-lo. 180 ug/mouse, ip,
C 10 (5) 8 weeks
(9H10) every 4th day
anti-IL—lB 180 ug/mouse, ip,
D 10 (8) 8 weeks
(10G11) every 4th day
L-lo.
(9H10) 180 pg/mouse for each
E + antibody, ip, every 4th 8 weeks
anti-IL— 1[3 day
(10G1 1)
62.5 ug/mouse, ip,
F mIL-IOLB DVD-1g 8 weeks
3x/week
125 ug/mouse, ip,
G mIL—lotB DVD-1g 10 8 weeks
3x/week
250 ug/mouse, ip,
H LB DVD-lg 10 8 weeks
3x/week
The numbers in parentheses in column 3 of the above table (Number of Animals) are the
actual numbers of animals included in the data set. A brief description of exclusions s:
Group B: Only 9 animals were included in Group B. One animal was excluded from the
data set because at ogic examination the medial meniscus appeared intact and there was
essentially no osteoarthritic change.
Group C: Only 5 animals were included in Group C. Five animals were excluded from the
data set because at ogic examination the medial meniscus appeared mostly intact and there was
little osteoarthritic change.
Group D: Only 8 animals were included in Group D. Slides for one animal were not present.
Another animal was excluded from the data set because at histologic examination the medial
meniscus appeared mostly intact and there was little osteoarthritic .
Group E: Only 8 animals were included in Group E. Two s were excluded because
they were considered outliers.
Group F: Only 9 animals were included in Group F. One animal was excluded from the data
set because at histologic examination the medial meniscus appeared intact and there was ially
no osteoarthritic change.
Example 3.3.6.B. Tissue Preparation and Examination
Tissues were prepared and scored as described above in Example 3.3.5.
Example 3.3.6.C. Results
The results are shown in Figure 7. Similar to the results obtained in the joint ility
model (JIM) for osteoarthritis (above), treatment with either L-loc monoclonal antibody (9H10)
or L-IB monoclonal antibody ) alone resulted in a decrease in cartilage degeneration
that was not statistically significant from that observed in vehicle control joints. r, a
combination therapy with both monoclonal antibodies or with IL-1 a/B DVD-lg binding protein
(except for IL—lu/B DVD at 1.5 mgikg) icantly reduced the mean sum Chambers scores
ating overall cartilage degeneration) and mean maximum Chambers scores (most affected area
in the joint). A statistically significant dose effect was observed for mean sum Chambers scores in
the mIL-la/B DVD-1g treatment groups. Accordingly, in this study, 8 weeks of treatment with both
anti-mIL-lu monoclonal antibody and anti-mIL-IB monoclonal antibody (6 mg/kg, each) and with
mIL-lu/B DVD-1g binding protein (at 3 and 6 mg/kg) ameliorated progression of cartilage
degeneration induced in the DMM model of osteoarthritis.
Example 3.3.7. Effects of Anti-IL-loe and Anti-IL-lB Activities and Small Molecule Treatment
on Cartilage Degeneration in Animals in Destabilization 0f Medial Meniscus (DMM) Model of
Osteoarthritis
Doxycycline has been shown to prevent cartilage degradation in the DMM model of
osteoarthritis (Effects of Disease-modifying Osteoarthritis Drugs in an in-vivo Animal Model
1Silva et al., Univ. Mass. Med. School, Worcester, MA, USA, Trans ORS 2009 — need full on)
2O and also in a human clinical trial (Brandt et a1. (2005) Arthrit. Rheum. 52(7):2015-2025). In this
study, the effect of treating animals in the DMM model with doxycycline was compared to the effect
of treating animals with a combination of L-loc and anti-IL-lB monoclonal antibodies.
Example 3.3.7.A. Study Design
Male SV129 mice weighing approximately 30 grams had the medial eral nt
exposed by blunt dissection, and transected to reflect the meniscus toward the femur. The joint
space was closed with 8-0 vicryl suture. The skin was closed with wound glue. For sham surgeries,
a vertical skin incision was made over the medial aspect of the knee and the joint capsule was
opened. The capsule was closed with 8-0 vicryl suture, and the skin was closed with wound glue.
Groups of animals were then treated per os (po) or Via intraperitoneal (ip) injections of vehicle or
treatments according to the study design table below. Three sex-matched, age-matched, and strain-
matched naive mice were also included in the study. Animals were ized after 4 weeks of
treatment, and knee joints were ted in 10% neutral buffered formalin.
Table 25. Design of Study to Test Various Anti-IL-l Antibodies and Doxycycline Treatments
in DMM Model of Osteoarthritis
Sacrifice Time
Grou Com oundp N11231:]? Dose, Route
and Regimen Point
A Sham (None) None 4 weeks
Vehicle
B (0.02% Tween80/ p0, BID 4 weeks
0.5% HPMC)
. 30 mg/kg, po,
C Doxycycline 10 4 weeks
L-l (x (9H10) 180 ug/mouse
D + 10 each, ip, every 4 weeks
anti-IL-IB (10G11) 4th day
Example 3.3.7.B. Tissue Preparation And ation
Tissues were prepared and scored as described above in e 3.3.5.
Example 3.3.7.C. Results
The s are shown in Figure 8. Under the conditions of the study, 4 weeks of treatment
with a ation of anti-IL-lo. and anti—IL—lB monoclonal antibodies, closed at 180 ug/mouse
each, resulted in significant amelioration of the osteoarthritic changes induced by ilization of
the medial meniscus in male SV129 mice. Mean sum Chambers scores and mean maximum
Chambers scores were icantly reduced, and mean total summed Chambers scores were notably
reduced by this combination ent compared to the vehicle control group. Doxycycline
treatment at 30 mg/kg also resulted in a similar treatment , but the antibody combination
therapy was more effective.
Example 4. Pain Efficacy of Anti-IL-lou’B Therapy
The DMM model also generates measurable pain in the mice. Recently, Malfait et a1. (see,
Malfait et a1. (2010) Osteoarthritis Cartilage, 18: 572-580) showed robust decrease in paw
withdrawal threshold (mechanical allodynia indication of pain) in hind paws after DMM but not
sham surgery. The efficacy of anti-IL-lw’fi therapy was studied in the DMM animal model. As
shown in this series of studies, mice with DMM surgery were allodynic as early as day 7 after the
surgery and exhibited a decrease in paw withdrawal threshold till day 35.
The potential of anti-IL-l therapy to ameliorate pain was tested in the DMM mouse model
of 0A in terms of mechanical allodynia. Dosing of the combination of IL-loc and IL-1[3 mAbs was
initiated on the day of the surgery and was repeated twice a week for 5 weeks. Animals were treated
with PBS e alone, with an IgG isotype control, or with a combination of anti-IL-loc and anti-
IL-lB mAbs (at a dose of 6 mg/kg for each mAb). Animals were tested weekly for paw withdrawal
threshold. The ipsilateral (surgical) limb of groups treated with PBS or IgG isotype control was
allodynic (painful) compared to the contra lateral (non—surgical) limb or compared to s that
had undergone sham surgery. See Figure 9. In contrast, the group treated with the combination of
anti-IL-IOL and anti-IL-ll?) mAbs demonstrated a cantly higher paw withdrawal threshold
indicating reduction in development of allodynia (pain) as compared to PBS vehicle or IgG isotype
treated groups at week 5 (day 35). See Figure 10. This reduction in pain was seen as early as week
1 following treatment (data not shown).
To evaluate the effect of lL-l y in established pain, animals in the IgG control group
with established OA and mechanical allodynia were treated on day 35 with the combination of anti-
IL-la and anti-lL-l B monoclonal antibodies and the paw withdrawal threshold was tested 24 hours
later (day 36). The data demonstrated that combination therapy with anti-IL-l 0c and anti-lL-lB
mAbs reversed nia ed OA pain) in animals with established disease. These data indicate
that anti-IL-l therapy provides an analgesic effect independent of a potential disease modifying
effect. See Figure 11.
2O Example 5. Further Study of Pain cy of Anti-IL-lu/B Combination Therapy
The potential of anti-IL-l therapy to ameliorate pain in the DMM mouse model of OA (see,
above) in terms of mechanical allodynia was further evaluated. Dosing of the combination of IL-la
and IL-lB mAbs was ted on the day of the surgery and was repeated twice a week for 4 weeks.
DMM animals were treated with PBS vehicle only, with anti-IL-lu mAb (6 mg/kg), with anti-lL-lB
mAb (6 mg/kg), or with a combination of anti-IL—la mAb (6 mg/kg) and anti-IL-lB mAb (6 mg/kg),
administered eritoneally (ip) twice per week for four weeks. s were tested for allodynia
on day 28. The teral cal) limb of groups treated with vehicle was allodynic ul)
compared to the contra lateral (non—surgical) limb or compared to s that had undergone sham
surgery. See Figure 12. Similarly, a group d with either anti-IL-la or anti-IL-IB mAbs alone
was allodynic (painful). In contrast, a group treated with the combination of anti-IL-la and anti-IL-
IB mAbs demonstrated a significantly higher pain withdrawal threshold ting reduction in
development of allodynia (pain) as compared to vehicle treated groups (Figure 12).
Example 6. Dose-Dependent Pain Efficacy of Anti-IL-lw’B Combination y
Dosing of the combination of anti-IL—la and anti-IL—lB mAbs was initiated on the day on
which surgery was performed on animals in the DMM mouse model and was repeated twice a week
for four weeks. Animals were treated with PBS vehicle only or with a combination of anti-IL-la
mAb and anti-IL-lB mAb, both stered intraperitoneally (ip) every four days for four weeks at
1 mg/kg, at 3 mg/kg, or at 6 mg/kg. s were tested on Day 28 for paw withdrawal threshold.
The ipsilateral (surgical) limb of groups treated with vehicle showed icant reduction in the paw
withdrawal threshold indicating allodynia (pain) compared to the contra lateral (non-surgical) limb
or compared to animals that had undergone sham surgery (Figure 13). In contrast, the group treated
with the combination of anti-IL—lo. and L—lB mAbs demonstrated a dose-dependent se in
paw withdrawal threshold indicating reduction in development of allodynia (pain) as compared to
vehicle treated groups (Figure 13).
Example 7. Anti-IL-la/B Combination Therapy in ished Pain
To evaluate the effect of anti-11.40013 combination therapy in established pain, animals in
the DMM mouse model with established OA and mechanical allodynia were treated at day 27 with a
combination of anti-IL-ld mAb and anti-lL-l B mAb, both administered intraperitoneally (ip) at
1 mg/kg, at 3 mg/kg, or at 6 mg/kg at 24 hours prior to testing for allodynia on day 28. Results are
shown in Figure 14. The data demonstrated that combination therapy with anti-IL-lu and L-lB
mAbs reversed mechanical allodynia (reduced OA pain) in animals with established disease in a
dose-related manner (Figure 14).
e 8. Anti-Hyperalgesic Effect of L—loz/B Combination y
To evaluate whether neutralization of IL—loc and IL-lB produces antinociceptive effects in
2O inflammatory pain conditions, anti-IL—loc and anti-IL—lB mAbs were evaluated for the ability to
reverse established pain in the mouse carrageenan paw model of nociceptive pain.
The efficacy of the anti-lL—loc and anti—IL-ll3 mAbs was evaluated when administered alone
or in combination in the mouse carrageenan model (Figure 15). At 30 hours after intraplantar
eenan injection: 900 ug of either anti-IL-loc mAb, anti-IL-lB mAb, or their combination were
administered in different groups of mice. Thermal hyperalgesia testing was performed 48 and 96
hours after carrageenan. As seen in the previous study, the 900 ug dose combination significantly
attenuated l hyperalgesia (carrageenan paw 8.11 i 0.62 3 compared to 4.98 i 0.34 s in PBS
group at 48 hours, p<0.01, Figure 15A; carrageenan paw 7.62 i 0.45 s compared to 4.45 i 0.55 s in
PBS group at 96 hours, p<0.01, Figure ISB). The antinociceptive effect in 900 ug combination
3O group was 53 i 7% at 48 hours, and 82 i 11% at 96 hours. The diclofenac (non-steroidal, anti-
atory analgesic) positive control group again exhibited a significant attenuation of l
hyperalgesia (p<0.01 at both time points). In contrast, no icant antinociceptive effect was seen
at both time points when anti-IL—loc and anti-IL-IB mAbs were administered alone indicating that
simultaneous neutralization of both lL-loc and IL-1|3 is required for antinociceptive efficacy in the
mouse carrageenan inflammatory pain model.
e 9. Dose-Dependent Anti-Hyperalgesic Effect of Anti-IL-la/B Combination Therapy
As shown in Figure 16, lantar eenan injection in mice (female BALB/c)
produces a long lasting thermal hyperalgesia as evidenced by a decrease in paw withdrawal latency
to a radiant heat us ng performed 48 and 96 hours after eenan injection; p<0.01 for
l uninjured versus carrageenan paws in PBS vehicle group at both time points). Different
groups of animals were treated either with vehicle or a ation of anti-IL-loc and anti-IL-ll?)
mAbs (100, 300, or 900 Mg /mouse of each mAb) 30 hours after carrageenan injection. A dose-
related effect was seen, with the 900 ttg dose combination of anti-IL-loc and anti-IL-ll?) mAbs
significantly attenuating thermal hyperalgesia (carrageenan paw 3.23 i 0.34 s in PBS compared to
7.88 i 0.93 s in 900 11g groups at 48 hours, p<0.01, Figure 16A; eenan paw 4.45 i 0.55 s in
PBS compared to 7.62 i 0.45 s in 900 ug groups at 96 hours, p<0.01, Figure 16B). The
antinociceptive effect in 900 ug treatment group was 70 i 9% at 48 hours, and 62 i 4% at 96 hours.
Diclofenac (30 mg/kg), a non-steroidal, anti-inflammatory analgesic, was included as positive
control in the study, and it increased the mean paw withdrawal latency of the injured paw to 7.01 i
0.58 s at 48 hours and 7.48 i 0.34 s at 96 hours when stered p.o. 60 minutes before testing
(p<0.01 at both time points). The IgG control and low dose 100 ug mAb groups did not attenuate
l hyperalgesia at either time point. The mAbs and diclofenac did not significantly change the
paw withdrawal latency values in the control uninjured paw.
Example 10. Efficacy of Anti-IL-lu/B Combination Therapy in CFA Pain Model
2O The CFA (Complete Freund's Adjuvant) inflammatory pain model was used to test whether
the anti-IL-loc and L-IB mAb combination would produce efficacy against a mechanical
endpoint. Therefore, mechanical allodynia was assessed using von Frey monofilaments in animals
(female BALB/c mice) 48 hours after they were injected intraplantar with CFA. As seen in Figure
17A, intraplantar CFA produced robust mechanical nia as evidenced by a decreased paw
withdrawal threshold in the CFA injected paw treated with PBS vehicle only (0.052 i 0.028 g versus
0.860 i 0.090 g in contralateral uninjured paw, p<0.01). Separate groups of animals were treated
either with IgG isotype control or a combination of anti—IL—loc and anti—IL—ll3 mAbs (900 Mg /mouse
of each mAb) 30 hours after CFA injection. The mAb treated group showed a significant
attenuation of mechanical allodynia (0.419 t 0.101 g, p<0.01 versus PBS vehicle, Figure 17A). The
3O magnitude of efficacy (% MPE) was 65.51 i 12.35% (Figure 17B). The anti-inflammatory,
analgesic positive control diclofenac (30 mg/kg, 1 hour pretreatment) also attenuated mechanical
nia by increasing paw withdrawal thresholds (0.359 1 0.088 g, p<0.01 versus PBS vehicle)
with %MPE of 64.51 i 10.20%.
Example 11. Efficacy of Anti-IL-ltx/B Combination Therapy in Neuropathic Pain
Whether an L-10t and anti—IL—IB mAb ation therapy would produce efficacy in
neuropathic pain ions was examined in an L5/L6 spinal nerve ligation (SNL) model in mice
(male CD1). Testing was performed six days after SNL surgery, 24 and 72 hours after animals were
treated with mAb combination (900 ttg [mouse of each mAb). ical nia was ed
in mice treated with PBS vehicle only after SNL surgery as evidenced by a decreased paw
withdrawal threshold to von Frey monofilament stimulation (0.073 i 0.032 g versus 0.735 i 0.109 g
for contralateral paw at 24 hours, Figure 18A; 0.128 1 0.048 g versus 0.732 1 0.132 g for
contralateral paw at 72 hours, Figure 18B; p<0.01 at both time points). The mAb treated group
showed a significant attenuation of mechanical allodynia at both time points (0.477 1 0.131 g,
p<0.01 versus PBS vehicle at 24 hours, Figure 18A; 0527 i 0.111 g, p<0.01 versus PBS vehicle at
72 hours, Figure 18B). The magnitude of cy (% MPE) was 72.20 i 14.39% at 24 hours and
80.62 i 12.33% at 72 hours (Figure 19). The positive control gabapentin (100 mg/kg, 1 hour
pretreatment) was fully efficacious in attenuating mechanical allodynia by significantly increasing
paw withdrawal thresholds (0.858 i 0.077 g at 24 hours and 1.138 i 0.096 g at 72 hours, p<0.01
versus PBS vehicle at both time points). In contrast, the IgG control group did not produce any
effect on mechanical allodynia at both time .
Conclusion of Pain Treatment Studies
The results of the pain studies described herein te that an anti-IL-ltx/B combination
2O y according to the invention is effective as a treatment for any form of pain and not just pain
associated with osteoarthritis. Such anti—IL—loc/B combination therapy can be used to treat pain in an
individual suffering from any type of pain condition including, but not limited to, the pain conditions
allodynia, hyperalgesia, and a combination of allodynia and hyperalgesia. Anti-IL-lot/B combination
therapy can be provided to an individual by administering to the individual a combination (for
example, a mixture, concurrent administration, or successive administration) of IL-lu and IL-IB
g ns, such as a combination of anti-IL-la and anti-IL-IB monoclonal antibodies, or by
administering to the individual a protein that binds both IL-oc and IL-lB, such as a bispecific
antibody or an lL-l (x/B DVD-1g binding protein that binds both IL—oc and IL—1 [3.
[near oration 1) Re erence
The contents of all cited references (including literature references, patents, patent
applications, and websites) that maybe cited throughout this application are hereby sly
incorporated by reference in their entirety, as are the references cited therein. The practice of the
t invention will employ, unless otherwise indicated, conventional techniques of
pharmaceutical science, immunology, molecular y, and cell biology, which are well known in
the art.
lents
The invention may be embodied in other specific forms without departing from the spirit or
essential characteristics thereof. The foregoing embodiments are therefore to be considered in all
ts illustrative rather than limiting of the invention described herein. Scope of the invention is
thus indicated by the appended claims rather than by the foregoing description, and all changes that
come within the meaning and range of equivalency of the claims are therefore intended to be
embraced herein.
Claims (29)
1. Use of a binding protein that binds both IL-1α and IL-1β for the manufacture of a ment for treating pain in an individual.
2. The use according to claim 1, wherein the individual suffers from a pain condition selected from the group consisting of allodynia, hyperalgesia, and a combination of allodynia and hyperalgesia.
3. The use ing to claim 1, wherein said g protein that binds both IL-1and IL-1 is a bispecific antibody.
4. The use according to claim 1, wherein said binding protein that binds both IL-1 and IL-1 is a dual variable domain immunoglobulin (DVD-Ig) binding protein.
5. The use ing to any one of claims 1 to 4, wherein said binding protein that binds both IL-1 and IL-1 is formulated in a pharmaceutical composition comprising a pharmaceutically acceptable carrier.
6. The use according to any one of claims 1 to 4, wherein said binding protein that binds both IL-1 and IL-1 is llized.
7. The use according to claim 6, wherein said crystallized binding protein that binds both IL-1 and IL-1 is formulated in a ition further comprising: optionally, an ingredient; and a ric carrier.
8. The use according to claim 7, wherein said polymeric carrier is a polymer selected from one or more of the group consisting of a poly (acrylic acid), a poly (cyanoacrylate), a poly (amino acids), a poly (anhydride), a poly (depsipeptide), a poly (ester), a poly (lactic (10721333_1):GGG acid), a poly (lactic-co-glycolic acid) or PLGA, a poly (b-hydroxybutryate), a poly (caprolactone), a poly (dioxanone); a poly (ethylene glycol), a poly ((hydroxypropyl) methacrylamide, a poly [(organo)phosphazene], a poly (ortho esters), a poly (vinyl alcohol), a poly (vinylpyrrolidone), a maleic anhydride- alkyl vinyl ether copolymer, a pluronic polyol, an albumin, an alginate, a ose, a cellulose derivative, a collagen, a fibrin, a gelatin, a onic acid, an oligosaccharide, a glycaminoglycan, a sulfated polysaccharide, a blend, and a copolymer thereof.
9. The use according to claim 7, wherein said ingredient, when present, is selected from the group consisting of albumin, sucrose, trehalose, lactitol, gelatin, hydroxypropyl- dextrin , methoxypolyethylene glycol, and polyethylene .
10. The use according to any one of claims 1 to 4, further comprising stering to the individual a second agent, n said second agent is one or more compounds in the group consisting of budenoside, epidermal growth factor, corticosteroids, cyclosporin, sulfasalazine, aminosalicylates, 6-mercaptopurine, oprine, metronidazole, lipoxygenase inhibitors, mesalamine, olsalazine, balsalazide, antioxidants, thromboxane inhibitors, IL-1 receptor antagonists, anti-IL-1β monoclonal antibodies, anti-IL-6 monoclonal antibodies, growth factors, elastase inhibitors, nyl-imidazole compounds, antibodies of TNF, LT, IL-2, IL-6, IL-7, IL-8, IL-12, IL-13, IL-15, IL-16, IL-18, IL-23, EMAP-II, , FGF, and PDGF, antibodies of CD2, CD3, CD4, CD8, CD-19, CD25, CD28, CD30, CD40, CD45, CD69, CD90 or their ligands, methotrexate, cyclosporin, FK506, rapamycin, mycophenolate mofetil, leflunomide, NSAIDs, ibuprofen, corticosteroids, prednisolone, phosphodiesterase tors, adenosine agonists, antithrombotic agents, complement inhibitors, adrenergic agents, IRAK, NIK, IKK, p38, MAP kinase inhibitors, IL-1β converting enzyme inhibitors, TNFα converting enzyme inhibitors, T-cell signalling tors, metalloproteinase tors, sulfasalazine, azathioprine, 6-mercaptopurines, angiotensin converting enzyme inhibitors, soluble cytokine ors, soluble p55 TNF receptor, soluble p75 TNF receptor, sIL-1RI, sIL-1RII, sIL-6R, nflammatory cytokines, IL-4, IL-10, IL-11, IL-13, and TGFβ. (10721333_1):GGG
11. The use according to any one of claims 1 to 4, wherein the dual is ing from a disease or disorder selected from the group comprising osteoarthritis, toid arthritis, juvenile chronic tis, septic arthritis, Lyme arthritis, psoriatic arthritis, reactive arthritis, spondyloarthropathy, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, inflammatory bowel e, insulin dependent diabetes mellitus, thyroiditis, asthma, allergic diseases, sis, dermatitis, scleroderma, graft versus host disease, organ lant rejection, acute immune disease associated with organ transplantation, chronic immune disease ated with organ transplantation, dosis, atherosclerosis, disseminated intravascular coagulation, Kawasaki's disease, Grave's disease, nephrotic syndrome, chronic fatigue syndrome, Wegener's granulomatosis, Henoch-Schoenlein purpurea, microscopic vasculitis of the kidneys, chronic active hepatitis, uveitis, septic shock, toxic shock syndrome, sepsis syndrome, cachexia, infectious diseases, parasitic diseases, acute transverse myelitis, Huntington's chorea, Parkinson's disease, Alzheimer's disease, stroke, primary biliary cirrhosis, hemolytic anemia, malignancies, heart e, myocardial infarction, Addison's disease, sporadic andular ency type I, polyglandular deficiency type II (Schmidt's syndrome), adult (acute) respiratory distress syndrome, alopecia, alopecia areata, seronegative arthropathy, arthropathy, Reiter's e, psoriatic arthropathy, ulcerative colitic arthropathy, enteropathic synovitis, dia-associated arthropathy, ia-associated arthropathy, Salmonella-associated arthropathy, spondyloarthropathy, atheromatous disease/arteriosclerosis, atopic allergy, mune bullous disease, gus vulgaris, pemphigus foliaceus, pemphigoid, linear IgA disease, autoimmune haemolytic anaemia, Coombs positive haemolytic anaemia, ed pernicious anaemia, le pernicious anaemia, myalgic encephalitis/Royal Free disease, chronic mucocutaneous candidiasis, giant cell arteritis, primary sing hepatitis, cryptogenic autoimmune hepatitis, acquired immunodeficiency syndrome, acquired immunodeficiency related diseases, hepatitis B, hepatitis C, common variable immunodeficiency (common variable hypogammaglobulinaemia), dilated cardiomyopathy, female infertility, ovarian failure, premature ovarian e, fibrotic lung disease, cryptogenic fibrosing alveolitis, postinflammatory interstitial lung disease, interstitial pneumonitis, connective tissue disease associated interstitial lung disease, mixed connective tissue disease associated lung disease, systemic sclerosis associated interstitial lung disease, rheumatoid arthritis associated (10721333_1):GGG interstitial lung disease, systemic lupus erythematosus associated lung e, omyositis/polymyositis associated lung disease, Sjögren's disease associated lung disease, ankylosing spondylitis associated lung disease, itic diffuse lung disease, haemosiderosis associated lung disease, drug-induced interstitial lung disease, fibrosis, radiation fibrosis, bronchiolitis rans, chronic eosinophilic pneumonia, lymphocytic infiltrative lung disease, postinfectious titial lung disease, gouty arthritis, autoimmune hepatitis, type-1 autoimmune hepatitis (classic autoimmune or lupoid hepatitis), type-2 autoimmune hepatitis (anti-LKM antibody hepatitis), autoimmune mediated hypoglycemia, type B insulin resistance with acanthosis ans, hypoparathyroidism, osteoarthrosis, y sclerosing cholangitis, psoriasis type 1, psoriasis type 2, idiopathic leucopaenia, autoimmune neutropaenia, renal disease NOS, glomerulonephritides, Lyme disease, discoid lupus erythematosus, male infertility idiopathic or NOS, sperm autoimmunity, multiple sclerosis (all subtypes), sympathetic ophthalmia, pulmonary hypertension secondary to tive tissue e, Goodpasture's syndrome, pulmonary manifestation of polyarteritis nodosa, acute rheumatic fever, toid spondylitis, Still's disease, systemic sclerosis, Sjögren's me, Takayasu's disease/arteritis, autoimmune thrombocytopaenia, idiopathic ocytopaenia, autoimmune thyroid disease, hyperthyroidism, goitrous autoimmune yroidism (Hashimoto's e), ic autoimmune hypothyroidism, primary myxoedema, phacogenic s, primary vasculitis, vitiligo, acute liver disease, c liver diseases, alcoholic cirrhosis, alcohol-induced liver injury, cholestasis, idiosyncratic liver disease, drug-induced hepatitis, non-alcoholic steatohepatitis, allergy, group B streptococci (GBS) infection, mental disorders (e.g., depression and schizophrenia), Th2 Type and Th1 Type mediated diseases, acute and chronic pain (different forms of pain), cancers such as lung, breast, stomach, bladder, colon, pancreas, ovarian, prostate and rectal cancer. hematopoietic malignancies (leukemia and lymphoma), abetalipoproteinemia, acrocyanosis, acute and chronic parasitic or infectious processes, acute leukemia, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), acute or c bacterial ion, acute pancreatitis, acute renal failure, adenocarcinomas, atrial ectopic beats, AIDS dementia complex, alcohol-induced hepatitis, allergic conjunctivitis, allergic contact dermatitis, allergic rhinitis, allograft rejection, alpha-l- antitrypsin deficiency, amyotrophic lateral sclerosis, , angina pectoris, anterior horn cell degeneration, anti-CD3 therapy, antiphospholipid (10721333_1):GGG syndrome, anti-receptor hypersensitivity reactions, aortic and peripheral aneurysms, aortic dissection, arterial ension, arteriosclerosis, arteriovenous fistula, , atrial fibrillation (sustained or paroxysmal), atrial r, atrioventricular block, B cell lymphoma, bone graft rejection, bone marrow transplant (BMT) rejection, bundle branch block, Burkitt's lymphoma, burns, cardiac hmias, cardiac stun syndrome, cardiac tumors, cardiomyopathy, pulmonary bypass inflammation se, age transplant rejection, cerebellar cortical degenerations, cerebellar disorders, chaotic or multifocal atrial tachycardia, chemotherapy associated disorders, chronic myelocytic leukemia (CML), c alcoholism, chronic inflammatory pathologies, chronic cytic leukemia (CLL), chronic obstructive pulmonary disease (COPD), chronic salicylate intoxication, colorectal carcinoma, congestive heart failure, conjunctivitis, contact dermatitis, cor pulmonale, coronary artery disease, Creutzfeldt-Jakob disease, culture negative sepsis, cystic is, cytokine therapy associated disorders, dementia pugilistica, demyelinating diseases, dengue hemorrhagic fever, dermatologic conditions, diabetes, ic arteriosclerotic disease, diffuse Lewy body disease, dilated congestive cardiomyopathy, disorders of the basal ganglia, Down's syndrome in middle age, drug- induced movement disorders induced by drugs which block CNS dopamine receptors, drug sensitivity, eczema, encephalomyelitis, endocarditis, endocrinopathy, epiglottitis, Epstein-Barr virus infection, erythromelalgia, extrapyramidal and cerebellar disorders, familial hemophagocytic lymphohistiocytosis, fetal thymus implant rejection, Friedreich's ataxia, functional peripheral arterial disorders, fungal , gas gangrene, gastric ulcer, glomerular nephritis, graft rejection of any organ or tissue, gram negative sepsis, gram positive sepsis, granulomas due to intracellular organisms, hairy cell leukemia, Hallervorden-Spatz disease, Hashimoto's thyroiditis, hay fever, heart transplant rejection, hemochromatosis, hemodialysis, hemolytic uremic syndrome/thrombolytic ocytopenic purpura, hage, hepatitis A, His bundle arrhythmias, HIV infection/HIV neuropathy, n's disease, hyperkinetic movement disorders, hypersensitivity reactions, hypersensitivity pneumonitis, hypertension, hypokinetic movement disorders, hypothalamic-pituitary-adrenal axis evaluation, idiopathic Addison's disease, idiopathic pulmonary fibrosis, antibody mediated xicity, asthenia, infantile spinal muscular y, inflammation of the aorta, influenza A, ng radiation exposure, iridocyclitis/uveitis/optic neuritis, ischemia- reperfusion injury, ischemic stroke, juvenile (10721333_1):GGG rheumatoid arthritis, juvenile spinal muscular atrophy, Kaposi's sarcoma, kidney transplant rejection, ella, leishmaniasis, leprosy, lesions of the corticospinal system, lipedema, liver lant rejection, lymphedema, a, malignant lymphoma, malignant histiocytosis, malignant melanoma, meningitis, meningococcemia, metabolic migraine he, idiopathic migraine he, mitochondrial multisystem disorder, mixed connective tissue disease, monoclonal gammopathy, multiple myeloma, multiple systems degenerations (Menzel, Dejerine-Thomas, Shy-Drager, and Machado-Joseph), enia , cterium avium intracellulare, mycobacterium tuberculosis, myelodysplastic syndrome, myocardial ischemic disorders, nasopharyngeal carcinoma, neonatal chronic lung disease, nephritis, nephrosis, neurodegenerative diseases, neurogenic muscular atrophies, neutropenic fever, non- n's lymphoma, occlusion of the abdominal aorta and its branches, ive arterial disorders, OKT therapy, orchitis/epididymitis, orchitis/vasectomy reversal procedures, organomegaly, osteoporosis, pancreas transplant rejection, pancreatic carcinoma, paraneoplastic syndrome/hypercalcemia of malignancy, parathyroid transplant rejection, pelvic matory disease, perennial rhinitis, pericardial disease, peripheral atherosclerotic disease, peripheral vascular disorders, peritonitis, pernicious , pneumocystis carinii pneumonia, pneumonia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome), post perfusion syndrome, post pump syndrome, post-MI cardiotomy syndrome, preeclampsia, progressive supranucleo palsy, primary ary hypertension, radiation therapy, d's phenomenon, Raynaud's disease, Refsum's disease, regular narrow QRS tachycardia, renovascular hypertension, usion injury, restrictive cardiomyopathy, sarcomas, senile chorea, senile dementia of Lewy body type, seronegative arthropathies, shock, sickle cell anemia, skin allograft rejection, skin changes syndrome, small bowel transplant rejection, solid , specific arrhythmias, spinal ataxia, spinocerebellar degenerations, streptococcal myositis, structural lesions of the cerebellum, subacute sing panencephalitis, syncope, syphilis of the cardiovascular , systemic anaphylaxis, systemic inflammatory response syndrome, systemic onset juvenile rheumatoid arthritis, T- cell or FAB ALL, telangiectasia, thromboangiitis obliterans, thrombocytopenia, toxicity, transplants, trauma/hemorrhage, type III hypersensitivity reactions, type IV hypersensitivity, unstable , uremia, urosepsis, ria, valvular heart diseases, varicose veins, vasculitis, venous diseases, venous (10721333_1):GGG thrombosis, ventricular fibrillation, viral and fungal ions, viral encephalitis/aseptic meningitis, viral-associated hemophagocytic syndrome, Wernicke- Korsakoff syndrome, 's disease, xenograft rejection of any organ or tissue, acute coronary syndromes, acute idiopathic polyneuritis, acute matory demyelinating polyradiculoneuropathy, acute ischemia, adult Still’s disease, alopecia , anaphylaxis, anti-phospholipid antibody syndrome, aplastic anemia, arteriosclerosis, atopic eczema, atopic dermatitis, autoimmune dermatitis, autoimmune disorder associated with streptococcus infection, autoimmune enteropathy, autoimmune hearing loss, autoimmune lymphoproliferative me (ALPS), autoimmune myocarditis, autoimmune premature ovarian failure, blepharitis, bronchiectasis, bullous pemphigoid, vascular disease, catastrophic antiphospholipid syndrome, celiac disease, cervical spondylosis, chronic ischemia, icial pemphigoid, clinically isolated syndrome (CIS) with risk for multiple sclerosis, childhood onset atric disorder, dacryocystitis, dermatomyositis, diabetic retinopathy, disk herniation, disk prolapse, drug induced immune hemolytic anemia, endocarditis, endometriosis, endophthalmitis, episcleritis, erythema orme, erythema multiforme major, gestational pemphigoid, Guillain-Barré syndrome (GBS), hay fever, Hughes syndrome, idiopathic Parkinson’s disease, thic interstitial pneumonia, IgE-mediated allergy, immune hemolytic anemia, inclusion body myositis, infectious ocular inflammatory disease, inflammatory demyelinating disease, inflammatory heart e, inflammatory kidney disease, P, iritis, keratitis, junctivitis sicca, Kussmaul disease or Kussmaul-Meier disease, Landry's paralysis, Langerhan's cell histiocytosis, livedo reticularis, r degeneration, microscopic polyangiitis, morbus Bechterew, motor neuron disorders, mucous membrane pemphigoid, multiple organ failure, myasthenia gravis, myelodysplastic me, myocarditis, nerve root ers, neuropathy, non-A non-B tis, optic neuritis, osteolysis, ovarian cancer, pauciarticular JRA, peripheral artery ive disease (PAOD), peripheral vascular disease (PVD), peripheral artery e (PAD), phlebitis, polyarteritis nodosa (or periarteritis nodosa), polychondritis, polymyalgia rheumatica, poliosis, polyarticular JRA, polyendocrine deficiency syndrome, polymyositis, polymyalgia rheumatica (PMR), post-pump syndrome, primary Parkinsonism, prostatitis, pure red cell aplasia, primary adrenal insufficiency, recurrent neuromyelitis , restenosis, rheumatic heart disease, SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis), secondary amyloidosis, shock lung, scleritis, sciatica, (10721333_1):GGG secondary adrenal insufficiency, silicone associated connective tissue e, Sneddon- Wilkinson dermatosis, spondylitis ankylosans, Stevens-Johnson syndrome (SJS), systemic inflammatory response syndrome, temporal arteritis, toxoplasmic retinitis, toxic epidermal necrolysis, transverse myelitis, TRAPS (tumor-necrosis factor receptor type 1 (TNFR)- associated periodic syndrome), type 1 allergic reaction, type II diabetes, usual interstitial pneumonia (UIP), vernal ctivitis, viral retinitis, Vogt-Koyanagi-Harada syndrome (VKH syndrome), wet macular degeneration, and wound healing.
12. The use according to any one of claims 1 to 4, n the individual is ing from a disease selected from the group consisting of a primary cancer, a metastatic cancer, breast cancer, colon cancer, rectal cancer, lung cancer, oropharynx cancer, hypopharynx cancer, esophagus cancer, h cancer, pancreatic cancer, liver cancer, gallbladder , bile duct cancer, small ine cancer, colon cancer, urinary tract cancer, kidney cancer, bladder , urothelium cancer, female genital tract cancer, cervical cancer, uterine cancer, ovarian , carcinoma, gestational trophoblastic disease, male l tract cancer, prostate cancer, seminal vesicle cancer, testicular cancer, germ cell tumor, endocrine gland cancer, thyroid cancer, l cancer, pituitary gland , skin cancer, hemangioma, melanoma, sarcoma, bone cancer, soft tissue cancer, Kaposi’s sarcoma, tumor of the brain, nerve cancer, eye cancer, cancer of the meninges, ytoma, glioma, glioblastoma, retinoblastoma, neuroma, lastoma, Schwannoma, meningioma, a solid tumor arising from hematopoietic malignancy, leukemia, Hodgkin's ma, and non -Hodgkin's lymphoma.
13. Use of a binding protein that binds both IL-1α and IL-1β for the manufacture of a medicament of treating osteoarthritis in an individual.
14. The use according to claim 13, wherein said binding protein that binds both IL-1and IL-1 is a bispecific antibody.
15. The use according to claim 13, wherein said binding protein that binds both IL-1and IL-1 is a dual variable domain immunoglobulin (DVD-Ig) binding protein. (10721333_1):GGG
16. The use according to any one of claims 13 to 15, wherein said binding protein that binds both IL-1 and IL-1 is formulated in a pharmaceutical composition comprising a pharmaceutically acceptable carrier.
17. The use according to any one of claims 13 to 15, wherein said binding protein that binds both IL-1 and IL-1 is crystallized.
18. The use ing to claim 17, wherein said crystallized binding protein is formulated in a composition further comprising an optional ingredient and a polymeric carrier.
19. The use according to claim 18, wherein said polymeric carrier is a r selected from one or more of the group consisting of a poly (acrylic acid), a poly (cyanoacrylate), a poly (amino acid), a poly (anhydride), a poly (depsipeptide), a poly (ester), a poly (lactic acid), a poly (lactic-co-glycolic acid) or PLGA, a poly (b-hydroxybutryate), a poly (caprolactone), a poly none); a poly ene glycol), a poly ((hydroxypropyl) methacrylamide, a poly [(organo)phosphazene], a poly (ortho ester), a poly (vinyl alcohol), a poly (vinylpyrrolidone), a maleic anhydride- alkyl vinyl ether copolymer, a ic , an albumin, an alginate, a cellulose and a cellulose tive, a collagen, a fibrin, a gelatin, a hyaluronic acid, an oligosaccharide, a glycaminoglycan, a sulfated polysaccharide, a blend, and a copolymer thereof.
20. The use according to claim 18, wherein said optional ingredient is selected from the group consisting of albumin, sucrose, trehalose, lactitol, gelatin, hydroxypropyl-βcyclodextrin , methoxypolyethylene glycol and polyethylene glycol.
21. The use according to claim 13 further comprising administering to the individual a second agent, wherein said second agent is one or more nds in the group consisting of budenoside, epidermal growth factor, corticosteroids, cyclosporin, alazine, aminosalicylates, 6-mercaptopurine, azathioprine, idazole, lipoxygenase inhibitors, (10721333_1):GGG mesalamine, olsalazine, balsalazide, antioxidants, thromboxane inhibitors, IL-1 receptor antagonists, anti-IL-1β monoclonal antibodies, anti-IL-6 monoclonal antibodies, growth factors, elastase inhibitors, pyridinyl-imidazole compounds, antibodies of TNF, LT, IL-2, IL- 6, IL-7, IL-8, IL-12, IL-13, IL-15, IL-16, IL- 18, IL-23, EMAP-II, GM-CSF, FGF, and PDGF, antibodies of CD2, CD3, CD4, CD8, CD-19, CD25, CD28, CD30, CD40, CD45, CD69, CD90 or their ligands, methotrexate, cyclosporin, FK506, rapamycin, mycophenolate l, leflunomide, NSAIDs, ibuprofen, corticosteroids, prednisolone, phosphodiesterase tors, adenosine agonists, antithrombotic agents, complement inhibitors, adrenergic agents, IRAK, NIK, IKK, p38, MAP kinase inhibitors, IL- 1β ting enzyme inhibitors, TNFα converting enzyme tors, T-cell signalling inhibitors, metalloproteinase inhibitors, sulfasalazine, azathioprine, 6-mercaptopurines, angiotensin converting enzyme inhibitors, soluble cytokine ors, soluble p55 TNF receptor, soluble p75 TNF receptor, sIL-1RI, sIL-1RII, , anti-inflammatory cytokines, IL-4, IL-10, IL-11, IL-13, and TGFβ.
22. The use ing to any one of claims 13 to 21, wherein said step of administering to said individual is by at least one mode selected from parenteral, subcutaneous, intramuscular, enous, intra-articular, intrabronchial, intraabdominal, apsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and ermal.
23. The use ing to claim 13, wherein the osteoarthritis comprises an osteoarthritis lesion.
24. The use according to claim 13, wherein the osteoarthritis comprises an injury to an anterior cruciate ligament.
25. The use according to claim 13, wherein osteoarthritis comprises cartilage (10721333_1):GGG ration and sion of IL-6.
26. The use according to claim 25, wherein the cartilage degeneration ses femoral cartilage degeneration or tibial cartilage degeneration.
27. The use according to claim 13, wherein administering the binding protein produces an antinociceptive effect.
28. The use according to claim 13, wherein the binding protein further treats pain.
29. The use according to claim 28, wherein the pain is selected from the group consisting of allodynia, hyperalgesia, and a combination of allodynia and hyperalgesia.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161440853P | 2011-02-08 | 2011-02-08 | |
US61/440,853 | 2011-02-08 | ||
PCT/US2012/024356 WO2012109373A2 (en) | 2011-02-08 | 2012-02-08 | Treatment of osteoarthritis and pain |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ614207A NZ614207A (en) | 2015-12-24 |
NZ614207B2 true NZ614207B2 (en) | 2016-03-30 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2826564C (en) | Treatment of osteoarthritis and pain | |
RU2650767C2 (en) | Interleukin-13-binding proteins | |
US8383778B2 (en) | IL-1 binding proteins | |
US8398966B2 (en) | IL-1 binding proteins | |
US10899842B2 (en) | 4-1BB binding proteins and uses thereof | |
US9226983B2 (en) | TNF-α binding proteins | |
US20120275996A1 (en) | IL-1 Binding Proteins | |
US20100040537A1 (en) | Prostaglandin E2 Binding Proteins and Uses Thereof | |
US20110165063A1 (en) | Il-1 binding proteins | |
NZ614207B2 (en) | Treatment of osteoarthritis and pain |